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ABSTRACT 
Nan Li: Sugar/carbohydrate intake and the Barrett’s esophagus-adenocarcinoma continuum 
(Under the direction of Marilie D. Gammon) 
 
The incidence of esophageal and gastric cardia adenocarcinoma (EA/GCA) has 
increased rapidly in Westernized countries during the past few decades, whereas survival 
remains low. Barrett’s esophagus (BE), the only known precursor lesion of EA/GCA, has been 
increasing. Long-term high sugar/carbohydrate intake may promote carcinogenesis by inducing 
hyperinsulinemia. In this dissertation, four United States-based case-control studies were 
pooled to examine the associations between sugar/carbohydrate intake and risk of developing 
BE, risk of developing EA/GCA, and mortality after a diagnosis of EA/GCA. In total, there were 
513 BE cases/528 controls, and 513 EA cases/538 GCA cases/2051 controls. EA/GCA cases 
were followed for vital status. Dietary intake was assessed by study-specific food frequency 
questionnaires, and then linked with the University of Minnesota Nutrient Database to 
harmonize and estimate intake of twelve sugar/carbohydrate measures. Sugar/carbohydrate 
intake was then pooled using study-specific quantiles and absolute cut-points. Odds ratios and 
95% confidence intervals were calculated using: logistic regression for BE incidence; and 
multinomial logistic regression for EA incidence and GCA incidence as distinct outcomes. 
Hazard ratios and their 95%CIs were calculated using Cox proportional hazards regression for 
EA/GCA survival analysis. Sucrose was found to be associated with 79% and 51% increase in 
risk of developing BE and EA, respectively. Intake of sweetened desserts/beverages was 
associated with 71% and 55% increase in risk of developing BE and EA, respectively. Added 
sugar was associated with 71% increase in risk of developing BE, but not with EA. Glycemic 
index was associated with 58% increase in risk of developing EA, but not with BE. Waist
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circumference modified the sweetened desserts/beverages-BE association, and body mass 
index (BMI) modified all of the above positive associations with EA incidence. The sucrose-EA 
association was modified by frequency of gastroesophageal reflux disease (GERD). If the 
results from this dissertation are confirmed, there could be potential to reduce risk of BE/EA by 
reducing intake of sucrose (especially among those with BMI<25 or GERD<weekly) and 
sweetened desserts/beverages (especially among those with lower waist circumference or 
BMI<25). Reducing added sugar intake and dietary glycemic index (especially among those 
with BMI≥25), may also be plausible risk reduction strategies. 
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CHAPTER 1: BACKGROUND 
 
Introduction 
The incidence of esophageal and gastric cardia adenocarcinoma (EA/GCA) has been 
increasing in many Westernized countries since 1970s.1-5 Prognosis remains poor, with a 5-year 
survival of less than 20%.6, 7 The only known potential precursor lesion of esophageal 
adenocarcinoma is Barrett’s esophagus (BE), which has also been increasing.8-12 Given the 
rapid increase in incidence and the sustained poor survival, instead of focusing on reducing the 
risk of developing invasive cancer alone, identification of key windows of susceptibility along the 
entire cancer continuum (normal tissue  precancerous condition  invasive cancer  
mortality) could potentially be more fruitful. This approach may identify optimal times that could 
be targeted for intervention with specific risk reduction strategies.  
Thus, this dissertation aimed to determine the role of dietary sugar/carbohydrate intake 
along the cancer development and progression continuum by examining whether dietary 
sugar/carbohydrate intake increases the risk of developing BE, the risk of developing 
esophageal and gastric cardia adenocarcinoma, or the risk of dying once diagnosed with these 
deadly tumors. 
Sugar/sweetener intake (per capita) is much higher in Western populations than Asian 
populations,13 which corresponds to the global distribution of EA/GCA - higher incidence of 
EA/GCA in Western countries compared to developing countries (Figure 1.1).14, 15 Intake of 
caloric sweeteners has increased dramatically since 1960s,16 which corresponds to the rapid 
increase in the EA/GCA incidence in the past few decades. The hypothesis of this study was 
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that sugar/carbohydrate intake is associated with increased risk of developing esophageal and 
gastric cardia adenocarcinoma. The potential underlying mechanism is that long-term 
consumption of a high-sugar/carbohydrate diet may lead to chronic hyperglycemia and 
hyperinsulinemia, and the elevated levels of insulin and insulin-like growth factor 1 (IGF-I) may 
promote carcinogenesis by stimulating cell proliferation and inhibiting apoptosis.17-20 Therefore 
excess dietary intake of sugar/carbohydrate may play a role in the etiology of BE-EA/GCA 
cancer continuum outcomes.  
Specific aims of this study included the following. Aim 1: Determine if 
sugar/carbohydrate intake is associated with the development of Barrett’s esophagus (with aim 
1A: Explore whether overweight/obesity [measured by body mass index] or gastroesophageal 
reflux disease [GERD] are effect measure modifications [EMMs] of the significant associations 
between sugar/carbohydrate intake and risk of developing BE). Aim 2: Determine if 
sugar/carbohydrate intake is associated with the development of EA/GCA (with aim 2A: Explore 
whether overweight/obesity [measured by body mass index] or GERD are EMMs of the 
significant associations between sugar/carbohydrate intake and risk of developing EA/GCA). 
Aim 3: Determine if sugar/carbohydrate intake is associated with survival following a diagnosis 
of EA/GCA. The study is significant because the increasing incidence and poor prognosis of 
EA/GCA underscore the importance of identifying modifiable risk factors and relevant risk 
reduction strategies. However, the currently well-established risk factors, GERD, obesity, and 
smoking, may be difficult to modify: weight loss and smoking cessation are difficult to achieve or 
maintain;21, 22 and GERD is a chronic disease that usually requires continued therapy to prevent 
relapse.23 Because dietary sugar intake is a modifiable factor, there might be potential to reduce 
the disease burden by limiting sugar intake. The study is innovative because the entire cancer 
continuum from BE, invasive cancer by subtype, to mortality, was considered. If we find that 
sugar/carbohydrate, or a specific type of sugar, are associated with risk of BE, or 
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incidence/mortality of EA/GCA, there is potential to reduce the disease burden of these lethal 
cancers by implementing a risk reduction strategy of limiting dietary sugar/carbohydrate intake. 
 
Esophageal and Gastric Cancer 
Esophageal Cancer: Squamous Cell Carcinoma vs. Adenocarcinoma 
Esophageal cancer was the eighth most common cancer worldwide with 456,000 new 
cases estimated in 2012 (most recently published), and also was the sixth most common cause 
of death from cancer with an estimated 400,000 deaths in 2012.24 Esophageal cancer is a lethal 
cancer with a very poor prognosis, and the overall ratio of mortality to incidence was 0.88.24 As 
a result, the geographical distribution pattern for esophageal cancer mortality closely fol lows the 
pattern for esophageal cancer incidence.24 The major histological types of esophageal cancer 
include esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma, with 
other sub-types occurring only very rarely.1, 25 ESCCs generally occur in the upper or middle 
third of the esophagus, whereas EAs occur in the lower third of the esophagus or at the 
gastroesophageal junction.26 ESCC is the predominant histological type of esophageal cancer 
worldwide.1, 25 ESCC mainly occurs in less-developed regions such as Eastern Asia, Southern 
Africa, and Eastern Africa, whereas EA predominantly occurs in more-developed regions such 
as the United States (US) and many Western countries.1 Although the global incidence of 
esophageal squamous cell carcinoma has slightly decreased in the past four decades, the 
incidence of esophageal adenocarcinoma has been increasing rapidly in the US and some 
Western countries.1-5 As a result, adenocarcinoma has slowly replaced squamous cell 
carcinoma as the most common type of esophageal cancer in the US and many Western 
countries.3, 27-29 
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Gastric Cancer: Cardia vs. Non-Cardia 
Gastric cancer was the fifth most common cancer worldwide with almost one million new 
cases estimated in 2012, and also was the third most common cause of death from cancer with 
an estimated 723,000 deaths in 2012.24 The vast majority of gastric cancers are 
adenocarcinomas.30 Because the differences between gastric cardia and non-cardia cancer 
were once not evident, not until the 8th revision of the International Classification of Diseases 
(1968) that cancer of the gastric cardia was coded separately from other gastric cancers. 31 
Based on the new classification, gastric cancers are usually anatomically classified as 
noncardia and cardia cancers.1 Gastric cardia cancer occurs in the proximal portion of the 
stomach next to or at the gastroesophageal junction, whereas the gastric non-cardia cancer 
occurs at the distal portion of the stomach.32 Non-cardia cancers constitute the majority of 
gastric cancer cases worldwide.1 Gastric cardia and non-cardia cancers are epidemiologically 
distinct: the incidence of non-cardia gastric cancer has remarkably decreased in the past 50 
years particularly in developed countries,33-36 whereas the incidence of gastric cardia cancer 
increased rapidly in the US and many Western countries in the past four decades.26, 33, 37-39  
Summary. Cancers of esophageal and gastric are among the most common causes of 
cancer morbidity and mortality worldwide.24 Among different sub-types of esophageal and 
gastric cancers, esophageal adenocarcinoma and gastric cardia adenocarcinoma are most 
similar in incidence trends and global distributions.26, 33, 37-39 The increasing incidence and poor 
survival of esophageal and gastric cardia adenocarcinoma calls for identification of modifiable 
risk factors for these cancers so that relevant risk reduction strategies could be implemented.  
 
Esophageal and Gastric Cardia Adenocarcinoma 
Esophageal and Gastric Cardia Adenocarcinoma Incidence and Survival 
Esophageal and gastric cardia adenocarcinoma were once rare, however, a rapid 
increase in the incidence for esophageal and gastric cardia adenocarcinoma was reported 
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during the past four decades from many population-based cancer registries, including United 
States, New Zealand, the United Kingdom, Norway, Denmark, Finland, and some other Western 
countries.3, 25, 26, 37, 40-43 As a result of the dramatic increase, EA/GCA was among the most 
rapidly increasing cancer types in the US and some Western countries.14, 44  
In the United States, according to the analysis based on data collected from Surveillance 
Epidemiology and End Results (SEER) 9 regions, the overall incidence of adenocarcinoma of 
the esophagus and the gastric cardia increased from 13.4 per million in 1973 to 51.4 per million 
in 2009, with a nearly 400 % increase.45 The incidence continued to increase in early twenty-first 
centuries, although the increase somewhat slowed down during 1987-2009 compared to the 
increase during 1973-1987.45 
Stratified by anatomic sites, the incidence of GCA increased rapidly since 1973, from 9.5 
per million to >20 per million in late 1980s, with an annual increase of 5.2%. 45 However, the 
incidence seems to have reached a plateau in late 1980s, and the incidence remained more or 
less stable from 1987 to 2009.45 In contrast, the incidence of EA kept increasing from 3.9 per 
million in 1973 to 28.9 per million in 2009, surpassing the incidence of GCA in 1996. 45  
Stratified by race and sex, the most prominent increase in the incidence of EA was 
observed among white men, with a yearly increase in incidence of 2.3 per million reach ing 107.3 
per million in 2009.45  A smaller yearly increase was observed in white women (0.7 per million 
before 1988 to 0.4 per million after 1988).45 In contrast to the continuous rise among both white 
men and women, the incidence remained stable or even declined in non-white men and 
women.45  The incidence of EA in non-white men increased before 1992, and has been slightly 
decreasing since 1992, reached 30 per million in 2009.45  EA incidence in non-white females 
remained relatively constant between 7 and 17 per million.45 
Stratified by stage, esophageal and gastric cardia adenocarcinoma at all of the stages 
continued to rise between 1973 and 2009, except for non-invasive cancer (in situ carcinoma, 
makes up no more than 2.5% of the all EA/GCA cancers), which decreased with a yearly 
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decrease of 0.22 per million since 2003 and reached 0.25 per million in 2009.45  Yearly increase 
of incidence of localized disease slowed down after 1999, and the incidence was approximately 
13 per million in 2009.45  Similarly, the increase in regional disease slowed down after 1985, and 
the incidence was slightly over 13 per million in 2009.45  In contrast, the incidence of metastatic 
disease, which makes up 38% of all EA/GCA cancers, has been increasing constantly and was 
slightly over 20 per million in 2009.45  
According to SEER9 data collected from 1975 to 2009, EA mortality has been rapidly 
increasing, from around 4 per million in 1977 to 23 per million in 2009.46 The mortality trends 
followed a similar pattern to that of EA incidence - a rapid increase since late 1970s followed by 
a less rapid increase since mid-1990s.46 Noticeably, different from the overall pattern, mortality 
and incidence of localized disease have diverged beginning in the late 1990s due to the fact that 
the mortality increased less rapidly then incidence, possibly due to the great improvement in the 
5-year relative survival in people diagnosed with localized disease.46 The 5-year relative survival 
was around 2.1% in patients diagnosed with localized disease in 1975, compared to a rate 
of >50% in all patients diagnosed with localized EA in 2004.46 Although the 5-year relative 
survival in patients diagnosed with regional and distant stage has also been improving since 
1975, the 5-year survival remains low.46 The 5-year relative survival were 20% and 2.8%, 
respectively, in patients diagnosed with regional staged and distant staged EA in 2004. 46 EA 
and GCA were shown to have little survival difference.47, 48 It is noteworthy that because early-
stage esophageal and gastric cardia adenocarcinomas are often asymptomatic, most of the 
patients were diagnosed at a late stage.45, 46, 49 The local staged EA/GCA makes up 20-30% of 
all diagnosed cases, whereas the distant staged EA/GCA makes up approximately 40% of all 
EA/GCA cases.45, 46, 49 As a result, the 5-year relative survival rate for all patients diagnosed with 
different stages remains less than 20%.6, 7 Median survival times in local, regional, and distant 
esophageal and gastric cancers were 11, 10, and 4 months respectively in the 1970s, and 35, 
15, and 6 months respectively after 2000.49  
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Summary. The incidence of EA/GCA has been increasing since 1970s, although at a 
slightly slower rate in recent years.45 The mortality trends followed a similar pattern to the 
incidence trends.46 Although the survival of EA/GCA has been improved in the past few 
decades, the 5-year relative survival remains lower than 20%.6, 7 Given the continuing increase 
in incidence and persistent poor prognosis, identification of potentially modifiable risk factors 
may help to develop and/or refine relevant risk reduction strategies.  
 
Esophageal and Gastric Cardia Adenocarcinoma Risk Factors and Risk Reduction 
Factors 
Esophageal adenocarcinoma and gastric cardia adenocarcinoma are often considered 
as one clinical entity because they occur contiguously at or near the gastroesophageal (GE) 
junction and have comparable 5-year survival rates.47 In addition, esophageal and gastric cardia 
adenocarcinomas share many risk factors, as presented in the sections below. 
Medical Conditions. GERD and Barrett’s esophagus are two well-established risk 
factors for esophageal and gastric cardia adenocarcinoma.50-55 Barrett’s esophagus is a 
precursor lesion of EA, and usually arises from GERD.52, 55, 56 GERD not only increases the risk 
of EA/GCA by increasing the risk of BE development, but appears to increase the risk of 
EA/GCA in the absence of BE as well.54, 57 Diabetes mellitus (DM), has also been evaluated as 
a risk factor for EA/GCA.58-63  
Gastroesophageal Reflux Disease. GERD develops when the lower esophageal 
sphincter allows gastric acid and other gastric contents to flow back into the esophagus and 
subsequently causes troublesome symptoms or complications.64 GERD is common in Western 
populations, with highest prevalence in the US.65 The prevalence of at least weekly GERD 
symptoms in the US is approximately 20%.65 In the pooled analysis of five studies from the 
international Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON), both frequency 
and duration of heartburn/regurgitation symptoms were found to be independently associated 
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with increased risk of EA and esophagogastric junction adenocarcinoma.66 Recurrent symptoms 
of heartburn/regurgitation was reported to be associated with an increased risk of EA (OR and 
95%CI: 4.81 [3.39−6.82]).66 The study also suggested that the risk of EA increased with the 
increase of the frequency of regurgitation/heartburn (ORs and 95%CIs were 7.96 [4.51 -14.04], 
5.07[3.07-8.38], and 2.08[1.14-3.79] for >daily, >weekly to daily, and ≤weekly, respectively, all 
compared with those had never experienced symptoms).66 It was suggested that risk of EA also 
increased with increased duration of heartburn/regurgitation symptoms (ORs and 95%CIs were 
2.80[1.60-4.91], 3.85[2.93-5.07], and 6.24[3.37-11.55] for symptom durations of <10 years, 10 
to <20 years, and ≥20 years, respectively).66 Frequency and duration of heartburn/regurgitation 
symptoms were also found to be positively associated with increased risk of esophagogastric 
junction adenocarcinoma, although the associations were slightly weaker.66 A meta-analysis 
reported that GERD symptoms were associated with elevated risk of EA (pooled ORs and 
95%CIs were 4.92[3.90-6.22] and 7.40[4.94-11.1], for at least weekly symptoms and daily 
symptoms, respectively).50 Another study examined the association between GERD and 
EA/GCA also suggested that the risk of EA/GCA increased with the frequency, severity, and 
duration of symptomatic GERD.54 Consistent with the pooled analysis, the association between 
GERD and EA was found to be stronger than that between GERD and GCA.54 
One hypothesized mechanism for the GERD-EA/GCA association is that the acid reflux 
injures the esophageal epithelium and subsequently results in inflammation and cell 
proliferation.67 Another potential mechanism is that acid reflux causes the production of nitrous 
oxide, which results in elevated levels of DNA damage.68 
Barrett's Esophagus. Barrett's esophagus is a metaplastic change of the lining of the 
esophagus, and it is characterized by the replacement of the normal squamous epithelium by 
specialized or intestinalized columnar epithelium.69 BE is the precursor lesion of EA, and is 
associated with an increased risk of EA.70-73 Earlier studies reported that the incidence rate of 
adenocarcinoma was around 5-10 cases per 1000 person-years among patients with BE.70-72 In 
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addition, the risk of EA in patients with BE was estimated to be approximately 30-500 times of 
the risk in the general population.73 A recent large cohort study conducted within the entire 
Danish population studies reported a lower incidence rate and lower risk ratio. 74 The annual risk 
of esophageal adenocarcinoma was found to be 1.2 cases per 1000 person-years (95%CI, 0.9-
1.5) among patients with BE.74 The risk ratio of adenocarcinoma among patients with BE was 
reported to be 11.3 (95%CI, 8.8-14.4), compared with the risk in the general population.74 
Although the earlier studies might have overestimated the incidence rates and risk ratio due to 
the smaller sample size, both earlier and recent studies suggested that BE increases the risk of 
EA.71, 75 
As the adenocarcinoma arises through a progressive sequence (from metaplasia to low-
grade dysplasia, to high-grade dysplasia, to adenocarcinoma), risk of developing 
adenocarcinoma is associated with the histologic grade of the dysplasia in BE.76 In the Danish 
study, the incidence rate among patients with low-grade dysplasia (LGD) was 5.1 cases per 
1000 person-years, compared to 1.0 case per 1000 person-years among patients without 
dysplasia.74 In a Dutch population-based study, the EA incidence rate among patients with high-
grade dysplasia (HGD) was reported to be 42 cases per 1000 person-years.77 Another 
characteristic of BE that is associated with the risk of developing adenocarcinoma is the length 
of BE segment.78-80 In a large cohort study of patients with non-dysplastic BE, the length of BE 
was longer in patients who progressed to HGD or EA compared to those who did not 
progress.80 It was also estimated that 1 cm increase in the length of BE was associated with 28% 
increased risk of progression.80 They also found that it took patients with a BE length of ≤3 cm 
longer to progress to HGD or EA compared to patients with a BE length of >4 cm (6 years 
versus 4 years).80 Another population-based study conducted in Northern Ireland found that BE 
patients with a long-segment BE (LSBE, defined as ≥3 cm) have an increased risk of 
progressing to high-grade dysplasia or EA.79 
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Diabetes Mellitus.  A few studies have investigated the association between DM and 
esophageal cancer, however, not all have distinguished EA from ESCC.61, 63 The results from 
these studies are inconsistent. Most of the case-control studies suggested a positive association 
between DM and EA,58-62 whereas the only prospective study (HR and 95%CI, 0.98 [0.73-1.31]) 
and one case-control study (OR and 95%CI, 1.1 [0.8-1.5]) suggested little or no association.63, 81 
The results from studies that investigated the DM-GCA associations also yield inconsistent 
results.61, 63 The prospective study suggested a positive association,63 whereas a large case-
control study suggested no association.61 In the prospective study, DM was associated with risk 
of GCA even when restricted to only overweight subjects (HR and 95%CI, 1.83 [1.18-2.85]).63 
Further prospective studies are needed to investigate the association between DM, EA, and 
GCA.  
Demographic Factors. Several demographic factors, including age, sex, race/ethnicity, 
were found to be associated with risk of EA/GCA.82-85 Some studies also suggest an association 
between socioeconomic status (SES) and risk of EA/GCA.86-89  
Age, Sex, Race/Ethnicity. Consistent with other cancers, risk of developing EA/GCA 
increases with increasing age.82, 83 Based on SEER data, the EA/GCA incidence was low 
among younger people, and then increases rapidly starting at around 45 years old of age, until 
75-79 and 80-84 years of age for EA and GCA, respectively, then starts to decline in the older 
age groups.82 Men are associated with a higher risk of EA/GCA compared to women.82, 84, 85 
Non-Hispanic whites are associated with a higher risk compared to non-Hispanic blacks, 
Hispanics, Asians, and other races/ethnicities.82, 84, 85 Based on SEER data, between 1977 and 
1996, the age-adjusted incidence of EA was six to eight times higher in men than in women, 
and three to four times higher in whites than in blacks.82 Compared with EA, the sex and 
race/ethnicity discrepancy was less pronounced in GCA incidence.82 The age-adjusted 
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incidence of GCA was three to five times higher in men than in women, and no more than twice 
higher in whites than in blacks.82  
Socioeconomic Status. Several studies suggested that low income and low education 
were associated with an increased risk of EA/GCA.86-89 In the US Multi-Center Study, comparing 
study subjects with an income of ≥ $75,000 to those with an income of <$15,000 per year, the 
odds ratios (ORs) and 95% confidence intervals (CIs) were 0.5 (0.3-1.0) and 0.8 (0.4-1.6) for EA 
and GCA, respectively.89 Comparing study subjects who completed graduate school to those 
with less than high school education, the ORs and 95%CIs  were 0.7 (0.3-1.3) and 0.8 (0.4-1.6) 
for EA and GCA, respectively.89  
Epidemiologic Factors. Obesity and cigarette smoking are two well-established 
epidemiologic factors for EA/GCA. 51, 89-92  Alcohol has been evaluated as a risk factor, but most 
studies suggested no association between alcohol and EA/GCA.93  Dietary fat has also been 
evaluated as a risk factor, but the results were inconsistent.94-96  
Obesity. Elevated body mass index (BMI, defined as weight in kilograms/height in 
meters squared) has consistently been shown to be associated with an increased risk of 
EA/GCA.51, 90-92 In a pooled analysis of BEACON studies, the risk of EA was found to increase 
with increasing BMI (ORs and 95%CIs were 1.54 [1.26–1.88], 2.39[1.86–3.06], 2.79[1.89–4.12] 
and 4.76[2.96–7.66] for BMI of 25.0-29.9, 30.0-34.9, 35.0-39.9, and ≥40.0, respectively, all 
compared with those with a BMI of <25.0).92 Similarly, the risk of esophagogastric junction 
adenocarcinoma also increases with increasing BMI (ORs and 95%CIs were and 1.28[1.13–
1.45], 2.08[1.75–2.47], 2.36[1.75–3.17], and 3.07[1.89–4.99] for BMI of 25.0-29.9, 30.0-34.9, 
35.0-39.9, and ≥40.0, respectively, all compared with those with a BMI of <25.0).92 
Recent studies have focused more on body fat distribution and have reported that 
increased central adiposity (measured by waist circumference, waist-to-hip ratio, etc.) were 
strongly associated with increased BE/EA/GCA risk, after adjusting for BMI.97-100 The large 
prospective cohort study - National Institutes of Health-American Association for Retired 
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Persons (NIH-AARP) Diet and Health Study suggested that waist circumference was positively 
associated with both EA (hazard ratios [HRs] and 95%CIs: Q4th vs. Q1st, 2.01[1.35-3.00]; Q3rd vs. 
Q1st, 1.51[1.02–2.25]; Q2nd vs. Q1st, 1.36[0.89–2.09]) and GCA risk (HRs and 95%CIs: Q4th vs. 
Q1st, 2.22[1.43-3.47]; Q3rd vs. Q1st, 1.29[0.82–2.04]; Q2nd vs. Q1st, 1.32 [0.82–2.14]).
101 It was also 
suggested in this study that the waist-to-hip ratio was positively associated with both EA and 
GCA risk (HRs and 95%CIs: highest vs. referent, 1.81 [1.24 - 2.64] and 1.37 [0.92–2.05], 
respectively).101  Abdominal obesity was found to be associated with increased risk of EA even 
in patients with normal BMI (18.5-<25 kg/m2).101 Abdominal obesity may increase intra-
abdominal pressure and subsequently relax the lower esophageal sphincter, which may 
promote GERD and increase the risk of EA/GCA.92  However, this may only partly explain the 
mechanism since a pooled analysis of BEACON studies suggested that obesity was associated 
with increased risk of EA in absence of GERD.92 Another potential mechanism could be that 
abdominal obesity may lead to insulin resistance and chronic inflammation, which may increase 
the risk of EA/GCA.102 
Although obesity was found to be associated with risk of EA/GCA and the rapid increase 
in obesity in the general population is in parallel to the increasing EA/GCA incidence, studies 
suggested that the rise in EA incidence was prior to the rise in obesity and the rise in obesity 
cannot fully explain the rise in EA/GCA incidence.103, 104  
Cigarette Smoking. Studies have consistently found an association between cigarette 
smoking and increased EA/GCA risk.87, 89, 105-107 In a pooled analysis of cigarette smoking from 
twelve BEACON studies, the risk of adenocarcinomas among ever smokers was approximately 
two times the risk of adenocarcinomas among never smokers (summary ORs were 1.96 [1.64 -
2.34] and 2.18 [1.84-2.58], for EA and gastroesophageal junction adenocarcinoma, 
respectively).108 In addition, the results suggested a trend of increasing risk of EA with increased 
pack-years smoked (ORs and 95%CIs were 1.25 [1.02-1.53], 1.96 [1.58-2.45], 2.07 [1.66-2.58], 
and 2.71 [2.16-3.40] for pack-years of smoking <15, 15-<30, 30-<45, and ≥45, respectively, all 
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compared with non-smokers).108 A similar trend was suggested for GE junction adenocarcinoma, 
with the corresponding ORs (95%CIs) of 1.32 (0.99-1.75), 2.44 (1.98-3.00), 2.64 (2.07-3.38), 
and 2.68 (2.23-3.23), respectively.108 Cigarette smoking has also been reported to increase the 
risk of progression from BE to EA/GCA or high-grade dysplasia (HR with 95%CI was 2.03 [1.29-
3.17], current smoker vs. never smoker).109  
Alcohol. Alcohol has been evaluated as a risk factor in previous studies. Most studies 
suggested no association between alcohol consumption and EA.93 Several studies reported an 
increased risk of EA/GCA among alcohol drinkers,110-112 whereas a slight decrease of EA/GCA 
risk among wine drinkers and drinkers with moderate alcohol intake was found in some 
studies.52, 113 A pooled analysis from the BEACON consortium found that there was little or no 
strong evidence that heavy alcohol consumption was associated with increased risk of 
esophageal adenocarcinoma or adjacent adenocarcinomas of the esophagogastric junction 
(ORs and 95%CIs for the highest frequency category [≥7 drinks/day] were 0.97 [0.68-1.36] and 
0.77 [0.54-1.10], respectively, for EA and adjacent adenocarcinomas of the esophagogastric 
junction, all compared to non-drinkers).52, 113 Additional studies are needed to further elucidate 
the association between alcohol consumption and EA/GCA. 
Dietary Fat. Dietary fat has been evaluated as a risk factor in previous studies, and the 
results were inconsistent.94-96 Some studies have not shown an association between dietary fat 
and EA whereas others suggested a positive association.94-96 However, it is possible that some 
important associations were masked due to the fact that most studies had not differentiated the 
various types of fatty acid.94 For instance, omega-3 and omega-6 are different types of 
polyunsaturated fatty acids.114-116 Omega-3 fatty acids may decrease cancer risk whereas 
omega-6 fatty acids may increase the risk.114-116 The large prospective cohort study, NIH-AARP 
study, has comprehensively investigated fat intake by various types, however, little or no 
association was found between dietary fat, regardless of the definitions used, and EA/GCA. 95 
More studies are needed to examine the association between various types of fat and EA/GCA.  
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Risk Reduction Factors. Fruits and vegetables are well-established risk reduction 
factors for EA/GCA.117-121 Other dietary factors, such as fiber intake122, dietary antioxidants 
(including vitamin C, vitamin E, β-carotene)94, 123-127, and folate94, 126, 127 have also been 
suggested to be risk reduction factors for EA/GCA. Non-steroidal anti-inflammatory drugs use is 
also established risk reduction factor for EA/GCA.128-130 Helicobacter Pylori infection has been 
evaluated as a risk factor in several studies, and perhaps, it is a risk reduction factor.131-134  
Dietary Intake.  
Fruits and Vegetables. Studies suggested that fruit and vegetable intake were inversely 
associated with EA and GCA.117-121, 135 A recent meta-analysis reported an EA risk reduction of 
32% (summary RR and 95%CI, 0.68 [0.49-0.93]) at higher level of intake.121 The risk reduction 
remained when examining fruit and vegetables separately.121  
Fiber. The highest level of total fiber intake was associated with a 34% decreased EA 
risk (summary OR and 95%CI 0.66[0.44-0.98]), as suggested in a recent meta-analysis.122  
Dietary Antioxidants. Studies suggested that dietary antioxidants, including β-carotene, 
vitamin C, and vitamin E, were associated with reduced risk of EA/GCA.94, 123-127, 135 A meta-
analysis has reported a 54% reduction in EA risk with higher intake of β-carotene (summary OR 
and 95%CI, 0.46 [0.36-0.58]).124 Higher intake of vitamin C was also suggested to be associated 
with a 35% reduction in risk of EA/GCA in a meta-analysis (summary OR and 95%CI, 0.65 
[0.54-0.78].123 As summarized in a recent qualitative review, vitamin E was found to be inversely 
associated with EA risk reductions ranging from 10-87% in case-control studies.135  
Folate. Studies reported that higher dietary folate intake was associated with an 
approximately 30-50% decreased EA risk.94, 126, 127, 135  
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Use. In a pooled analysis of NSAIDs 
use from BEACON studies, risks were reduced for the association between NSAID use and EA 
(OR and 95%CI, 0.68[0.56-0.83]) and esophagogastric junctional adenocarcinoma (OR and 
95%CI, 0.83[0.66-1.03]).128 The reductions in risk were similar when examining the effect of 
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aspirin and non-aspirin NSAIDs intake respectively.128 The highest level of frequency (daily or 
more frequently) and the second highest level of frequency (occasionally-<daily) of NSAIDs use 
were associated with 44% and 34% reduction in risk of EA, respectively (ORs and 95%CIs were 
0.56 [0.43-0.73] and 0.66[0.44-1.00]).128 A meta-analysis also suggested that aspirin was 
associated with reduced risk of EA (OR and 95%CI, 0.64[0.52-0.79]) and GCA (OR and 95%CI, 
0.82 [0.65-1.04]).130 Similarly, non-aspirin NSAIDs were also associated with reduced risk of EA 
(OR and 95%CI, 0.65[0.50-0.85]) and GCA (OR and 95%CI, 0.80[0.67-0.95]).130 NSAID use has 
also been reported to reduce the risk of progression from BE to adenocarcinoma in a 
prospective study (HR and 95%CI, 0.32[0.14-0.76]).129  
Helicobacter Pylori (H. pylori) Infection. H. pylori is a bacterium that colonizes the human 
stomach, and is a major cause of non-cardia gastric cancer.32, 136 Several studies have reported 
that H. pylori infection was associated with reduced risk of EA/GCA.131-134 In an Australian, 
population-based study, H. pylori infection was inversely associated with risks of EA (OR and 
95%CI, 0.45[0.30-0.67]) and esophagogastric junctional adenocarcinoma (OR and 95%CI, 
0.41[0.27-0.60]).132 If H. pylori infection is indeed a risk reduction factor for EA, then the 
increase in EA incidence in Western population may, perhaps, be partly explained by the 
decline in rate of H. pylori infection.137 The potential underlying mechanisms might be: (1) H. 
pylori may decrease risk of acid reflux by reducing acid production in the stomach;138 and/or (2) 
H. pylori may reduce EA risk by decreasing the production of the hormone ghrelin, which may in 
turn lead to lower rates of obesity.51, 139 
Summary. Risk factors for EA/GCA include GERD66, Barrett’s esophagus70-73, obesity51, 
89-92, cigarette smoking87, 89, 105-107, and some demographic factors (age, sex, race/ethnicity, and 
SES) 82, 85-89. Risk reduction factors include fruits and vegetables117-121, dietary fiber122, dietary 
antioxidants (including vitamin C, vitamin E, β-carotene) and folate94, 123-127, NSAIDs use,128-130 
and, perhaps, H. pylori infection.131-134 These factors were important to consider when 
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examining the association between sugar/carbohydrate and development of EA/GCA since they 
are potential confounders, mediators, or effect measure modifiers. 
 
Esophageal and Gastric Cardia Adenocarcinoma Prognostic Factors  
Many factors (e.g. demographics, clinical characteristics, epidemiologic factors) have 
been explored as prognostic factors for EA/GCA, and a few were found to be predictors of 
prognosis.140-146 However, most factors are still understudied and more studies are needed to 
elucidate or confirm the association, especially with epidemiologic factors.  
Demographic Factors. Two previous studies suggested that age, sex, and education 
were not associated with EA/GCA survival.140, 142 In a recent US study, sex was also not 
associated with superficial (T1) esophageal adenocarcinoma survival, however, age was 
associated with a decrease in overall survival (HR and 95%CI, 1.71 [1.36–2.17], per 10-year 
increment).141 Higher household income (≥$15,000) was found to be associated with better EA 
and GCA survival (HRs and 95%CIs were 0.64 [0.48-0.87] and 0.62 [0.43-0.88], for EA and 
GCA, respectively, both compared to <$15,000 income).140 
Clinical Characteristics. Tumor site has been suggested to be associated with long-
term survival.142 Cancer in the esophagus has a better prognosis than in cardia, possibly due to 
earlier detection resulted from post-BE surveillance and earlier presentation of dysphagia in 
cancers of esophagus.142 Stage was found to be a predictor of prognosis in several studies,140, 
142 regardless of the staging systems used. In the US Multi-Center Study, compared with distant 
stage, patients diagnosed at regionalized, localized, or unknown stage have a better survival 
(the corresponding HRs and 95%CIs were 0.32 [0.23-0.45], 0.22 [0.15-0.31], and 0.42 [0.30-
0.60] for EA and 0.48 [0.35-0.65], 0.18 [0.11-0.31], and 0.54 [0.35-0.83] for GCA.140 Tumor 
grade was not associated with overall survival in EA and GCA.140, 141 
Presence of lymphovascular invasion was found to be associated with reduced overall 
survival in patients with T1 EA.141, 143 In a recent US study, an HR of 1.95 was reported (95%CI, 
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1.18–3.22) for overall mortality in patients with T1 EA.141 Leggett et al. reported that deep 
margin involvement by carcinoma was associated with reduced overall survival in patients with 
T1 EA (HR and 95%CI, 1.67[1.09–2.55]).141 In a prospective study, Dexter et al. found that the 
presence of tumor cells within 1 mm of the circumferential margin was an independent 
prognostic factor for survival.144  
Medical Conditions/Treatment Several studies have found that patients with BE 
appeared to have a better survival compared to those without BE.147-149 It was also suggested in 
several studies that tumors without BE may not be of a different origin, but were larger tumors 
that may have overgrown areas of BE.150-152 Therefore, the better prognosis among patients with 
a prior diagnosis of BE is likely due to the fact that tumors with BE were detected earlier and 
have a smaller diameter.142 
Gastroesophageal reflux disease may be associated with EA and GCA survival 
(unadjusted HRs and 95%CIs were 0.80 [0.63-1.03] and 0.74 [0.56-0.98] for EA and GCA, 
respectively, both compared to those without GERD).140 More studies are needed to further 
elucidate the association. In addition, the presence of dysphagia at diagnosis was associated 
with an advanced disease and worse prognosis.142  
Another important prognostic factor is treatment. Analysis based on SEER data 
suggested that patients who received esophagectomy had longer overall survival than those 
without esophagectomy.145 In another population-based study, patients who received 
chemoradiation had a better survival among both patients treated with surgery (HR and 95%CI, 
0.56 [0.35-0.89]) and patients treated without surgery (HR and 95%CI, 0.62 [0.43-0.92]).146 
Epidemiologic Factors. In the US Multi-Center Study, cigarette consumption, alcohol 
use, and NSAIDs use were found to be not associated with EA and GCA survival. 140 Overweight 
individuals (BMI 25-29.9 kg/m2) appeared to have better overall survival compared to individuals 
who were normal weight (BMI <25 kg/m2) or obese (BMI ≥30 kg/m2).140 BMI appeared to be 
possibly associated with EA survival (the HRs and 95%CIs were 0.78 [0.55-1.12] and 0.67 
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[0.51-0.88], for obese and overweight, respectively, both compared to those who were normal 
weight) but not GCA survival (the unadjusted HRs and 95%CIs were 0.98 [0.67-1.43] and 0.90 
[0.67-1.20], for obese and overweight, respectively, both compared to normal weight 
participants).140 Weight loss is another important prognostic factor. Several studies have 
suggested that weight loss was associated with advanced disease and worse prognoses.142, 153-
155  
Summary. Income140, BE147-149, presence of dysphagia140, 142, BMI140, weight loss142, 153-
155, tumor location (tubular esophagus)142, stage140, 142, presence of lymphovascular invasion141, 
surgical margin involvement by carcinoma141, and treatment145, are likely to be prognostic 
factors of EA/GCA survival. These factors were important to consider when examining the 
association between sugar/carbohydrate and EA/GCA survival since they are potential 
confounders, mediators, or effect measure modifiers. If sugar/carbohydrate intake is found to 
increase the risk of mortality after EA/GCA diagnosis, we would be able to improve EA/GCA 
survival by limiting sugar/carbohydrate intake. 
 
Sugar/Carbohydrate and Esophageal/Gastric Cardia Adenocarcinoma: Potential Biologic 
Mechanisms 
The three main types of carbohydrate are starch, fiber, and sugar.156 Based on chemical 
structure, starch and fiber are complex carbohydrate, whereas sugar is simple carbohydrate. 156 
Starch is digestible carbohydrate, and foods high in starch include grains (wheat, rice, oats, 
barley, etc.), starchy vegetables (potatoes, taro root, etc.), and legumes (beans, peas, etc.).156 
Fiber is indigestible carbohydrate, and foods high in fiber include vegetables, fruits, whole grains, 
legumes, and nuts. Sugar includes naturally occurring sugar (e.g., sucrose, fructose, and 
glucose in fruits and vegetables, lactose in milk, etc.) and sugar added during food processing 
and preparation (table sugar, syrup, molasses, honey, etc.).156 
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Sugar/Carbohydrate and EA/GCA Development.  Frequent over-consumption of high-
sugar/carbohydrate food may lead to hyperglycemia and hyperinsulinemia. Chronically elevated 
levels of insulin reduces the production of IGF binding proteins, which normally bind to IGF-I 
and inhibit its action, and consequently result in elevated circulating concentration of bioactive 
IGF-I.17-19 Several cellular actions of IGF-I support tumor growth, including mitogenic action, 
inhibition of apoptosis, induction of vascular endothelial growth factor, and promoting tumor cell 
migration.17, 19, 20 In addition, postprandial hyperglycemia (especially acute glucose fluctuations) 
may increase oxidative stress and subsequently promote carcinogenesis.157-160 The potential 
biological mechanism between sugar/carbohydrate consumption and EA/GCA development is 
illustrated in Figure 1.2. 
Human studies suggested associations between blood glucose/insulin resistance and 
development of esophageal cancer.161, 162 A large prospective cohort study in Korean reported 
that men with a fasting serum glucose level 110-125 mg/dL had increased risk of esophageal 
cancer after controlling for multiple confounders (HR and 95%CI, 1.37 [1.20-1.80], compared to 
men with a fasting serum glucose level <90 mg/dL).161 A US study of patients with BE has 
reported that homeostatic model assessment scores (a measure of insulin sensitivity) were 
significantly associated with increased risk of EA 3 years and 6 years after entering the study, 
and full follow-up (HRs and 95%CIs, 2.45 [1.43–4.19], 2.06 [1.30–3.25] and 1.64 [1.08–2.48], 
respectively).162 
Obesity is a known risk factor for EA, and one of the potential mechanisms is that 
obesity promotes carcinogenesis by inducing insulin resistance.102 However, a large population-
based case-control study in UK found that type 2 diabetes mellitus (T2DM) was associated with 
increased BE, after controlling for obesity (as measured by BMI) and other risk factors (smoking 
and GERD) (OR and 95%CI, 1.49 [1.16-1.91]).163 The study suggested that obesity may not 
necessarily mediate the association between sugar/carbohydrate intake and BE-EA cancer 
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continuum. However, it was not a formal test of mediation, and therefore the results need to be 
interpreted cautiously. 
Foods with carbohydrate increase postprandial blood glucose level and insulin secretion 
at different rates, depending on the chemical structure of the carbohydrate, presence of fiber 
and other nutrients, and the food processing method. For instance, fiber has the ability to alter 
the glycemic response by slowing digestion and absorption of carbohydrates. 164 Starch, which 
contains a large number of monosaccharide molecules, takes longer to break down and digest, 
and therefore enters the bloodstream slowly and causes a flattened blood glucose rise.156 Sugar 
that is naturally found in whole food, is a simple carbohydrate with one or two molecules, usually 
comes with vitamins, minerals, protein, and fiber, which may slow down the absorption of sugar 
and moderate its impact on blood glucose. In contrast, added sugar, which is added during food 
processing and preparation, can be quickly digested and absorbed, and thus usually causes a 
spike in blood glucose and insulin level. Therefore, it is commonly accepted that refined sugars 
affect glucose metabolism more detrimentally than naturally occurring sugar, starches and 
fiber.165 Evidence from studies of both humans and animals suggested that the h igh intake of 
refined sugars had deleterious effects on glucose metabolism.165 For example, the quick 
absorption of a large amount of refined sugar may lead to acute glucose fluctuations, which may 
increase the oxidative stress and thereby promoting carcinogenesis.159, 160, 166 
Glucose, sucrose, and fructose are common types of sugar that are found naturally in 
many fruits and vegetables.156 Sucrose is also found in table sugar, brown sugar, and molasses, 
all of which are added to foods and drinks during food processing and preparation. Fructose is 
also often added to beverages and prepared foods in the US in the form of high fructose corn 
syrups (HFCS).167 Sucrose is broken down into free glucose and free fructose after 
consumption.168 Glucose is the body’s preferred energy source, and it stays in the blood stream 
for cells in the body to use.168 In contrast, fructose is cleared on its first pass through the liver.168 
Fructose is almost exclusively metabolized in the liver, and has a different metabolic pathway 
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than glucose.169, 170 The metabolism of fructose may contribute to metabolic abnormalities by 
inducing impaired liver functions, generation of reactive oxygen species, reduced copper, and 
elevated iron.165 Evidence from biomedical and epidemiologic studies suggested that the high 
intake of fructose increases the risk of metabolic syndrome.171 The different metabolisms of 
glucose, sucrose, and fructose may have different impact on carcinogenesis.  
High levels of postprandial glucose and insulin were suggested to be involved in the 
etiology of several obesity-related cancers, including colorectal cancer, breast cancer, and 
endometrial cancer.172-175 In particular, a carbohydrate-rich diet may play a role in the etiology of 
colon cancer by inducing hyperglycemia and hyperinsulinemia.172, 173 Sucrose and fructose were 
suggested to be associated with increased colonic proliferation and aberrant crypt foci in most 
animal experiments, possibly by interfering with levels of blood glucose/triglycerides (directly or 
through insulin and others).176 Epidemiologic studies indicate a suggestive association between 
sugar/carbohydrate intake and colorectal cancer.176 A recent meta-analysis suggested that high 
intake of added sugar was associated with colorectal cancer (pooled RR and 95%CI, 1.25 [1.03-
1.50], the highest vs. the lowest added sugar intake).177 However, the results were subject to 
presence of high heterogeneity (I2 = 74%, P < 0.001), and the only cohort study included 
suggested a non-association.177 It was also suggested in this study that glycemic index was 
associated with colorectal cancer (pooled RR and 95%CI, 1.17 [1.00–1.36], the highest vs. the 
lowest category of dietary glycemic index).177 This positive association was also subject to 
presence of heterogeneity (I2 = 73%, P < 0.001), with the pooled estimate among cohort studies 
suggesting non-association (pooled RR and 95%CI, 1.01 [0.88–1.16]).177 These epidemiologic 
studies suggested that high levels of glucose and insulin might be involved in the etiology of 
obesity-related cancer, which further supported the potential mechanisms underlying the 
association between high sugar/carbohydrate consumption and development of EA/GCA.  
Sugar/Carbohydrate and EA/GCA Survival. Glucose acts as an energy source for the 
development of cells.178 Tumor cells have increased glucose uptake and elevated glycolysis 
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compared to benign cells of the same tissue.178 It was suggested that many cancer cells may 
express insulin receptors (IRs) and show hyperactivation of the IGF-I receptor (IGF-IR) - IR 
pathway.178 A clinical study reported that 75% (90 out of 120) of adenocarcinoma specimens 
displayed overexpression of IGF-IR, and suggested that IGF-IR was associated with reduced 
overall survival for EA (p = 0.05).179 Chronically elevated levels of blood glucose, insulin, and 
IGF-I were suggested to worsen the outcome in cancer patients.178 The Korean study 
mentioned above suggested that among a cohort of men, who were initially cancer-free at 
baseline and with a fasting serum glucose level of >140 mg/dL had increased risk of death from 
esophageal cancer (HR and 95%CI, 1.44 [1.08-1.93], compared to men who were initially 
cancer-free at baseline and with a fasting serum glucose level <90 mg/dL).161 Studies have 
proposed to restrict carbohydrate intake/control hyperglycemia as an adjunct to cancer 
therapy.178, 180, 181 An animal study suggested that a high amylose containing low carbohydrate 
slowed tumor growth.181  
Summary. Sugar/carbohydrate intake may promote carcinogenesis by inducing 
hyperglycemia and hyperinsulinmia.17-20 This potential mechanism supports the hypothesis of a 
positive association between sugar/carbohydrate intake and risk of developing EA/GCA, and 
survival among EA/GCA cases. If an association between sugar/carbohydrate intake and risk of 
developing EA/GCA, or survival among EA/GCA cases, is found, there could be potential to 
reduce disease burden by limiting sugar/carbohydrate intake. 
 
Epidemiology of Sugar/Carbohydrate and Esophageal/Gastric Cardia Adenocarcinoma 
Several studies, as summarized in Tables 1.1-1.5 and Figure 1.3 have investigated on 
the association between sugar/carbohydrate consumption and Barrett’s esophagus and/or 
esophageal adenocarcinoma, and different measures of the exposure were used, including food 
groups, total carbohydrate, starch, total sugar, sucrose, fructose, added sugar, glycemic index, 
and glycemic load.182-193 In total, there were one study examined the association with risk of 
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developing BE, one study examined the association with EA survival, and several studies 
examined the association with risk of developing EA/GCA. 
Total Carbohydrate. As shown in Table 1.1, most of the few studies that have 
examined total carbohydrate with EA report an inverse association.182, 183, 187, 189, 190 A case-
control study conducted in Northern Ireland and the Republic of Ireland recruited 224 BE cases 
and 260 population controls.182 It was found in this Irish study that total carbohydrate intake was 
inversely associated with risk of EA (OR and 95%CI, 0.39[0.16-0.98], >=340.3 g/day vs. <264.8 
g/day).182 Another population-based case-control study examining this association was 
conducted in Australia, and had recruited 299 EA cases, 337 gastro-esophageal junction 
adenocarcinoma (EGJAC) cases, 245 squamous cell carcinoma cases, and 1507 controls. 183 
This Australian study suggested that total carbohydrate intake possibly decreased the risk of EA 
and EGJAC (ORsQ4th v s. Q1st and 95%CIs, 0.79[0.49-1.25] and 0.75[0.48-1.16], respectively).
183 A 
nationwide Swedish population-based case-control study also suggested that a high dietary 
proportion of carbohydrates decreased the risk of EA and EGJAC (OR and 95%CI, 0.50[0.34 -
0.73]).194  
The inverse association may be driven by the risk reduction effect of fiber, which is also 
part of total carbohydrate. Fiber has several anti-carcinogenic properties, such as binding or 
diluting bile acids, reducing levels of circulating markers of inflammation, removing carcinogenic 
cells from the esophageal epithelium, altering the glycemic response by slowing digestion and 
absorption of carbohydrates.164, 195 Many studies have reported an inverse association between 
fiber and EA/GCA, and a recent meta-analysis suggested that the highest level of total fiber 
intake was associated with a 34% decreased EA risk (summary OR and 95%CI 0.66[0.44-
0.98]).122 
Starch. As shown in Table 1.2, three studies have examined the association between 
starch intake and EA.182, 183, 189 Two of the three studies suggested an inverse association,182, 183 
whereas one study suggested no reduced association.189 The latter is a multicenter study, which 
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suggested that starch intake was positively associated with GCA but not EA (ORs and 95%CIs 
were 1.12[0.80-1.59] and 1.61[1.14-2.28] for EA and GCA, respectively).189 In the Australian 
study, the starch intake was possibly associated with decreased risk of EGJAC (ORQ4th v s. Q1st 
and 95%CI, 0.71 [0.48-1.06]), although the association with esophageal adenocarcinoma was 
attenuated (ORQ4th vs. Q1st and 95%CI, 0.80 [0.53-1.21]).
183 The Irish study reported possible 
association between starch and EA, although the CI was wide and include the null value (OR 
and 95%CI, 0.76 [0.36-1.60], ≥175.0g/day vs. <136.0g/day).182 Similarly, the inverse association 
may also be somewhat affected by the risk reduction effect of fiber, which often occurs in whole 
grains and starchy vegetables, and thus is associated with starch intake. 
Total Sugar. As shown in Table 1.3, two case-control studies and one cohort study 
have examined the association between total sugar intake and EA, and the results were 
inconsistent.182-184 In the Australian study, a positive association was suggested between total 
sugar intake and EA, although the OR might be imprecise (ORQ4th vs. Q1st and 95%CI, 1.22 [0.77-
1.92]), but not with EGJAC (ORQ4th v s. Q1st and 95%CI, 0.88 [0.58-1.35]).
183 In contrast, the Irish 
study suggested an inverse association between total sugar intake and EA (OR and 95%CI, 
0.47 [0.21-1.05], ≥162.9g/day vs. <115.9g/day).182 In the prospective cohort study of NIH-AARP 
(452 esophageal cancer cases including both EA and ESCC), total sugar intake was possibly 
associated with increased risk in women (HRT3rd v s.T1st and 95%CI, 1.41[0.69-2.91]), but not in 
men (HRQ5th v s.Q1st and 95%CI, 1.09 [0.73-1.63]).
184 The naturally occurring sugar intake is highly 
associated with intake of fruits and vegetables, which was suggested to have a risk reduction 
effect on EA/GCA (due to the large variety of potentially anticarcinogenic substances contained 
in fruits and vegetables).121, 196, 197 Therefore, the association between total sugar intake and 
EA/GCA may be affected by the effect of fruits and vegetable intake.  
Individual Sugar Components (Fructose, Sucrose). Two studies have examined the 
association between individual sugar components and esophageal cancer (see Table 1.3).184, 
190 Fructose, but not sucrose, was possibly associated with risk of esophageal cancer. 184, 190 In 
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the NIH-AARP Diet and Health Study, total fructose was possibly weakly associated with 
increased risk of esophageal adenocarcinoma in men (HRQ5th vs.Q1st and 95%CI, 1.28 [0.87-1.87]) 
and in women (HRT3rd v s.T1st and 95%CI, 1.71 [0.83-3.54]), whereas sucrose was possibly not 
associated with esophageal cancer either in men (HRQ5th v s.Q1st and 95%CI, 1.05 [0.75-1.48]) or 
in women (HRT3rd v s.T1st and 95%CI, 1.13[0.58-2.20]).
184 
Added Sugar. Only one study has examined the association between added sugar 
intake and EA, and a positive association was found (see Table 1.3).184 In the NIH-AARP Diet 
and Health Study, added sugar increased the risk of esophageal adenocarcinoma by 62% 
(HRQ5th v s.Q1st and 95%CI, 1.62[1.07-2.45]).
184  
Sweetened Desserts/Beverages. Only one study to-date has examined the association 
between desserts and EA development, and no association was found (see Table 1.4).186 This 
study is a population-based case-control study that recruited 124 EA cases, 124 distal stomach 
adenocarcinoma cases, and 449 control subjects.186 They found that high-dessert dietary 
pattern was possibly associated with risk of EA, however the CI was wide and included null 
value (ORs and 95%CIs, 1.6 [0.39, 6.9]).186 Desserts intake was possibly not associated with 
EA (ORQ4th v s. Q1st and 95%CI, 1.1 [0.44, 2.7]).
186 In their study, desserts were simply defined as 
doughnuts, cookies, cakes, pastry, and pie, and thus they may not be able to capture intake of 
all added sugar.186 A small hospital-based case-control study conducted in Athens suggested 
that sugars and syrups were positively associated with EA incidence (ORQ5th vs.Q1st and 95%CI, 
1.23 [0.96-1.59]).190   
Three large population-based case-control studies and one prospective cohort study 
have examined the association between carbonated soft drink intake and the risk of EA and 
GCA/EGJAC.188, 191-193 The two case-control studies in Sweden and Australia, and the 
prospective cohort study in the US (NIH-AARP) suggested no association,188, 192, 193 In contrast, 
one US multicenter case-control study suggested an inverse association between carbonated 
soft drink intake and EA (OR and 95%CI, 0.47[0.29-0.76]).191  
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One small US case-control study has examined the association between sugary 
beverages and EA survival, and found increased but non-significant association (HRs and 
95%CIs: soft drinks, 1.84 [0.92-3.68]; fruit juices, 1.60 [0.79-3.25]; sugar from soft drinks and 
fruit juices, 1.51 [0.72–3.16]; sugar from all sweetened beverages, 1.44 [0.57–3.62]).198 
Glycemic Index and Glycemic Load. Glycemic index and glycemic load are proxy 
measures designed to estimate the effect of diet on blood glucose levels.199, 200 The glycemic 
index is an assessment of foods based on the incremental glucose response and insulin 
demand they produce for a given amount of carbohydrate.201, 202 Glycemic load estimates the 
impact of carbohydrate consumption using the glycemic index while taking into account the 
amount of carbohydrate that is consumed.199 Glycemic index is calculated by summing the 
products of the carbohydrate content per serving for each food times the average number of 
servings of that food per day, times its glycemic index (based on International Tables of 
glycemic index,203 all divided by the total amount of carbohydrate daily intake.199, 200 Glycemic 
load is calculated by multiplying the carbohydrate content of each food by its glycemic index, 
then multiplying this value by the frequency of consumption and summing the values from all 
foods.199  
One cohort study and two case-control study have examined the association between 
glycemic index/glycemic load and EA (See Table 1.5).182, 183, 185 In another analysis based on 
data collected in NIH-AARP Diet and Health Study, glycemic index possibly increased risk of 
esophageal cancer in both men and women (RRsQ5th v s. Q1st and 95%CIs, 1.50[1.10-2.05] and 
1.27[0.60-2.67], respectively).185 Glycemic load was found to possibly decrease the risk of 
esophageal cancer in men but increase risk of esophageal cancer in women (RRsQ5th vs. Q1st and 
95%CIs, 0.65[0.38-1.11] and 2.18[0.57-8.32], respectively).185 In the Australian study, glycemic 
index and glycemic load were found to possibly slightly decrease the risk of EA (ORsQ4th vs. Q1st 
and 95%CIs, 0.82 (0.54-1.26) and 0.73 (0.48-1.13), for glycemic index and glycemic load, 
respectively).183 The associations with EGJAC were similar.183 In the Irish study, glycemic index 
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was possibly associated with increased risk of EA, although the OR might be imprecise (OR and 
95%CI, 1.44 (0.78-2.63), ≥44.2 vs. <36.5).182 Glycemic load was possibly not associated with 
risk of EA (OR and 95%CI, 1.11 [0.53-2.32], ≥135.6 vs. <102.3).182  
The inconsistent results may be partially explained by the use of the glycemic 
index/glycemic load measures themselves. The use of glycemic index/glycemic load has been 
controversial.204 First, glycemic index/glycemic load pertains only to individual foods but not food 
combinations, and therefore may not accurately reflect the glycemic effect of a mixed meal.205, 
206 In addition, the effects of concurrent intake of non-carbohydrate contents on blood glucose 
are not taken into account in the current formula for glycemic index/glycemic load calculation.207 
Therefore, postprandial insulin responses may not be proportional to the carbohydrate content 
of a meal. One study suggested that the postprandial glycemic response to foods explains only 
approximately 23% of the variation in insulin levels.208 A recent study suggested that glycemic 
index may even fail to capture the variation in insulin response between slowly digestible starch 
and rapidly digestible starch.209  Further, considering the effect on a mixed meal, the glycemic 
index/glycemic load may be more appropriated when derived from 24-hour diet recall than a 
FFQ, however, FFQ was used to measure food intake in the previous studies examining the 
association between glycemic index/glycemic load and BE/EA/GCA. In addition, glycemic index 
measurements have been found to differ both between individuals and within individuals,210 
which may lead to exposure misclassifications. This may also partly explain the inconsistency in 
the results. 
Effect Measure Modification by Obesity or GERD. Two studies have previous 
examined the EMM by obesity (measured by BMI).182, 184 The Irish study and the NIH-AARP 
study reported difference in effect estimates respectively for glycemic index and added sugar 
stratified by obesity, but the interaction was not statistically significant,182, 184 mostly likely due to 
the small number of cases within ideal-weight (n=51 and n=54 in the two studies, respectively), 
which was the high-risk subgroup. I hypothesized that obesity and sugar were two individual 
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markers of the insulin resistance/IGF-1 pathway – and I assumed that obesity would be the 
stronger marker. Thus, I expected the effects would be most evident among those that were of 
ideal weight rather than among those who were obese. This hypothesis is consistent with 
observations from studies of sugar with other tumors (such as breast cancer) 211, and the Irish 
study182. Other than this dissertation, no studies to-date have examined effect measure 
modification by GERD. 
Summary. Total carbohydrate and starch have been reported to decrease the risk of 
developing EA.182, 183, 187, 189, 190 Added sugar and fructose were found to increase the risk of EA 
in one study.184 Studies examining the associations between glycemic index/glycemic load, total 
sugar, desserts, carbonated soft drinks, and EA/GCA were inconsistent.  This may be partly 
explained by consideration of fruits and vegetables intake as confounders, accuracy of glycemic 
index/glycemic load measures, or perhaps the different distribution of the sources of sugar 
intake by sex or geographic regions (e.g., Australia, US, European countries).  In addition, 
previous studies either had incomplete consideration or inadequate assessment of dietary 
sugar/carbohydrate intake182-193, or had inadequate consideration of a specific underlying 
biological model which would influence consideration of specific confounders and effect 
modifiers to include in a statistical model182-193. Further, no population studies have considered 
the impact of these dietary compounds on mortality among EA/GCA patients.182-193 Therefore, 
additional studies are needed to further explore the association between sugar/carbohydrate 
and EA/GCA, by including multiple measures of sugar/carbohydrate exposure, establishing 
statistical models on the basis of the underlying biological mechanism, and fully examining the 
impact on the entire cancer development continuum. Although the different distribution of the 
sources of sugar intake by sex or geographic regions cannot be examined in this study due to 
power considerations and the similar origins of the four parent study populations, the different 
distribution of the sources of sugar intake may be resolved by using multiple measures of 
sugar/carbohydrate exposure. 
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Precursor Lesion of Esophageal Adenocarcinoma: Barrett’s Esophagus  
The only known potential precursor of EA is BE.212 Barrett's esophagus is characterized 
by a metaplastic change in the epithelium of the distal esophagus from the normal squamous 
mucosa to intestinalized columnar mucosa.213 The process of metaplastic change is intestinal 
metaplasia, which is thought to arise as a protective response (wound healing) to chronic tissue 
inflammation, such as the inflammation caused by GERD.214 GERD develops when gastric acid 
and other gastric contents flow back into the esophagus and subsequently causes troublesome 
symptoms or complications.64 GERD is common in Western population, and the prevalence of 
GERD symptoms in the US is approximately 20%.65 BE is thought to progress to 
adenocarcinoma in a stepwise process from metaplasia to low-grade dysplasia, to high-grade 
dysplasia, to adenocarcinoma.76 It is unknown if BE is a necessary precursor to all EA cases.213 
GCA was postulated to arise from intestinal metaplasia of the gastric cardia following a similar 
process, however, it is still controversial.215-219  
Study of the precursor lesion of BE could help to elucidate the etiology and progression 
of EA, which could help to reduce the burden of disease associated with these fatal tumors. For 
example, if we are able to demonstrate an association between the exposure of interest and BE 
development, there would be potential to implement prevention strategies early in disease onset 
to reduce the risk of developing lethal cancers. Another strength of studying BE, besides the 
potential to prevent cancers early in disease onset, is that studying relative shorter time period 
(from normal tissue to precursor lesion vs. from normal tissue to adenocarcinoma) may mitigate 
recall error and loss to follow-up.220 The exposure of interest may be found to be associated with 
BE only, adenocarcinoma only, or both. These three conditions separately indicate the exposure 
of interest was involved in early stage of carcinogenesis (cancer initiation/promotion), later stage 
of carcinogenesis (cancer progression), or both. Therefore, studying BE helps us better 
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understand the underlying mechanisms, and identify at which stages along the cancer 
development continuum the exposure of interest plays a role.  
Summary. The development of EA appears to be a stepwise process, from normal 
squamous mucosa to GERD, followed by BE development (metaplasia  low-grade dysplasia 
 high-grade dysplasia), and then to neoplasia.76 GCA was postulated to arise from intestinal 
metaplasia of the gastric cardia following a similar process, however, it is still controversial.215-219 
It is of great importance to study the precursor lesion of BE since it may offer potential to 
implement prevention strategies early in disease onset to reduce the risk of developing lethal 
cancers. 
 
Epidemiology of Barrett’s Esophagus   
Because BE is frequently asymptomatic and many individuals live with undiagnosed BE 
for years, the actual incidence and prevalence of BE is largely unknown.221 BE develops more 
frequently in older people, and the most common age for BE diagnosis was approximately 65 
years old.222 Similar to EAC, BE is more common in Caucasians and men, compared to non-
Caucasians and women.222 
Several studies have tried to evaluate the prevalence of Barrett’s esophagus.223-226 One 
of the best estimates was from a Swedish study which surveyed a random sample (n = 3000) of 
the adult population in two municipalities and applied upper endoscopy in a random subsample 
(n = 1000).223 BE prevalence was estimated to be 1.6% in general Swedish population.223 The 
prevalence of BE were 2.3% and 1.2% in those with reflux symptoms and those without, 
respectively (P =0.18).223 Another study conducted among adults from two Italian villages 
reported a BE prevalence of 1.3%, which is similar to that of Swedish study.224 However, 
estimates reported from US studies were relatively high.225 Based on a simulation model, an 
estimated BE prevalence of 5.6% (5.49-5.70%) best aligns with the EA incidence in SEER 
registry.225 A screening test for BE in colonoscopy patients reported a BE prevalence of 6.8%.226 
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Consistent to the Swedish study, BE prevalence did not differ by heartburn symptoms. 226 The 
BE prevalence were 8.3% and 5.6% among those who had a history of any heartburn and those 
who had never had a heartburn, respectively (p=0.1).226  
Studies suggested that the incidence of BE had increased during the past few decades.8-
12 Although the increased use of diagnostic upper gastrointestinal endoscopy may contribute to 
the observed increase in BE diagnosis, a true increase in the incidence of BE seems likely since 
the increase was found to be independent of the increasing endoscopies. 8-10 A cohort study in 
the Netherlands reported that the incidence of BE increased from 14.3 per 100,000 person -
years in 1997 to 23.1 per 100,000 person-years in 2002 in the general population, independent 
of the number of endoscopies that were performed.8 The incidence of BE increased most 
markedly in men younger than 60 years, followed by women younger than 60 years.8 Another 
study based on the national registry data of the Netherlands reported a 40% increase in the 
incidence of BE among men and a 17% increase among women during 1992-2003.10 They also 
found that the increase in the number of BE diagnoses was greater than the increase in the total 
number of biopsies during the same time period.10 Consistent to the Netherlands studies, a 
population-based study in Northern Ireland reported an average annual increase of 159% in BE 
incidence from the time period of 1993-1997 to 2002-2005, which exceeded the corresponding 
increases in rates of endoscopies and biopsies.9 
Summary. The incidence of EA/GCA has been increasing rapidly in the US and other 
Western countries in the past 40 years.1-5 BE is the only known precursor of EA.8-12 Therefore, it 
is important to identify risk factors for BE so that relevant risk reduction strategies could be 
implemented.  
 
Barrett’s Esophagus Risk Factors and Risk Reduction Factors 
Because Barrett’s esophagus is the only precursor lesion of EA, identifying risk factors 
for BE may offer potential to reduce the risk of developing lethal cancers. Many factors (e.g. 
32 
 
demographics, clinical characteristics, epidemiologic factors) have been explored as the risk 
factors for BE, as presented in the sections below. 
Medical Conditions. Several studies suggested that GERD/reflux symptom is a major 
risk factor for BE.227-230 Both frequency and duration of GERD were found to be associated with 
risk of developing BE.229, 230 In a study of GERD patients, individuals who had heartburn more 
often than once a week were more likely to have BE (OR and 95%CI, 3.01 [1.35–6.73]).231 In a 
prospective, community-based study, compared with individuals with GERD symptoms for < 1 
year, the ORs for BE in individuals with GERD symptoms for 1-5 years and >10 years were 3.0 
and 6.4, respectively.229 
Demographic Factors. Several demographic factors, including age, sex, and 
race/ethnicity, were shown to be associated with risk of developing BE.222, 231-234 Studies 
examining the association between SES and risk of developing BE yield inconsistent results.  
Age, Sex, Race/Ethnicity. The risk of developing BE was found to increase steadily with 
age, to a peak at 61-70 years of age.222 In a study of GERD patients, it was found that the risk of 
BE increased 30% (95%CI, 1.02–1.67) for each 10-year increment of age.231 Many studies have 
found that BE occurred more commonly in men than women.222, 232-234 A meta-analysis of the 
men to women sex ratio for Barrett's esophagus reported an overall pooled estimate of 1.96 
(95%CI, 1.77-2.17).234 BE was found to be more common among non-Hispanic whites than 
other race/ethnicity groups.222, 232 In a large community-based study, the annual incidence of BE 
was found to be highest among non-Hispanic whites (39 per 100,000 member-years), followed 
by Hispanics (22 per 100,000 member-years), Asians (16 per 100,000 member-years), and 
blacks (6 per 100,000 member-years).222 
Socioeconomic Status. In a US study conducted in northern California, individuals with 
at least a college education was found to have a decreased risk of developing BE compared to 
individuals with high school or less education (OR and 95%CI, 0.47 [0.27-0.82]).235 Individuals 
with an income of >$75,000 were at a possibly decreased risk of developing BE (OR and 95%CI, 
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0.68 [0.42-1.11]), compared to individuals with an income of <$50,000.235 This finding is 
consistent with the inverse association between low income, low education, and EA/GCA risk.89 
However, in a large study conducted in United Kingdom, it was found that patients with BE were 
more likely to be of higher SES (ORT1st v s. T3rd and 95%CI: 1.58 [1.16, 2.15]).
232 Further studies 
are needed to examine the association between SES and BE. 
Epidemiologic Factors. Obesity is a well-established risk factor for BE. 98, 99, 236, 237 
Cigarette smoking and alcohol has been evaluated as risk factor, but the results were 
inconsistent. Dietary fat has also been evaluated as a risk factor, but the results were 
inconsistent.  
Obesity. Abdominal obesity was found to be a more important risk factor for 
development of BE than BMI.98, 99, 236, 237 In a pooled analysis from BEACON consortium, waist 
circumference, after adjusting for BMI, was found to be associated with risk of developing BE 
among both men and women (ORsQ4th v s.Q1st and 95%CIs were 2.24 [1.08 to 4.65] and 3.75 [1.47 
to 9.56], respectively, among men and women).236 In contrast, BMI was moderately associated 
with risk of BE, and the association was attenuated after adjusting for waist circumstance. 236 
Cigarette Smoking.  Cigarette smoking is a risk factor for BE, although the association 
was not very strong.106, 238-240 A pooled analysis of BEACON studies suggested that cigarette 
smoking was associated with BE (OR and 95%CI: 1.67 [1.04-2.67], ever vs. never).238  In 
addition, the results suggested increased risk of BE with increased pack-years smoked (ORs 
and 95%CIs were 1.59 [1.02-2.47], 1.44 [0.78-2.69], 1.99 [1.21-3.29], and 1.92 [1.05-3.51] for 
pack-years of smoking <15, 15-<30, 30-<45, and ≥45, respectively, all compared with non-
smokers).238 
Alcohol. Earlier studies suggested alcohol as a potential risk factor for BE223, 227, 230, 241 
whereas recent large population-based studies reported no overall effect of alcohol intake on 
the risk of BE.52, 235, 242  In addition, several studies found that wine consumption was associated 
with a decreased risk of BE.52, 235, 242 A recent pooled analysis of BEACON studies suggested 
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that alcohol consumption was possibly associated with decreased risk of BE (summary OR and 
95%CI: 0.77 [0.60-1.00], any consumption vs. none).242 Among alcohol types, wine consumption 
was found to be associated with a decreased risk of BE (OR and 95%CI, 0.71 [0.52-0.98], any 
consumption vs. none).242 Further studies are needed to further elucidate the associations 
between alcohol and BE. 
Dietary Fat. The association between fat intake and BE was under studied and the 
results were inconsistent. An Irish study found that neither intake of total fat nor any specific fat 
subtype were associated with the risk of BE.96 In contrast, a US study found saturated fat was 
associated with an increased risk of LSBE (OR and 95%CI, 1.05 [1.01–1.09], per gram per 
day).115 Jiao et al. also reported an increased risk associated with saturated fat (OR and 95%CI, 
1.80 [1.02–3.16]).243  
Risk Reduction Factors. Many dietary factors, such as fruits and vegetables intake106, 
120, 244, 245, and dietary antioxidants (including vitamin C, vitamin E, β-carotene)125, 127, 244, have 
been examined as risk reduction factors. Besides dietary factors, NSAIDs use246, 247 and 
Helicobacter Pylori infection133, 248, 249 have also been examined as risk reduction factors. 
Dietary Intake.  
Fruits and Vegetables. Studies suggested that intake of fruits and vegetables combined 
were associated with decreased risk of BE.106, 120, 244, 245 Jiao et al. found that vegetables 
consumption was possibly associated with a risk reduction of 39% (ORT3rd v s. T1st and 95%CI, 
0.61 [0.35-1.06]).127 They also found a possibly inverse association between fruit intake and BE, 
although the OR might be imprecise (ORT3rd v s. T1st and 95%CI, 0.81 [0.47-1.38]).
127  Similarly, 
reduced risk of BE was found to be possibly associated with vegetables consumption (HRQ5th vs. 
Q1st and 95%CI, 0.66 [0.43, 1.01]), but not fruits consumption (HRQ5th vs. Q1st and 95%CI, 1.00 
[0.65-1.53]) among men in a Dutch study.250 A recent qualitative review summarized that fruits 
and vegetables consumption or vegetables consumption alone was associated with reduced 
risk of EA.135 
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Dietary Antioxidants. Several studies suggested risk reductions associated with intake of 
vitamin C, vitamin E, and/or β-carotene.125, 127, 244 Jiao et al. found that vitamin E intake was 
associated with a 54% of reduced risk (ORT3rd v s. T1st and 95%CI, 0.46 [0.26-0.83]), and β-
carotene intake was possibly associated with a 36% of reduced risk (ORT3rd vs. T1st and 95%CI, 
0.64 [0.37-1.10]).127  Intake of vitamin C was possibly inversely associated with risk of BE, 
although the OR might be imprecise (ORT3rd v s. T1st and 95%CI, 0.79 [0.47-1.34]).
127 Kubo et al. 
found that dietary intake of vitamin C, vitamin E, and β-carotene were all inversely associated 
with the risk of BE (ORsQ4th v s. Q1st and 95%CIs were 0.48 [0.26-0.90], 0.25 [0.11-0.59], and OR 
0.56 [0.32-0.99], respectively).244 
NSAIDs Use. Some studies found an inverse association between Aspirin/NSAIDs use 
and BE,246, 247 whereas other studies found no association.251, 252 A US study by Schneider et al. 
reported that individuals with BE were less likely to use aspirin than population controls (OR and 
95%CI, 0.59 [0.39-0.87]).247 A study conducted in Ireland reported that use of aspirin and 
NSAIDs were both associated with a reduced risk of BE [ORs and 95%CIs were 0.53 [0.31-0.90] 
and 0.40 [0.19-0.81], respectively].246 In contrast, a US study of individuals who underwent 
esophagogastroduodenoscopy suggested that the use of any NSAIDs, aspirin, and non-aspirin 
NSAIDs were not associated with BE (ORs and 95%CIs were 0.89 [0.75-1.28], 1.16 [0.90-1.51], 
0.88 [0.55-1.39], respectively, all compared to never use).252 The association between NSAIDs 
and BE remains to be examined. 
H. Pylori  Infection. Several studies have found that H. Pylori infection was inversely 
associated with BE.133, 248, 249 A meta-analysis by Rokkas et al. reported an inverse association 
between and BE (pooled OR and 95%CI, 0.64 [0.43-0.94]).133 The association was stronger with 
H. pylori cagA+ strain (pooled OR and 95%CI, 0.39 [0.21-0.76]).133 
Summary. Risk factors for BE include GERD227-230, abdominal obesity98, 99, 236, 237, 
cigarette smoking106, 238-240, and some demographic factors (age, sex, race/ethnicity)222, 232. Risk 
reduction factors include vegetables127, dietary antioxidants (including vitamin C, vitamin E, β-
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carotene)125, 127, 244, and perhaps H. Pylori infection133, 248, 249. These factors were important to 
consider when examining the association between sugar/carbohydrate and development of BE 
since they are potential confounders, mediators, or effect measure modifiers. 
 
Sugar/Carbohydrate and Barrett’s Esophagus: Biologic Mechanisms 
Similarly to the carcinogenesis of EA, sugar/carbohydrate intake may also promote 
pathogenesis of the precursor lesion (Barrett’s esophagus), by inducing hyperglycemia and 
hyperinsulinmia. Greer et al. reported that both serum insulin and IGF-I levels were associated 
with an increased risk of BE (ORsT3rd v s.T1st and 95%CIs, 2.02 [1.15-3.54] and 4.05 [2.01-8.17], 
respectively).253 Level of insulin-like growth factor binding protein-1 (which normally binds to 
IGF-I and inhibits its action) was reported to be inversely associated with risk of BE (ORsT3rd 
v s.T1st and 95%CIs, 0.11 [0.05- 0.24]).
253 All of these results suggested that the insulin/IGF 
signaling pathways have a role in BE development.253 A large population-based case-control 
study in UK found that type 2 diabetes mellitus was associated with an increase of 49% in BE, 
after controlling for BMI, smoking, and GERD (OR and 95%CI, 1.49 [1.16-1.91]), which also 
suggested that metabolic pathways related to type 2 diabetes mellitus may play a role in BE 
pathogenesis.163 In addition, the metabolic syndrome was found to be associated with the length 
of BE.254 In an Irish study, 60% of patients with LSBE had metabolic syndrome, compared with 
23.8% of patients with short-segment BE (SSBE) (P = 0.007).254 A higher proportion of patients 
with LSBE had hyperinsulinemia compared with SSBE (20% vs. 0%, P=0.026).254 The results 
suggested that the metabolic syndrome may be associated with the continuum of metaplasia 
within BE, and may play a role in the development of BE.254 
Summary. Sugar/carbohydrate intake may promote BE pathogenesis by inducing 
hyperglycemia and hyperinsulinmia. Therefore the hypothesis of a positive association between 
sugar/carbohydrate intake and risk of developing BE is biologically plausible. An association 
between sugar/carbohydrate intake and BE development would suggest potential to 
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implementing prevention strategies early in disease onset to reduce the risk of developing lethal 
cancers. 
 
Epidemiology of Sugar/carbohydrate and Barrett’s Esophagus  
Other than this dissertation, only one epidemiologic study has examined the association 
between sugar/carbohydrate intake and risk of developing Barrett’s esophagus (see Tables 1.1-
1.5).182 This case-control study recruited 224 BE cases and 260 population controls from 
Northern Ireland and the Republic of Ireland.182 The study considered total carbohydrate, total 
sugars, glycemic index, glycemic load, and starch as exposures, and found none of these 
exposures were associated with risk of BE.182  
Summary. The only study (other than this dissertation) that has investigated the 
association between sugar/carbohydrate intake and risk of BE found non-association.182 
However, in their study, total sugar did not distinguish between added sugar and naturally 
occurring sugar, which may have confounded the results since naturally occurring sugar were 
mostly from fruits and vegetables which may reduce risk of BE.182 Therefore, further studies are 
needed to investigate the association between sugar/carbohydrate intake and BE.  
 
 
Specific Aims  
This dissertation aimed to determine the role of dietary sugar/carbohydrate intake along 
the cancer development and progression continuum (normal tissue  BE  EA/GCA  
mortality). By examining if dietary sugar/carbohydrate intake increases the risk of developing BE, 
risk of developing or dying from EA/GCA, optimal times were identified and targeted for 
intervention with a specific risk reduction strategy. 
The hypotheses of this dissertation were as follows.  
Hypothesis 1: Sugar/carbohydrate intake is positively associated with BE incidence, 
EA/GCA incidence, and/or mortality among patients diagnosed with EA/GCA. The strength of 
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this association will vary by: (1) the definition of sugar/carbohydrate intake (defined as 
sweetened desserts, sweetened beverages, sweetened desserts/beverages; added sugar; total 
sugar; sugar components (dietary free glucose, free fructose, sucrose); glycemic index, 
glycemic load; starch; or total carbohydrate) in this ancillary analysis because of the differences 
in foods and beverages that contribute to different type of sugar; and (2) disease type 
(BE/EA/GCA); and (3) disease severity of BE (LSBE/SSBE). 
Hypothesis 2: Obesity is an effect measure modifier of added sugar - risk of developing 
EA/GCA association. Obesity is a major risk factor for BE and EA/GCA, and was associated 
with an increased EA/GCA risk of 2-5 times.53, 92 Obesity may enhance tumor development by 
increasing the risk of insulin resistance and metabolic syndrome.255 Because diets high in 
sugar/carbohydrate may also promote carcinogenesis by inducing chronic hyperglycemia and 
hyperinsulinemia, it is important to explore if there exists any complicated associations, such as 
effect modification by obesity. Among the multiple measures of sugar/carbohydrate intake, 
added sugar is most likely to interact with obesity, since added sugar can be quickly 
digested/absorbed and cause peaks and valleys in levels of blood glucose and insulin. 
Therefore, the EMMs will be examined in the association between added sugar and EA/GCA 
incidence. However, if other measures are found to be more strongly associated with the 
outcome, those measures will be used instead of added sugar.   
 Hypothesis 3: GERD is an effect measure modifier of the added sugar – risk of 
developing EA/GCA association. One major risk factor for BE and EA/GCA is GERD, which was 
associated with an increased EA risk of 2.6-7 times, depending on the severity and duration of 
the disease.53, 66 However, only 10% of patients with chronic GERD develop BE or EA/GCA.53 It 
is likely that GERD interacts with other risk factors to increase tumor risk.53 This study will 
explore if there is interaction between GERD and added sugar (which has a greater impact on 
levels of blood glucose and insulin and is most likely to interact with GERD among multiple 
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measures of sugar/carbohydrate intake). Similarly, if other measures are found to be more 
strongly associated with the outcome, those measures will be used instead of added sugar.    
Specific Aim 1: Determine if sugar/carbohydrate intake is associated with the 
development of BE. Specific Aim 1A. Explore whether overweight/obesity (measured by BMI) 
or GERD are EMMs of the significant associations between sugar/carbohydrate intake and risk 
of BE development.  
Specific Aim 2:  Determine if sugar/carbohydrate intake is associated with the 
development of EA/GCA. Specific Aim 2A. Explore whether overweight/obesity (measured by 
BMI) or GERD are EMMs of the significant associations between sugar/carbohydrate intake and 
risk of EA/GCA development.  
Specific Aim 3:  Determine if sugar/carbohydrate intake is associated with survival 
following a diagnosis of EA/GCA.   
 
Summary  
The incidence of esophageal and gastric cardia adenocarcinoma has been increasing in 
the US and many Western countries since 1970s.2-5 However, the prognosis remains poor, with 
a 5-year survival of less than 20%.6, 7 The only known potential precursor lesion of esophageal 
adenocarcinoma is Barrett’s esophagus, which has also been increasing.8-12 Studying the 
cancer development and progression continuum (normal tissue  precancerous condition  
invasive cancer  mortality) would provide a better understanding of the underlying 
mechanisms and the potential to implement prevention strategies early in disease onset to 
reduce the risk of developing lethal cancers. Epidemiologic studies suggest that diabetes 
mellitus/metabolic syndromes/insulin resistance are associated with esophageal and gastric 
cancer and BE.58-62, 161-163 Long-term consumption of diets high in sugar/carbohydrate are 
thought to induce hyperglycemia and hyperinsulinemia, stimulate insulin/IGF-I signaling 
pathways, and subsequently increase risk of esophageal/gastric cancer and BE.17-20 Previous 
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studies examining the associations between sugar/carbohydrate intake and risk of BE-EA/GCA 
continuum have several limitations. The studies either had incomplete consideration or  
inadequate assessment of dietary sugar/carbohydrate intake,182-193 or had inadequate 
consideration of a specific underlying biological model which would influence consideration of 
specific confounders and effect modifiers to include in a statistical model.182-193 In addition, no 
population studies have considered the impact of these dietary compounds on mortality among 
EA/GCA patients.182-193  
By pooling data from four US studies (with similar dietary intake methods), this 
dissertation is the largest study to date to examine the association between sugar/carbohydrate 
intake and BE-EA/GCA cancer continuum (including 513 BE cases, 513 EA cases, 538 GCA 
cases, and 2579 controls).118, 244, 245, 256 This study is innovative because it is the first study to 
consider the entire cancer continuum from BE, invasive cancer by subtype, to mortality. Further, 
multiple measures of exposure were used to capture the complexity of sugar/carbohydrate 
intake. In addition, this study is the first to explore if the sugar/carbohydrate-cancer association 
is modified by GERD.  
This dissertation is significant because Barrett’s esophagus and esophageal 
adenocarcinoma have been increasing rapidly and the survival of esophageal and gastric cardia 
adenocarcinoma remains poor. Further, the currently well-established risk factors are difficult to 
modify. Some risk reduction factors, such as NSAIDs use and perhaps H. Pylori infection, may 
not be applicable as intervention strategies since the risks may outweigh the benefits given the 
rarity of EA/GCA in general population and the harmful side effects (H. Pylori infection as a 
major risk factor for gastric cancer and NSAIDs use is associated with increased bleeding and 
perforation in gastrointestinal tract, increased risk of cardiovascular disease, etc. ).257-259 In 
contrast, dietary sugar intake is a modifiable factor, and limiting dietary sugar intake would also 
provide the potential to reduce the risks of obesity and obesity-related diseases. 
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In sum, this dissertation investigated the association between dietary 
sugar/carbohydrate intake and the Barrett’s esophagus-esophageal/gastric cardia 
adenocarcinoma continuum. If I demonstrate an association between sugar/carbohydrate intake 
and risk of developing BE, risk of developing or dying from esophageal and gastric cardia 
adenocarcinoma, there would be potential to implement prevention strategies (e.g. limiting 
sugar/carbohydrate intake) to reduce the disease burden associated with these lethal cancers.  
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Figure 1.1. Worldwide sugar and sweetener consumption (grams per capita per day) in 2004 vs. age-standardized 
incidence rate (per 100,000) of esophageal adenocarcinoma in men.13, 15 
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Figure 1.2. Potential mechanisms underlying the association between sugar/carbohydrate 
intake and the Barrett’s esophagus-adenocarcinoma development. 
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Death Normal tissue 
Esophageal and Gastric 
Cardia 
Adenocarcinoma 
Barrett’s 
Esophagus 
N=1 study  
 Total sugar, total 
carbohydrate, glycemic index, 
glycemic load 
o No association. 
Muholland 2009 
 
N=12 studies Inconsistent study quality, exposure measures and results 
across studies 
 Added sugar ↑ risk. Tasevska 2012 
 Total fructose possibly ↑ risk. Tasevska 2012 
 Total sugar 
o Possibly ↑ risk. Lahmann 2014 (EA only), Tasevska 2012 
(w omen only)  
o ↓ risk. Mulholland 2009. 
 Sugars & syrups ↑ increased risk. Tzonou 1996 
 Desserts no association. Chen 2002. 
 Carbonated soft drink  
o No association. Lagergren 2006, Ibiebele 2008, Ren 2010 
o ↓ risk . Mayne 2006 
 Starch 
o ↓ risk. Lahmann 2014, Mulholland 2009 
o Possibly ↑ risk. Mayne 2001 
 Total carbohydrate,  
o ↓ risk. Lahmann 2014, Mulholland 2009, Chen 2002, Mayne 
2001, Tzonou 1996 
 GI 
o ↑ risk. Mulholland 2009, George 2009.  
o Possibly ↓ risk. Lahmann 2014.  
 GL 
o no association. Mulholland 2009  
o Possibly ↓ risk. Lahmann, 2014, George 2009 (men only).  
N=1 study 
 Soft drinks, fruit 
juices, sugar from 
soft drinks and fruit 
juices, sugar from 
all sweetened 
beverages 
o Possibly ↑ risk 
of mortality. 
Miles 2016 
Figure 1.3. Epidemiologic studies supporting examination of the association between sugar/carbohydrate intake and the Barrett’s 
esophagus-adenocarcinoma continuum. 
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Table 1.1. Epidemiologic studies of total carbohydrate and development of Barrett's esophagus, esophageal and gastric cardia 
adenocarcinoma. 
Author, 
Year 
Population 
Study Design 
& Sample Size 
Cancer 
Continuum 
outcome 
Exposure 
Assessment & 
Categorization 
Results, Adjusted HR or OR (95%CI), & 
Covariates 
Mulholland 
et al., 2009 
Northern 
Ireland and 
the 
Republic of 
Ireland 
Case-control 
population-
based controls                 
220 BE cases;        
224 EA cases;       
256 controls 
BE 
101-item FFQ  
Categories 
Total carbohydrate                                                            
≥340.3g/day vs. <264.8g/day   1.02 (0.44-2.35)  
Covariates:                                                                     
age, sex, energy intake (standard multivariate 
approach), smoking status, BMI 5 years prior, 
education, occupation, alcohol, regular NSAID 
use, location 
Tzonou et 
al., 1996 
Athens 
Case-control 
hospital-based 
controls                    
56 EA cases;            
43 ESCC 
cases;          
200 controls 
EA 
115-item FFQ   
Quintiles 
Total carbohydrate                                       
(Q5 vs. Q1)    0.84( 0.59-1.19)                                                         
Covariates:                                                                     
gender, age, birthplace, schooling, height, 
analgesics, coffee drinking, alcohol intake, 
tobacco smoking and energy intake  
Mayne et 
al., 2001 
US: 
Multicenter 
EA study 
Case-control  
population-
based controls                 
282 EA cases;            
255 GCA cases;       
687 controls 
EA and 
GCA 
124-item FFQ   
Quartiles 
Total carbohydrate  (75th vs. 25th)                                    
EA: 0.34 (0.20–0.58)  GCA: 0.70 (0.42–1.17)   
Covariates:                                                                   
sex, site, age, race, proxy status, income, 
education, usual body mass index, cigarettes, 
years of consuming beer/wine/liquor, and 
energy intake (standard multivariate approach) 
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Table 1.1. (cont.) Epidemiologic studies of total carbohydrate and development of Barrett's esophagus, esophageal and gastric 
cardia adenocarcinoma. 
Author, Year Population 
Study Design 
& Sample Size 
Cancer 
Continuum 
outcome 
Exposure 
Assessment & 
Categorization 
Results, Adjusted HR or OR (95%CI), & 
Covariates 
Chen et al., 
2002 
US: eastern 
Nebraska 
Case-control  
population-
based controls                  
124 EA cases;             
154 stomach 
cancer cases;                          
449 controls 
EA 
A modified 
version of the 
short Health 
Habits and 
History 
Questionnaire 
Quartiles 
Total carbohydrate                                                                                 
Q4 vs. Q1             0.4 (0.2-0.9)                                         
Covariates:                                                                      
age, age squared, gender, respondent type, 
BMI, alcohol use, tobacco use, education level, 
family history of respective cancers, and 
vitamin supplement use 
Mulholland et 
al., 2009 
Northern 
Ireland and 
the 
Republic of 
Ireland 
Case-control 
population-
based controls                 
220 BE cases;        
224 EA cases;       
256 controls 
EA 
101-item FFQ  
Categories 
Total carbohydrate                                                                    
≥340.3 g/day vs. <264.8 g/day  0.39 (0.16-0.94)   
Covariates:                                                                          
age, sex, energy intake (standard multivariate 
approach), smoking status, BMI 5 years prior, 
education, occupation, alcohol, regular NSAID 
use, location 
Lahmann et 
al., 2014 
Australia 
Case-control 
population-
based controls                         
288 EA cases;      
318 EGJAC 
cases;       1490 
controls 
EA and 
EGJAC 
135-item FFQ  
Quartiles 
Total carbohydrate [g/day (median, range)]                                             
Q4 [273 (256-438)] vs. Q1 [196 (94-212)]:                                     
EA: 0.79 (0.49-1.25)    EGJAC: 0.75 (0.48-1.16)  
Covariates:                                                                         
age, sex, education, BMI, smoking, physical 
activity, lifetime mean alcohol intake, acid reflux 
symptoms in last 10 years, non-steroidal anti-
inflammatory drug use, presence of diabetes, 
total fruit intake (except for fiber intake), red 
meat, processed meat, and total energy 
(nutrient residual model) 
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Table 1.2. Epidemiologic studies of starch and development of Barrett's esophagus, esophageal and gastric cardia adenocarcinoma. 
Author, 
Year 
Population 
Study Design 
& Sample Size 
Cancer 
Continuum 
outcome 
Exposure 
Assessment & 
Categorization 
Results, Adjusted HR or OR (95%CI), & 
Covariates 
Mulholland 
et al., 
2009 
Northern 
Ireland and 
the 
Republic of 
Ireland 
Case-control 
population-
based controls                 
220 BE cases;        
224 EA cases;       
256 controls 
BE 
101-item FFQ  
Categories 
Starch                                                                                            
≥175.0 g/day vs. <136.0 g/day  1.08 (0.52-
2.22)                                                                     
Covariates: age, sex, energy intake 
(standard multivariate approach), smoking 
status, BMI 5 years prior, education, 
occupation, alcohol, regular NSAID use, 
location 
Mayne et 
al., 2001 
US: 
Multicenter 
EA study 
Case-control  
population-
based controls                 
282 EA cases;            
255 GCA 
cases;        
687 controls 
EA and 
GCA 
124-item FFQ   
Quartiles 
Starch (75th vs. 25th)                                                             
EA: 1.12 (0.80-1.59)    GCA: 1.61 (1.14-
2.28)  Covariates: sex, site, age, race, proxy 
status, income, education, usual body mass 
index, cigarettes, beer/wine/liquor 
consumption, and energy intake (standard 
multivariate approach) 
Mulholland 
et al., 
2009 
Northern 
Ireland and 
the 
Republic of 
Ireland 
Case-control 
population-
based controls                 
220 BE cases;        
224 EA cases;       
256 controls 
EA 
101-item FFQ  
Categories 
Starch                                                                                           
≥175.0g/day vs. <136.0g/day   0.84 (0.40-
1.76)  Covariates: age, sex, energy intake 
(standard multivariate approach), smoking 
status, BMI 5 years prior, education, 
occupation, alcohol, regular NSAID use, 
location 
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Table 1.2. (cont.) Epidemiologic studies of starch and development of Barrett's esophagus, esophageal and gastric cardia 
adenocarcinoma. 
Author, 
Year 
Population 
Study Design 
& Sample Size 
Cancer 
Continuum 
outcome 
Exposure 
Assessment & 
Categorization 
Results, Adjusted HR or OR (95%CI), & 
Covariates 
Lahmann 
et al., 2014 
Australia 
Case-control 
population-
based controls                         
288 EA cases;      
318 EGJAC 
cases;       1490 
controls 
EA and 
EGJAC 
135-item FFQ  
Quartiles 
Starch [g/day (median, range)]                                             
Q4 [128 (116-249)] vs. Q1 [74 (31-85)]:                                     
EA: 0.80 (0.53-1.21)   EGJAC: 0.71 (0.48-
1.06)  Covariates: age, sex, education, BMI, 
smoking, physical activity, lifetime mean 
alcohol intake, acid reflux symptoms in last 
10 years, non-steroidal anti-inflammatory 
drug use, presence of diabetes, total fruit 
intake (except for fiber intake), red meat, 
processed meat, and total energy (nutrient 
residual model) 
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Table 1.3. Epidemiologic studies of sugar and development of Barrett's esophagus, esophageal and gastric cardia adenocarcinoma. 
Author, Year Population 
Study Design 
& Sample Size 
Cancer 
Continuum 
outcome 
Exposure 
Assessment & 
Categorization 
Results, Adjusted HR or OR (95%CI), & 
Covariates 
Mulholland et 
al., 2009 
Northern 
Ireland and 
the 
Republic of 
Ireland 
Case-control 
population-
based controls                 
220 BE cases;        
224 EA cases;       
256 controls 
BE 
101-item FFQ  
Categories 
Total sugar                                                                                 
≥162.9g/day vs. <115.9g/day    1.12 (0.53-2.37)  
Covariates:                                                                   
age, sex, energy intake (standard multivariate 
approach), smoking status, BMI 5 years prior, 
education, occupation, alcohol, regular NSAID 
use, location 
Mulholland et 
al., 2009 
Northern 
Ireland and 
the 
Republic of 
Ireland 
Case-control 
population-
based controls                 
220 BE cases;        
224 EA cases;       
256 controls 
EA 
101-item FFQ  
Categories 
Total sugar                                                                                  
≥162.9g/day vs. <115.9 g/day   0.43 (0.19-0.94)  
Covariates:                                                                            
age, sex, energy intake (standard multivariate 
approach), smoking status, BMI 5 years prior, 
education, occupation, alcohol, regular NSAID 
use, location 
Tasevska et 
al.,2012 
US: NIH-
AARP 
study 
Cohort study        
435674 
participants 
aged 50-71 
years              
452 esophageal 
cancer cases, 
7.2 years of 
follow up 
Esophageal 
cancer 
(including 
both EA 
and ESCC) 
124-item FFQ  
Quintiles for 
men Tertiles for 
women 
Total sugar                                                                              
Men: Q5 vs. Q1: 1.09 (0.73-1.63)                             
Women: T3 vs. T1: 1.41 (0.69-2.91)                                         
Covariates:                                                                           
age, BMI, family history of cancer, marital 
status, smoking, race, education, physical 
activity, energy intake (nutrient density 
method), alcohol intake, and vegetables intake. 
Additionally adjusted for red meat, beta-
carotene and vitamin C intake for women 
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Table 1.3. (cont.) Epidemiologic studies of sugar and development of Barrett's esophagus, esophageal and gastric cardia 
adenocarcinoma. 
Author, Year Population 
Study Design 
& Sample Size 
Cancer 
Continuum 
outcome 
Exposure 
Assessment & 
Categorization 
Results, Adjusted HR or OR (95%CI), & 
Covariates 
Lahmann et 
al., 2014 
Australia 
Case-control 
population-
based controls                         
288 EA cases;      
318 EGJAC 
cases;       1490 
controls 
EA and 
EGJAC 
135-item FFQ  
Quartiles 
Total sugar [g/day (median, range)]                                             
Q4 [168 (148-395)] vs. Q1 [90 (25-106)]:                                     
EA: 1.22 (0.77-1.92)  EGJAC: 0.88 (0.58-1.35)  
Covariates:                                                                    
age, sex, education, BMI, smoking, physical 
activity, lifetime mean alcohol intake, acid reflux 
symptoms in last 10 years, non-steroidal anti-
inflammatory drug use, presence of diabetes, 
total fruit intake (except for fiber intake), red 
meat, processed meat, and total energy 
(nutrient residual model) 
Tzonou et 
al., 1996 
Athens 
Case-control 
hospital-based 
controls                    
56 EA cases;            
43 ESCC 
cases;          
200 controls 
EA 
115-item FFQ   
Quintiles 
Sucrose (Q5 vs. Q1)         0.93(0.68-1.26)                                                         
Covariates:                                                                         
gender, age, birthplace, schooling, height, 
analgesics, coffec drinking, alcohol intake, 
tobacco smoking and energy intake 
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Table 1.3. (cont.) Epidemiologic studies of sugar and development of Barrett's esophagus, esophageal and gastric cardia 
adenocarcinoma. 
Author, Year Population 
Study Design 
& Sample Size 
Cancer 
Continuum 
outcome 
Exposure 
Assessment & 
Categorization 
Results, Adjusted HR or OR (95%CI), & 
Covariates 
Tasevska et 
al.,2012 
US: NIH-
AARP 
study 
Cohort study        
435674 
participants 
aged 50-71 
years              
452 esophageal 
cancer cases, 
7.2 years of 
follow up 
Esophageal 
cancer 
(including 
both EA 
and ESCC) 
124-item FFQ  
Quintiles for 
men Tertiles for 
women 
Added sugar                                                                                  
Overall (EA only): Q5 vs. Q1: 1.62 (1.07-2.45)                                
Men:      Q5 vs. Q1: 1.44 (1.03-2.03)                             
Women: T3 vs. T1:  1.04 (0.56-1.93)                                         
Total fructose                                                                                 
Men:      Q5 vs. Q1: 1.28 (0.87-1.87)                             
Women: T3 vs. T1:  1.71 (0.83-3.54)                                       
Sucrose                                                                                               
Men:      Q5 vs. Q1: 1.05 (0.75-1.48)                             
Women: T3 vs. T1:  1.13 (0.58-2.20)                    
Covariates:                                                                      
age, BMI, family history of cancer, marital 
status, smoking, race, education, physical 
activity, energy intake (nutrient density 
method), alcohol intake, and vegetables intake. 
Additionally adjusted for red meat, beta-
carotene and vitamin C intake for women. 
Additionally adjusted for fruit without juice and 
fruit juice for added sugar 
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Table 1.4. Epidemiologic studies of sweetened desserts/beverages and development of Barrett's esophagus, esophageal and gastric 
cardia adenocarcinoma. 
Author, Year Population 
Study Design & 
Sample Size 
Cancer 
Continuum 
outcome 
Exposure 
Assessment & 
Categorization 
Results, Adjusted HR or OR (95%CI), & 
Covariates 
Tzonou et 
al., 1996 
Athens 
Case-control 
hospital-based 
controls                    
56 EA cases;            
43 ESCC cases;          
200 controls 
EA 
115-item FFQ   
Quintiles 
Sugars and syrups (Q5 vs. Q1)                                                         
1.23 (0.96-1.59)                                                        
Covariates:                                                                        
gender, age, birthplace, schooling, height, 
analgesics, coffee drinking, alcohol intake, 
tobacco smoking and energy intake 
Chen et al., 
2002 
US: eastern 
Nebraska 
Case-control  
population-
based controls                  
124 EA cases;             
124 distal 
gastric 
adenocarcinoma 
cases;                          
449 controls 
EA 
A modified 
version of the 
short Health 
Habits and 
History 
Questionnaire 
Quartiles 
Desserts: Q4 vs. Q1     1.1 (0.44-2.7)                                     
High dessert dietary pattern: 1.6 (0.39-6.9)                    
Covariates:                                                                         
age, sex, energy intake, respondent type, BMI, 
alcohol use, tobacco use, education, family 
history, and vitamin supplement use 
Lagergren et 
al., 2006 
Sweden 
Case-control  
population-
based controls                   
189 EA cases;            
262 GCA cases;          
820 controls  
EA and 
GCA 
FFQ                 
Categories  
Carbonated soft drinks  
(>6 times/week vs. none)          
EA: 0.89 (0.49 -1.64)     GCA: 1.09 (0.64 -1.85)     
Covariates:                                                                            
age and sex (matching factors), and adjusted 
for tobacco smoking status, alcohol use, 
socioeconomic status, and dietary intake of 
fruits and vegetables 
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Table 1.4.(cont.) Epidemiologic studies of sweetened desserts/beverages and development of Barrett's esophagus, esophageal and 
gastric cardia adenocarcinoma. 
Author, Year Population 
Study Design 
& Sample Size 
Cancer 
Continuum 
outcome 
Exposure 
Assessment & 
Categorization 
Results, Adjusted HR or OR (95%CI), & 
Covariates 
Mayne et al., 
2006 
US: 
Multicenter 
EA study 
Case-control  
population-
based controls                 
282 EA cases;            
255 GCA cases;       
687 controls 
EA and 
GCA 
124-item FFQ   
Quartiles 
Carbonated soft drink   (Q4 vs. Q1)                                                      
EA: 0.47 (0.29-0.76)   GCA: 0.74 (0.46-1.16)  
Covariates:                                                                     
age, sex, center, race, proxy interview status, 
average adult body mass index, mean caloric 
intake, consumption of beer/wine/liquor, 
consumption of meat, cigarettes per day, 
education, income, and frequency of reflux 
symptoms 
Ibiebele et 
al., 2008 
Australia 
Case-control  
population-
based controls                 
294 EA cases;            
325 EGJAC 
cases;          
1484 controls 
EA and 
EGJAC 
135-item FFQ 
Categories 
Carbonated soft drink (ever vs. never)                                                                         
EA: 1.06 (0.72-1.56)    EGJAC: 0.71 (0.51-0.99)                                                
Covariates:                                                                     
adjusted for age, gender, body mass index, 
heartburn and acid reflux symptoms, 
cumulative history of smoking in pack years, 
alcohol intake status, educational status, total 
energy intake, and total vegetable intake  
Ren et al., 
2010 
US: NIH-
AARP 
study 
Cohort study 
481563 
participants 
aged 50-71 
years              
305 EA cases, 
231 GCA cases 
EA and 
GCA 
124-item FFQ  
Categories 
Carbonated soft drinks  (≥1 can/day vs. none)                                                              
EA: 1.11 (0.66, 1.85)      GCA: 0.89 (0.55, 1.45)  
Covariates:                                                                          
age, sex, tobacco smoking, alcohol drinking, 
BMI, education, ethnicity, usual physical activity 
throughout the day, vigorous physical activity, 
and the daily intake of fruit, vegetables, red 
meat, white meat, and calories 
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Table 1.4.(cont.) Epidemiologic studies of sweetened desserts/beverages and development of Barrett's esophagus, esophageal and 
gastric cardia adenocarcinoma. 
Author, Year Population 
Study Design 
& Sample Size 
Cancer 
Continuum 
outcome 
Exposure 
Assessment & 
Categorization 
Results, Adjusted HR or OR (95%CI), & 
Covariates 
Miles et al., 
2016 
US Case-control  
population-
based controls 
with follow-up 
approach                 
42 EA deaths;     
74 EA cases.         
EA survival Brief Block FFQ   
Medians 
Soft drink   (upper vs. lower median)                                                      
EA: 1.84 (0.92-3.68) 
Fruit juice (upper vs. lower median)                                                       
EA: 1.60 (0.79-3.25) 
Sugar from soft drink and fruit juice 
(upper vs. lower median)                                                      
EA: 1.51 (0.72–3.16) 
Sugar from all sweetened beverages 
(upper vs. lower median)                                                      
EA: 1.44 (0.57–3.62) 
Covariates:                                                                     
age, gender, ethnicity, education, smoking, 
alcohol drinking, caloric intake, pathology type, 
and tumor differentiation grade. 
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Table 1.5. Epidemiologic studies of glycemic Index, glycemic Load, and development of Barrett's esophagus, esophageal and gastric 
cardia adenocarcinoma. 
Author, 
Year 
Populatio
n 
Study Design 
& Sample Size 
Cancer 
Continu
um 
outcome 
Exposure 
Assessment & 
Categorization 
Results, Adjusted HR or OR (95%CI), & 
Covariates 
Mulholland 
et al., 2009 
Northern 
Ireland and 
the 
Republic of 
Ireland 
Case-control 
population-
based controls                 
220 BE cases;        
224 EA cases;       
256 controls 
BE 
101-item FFQ  
Categories 
Glycemic index  ≥44.2 vs.<36.5    0.93 (0.53-1.64)      
Glycemic load ≥135.6 vs. <102.3  0.79 (0.39-1.58) 
Covariates:                                                                           
age, sex, energy intake (standard multivariate 
approach), smoking status, BMI 5 years prior, 
education, occupation, alcohol, regular NSAID use, 
location 
Mulholland 
et al., 2009 
Northern 
Ireland and 
the 
Republic of 
Ireland 
Case-control 
population-
based controls                 
220 BE cases;        
224 EA cases;       
256 controls 
EA 
101-item FFQ  
Categories 
Glycemic index  ≥44.2 vs. <36.5   1.52 (0.84-2.76)      
Glycemic load  ≥135.6 vs. <102.3 1.14 (0.55-2.33) 
Covariates:                                                                        
age, sex, energy intake (standard multivariate 
approach), smoking status, BMI 5 years prior, 
education, occupation, alcohol, regular NSAID use, 
location 
George et 
al., 2009  
US: NIH-
AARP 
study 
Cohort study        
446177 
participants 
aged 50-71 
years              
501 
Esophageal 
cancer cases, 
6.89 years of 
follow up 
Esophag
eal 
cancer 
(including 
both EA 
and 
ESCC) 
124-item FFQ  
Quintiles for men 
Tertiles for 
women 
Men:                                                                                             
Glycemic index  ≥44.2 vs. <36.5   1.52 (0.84-2.76)          
Glycemic load  ≥135.6 vs. <102.3 1.14 (0.55-2.33)  
Women:                                                                                      
Glycemic index  ≥44.2 vs. <36.5   1.52 (0.84-2.76)      
Glycemic load ≥135.6 vs. <102.3 1.14 (0.55-2.33) 
Covariates:                                                                           
age, race/ethnicity, education, marital status, body 
mass index, family history of any cancer, physical 
activity, smoking, alcohol consumption, and total 
energy intake. Additionally adjust for menopausal 
hormone therapy use for women 
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Table 1.5.(cont.) Epidemiologic studies of glycemic index, glycemic load, and development of Barrett's esophagus, esophageal and 
gastric cardia adenocarcinoma. 
Author, Year Population 
Study Design 
& Sample Size 
Cancer 
Continuum 
outcome 
Exposure 
Assessment & 
Categorization 
Results, Adjusted HR or OR (95%CI), & 
Covariates 
Lahmann et 
al., 2014 
Australia 
Case-control 
population-
based controls                         
288 EA cases;      
318 EGJAC 
cases;        
1490 controls 
EA and  
EGJAC 
135-item FFQ  
Quartiles 
Glycemic index [median, range]                                             
Q4 [57 (54-71)] vs. Q1 [46 (27-49)]:                                           
EA: 0.82 (0.54-1.26)    EGJAC: 0.78 (0.52-1.18)       
Glycemic load [median, range]                                           
Q4 [146 (135-259)] vs. Q1 [95 (21-105)]:                                           
EA: 0.73 (0.48-1.13)    EGJAC: 0.72 (0.49-1.08)   
Covariates:                                                                    
age, sex, education, BMI, smoking, physical 
activity, lifetime mean alcohol intake, acid reflux 
symptoms in last 10 years, non-steroidal anti-
inflammatory drug use, presence of diabetes, 
total fruit intake (except for fiber intake), red 
meat, processed meat, and total energy 
(nutrient residual model) 
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CHAPTER 2: METHODS 
 
Overview  
 This dissertation aimed to determine the associations between dietary intake of 
sugar/carbohydrate and (1) the risk of developing Barrett’s esophagus (BE), (2) the risk of 
developing esophageal and gastric cardia adenocarcinoma (EA/GCA), and (3) survival 
among esophageal and gastric cardia adenocarcinoma cases. To address these aims, this 
study incorporated both case-control and follow-up designs. The case-control design was 
used to address the research questions focused on determine whether sugar/carbohydr ate 
intake are associated with tumor development, and the follow-up approach was used to 
address the questions focused on survival. A pooled analysis of four existing United States 
(US) case-control studies1-4 was conducted to complete the following three steps. Step 1: 
Estimation of sugar/carbohydrate intake for each participant. The four study-specific food 
frequency questionnaires (FFQs) were linked with the University of Minnesota nutrient 
database. Frequency of consumption, serving size, and nutrient contents, were utilized to 
determine sugar/carbohydrate consumption. Step 2: Pooling of the sugar/carbohydrate 
intake across studies. Both study-specific quantiles and identical absolute intake cut-points 
across studies were used to identify intake categories. Step 3: Estimation of the odds ratios 
for the associations between sugar/carbohydrate intake and the risk of developing BE and 
esophageal/gastric cardia adenocarcinoma, and the hazard ratios for the association 
between sugar/carbohydrate intake and survival among cases of esophageal/gastric cardia 
adenocarcinoma. Whether risk varies by different measures of sugar/carbohydrate intake, 
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the severity of BE, or tumor location, were also explored. In addition, obesity and 
gastroesophageal reflux disease (GERD) were examined as effect measure modifiers 
(EMMs) in the associations between sugar/carbohydrate intake and BE-EA/GCA cancer 
continuum outcomes.  
 
Study Populations 
To address the study aims, I pooled resources from: (1) two parent case-control studies 
of EA/GCA (US Multi-Center Study1 and Los Angeles (LA) County Multi-Ethnic Case-Control 
Study2), both of which included a follow-up component to determine vital status; and (2) two 
parent case-control studies of BE (Study of Reflux Disease3, and Epidemiology and Incidence of 
BE Study4) (Table 2.1).  
The US Multi-Center Study was conducted in the state of Connecticut, a 15-county area 
of New Jersey, and a three-county area of western Washington State during 1993-1995.5 The 
LA Multi-Ethnic Case-Control Study was conducted in Los Angeles county during 1992-1997.2 
In both parent EA/GCA studies, cases were identified by the population-based cancer registries 
of their residing geographic areas.2, 5 Cases included those who were histologically diagnosed 
with invasive cancer of the esophagus or stomach during the study period.2, 5  
In US Multi-Center Study, cases were identified through rapid-reporting systems.5 
Eligible cases were English-speaking men and women, aged 30-79 years, who were diagnosed 
with primary invasive cancer of the esophagus or stomach between 1993 and 1995. 5 Initial 
subject selections were based on the review of pathology reports. Case-subject eligibility was 
determined based on a systematic review by the study pathologists using standardized criteria. 5 
The site of tumor origin was determined by review of pathology slides and medical records 
including endoscopic, surgical, and pathologic data.5 Population-based controls were frequency 
matched to the cases on 5-year age group and sex.5 Controls aged 30-64 years were identified 
by Waksberg's random digit-dialing (RDD) method, and random sampling of Health Care 
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Financing Administration rosters identified controls aged 65-79 years.5 The trained interviewers 
used a structured questionnaire to collect information on demographics, tobacco and alcohol, 
medical history, medication use, diet, etc. from cases/proxies and controls during a face-to-face 
interview.5 The average time to complete interview was 130 minutes.5 The average lengths of 
time between cancer diagnosis and the interview were 3.7 months and 8.5 months, when the 
interview was conducted with the case himself/herself and a proxy, respectively. 5 
In LA Multi-Ethnic Study, cases were men and women who were 30-74 years of age and 
were histologically diagnosed with first cancer of esophagus or stomach during 1992-1997.2 
Pathology reports were used to identify the histological classification or the sub-site of the 
gastric cancer.6 Controls were individually matched to cases by date of birth (±5 years) , sex, 
and race.2 A systematic algorithm based on the address of the case was used to seek 
neighborhood control for the case, and two controls were sought for each case whenever 
possible.2 An in-person interview was administered using structured questionnaire to collect 
information on smoking habits, alcoholic beverages intake, body size characteristics, family 
history, and diet history from cases or their next-of-kin (when patients were unable to participate 
the interview due to illness or death).2 
The Study of Reflux Disease was conducted in western Washington state.7 Eligible 
cases were selected from men and women, aged 20-80 years, without previously diagnosed BE 
who were undergoing an upper endoscopy for GERD symptoms at one of four community 
gastroenterology clinics between 1997 and 2000.7 A four-quadrant biopsy specimen was 
collected for consenting participants and was evaluated by one of three pathologists. 7 Cases 
were those with specialized intestinal metaplasia on at least one of the four biopsy specimens.7 
Population controls were selected among current residents of western Washington using a 
modified Waksberg RDD technique.7 Controls were individually matched to cases by age (±3 
years) and sex.7 Cases and controls underwent structured interviews by trained interviewer, and 
the interview covered demographics, tobacco and alcohol use, diet, medical history, and 
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medication use.7 Detailed diet information was collected through self-administered food 
frequency questionnaire.7 The length of interview was approximately 45 minutes.7 The interview 
occurred approximately 1-2 months after endoscopy for cases.7  
The Epidemiology and Incidence of BE Study was conducted within the Kaiser 
Permanente Northern California (KPNC, an integrated health services delivery organization) 
population.8 Cases and controls were selected from 18-79 years-old KPNC members who were 
continuously enrolled for at least 2 years before their index period, were able to understand 
spoken and written English, and met the case or control criteria.8 Cases were eligible KPNC 
members who were diagnosed with incident BE between 2002 and 2005.8 BE cases were 
identified using the International Classification of Disease, Ninth Revision code 530.2.8 To 
identify cases, endoscopy and pathology records of potentially eligible cases were reviewed by 
a gastroenterologist (DAC) to determine if they met the stated Barrett’s esophagus definition. 8 A 
separate review of pathologic slides was subsequently conducted by an independent 
gastrointestinal pathologist to evaluate for the presence of intestinal metaplasia. 8 Patients were 
excluded if they had a prior diagnosis of BE, only gastric-type metaplasia of the esophagus on 
all pathologic evaluations, didn’t have a biopsy specimen of esophagea l origin, or their columnar 
metaplasia demonstrated no features of intestinal metaplasia on any pathologic evaluation. 8 
Population controls were randomly selected from the KPNC members without previous 
diagnosis of Barrett’s esophagus using risk set sampling.8 An in-person interview was 
conducted by trained interviewers to collect information on GERD symptoms, tobacco and 
alcohol use, medication use, medical history, diet, and body size.8  
Demographics of the four parent studies have been previously published 5-8 and are 
summarized in Table 2.2-2.3. In all parent studies, the majority of participants were Caucasian 
males. For the parent studies of EA, the median age at diagnosis was 66 years old in US Multi-
Center Study and the mean age at diagnosis was 61 years old in LA Multi-Ethnic Study. For the 
parent studies of BE, the mean age at diagnosis were 55 and 62 years old, respectively, in 
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Study of Reflux Disease and Epidemiology and Incidence of BE Study. In all of the four parent 
studies, control participants were more likely to be well educated than cases.  
In addition to the inclusion criteria of the parent studies, only cases and controls that 
have completed a FFQ were included. Completed FFQs were obtained for: 96% of EA cases, 
98% of GCA cases, and 99% of controls in US Multi-Center Study; 93% of EA cases, 93% of 
GCA cases, and 96% of controls in LA Multi-Ethnic Study; 88% of BE cases and 86% of 
controls in Study of Reflux Disease; 93% of BE cases and 97% of controls in Epidemiology and 
Incidence of BE Study.1-8 Therefore, combining the two EA/GCA studies yielded 513 EA cases, 
538 GCA cases, and 2051 non-cases, combining the two BE studies yielded 513 BE cases and 
528 controls.1-4 Distribution of age, sex, race/ethnicity, and geographic area were not 
significantly different between the subjects included in the parent study and those that were 
included in this ancillary study.1-8 
The study population for this dissertation is of great generalizability. The four parent 
studies were either population-based1-3 or community-based case-control studies.8 This pooled 
analysis had a wide coverage of US population, which greatly extended the generalizability of 
this study compared to a single case-control study. In addition, the mortality data of EA/GCA 
patients allowed this study to be the first to determine if sugar/carbohydrate intake is associated 
with the entire cancer continuum. Because BE and EA/GCA are rare diseases, there are not 
many existing large studies of BE or EA/GCA in the US that have collected dietary data, and a 
pooled analysis of existing studies would be more efficient. Parent studies were selected from 
international Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON, formed in 2005 
by an international group of investigators to provide an open scientific forum for epidemiological 
research by facilitating the sharing of data across studies, http://beacon.tlvnet.net/), based on 
the similarities in: (a) targeting US source populations; (b) study designs employed; (c) structure 
of their food frequency questionnaires; and (d) covariate assessment through in -person 
interviews. The NIH-AARP cohort study in the BEACON consortium was not selected because 
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of the differences in study design and FFQ management.9  
 
Exposure Assessment 
All parent studies collected dietary information using a food frequency questionnaire 
(FFQ), during a structured interview by trained interviewers1, 2, 4 or a self-administered 
questionnaire.3 Relative validity of the FFQs utilized using diet records and/or multiple 24-hour 
recall instruments has been reported.10-15 The FFQs included both frequency and portion size 
questions in three of the studies. Only frequency questions were used in the US Multi-Center 
Study, however, medium serving sizes were assumed for the food items, which is consistent 
with Fred Hutchinson Cancer Research Center (FHCRC) procedures.  
The US Multi-Center Study utilized a 104-item FFQ that was modified from the FFQ 
developed by investigators at the FHCRC.1 Participants were asked to report their usual diet in 
the 3-5 years before diagnosis (cases) or interview (controls).1 The LA Multi-Ethnic Study 
utilized a 124-items FFQ developed by investigators at University of Hawaii.2 Cases were asked 
to report their diet in 1 year prior to diagnosis, and their matched controls were asked to report 
their diet at the same time as cases.2 The Study of Reflux Disease utilized the standard 131-
item FFQ developed by FHCRC.3 Both cases and controls were asked to report their dietary 
intake for the year before interview.3 The Epidemiology and Incidence of BE Study utilized a 
110-item FFQ (Block 98) to assess nutritional intake. The participants were asked to report their 
diet over the year before the index date.4 The index date was the date of diagnosis for cases.4 
For controls, the index date was the midpoint of the 2-3 month selection interval for the cases.4 
Although the parent studies utilized different FFQs, these FFQs share similarities in food items, 
FFQ structure, and nutrient database. Nutrient intake was assessed using University of 
Minnesota nutrient database (US Multi-Center EA/GCA Study and Study of Reflux Disease)3, 16 
or University of Hawaii nutrient database (LA Multi-Ethnic EA/GCA Study)2, both of which were 
developed based on United States Department of Agriculture (USDA) nutrient database. 
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Nutrient intake for Epidemiology and Incidence of BE Study was assessed using Block dietary 
nutrient system, 4 which is also similar to the USDA nutrient database.  
In US Multi-Center Study, in-person interviews (including target subjects and proxies) 
were conducted for 80.6% (n=554) of the eligible cases, and 73.7% (n=695) of the eligible 
controls.5 Interviews were administered to the closest next of kin (usually the spouse) when the 
patient was unable to be interviewed due to illness or death.5 Proxy interviews were conducted 
for 29.6% of the target cases, and 3.4% of the controls.5 In the LA Multi-Ethnic Study, interviews 
were conducted for 77% (947/1230) of the cases that were approached (77% for EA, 74% for 
GCA, and 78% for distal gastric cancer).6 In-person next of kin (NOK) interviews accounted for 
29% of interviews with case patients (66 for EA, 85 for GCA, and 125 for distal gastric cancer 
patients).6 Combining the two EA studies, complete dietary data were available for 1038 
EA/GCA cases and 2045 EA/GCA controls.1, 2 Previous studies have examined reliability and 
validity of proxy versus self-report for many factors including dietary intake.17, 18 The agreement 
between next-of-kin recall and self-report was shown to be fair/moderate for fruits and 
vegetables intake.17, 18 In addition, an ancillary study of the US Multi-Center Study examining the 
association between micronutrients and esophageal and gastric cancer reported that, results 
from analyses including versus excluding proxy interview data were almost identical. 16 In the 
Study of the Reflux Disease, 92.8% (n=193) of the BE cases and 68.7% (n=211) of the controls 
were successfully interviewed.7 In the Epidemiology and Incidence of BE Study, 47% (n=320) of 
the eligible BE cases and 37% (n=317) of eligible controls were interviewed. 8 Neither of the BE 
parents studies conducted interviews with proxy respondents. Combining the two BE studies, 
complete dietary data were available for 479 BE cases and 501 BE controls. 3, 4 
Twelve measures were used to capture the complex dietary exposure of 
sugar/carbohydrate, including sweetened desserts, sweetened beverages, sweetened 
desserts/beverages; added sugar; total sugar; sugar components (dietary free glucose, free 
fructose, sucrose); glycemic index, glycemic load; starch; or total carbohydrate (Table 2.4). 
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Examining the effect of added sugar was important because it is added during food 
processing/preparation and the absorption may be different from naturally occurring sugar. 
Studying the effects of different sugar component was important because each sugar 
component has different metabolism which may lead to different effects on carcinogenesis. 19 
Glycemic index and glycemic load are approximate measures of the effect of diet on blood 
glucose and insulin levels.20 Sweetened desserts/beverages was also an important measure 
because they may be easier to be identified by the general population when implementing risk 
reduction strategies. Therefore, examining multiple measures helped us better understand the 
underlying mechanism and provide guidance in intervention.  
 
Data Harmonization 
Because most of the sugar/carbohydrate measures of interest are not available in the 
originally processed nutrient data from parent studies, each of the four study-specific FFQs 
were linked with the University of Minnesota nutrient database,21 utilizing frequency of 
consumption, serving size, and nutrient contents, to determine sugar/carbohydrate consumption. 
Although USDA database also contains sugar/carbohydrate values (e.g. total sugar, total 
carbohydrate, glucose, sucrose, fructose, starch), data were not complete for some of the FFQ 
food items.22 In addition, the only version of added sugar database released by USDA was 
removed from their website due to the constant changes in formulations for commercial foods, 
multi-ingredient foods, and the primary contributor of added sugar to the diet. 23  
University of Minnesota nutrient database was created primarily based on the USDA 
database.24 Additional resources used to create the University of Minnesota nutrient database 
include values from other food and nutrient databases and articles in scientific journals 
containing values for food products were utilized when values for some nutrients, food 
components, and brand name food products were not available from USDA.24 In addition, 
several standardized procedures were utilized to impute or logically calculate estimations of 
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nutrient values. The steps followed by the University of Minnesota for the nutrient database 
include: (1) use of a proxy value from a different but similar food item; (2) calculate an estimate 
using the value for another form of the same food; (3) calculate an estimate of the value using 
other components in the same food; (4) calculate an estimate of the value using household 
recipes or commercial food product formulations for multi-component foods.24  
University of Minnesota nutrient database contains more food items, minimal missing 
nutrient values, and values of all nutrients of interest (including total carbohydrate, starch, total 
sugar, glucose, sucrose, fructose, added sugar, glycemic index, and glycemic load), and  
therefore was utilized in this study.  Although a unified nutrient database, rather than study-
specific nutrient database was used to determine sugar/carbohydrate intake, it is unlikely it 
would alter the study results since intake was essentially measured by relative intake (ranking) 
rather than the absolute values. Bingham et al. reported that the study results were similar using 
unified vs. study-specific nutrient database.25 A sensitivity analysis was conducted to compare 
the results based on the unified nutrient database with the results based on study-specific 
nutrient database to examine the robustness of this method (see sensitivity analysis section).  
To estimate sugar/carbohydrate intake, frequency of consumption and portion size of 
FFQ line items from each of the four study-specific FFQs were linked with the nutrients per 100 
grams of food from University of Minnesota nutrient database. For each of the four parent 
studies, participants were asked how often they consumed the food items. For both EA parent 
studies, participants gave the number of times the food item was consumed per day, week, 
month, or year. For both BE parent studies, different categorizes of frequency were provided for 
the participants to choose from, such as never or less than once per month, 1 per month, 2 -3 
per month, 1 per week, 2 per week, 3-4 per week, 5-6 per week, 1 per day, etc. 
The FFQs include portion size questions in three of the parent studies, but not in the US 
Multi-Center Study. However, medium serving sizes were assumed for the food items, which is 
consistent with procedures of the original nutrient data processing center - FHCRC. In the LA 
 86 
 
 
Multi-Ethnic Study, participants were given what each of the serving size represents specifically 
for each of the FFQ line items. For example, the three options for the line item ‘orange juice’ 
were 1/2 cup or 4 oz., 1 cup or 8 oz., and 1 ½ cups or 12 oz. Participants were asked to report 
both the usual serving size and the number of servings each time they consumed each line item. 
In the Study of Reflux Disease conducted in Seattle, participants were given a definition of 
medium serving size and asked to report the serving size of the FFQ line item they usually 
consumed. There options were provided for serving size, including small (≤ 1/2 of the medium 
serving), medium, and large (≥1 ½ of the medium serving). In the Epidemiology and Incidence 
of BE Study conducted in Kaiser in Northern California, four options were provided for serving 
size. Participants were given what each of the serving size represents for each of the FFQ line 
items respectively. For example, the four options for the line item ‘grapefruit’ were 1/2 cup, 1 
cup, 2 cups, and 3 cups. Participants were asked to report the serving size they usually 
consumed. 
For most of the FFQ items, serving size was defined in units other than grams (e.g. cups, 
glasses, slices, etc.). Therefore, the portion size files documenting the conversions between 
other units to grams for FFQ items were obtained from each of the original nutrient data 
processing centers and were used for this ancillary study. In the LA Multi-Ethnic Study 
conducted in Los Angeles, portion size conversions were missing for a few FFQ items. Because 
the original data were processed based on University of Hawaii nutrient database, which was 
developed based on USDA nutrient database, the USDA database for portion size conversions 
for those items were utilized.22 In the Kaiser Epidemiology and Incidence of BE Study, portion 
size conversions were provided based on FFQ line items rather than individual items. For most 
of the line items, the individual items were listed in a line item separately or the multiple foods in 
a line item were all similar in sizes, and therefore the portion size conversions from the file were 
used. However, there were a few line items that include multiple food items and are probably 
different in sizes, and therefore the USDA for portion size conversions were utilized.22 For 
 87 
 
 
example, for the line item ‘raw peaches, apricots, nectarines’, the smallest serving size option in 
the FFQ was 1/2 of the fruit. The portion size file provided by original nutrition data processing 
center gave 49 grams for 1/2 of the fruit for this line item. However, the gram weight for 1/2 of 
peach or nectarine should be different from the weight for 1/2 of apricot. Therefore, I looked up 
in USDA to determine the grams weight for 1/2 of peach, apricot, and nectarine, respectively.  
Some FFQ line items represent multiple foods (e.g. ‘pancakes or waffles’), and therefore 
the nutrient contents of the FFQ line item were weighted according to the assigned weights (e.g. 
0.65 for ‘pancakes’ and 0.35 for ‘waffles’). The relative weights were based on nationally 
consumed patterns of consumption as compiled by each of the studies. The files that 
documented the weights were provided by the original nutrition data processing centers for the 
LA Multi-Ethnic Study and the Seattle Study of Reflux Disease. For the US Multi-Center Study 
conducted in Connecticut, New Jersey and Western Washington, the FHCRC was unable to 
locate records of the weights that were originally utilized in processing nutrient data. However, 
verification of the weighting scheme was done previously by using the weighting scheme of a 
similar FHCRC FFQ and examining the correlations between the newly calculated total energy 
and the FHCRC originally reported total energy.26 The new weights that were used in this study 
were shown to be close to how the FHCRC originally weighted the FFQ items (the Pearson 
correlation coefficient was 0.97). For the Kaiser Epidemiology and Incidence of BE Study, 
weights file is unavailable and thus the weights (percentages) were determined by referring to 
the weights used by investigators that have utilized the FFQs of the other three parent studies. If 
the weight percentages were unavailable in the other FFQs, the weights for the foods in one 
FFQ line item were evenly split.27 The Block 98 FFQ utilized in the Kaiser Epidemiology and 
Incidence of BE Study was originally processed based on the ‘icon’ method (Dr. Doug Corley, 
personal communication, 2015), which is different from the standard method utilized by the 
other three parent studies. According to the ‘icon’ method, one USDA nutrient database food 
that represents the FFQ line item was selected based on the relative frequency of reports of 
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those foods in National Health and Nutrition Examination Survey (NHANES) (e.g. for "apples 
and pears" it would have been apples). Some items may have been constructed from more than 
one SR food. In contrast, the standard method is to use the food intake provided by national 
published surveys (e.g., NHANES) to weight line items that correspond to the years the study 
FFQ assessed intake (e.g. for "apples and pears" it would have been 60% apples and 40% 
pears) (FHCRC, personal communication 2015). However, values estimated using the ‘icon’ 
method and the standard method (using NHANES data) were compared, and have yielded 
highly correlated estimates (unpublished data, Dr. Doug Corley, personal communication 2015). 
Because the other three studies were originally processed based on the more commonly used 
standard method, I used the standard method rather than ‘icon’ method to estimate intake for 
this ancillary analysis.  
FFQ items that were categorized as sweetened desserts/beverages based on previous 
studies28-30 were listed in Table 2.5. To calculate the total intake of sweetened 
desserts/beverages, the number of times of consumption per day were multiplied by the number 
of medium servings each time, and then summed across all high-added sugar FFQ line items. 
Medium servings in US Multi-Center Study FFQs and Seattle Study of Reflux Disease FFQs 
were defined by the investigators from FHCRC, and medium servings were defined as the 
second answer options in the study-specific FFQs for LA Multi-Ethnic Study and Epidemiology 
and Incidence of BE Study. In addition, sweetened desserts/beverages were divided into two 
groups including sweetened desserts group and sweetened beverages group. The intake of 
each group of items was estimated respectively. 
Intake of total carbohydrate, starch, total sugar, free glucose, sucrose, free fructose, and 
added sugar was estimated by linking FFQ data with nutrient contents in University of 
Minnesota nutrient database.21 For example, intake of total sugar was calculated as follows: 
total sugar intake per day from an FFQ line item = the number of times of consumption per day * 
amount of consumption each time in grams * grams of total sugar per 100 grams of food.  Intake 
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of total sugar per day for each person was calculated by repeating the calculation above for 
each of the FFQ line items and summing up the sugar intake values across all FFQ line items. 
When FFQ line items represent multiple foods, the nutrient contents of the FFQ line item were 
weighted according to the assigned weights. For example, the FFQ line item of ‘pancakes or 
waffles’ was assigned a weight of 0.65 for ‘pancakes’ and 0.35 for ‘waffles’. To calculate the 
total sugar intake, the weight assigned to each food in the FFQ item were multiplied by the total 
sugar content of one medium serving of that food, summed across all foods in the FFQ line item, 
and then multiplied by the number of times consumed per day and the number of medium 
servings. In this example, 100 grams of pancakes contains 8.32 grams of total sugar and 100 
grams of waffles contains 4.91 grams of total sugar. A medium serving size of pancakes and 
waffles were 76 grams and 22 grams, respectively. If a participant reported consuming one 
medium serving of pancakes or waffles per day, the participant’s daily intake of total sugars 
from pancakes and waffles was calculated as: 1 serving of pancakes or waffles /day * [(0.65 * 
76 g * 8.32 g/100g pancakes) + (0.35 *22 g * 4.91 g/100g waffles)] = 4.49 g total sugar/day.  
Glycemic index and glycemic load were calculated as follows20, 31: glycemic index of a 
person’s diet per day = SUM (times of consumption per day * the amount of consumption in 
grams * carbohydrate contents/gram of food * glycemic index of individual food) / total 
carbohydrate consumption in grams / day; glycemic load of a person’s diet per day = SUM 
(times of consumption per day * the amount of consumption in grams * carbohydrate 
contents/gram of food * glycemic index of individual food) /100. Similarly, when FFQ line items 
represent multiple foods or beverages, glycemic index/glycemic load calculation were weighted 
according to the assigned weights of individual foods or beverages.  
 
Outcome Assessment: Vital Status 
For the follow-up component of the EA/GCA studies, the vital status and date of death of 
EA/GCA cases were determined by linking participants with the National Death Index. 32 An 
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event was defined as death from any cause during the follow-up period and patients alive at the 
end of the follow-up period were censored.32 Because EA/GCA are lethal diseases with median 
survival time of approximately 1 year,32 I used all-cause death as an approximate of EA/GCA 
specific death. The maximum lengths of follow-up were 90 months and 129 months, for the US 
Multi-Center study and the LA Multi-Ethnic study, respectively. 
 
Covariate Assessment 
Covariate information (excluding dietary intake) was collected by each parent study 
during a structured in-person interview conducted by trained research interviewers.5-8 The 
majority of covariates have already been harmonized by Drs. Wong-Ho Chow and Michael Cook, 
and other colleagues at the National Cancer Institute, for the purpose of previous BEACON 
pooled analyses.33-37 Covariates that may potentially confound the sugar/carbohydrate intake - 
BE/EA/GCA outcomes association include proxy status, age, sex, race, income, education, 
smoking, GERD frequency, body mass index (BMI), fruits and/or vegetables intake, tumor stage, 
treatment, and total energy intake. Directed acyclic graphs (DAGs, Figures 2.1-2.3) and hand-
driven backward elimination were utilized to identify potential confounders.38 First, covariates 
were determined whether to be included in the DAGs based on prior knowledge and existing 
literature.38-43 Further, potential confounders were determined using DAG rules. Finally, due to 
power considerations, hand-driven backward elimination was conducted starting with the 
adjustment sets identified from DAG analysis to identify a more parsimonious subset of 
confounders. Confounders identified from DAG analysis were assessed if inclusion of the 
confounder changed the loge form of the effect estimate by >10%.
38 In sum, the covariates were 
included in the statistical model if both criteria (DAG analysis and change-in-estimate >10%) 
were met.  
Obesity (measured by BMI) and GERD were examined as potential effect measure 
modifiers of the positive association between specific type of sugar/carbohydrate measurement 
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and specific tumor outcome. Obesity and GERD were selected because they are two currently 
well-established risk factors for BE and EA/GCA, and they are strongly associated with BE and 
EA/GCA. BMI (weight in kg/ height in m2) was calculated based on assessments that were 
obtained either by measuring participant’s height and weight using established protocols, 7, 8 or 
asking the participant about their height and usual weight one year prior to the diagnosis (cases) 
or interview (controls).6, 44 BMI was dichotomized in the EMM analysis (<25/≥25 kg/m2). GERD 
refers to the combined exposure of heartburn or regurgitation because heartburn and 
regurgitation symptoms essentially reflect a similar exposure of the esophagus to gastric juice.34  
GERD frequency (categorized at the median), rather than GERD (ever/never) was used to 
better reflect the impact of GERD. GERD frequency was not adjusted for antacid medication 
use due to the limited information on antacid medication use and heterogeneity of antacid 
medications by study/over time. 
 
Study Design 
This dissertation incorporated both case-control and follow-up designs to address the 
study aims. The case-control design was used to address the research questions focused on 
determine whether sugar/carbohydrate intake is associated with tumor development, and the 
follow-up approach was used to address the questions focused on survival. Because BE and 
EA/GCA are rare disease and require a long induction period for tumor development, 25, 45 a 
case-control study design is more efficient for addressing the aims focused on elucidating 
factors associated with disease incidence. This study pooled data from four existing case-
control studies,1-4 which not only greatly enlarged the sample size, but also improve time-
efficiency and cost-effectiveness because the dietary, covariates, and outcome data have been 
previously collected. Because the four studies share a lot of similarities, instead of  pooling 
published risk estimates via a meta-analytical approach, this study pooled individual-level study 
data, which allowed for standardization of the epidemiologic models and harmonization of the 
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variables. Because EA and GCA are lethal cancers and the median survival time is 
approximately 1 year,32 for the aims focused on mortality, I used this harmonized data and 
appropriately employ a follow-up approach.  
One possible alternative, when I addressed the research questions focused on disease 
development, would be to utilize a cohort study design. Although a cohort study design would 
enable me to more accurately capture the dietary exposure (e.g. measuring sugar/carbohydrate 
intake at various time points prior to disease development), it is less time-efficient and less cost-
effective than a case-control design due to the lengthy follow-up given that the study outcomes 
are rare. Therefore, a case-control design would be more practical and suitable for the aims 
focused on identifying whether sugar/carbohydrate intake is associated with the BE-
adenocarcinoma continuum.  
 
Results from Previous Analyses 
Of the four parent studies, only the US Multi-Center Study has published results on the 
association between sugar/carbohydrate intake and cancer development.16 It was suggested 
that starch intake was positively associated with GCA but not EA (ORs and 95%CIs were 
1.12[0.80-1.59] and 1.61[1.14-2.28] for EA and GCA, respectively).16 Total carbohydrate intake 
was suggested to be inversely associated with development of EA and GCA (ORs and 95%CIs 
were 0.34[0.20–0.58] and 0.70[0.42–1.17], respectively).16   
 
Statistical Analysis 
The first aim was to determine if sugar/carbohydrate intake is associated with the 
development of Barrett’s esophagus, utilizing existing data from two parent BE studies (the  
Study of Reflux Disease, and Epidemiology and Incidence of BE Study) . The second aim was to 
determine if sugar/carbohydrate intake is associated with the development of EA/GCA, utilizing 
existing data from two parent EA studies (the US Multi-Center Study and the LA Multi-Ethnic 
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Study). In addition, obesity (measured by BMI) or GERD (measured by frequency) was explored 
as EMMs of the significant associations between sugar/carbohydrate intake and risk of 
developing BE or EA/GCA. The third aim was to determine if sugar/carbohydrate intake is 
associated with survival following a diagnosis of EA/GCA, utilizing existing follow-up data from 
the two parent EA studies. Multiple measures of exposure (sugar/carbohydrate) were 
considered separately in this ancillary analysis, including sweetened desserts, sweetened 
beverages, sweetened desserts/beverages; added sugar; total sugar; sugar components 
(dietary free glucose, free fructose, sucrose); glycemic index, glycemic load; starch; or total 
carbohydrate.  
 
Data Management 
The parent studies were population-based1-3 or community-based8. Dietary data for the 
parent studies was collected during a structured paper-based interview by trained interviewers1, 
2, 4 or using a self-administered questionnaire.3 In the US Multi-Center Study, the principal 
investigators from different study sites (Dr. Marilie Gammon - NJ, Dr. Harvey Risch - CT, and Dr. 
Thomas Vaughan - WA) collaborated closely to ensure that the study methods were 
implemented and the same questionnaire was used at each study site.  Similarly, Dr. Anna Wu 
and colleagues specifically designed the Los Angeles study to be compatible with the US Multi-
Center Study (personal communication). Each parent study conducted quality control, and 
discrepancies were resolved by referencing the original interview documents.1-8 The validated 
data were then linked with nutrient databases for the analyses of nutrient intake and total energy 
intake.1-4 
 
Descriptive Analysis  
The distributions of exposure, outcome, and covariates by each study were first 
examined, followed by examination on the distribution of harmonized exposure, outcome, and 
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covariates after pooling. For both the pooled analysis of BE and EA/GCA, the distribu tion of sex, 
race, BMI, GERD frequency, cigarette smoking, income, education, fruits and/or vegetables 
intake, sugar/carbohydrate intake, by case-control status were assessed as categorical 
measures using frequency (n) and relative frequency (%). In addition, age, fruits/vegetables 
intake, sugar/carbohydrate intake, and total energy intake were also assessed as continuous 
measures using histograms and descriptive statistics.  
 
 
Exposure Variable Construction (Pooling) 
The sugar/carbohydrate intake values I obtained after linking FFQs with University of 
Minnesota nutrient database were in continuous form. First, for each individual study, each 
measures of sugar/carbohydrate intake were examined both in the continuous form and a 
categorized form. For the continuous form, the amount of added sugar, total sugar, free glucose, 
free fructose, sucrose, starch, and total carbohydrate, was modeled using a unit of g/day. 
Sweetened desserts/beverages were modeled using a unit of serving/day, and the continuous 
form of glycemic index and glycemic load was examined based on the numbers (no unit are 
available). For the categorical form, quantiles was used to divide each type of the exposure 
measure, based on the intake distribution of each study’s control group (case -control analysis) 
or case group (survival analysis), and the lowest quantile was used as the reference group.25 I 
explored the quantile cut-offs (quartiles, tertiles, etc.) and spline models to determine the 
optimal categorization of these data. Further, raw FFQ data were pooled from existing studies 
on sugar/carbohydrate intake based on the study-specific quantiles, where respondent intake 
were ranked and quantiled within study before pooling.25 In addition, I also tried pooling raw 
FFQ data based on absolute values, where respondent intake were ranked and quantiled with 
all studies combined. As described by Smith-Warner et al., I pooled FFQ data according to the 
identical cut-points based on absolute values from controls from both BE parent studies or both 
parent EA studies together.46 I used both categories based on study-specific quantiles, and 
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categories defined by identical absolute intake cut-points across studies, because both of the 
two approaches have strengths. True differences in population intake were considered when 
using identical absolute intake cut-points but not study-speciﬁc quantiles. However, because 
reported sweetened desserts/beverages intake may increase with the number of high-added 
sugar food items on each FFQ, which is likely to vary across studies, study-specific quantiles 
may be a better approach than absolute intake cut-points to account for the variations in FFQ 
design. In Smith-Warner’s pooled study,46 the inverse fruit/vegetable intake-cancer risk 
associations were similar for both approaches. Thus, for this dissertation, I used study-specific 
quantiles as my primary approach, and considered absolute intake cut-points in a sensitivity 
analysis.  
 
Analysis to Address Specific Aim 1 
The multiple measures of dietary sugar/carbohydrate exposure were used separately to 
determine the association with risk of developing BE. After pooling the two parent BE studies 
based on study-specific quantiles or identical absolute intake cut-points, unconditional logistic 
regression was utilized to calculate odds ratios (ORs) and 95% confidence intervals (CIs). 47 
Additionally, the associations with short-segment BE (SSBE, BE segment length <3cm) and 
long-segment BE (LSBE, BE segment length ≥3cm) were analyzed respectively, to cross-
sectionally examine the continuum within BE development. The Wald Test was used to formally 
evaluate differences by segment length (<3cm/≥3 cm).47 The best measure for the continuum of 
BE severity would be histologic type (defined by intestinal metaplasia, low-grade dysplasia, 
high-grade dysplasia), however, data on histologic type is unavailable. I therefore used BE 
length as a surrogate. 
 Potential confounders were assessed using both DAGs (Figure 2.1) and hand-driven 
backward elimination method (examine if inclusion of the confounder changed the loge form of 
the effect estimate by >10%).38 The minimal sufficient set identified by DAG analysis included 
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age (continuous), sex (male/female), race (white/other), BMI (<25/≥25 kg/m2), fruit/vegetable 
intake (≤study-specific median/>study-specific median), frequency of GERD (≤weekly/>weekly), 
and total energy intake (kcal/day).  Study (Study of Reflux Disease/Epidemiology and Incidence 
of BE) was adjusted in all models.  
Obesity and GERD frequency were assessed in the significant sugar/carbohydrate - BE 
incidence associations as EMMs. Multiplicative effect measure modification was first assessed 
using likelihood ratio tests to compare regression models that include a multiplicative term 
compared to a model without that term, using p<0.10 as a priori criteria. Subsequently, additive 
effect modification was assessed using interaction contrast ratios (ICRs, also refer red as 
relative excess risk due to interaction).  ICR was calculated as follows: ICR = OR11-OR01-
OR10+1. The doubly unexposed group (exposed to neither the exposure nor the effect modifier) 
serves as the referent group. OR01 and OR10 refer to the OR contrasts between those singly 
exposed to those doubly unexposed. OR11 refers to OR contrasts between those doubly 
exposed to those doubly unexposed. ICRs that were significantly different from zero suggest the 
presence of additive interaction.  
 
Analysis to Address Specific Aim 2 
Similarly, the multiple measures of dietary sugar/carbohydrate exposure were used 
separately to determine the association with risk of developing EA and GCA. After pooling the 
two parent EA studies based on study-specific quantiles or identical absolute intake cut-points, 
polytomous logistic regression was used to calculate ORs and 95%CIs for EA and GCA as 
distinct outcomes.48 Similarly, potential confounders were assessed using both DAGs (Figure 
2.2) and hand-driven backward elimination. The minimal sufficient set identified by DAG 
analysis included age (continuous), sex (male/female), race (white/other), cigarette smoking 
(ever, never), fruit/vegetable intake (<median/≥median), GERD frequency (<weekly/≥weekly), 
BMI (<25/≥25 kg/m2), and total energy intake (kcal/day, continuous). Study indicator (US Multi-
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Center/LA Multi-Ethnic) was adjusted in all models. I assessed the role of obesity and GERD 
frequency respectively as EMMs in the significant sugar/carbohydrate - EA/GCA incidence 
associations. The details on EMM assessment were stated previously in the “analysis to 
address specific aim 1” section. 
 
Analysis to Address Specific Aim 3 
To determine if sugar/carbohydrate intake is associated with survival among EA/GCA 
cases, Cox proportional hazards models were used to estimate hazard ratios (HRs) and 
95%CIs for EA and GCA as distinct outcomes.38 The proportional hazards (PH) assumption was 
evaluated using cross-product terms with log-time and exposure, and cross-product terms with 
log-time and each of the confounder. PH assumption was not violated in any of the models. The 
minimal sufficient set identified by DAG analysis included age (continuous), education (≤high 
school/some college or technical school/≥college graduate), study indicator, and total energy 
intake (kcal/day, continuous) (Figure 2.3). 
 
All Models 
In all models, linear trends were tested by modeling the sugar/carbohydrate measures 
as continuous variables. 
Because total energy intake is often positively correlated with absolute intake of a 
specific nutrient, and may confound relationships between specific nutrients and the outcome, it 
was adjusted in all models for each of the specific aims.49 The standard multivariate model 
(including a term for nutrient intake and total energy intake) was used for energy adjustment, 
which held energy constant when modeling nutrient intake in relation to the outcome. 49 
Individuals with implausible reporting of total energy (beyond ±3 standard deviations (SDs) from 
study-specific loge-transformed mean energy intake) was excluded.
49 
 98 
 
 
Previous pooled analysis used a meta-analytic approach46, 50-52 where the study-specific 
ORs/HRs (by quantiles) were calculated, and then pooled using random effect and/or fixed 
effect model. In this ancillary analysis, I pooled study-specific quantiles or categories defined by 
identical absolute intake cut-points across studies to calculate ORs/HRs, rather than using the 
meta-analytic approach. There are several reasons, as outlined here. (1) The number of studies 
to pool - two BE studies and two EA studies - is much smaller in this study compared to 
previous pooling studies focused on dietary intake. (2) The individual studies are all US studies, 
and the study subjects are primarily white and residents of highly educated and/or high-income 
areas in the US, and therefore may share similar diet, cultural, and environmental factors (e.g. 
Seattle BE study and KAISER BE study were conducted in western Washington and Northern 
California, respectively). (3) The four studies have very similar FFQ structures; for example, 
there is little variation in the number of food items covered in FFQ (ranging from 104 to 131), 
and the majority of food items were same/similar among the four studies. (4) Nutrient intake was 
assessed using a unified source - University of Minnesota nutrient database. Therefore, given 
the similarities in study approach and populations, I used a pooled approach. A sensitivity 
analysis was conducted using a meta-analytic approach to examine the robustness of the 
results. If study heterogeneity was present, for the pooled approach, an interaction term for 
study and the exposure variable was used to determine study heterogeneity, and the interaction 
term was included in the model if statistically significant (and was omitted if it is not statistically 
significant). 
. 
Sensitivity Analyses 
In addition to the sensitivity analyses mentioned above (examination of individual 
absolute cut-points in addition to study-specific cut-points, and consideration of a meta-analytic 
analysis), I also conducted the following sensitivity analyses.   
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A unified source - University of Minnesota nutrient database was used to estimate 
sugar/carbohydrate intake in this study since the majority of measures were not available from 
the originally processed nutrient data. However, carbohydrate intake values were available in 
the processed data from each of the four studies, and therefore a sensitivity analysis was 
conducted to estimate the ORs/HRs for the association between total carbohydrate intake and 
outcomes. The effect estimates based on study - specific nutrient database were compared with 
the estimates obtained by utilizing the unified source to examine if utilizing a unified nutrient 
database substantially altered the results. 
Both parent EA studies have included proxy responses since some patients were unable 
to participate in the interview due to illness or death. A sensitivity analysis was conducted by 
excluding data obtained from proxy interviews.  If the effect estimates are similar to the 
estimates obtained without exclusion, proxy responses were included to increase power. Given 
that most of the cases were male, and recall/reporting by wives may be better than that by 
husbands because wives do more of the food preparation,53 it is unlikely the effect estimates 
were altered due to the proxy responses. Due to power considerations, this sensitivity analysis 
was not conducted by differentiating sex. 
Income data were available for the US Multi-Center Study and the two BE parent studies, 
but not for the LA Multi-Ethnic Study. Therefore, in the aim 2 analysis, income variable was not 
adjusted in the models. Therefore, a sensitivity analysis was conducted to consider income as a 
potential confounder in US Multi-Center Study to examine whether the results were altered. 
Individuals with implausible reporting of total energy (as defined by beyond ±3 standard 
deviations (SDs) from study-specific loge-transformed mean energy intake) were excluded in the 
analysis. A sensitivity analysis was conducted to allow a wider exclusion, such as upper/lower 
2.5%.49 
To be consistent with previous studies and examine the robustness of the results based 
on the pooled approach described above (pooling study-specific quantiles or absolute intake 
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categories to calculate ORs/HRs), a meta-analytic approach was also utilized to calculate 
summary ORs/HRs.  First, study-specific ORs/HRs and 95%CIs were estimated for the 
association between exposure and outcome in each study, adjusting for harmonized covariates. 
Then, summary ORs/HRs were generated by pooling study-specific ORs/HRs using both 
random-effects and fixed-effects meta-analysis.54 The results based on pooled approach and 
meta-analytic approach were compared.  
For the pooled analysis of BE parent studies and EA/GCA parent studies, I also (1) 
excluded total energy intake (as it may be on the causal pathway) from the covariate  sets to see 
if the results were altered; and (2) considered an alternative energy adjustment method - 
nutrient density method. For the EA/GCA case-control analysis, I also adjusted for potential 
confounding by physical activity and diabetes, and explored ever history of diabetes as an EMM 
(using data from the LA Multi-Ethnic study (which included a limited number of positive 
responses), since this information was not available from the US Multi-Center study). However, I 
was not able to examine the associations by length of time with diabetes due to the small 
number of participants with diabetes. I further explored the effect of fructose from natural 
sources (fruits/vegetables) versus other fructose (mostly from added high-fructose corn syrup) 
on EA development. For examination of EMM in both BE and EA/GCA studies, I have used 
different cut-points to categorize the sugar/carbohydrate intake variables. For example, to 
maximize study power, I relied primarily on using medians as cut-points when examining EMM 
on sugar/carbohydrate-BE incidence associations. I also used the extreme quantiles (highest 
versus lowest) of sugar/carbohydrate intake when examining EMM on sugar/carbohydrate-BE 
incidence, and sugar/carbohydrate-EA incidence.  
All analyses in this study were conducted using SAS version 9.3 (SAS Institute, Cary, 
NC) and Stata version 14.0 (StataCorp LP, College Station, TX). Results from the main data 
analyses as well as the sensitivity analyses are shown in Tables 3.2-3.8, Tables 4.2-4.9, and 
Tables A.1-A.27. 
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Statistical Power 
This study was a pooled analysis of four existing US case-control studies. The specific 
aims are: (1) Determine if sugar/carbohydrate intake is associated with the risk of BE 
development (with aim 1A: explore whether overweight/obesity or GERD are effect measure 
modifiers [EMMs] of the significant associations between sugar/carbohydrate intake and risk of 
BE). (2) Determine if sugar/carbohydrate intake is associated with the development o f EA/GCA 
(with aim 2A: explore whether overweight/obesity or GERD are EMMs of the significant 
associations between sugar/carbohydrate intake and risk of developing EA/GCA). (3) Determine 
if sugar/carbohydrate intake is associated with survival following a diagnosis of EA/GCA. In 
addition to employing the case-control designs, which focus on the association between 
sugar/carbohydrate intake and BE/EA/GCA development, I also used the follow-up approach to 
address the questions focused on survival. The sample size used for power calculations was 
based on the number of individuals who have completed a study-specific FFQ. Combining the 
two EA/GCA studies yielded 504 EA cases, 534 GCA cases, and 2045 non-cases; combining 
the two BE studies yielded 479 BE cases and 501 controls. Power calculations shown below 
have combined the EA and GCA cases. Power (1-β) for aim 1-3 and aim 1a/2a were estimated 
using SAS version 9.3 (SAS Institute, Cary, NC) and NCI Power Version 3.0, respectively, 
assuming a two-sided test at 5% significance level (α). 
 
Aim 1 Study Power  
Multiple measures were used to capture the dietary exposure of sugar/carbohydrate, 
including sweetened desserts, sweetened beverages, sweetened desserts/beverages; added 
sugar; total sugar; sugar components (dietary free glucose, free fructose, sucrose); glycemic 
index, glycemic load; starch; or total carbohydrate. Since quantiles (quartiles, tertiles, median) 
were used to divide each type of the exposure measure, the percentage of controls in the 
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highest level of exposure were 25%, 33%, or 50%, respectively. The effect estimates used (OR) 
to calculate the power for the main effects of sugar/carbohydrate intake on risk of developing BE 
ranges from 1.5-1.7, which is consistent with the effect of added sugar on EA risk as reported by 
Tasevska et al. (OR=1.62).9 As shown in Table 2.6, for the effect on BE development, study 
power was good (>85%) when the exposure is dichotomized. 
 
Aim 2 Study Power 
Similar to aim 1, the percentage of controls in the highest level of exposure were 25%, 
33%, or 50%, respectively. The effect estimates used to calculate the power for the main effects 
of sugar/carbohydrate intake on EA/GCA incidence ranges from 1.5-1.7.9 As shown in Table 2.6, 
for the effect on EA/GCA incidence, study power was good (>90%).  
The strongest positive association that I expect to find in the specific aim 2 analysis was 
added sugar-EA/GCA incidence association, and thus I assessed if there was interaction 
between obesity and added sugar on EA/GCA incidence, or interaction between GERD and 
added sugar on EA/GCA incidence. GERD and added sugar consumption were also used as 
dichotomous variables in this power calculation. The prevalence of obesity (BMI≥30kg/m2) was 
estimated to range from 0.10 to 0.20, and the prevalence of GERD was estimated to range from 
0.20 to 0.50. As shown in Table 2.7, power was good to evaluate both interactions with obesity 
and interactions with GERD (power 85% and >90%, respectively). 
 
Aim 3 Study Power 
Similar to aim 1 & aim 2, the percentages of controls in the highest level of exposure 
were 25%, 33%, or 50%, respectively, and the effect estimates ranges from 1.5-1.7.9 Power 
calculations were based on the assumption that 13% of EA/GCA cases survived after a follow-
up of 7.5 years.32 As shown in Table 2.6, for the effect on EA/GCA survival, study power was 
excellent (>95%). 
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Data Interpretation Issues 
A 30%-60% of increased risk in BE/EA/GCA outcome among participants who had 
higher sugar/carbohydrate consumption was expected. However, my results should be 
interpreted with caution.  
Because the main exposure (sugar/carbohydrate intake) was assessed by FFQs, there 
are possibilities of misclassifications. Differential recall between cases and controls is possible 
due to the case-control study design of the parent studies. Another concern was that cases may 
alter their dietary habits when they experience some clinical symptoms. However, all of the 
parent studies attempted to capture the participants’ usual diet 1 -5 years prior to diagnosis or 
interview.1-4 In addition, the foods that GERD patients are commonly recommended to omit 
comprise a small portion of foods that contribute to sugar/carbohydrate intake. 55 There is also 
possibility of errors in recall or report since the dietary intake was assessed a few years later. 
However, previous studies have reported a good correlation varying from 0.5 to 0.7 between 
dietary intake originally assessed and assessed by recall 3-10 years later.56-59 Therefore, the 
dietary intake captured using FFQ is likely to be an appropriate estimate of the subjects’ normal 
diet before disease initiation.  
Another limitation is that since this study was a pooled analysis of multiple studies, there 
might be minor discrepancies in the original data collection, variable definitions, and data 
management, which may introduce misclassifications of exposure, covariates, or outcome. 
However, the demographic factors, the BMI, cigarettes smoking, alcohol drinking, nonsteroidal 
anti-inflammatory drug use, and GERD data have been successfully pooled in previous 
BEACON studies,35-37, 60-62 which show promise in pooled analysis.  
The four parent studies were conducted in late 1990s or early 2000s, whereas the 
University of Minnesota nutrient database I utilized was released in 2014. Therefore, there might 
be changes in sugar/carbohydrate contents in certain food items, especially in prepared foods 
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such as desserts. However, because University of Minnesota nutrient database was used as a 
unified source for all of the four studies and intake was compared based on relative values 
(ranking) rather than absolute values, it is unlikely the effect estimates would be altered. In 
addition, as discussed earlier, a sensitivity analysis was conducted by comparing the effect 
estimates based on study - specific nutrient database with the estimates obtained by util izing 
the unified source to examine the robustness of the results.  
Multiple comparisons issues also need to be considered. Twelve different measures of 
sugar/carbohydrate intake exposure and the outcomes of BE development, EA/GCA incidence, 
and survival among EA/GCA cases, were examined, which yielded 36 comparisons. It is 
possible that some statistically significant results were due to chance. I did not adjust for 
multiple comparisons due to power considerations. However, I evaluated associations 
individually based on consistency with published results, consistency of associations between 
studies included in this pooled analysis, and consistency across the continuum of cancer 
development.49, 63, 64 
This study also has several strengths. By pooling data from four US studies I had an 
enlarged sample size to evaluate EMMs and was the first to explore EMM by GERD. By 
considering multiple measures of sugar/carbohydrate consumption, the complexity o f this 
dietary exposure was better captured to help further understand the biological mechanisms. 
Another strength of this study is that multiple outcomes (BE incidence, EA/GCA incidence, and 
EA/GCA mortality) were examined, which allowed me to identify when along the cancer 
continuum (normal tissue  BE  EA/GCA  mortality) that sugar/carbohydrate intake 
intervenes and risk reduction strategies could be implemented. In addition, this study was the 
first to comprehensively examine the association between sugar/carbohydrate and EA/GCA 
survival. 
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Summary 
The goal of this dissertation was to examine the association between 
sugar/carbohydrate intake and BE-EA/GCA cancer outcomes by conducting a pooled analysis 
of four existing case-control studies. To address the study aims, this study incorporated both 
case-control (to address the association with tumor development) and follow-up designs (to 
address the association with survival). Misclassifications of exposure, covariates, or outcome 
are possible due to the data collection method (using FFQs), data harmonization and pooling, 
proxy-responses, etc. However, several sensitivity analyses were conducted to examine the 
robustness of the results. Overall, this study is significant and the strengths of this study 
outweighed its limitations. Because sugar/carbohydrate intake is a modifiable factor, 
demonstration of an association between sugar/carbohydrate intake and risk of developing BE, 
risk of developing or dying from esophageal and gastric cardia adenocarcinoma may suggest 
potential to reduce cancer burden by limiting sugar/carbohydrate intake.
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Figure 2.1. Directed acyclic graph of potential confounders of the association between sugar/carbohydrate intake and Barrett’s 
esophagus development. 
 
 
 
  
 
1
0
7 
Figure 2.2. Directed acyclic graph of potential confounders of the association between sugar/carbohydrate intake and 
esophageal/gastric cardia adenocarcinoma development. 
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Figure 2.3. Directed acyclic graph of potential confounders of the association between sugar/carbohydrate intake and survival 
among cases of esophageal/gastric cardia adenocarcinoma. 
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      Table 2.1. Description of four parent studies and the sample sizes. 
Name of the Study Location Study 
Period 
Cases Cont
rols 
 Nutrient 
Database 
# of 
FFQ 
Items 
    BE EA GCA   
US Multi-Center Study1 CT, NJ, WA 1993-1995 - 293 261 695 
University of 
Minnesota 
104 
LA Multi-Ethnic Study2 Southern CA 1992-1997 - 220 277 1356 University of Hawaii 124 
Study of Reflux Disease3 Western WA 1997-2000 193 - - 211 
University of 
Minnesota 
131 
Epidemiology and Incidence of BE4 Northern CA 2002-2005 317 - - 320 Block 98 110 
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Table 2.2. Distribution of demographic characteristics among case and control participants in the parent EA studies. 
 
US Multi-Center Study 
  
LA Multi-Ethnic Study 
 
Control 
Participants 
Esophageal 
Adeno-
carcinoma 
Gastric 
Cardia 
Adeno-
carcinoma 
  
Control 
Participants 
Esophageal 
Adeno-
carcinoma 
Gastric 
Cardia 
Adeno-
carcinoma 
Characteristic N=695 N=293 N=261   Characteristic N=1356 N=222 N=277 
Age, years 
    
Age, years 
          <57 179 (25.8) 76 (25.9) 65 (24.9) 
 
       <49 291 (21.4) 23 (10.4) 36 (13.0) 
       57-64 178 (25.6) 48 (16.4) 56 (21.5) 
 
       50-59 343 (25.3) 57 (25.7) 73 (26.4) 
       65-71 176 (25.3) 79 (27.0) 71 (27.2) 
 
       60-69 466 (34.4) 96 (43.2) 108 (39.0) 
       >71 162 (23.3) 90 (30.7) 69 (26.4) 
 
       70+ 256 (18.9) 46 (20.7) 60 (21.7) 
Sex 
    
Sex 
          Male 555 (79.9) 245 (83.6) 223 (85.4) 
 
       Male 999 (73.7) 202 (91.0) 231 (83.4) 
       Female 140 (20.1) 48 (16.4) 38 (14.6) 
 
       Female 357 (26.3) 20 (9.0) 46 (16.6) 
Race 
    
Race 
          White 646 (93.0) 289 (98.6) 252 (96.6) 
 
       White 841 (62.0) 172 (77.5) 210 (75.8) 
       Black 34 (4.9) 2 (0.7) 4 (1.5) 
 
       African-American 90 (6.6) 3 (1.4) 10 (3.6) 
       Other 15 (2.2) 2 (0.7) 5 (1.9) 
 
       Latino-American 308 (22.7) 40 (18.0) 40 (14.4) 
     
       Asian-American 117 (8.6) 7 (3.2) 17 (6.1) 
Education 
    
Education 
          ≤High School 308 (44.3) 158 (53.9) 141(54.0) 
 
       ≤High School 504 (37.2) 99 (44.6) 121 (43.6) 
       Technical 175 (25.2) 78 (26.6) 61 (23.4) 
 
       Some College 392 (28.9) 64 (28.8) 86 (31.0) 
       ≥College Graduate 212 (30.5) 57 (19.5) 59 (22.6) 
 
       ≥College Graduate 460 (33.9) 59 (26.6) 70 (25.3) 
Geographic Center 
    
Geographic Center 
          Connecticut 206 (29.6) 80 (27.3) 82 (31.4) 
 
       LA county 1356 (100.0) 222 (100.0) 277 (100.0) 
       New Jersey 333 (47.9) 138 (47.1) 113 (43.3) 
            Washington 156 (22.5) 75(25.6) 66 (25.3)           
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Table 2.3. Distribution of demographic characteristics among case and control participants in the parent BE studies. 
 
Study of Reflux Disease 
  
Epidemiology and Incidence of BE 
 
Controls 
Barrett's 
Esophagus 
  
Controls 
Barrett's  
Esophagus 
Characteristic N=211 N=193   Characteristic N=309 N=296 
Age, years 
   
Age, years 
         20-39 31 (14.7) 27 (14.0) 
 
       Mean (SD) 62.3 (10.3) 62.3 (10.7) 
       40-49 53 (25.1) 49 (25.4) 
           50-59 64 (30.3) 57 (29.5) 
           60-80 63 (29.9) 60 (31.1) 
    Sex 
   
Sex 
         Male 133 (63.0) 118 (61.1) 
 
       Male 208 (67) 218 (74) 
       Female 78 (37.0) 75 (38.9) 
 
       Female 101 (33) 77 (26) 
Race 
   
Race 
         White 192 (91.0) 172 (89.1) 
 
       White 262 (85) 255 (86) 
       Black 5 (2.4) 3 (1.6) 
 
       Black 16 (5) 5 (2) 
       Other 14 (6.6) 18 (9.3) 
 
      Other 31 (10) 36 (12) 
Education 
   
Education 
         ≤High school 42 (19.9) 49 (25.4) 
 
       ≤High school 85 (29) 77 (26) 
       Technical 9 (4.2) 9 (4.7) 
 
       Some college 105 (34) 134 (45) 
       ≥College graduate 160 (75.8) 135 (70.0) 
 
       ≥College graduate 132 (43) 85 (29) 
Income 
   
Income 
         <$45,000 61 (28.9) 57 (29.5) 
 
       <$50,000 104 (36) 125 (46) 
       $45,000-$74,999 68 (27.0) 56 (29.0) 
 
       $50,000-$75,000 67 (23) 61 (22) 
       ≥$75000 77 (36.5) 61 (31.6) 
 
       >$75,000 119 (41) 87 (32) 
       Unknown 16 (7.6) 19 (9.8)     173 (56) 197 (67) 
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Table 2.4. Comparison of the sugar/carbohydrate measures of the exposure. 
Exposure 
Measurement 
Definition/What the estimation was 
based on 
What it represents/Why 
use this measure 
Total sugar Estimated based on nutrient intake 
analyses of each parent study; 
including naturally occurring sugar and 
added sugar 
Representing the impact of 
total sugar 
Sugar components 
(free glucose, free 
fructose, sucrose) 
Estimated based on nutrient intake 
analyses of each parent study 
Each sugar component has 
different metabolisms, which 
may lead to different effects 
on carcinogenesis.19 
The amount of 
added sugar 
Sugars and syrups that are added to 
foods during processing or preparation; 
estimated based on University of 
Minnesota nutrient database 
Representing the impact of 
added sugar, which has 
different metabolisms than 
naturally occurring sugar  
Sweetened 
desserts/beverages 
Including sweetened desserts and 
sweetened beverages (Table 2.5) 
More closely parallel the real 
world in which nutrients and 
foods are consumed in 
combination 
Total carbohydrate Estimated based on nutrient intake 
analyses of each parent study; 
including sugar, complex carbohydrate, 
and dietary fiber 
Representing the impact of 
carbohydrate consumption, 
which affects blood glucose 
and insulin levels 
Starch Estimated based on nutrient intake 
analyses of each parent study 
Representing the impact of 
starch - a common type of 
carbohydrate that is rich in 
cereal, bread, and pasta 
Glycemic index Calculated by summing the products of 
the carbohydrate content per serving for 
each food times the average number of 
servings of that food per day, times its 
glycemic index, all divided by the total 
amount of carbohydrate daily intake.20, 
31 
The glycemic index is an 
assessment of foods based 
on the incremental glucose 
response and insulin 
demand they produce for a 
given amount of 
carbohydrate.65, 66  
Glycemic load Calculated by multiplying the 
carbohydrate content of each food by 
its glycemic index, then multiplied this 
value by the frequency of consumption 
and summed the values from all 
foods.20, 31  
Glycemic load estimates the 
impact of carbohydrate 
consumption using the 
glycemic index while taking 
into account the amount of 
carbohydrate that is 
consumed. Glycemic index 
and glycemic load are best 
measures of the effect of 
diet on blood glucose 
and insulin levels. 
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Table 2.5. Food frequency questionnaire items that were categorized as sweetened desserts/beverages. 
US Multi-Center Study LA Multi-Ethnic Study 
Cereals, cold or cooked 
Pancakes or w affles 
Yogurt, all types, except frozen 
Ice cream or milkshakes 
Low -fat frozen desserts, 
including frozen yogurt, sherbet, or ice milk 
Pudding, custard, or f lan 
Jello, any f lavor 
Doughnuts, cakes, or pastries 
Cookies 
Pies 
Chocolate candy or candy bars 
Hard candy, jelly, jam, honey, or syrup 
Sugar in coffee or tea or on cereal 
Regular soft drinks or soda, not diet 
Orange juice, grapefruit juice or Vitamin C enriched fruit drinks 
Other fruit juices and fruit juice drinks 
Kool-Aid 
 
Study of Reflux Disease 
Cold cereal 
Pancakes and w affles 
Nonfat yogurt (not frozen) 
All other yogurt (not frozen) 
Ice cream 
Pudding, custard, and f lan 
Low -fat or non-fat frozen desserts, 
such as frozen yogurt, Sherbet, ice milk, etc. 
Doughnuts, cakes, pastries, Pop-Tarts, pan dulce 
Cookies 
Pumpkin and sw eet potato pie 
All other pies, fried pastries, pastelitos, and fruit empanadas                                                                                            
Chocolate candy and candy bars 
Hard candy, jam, jelly, honey, or syrup 
Sugar in coffee or tea and on cereal 
Regular Soft drinks (not diet) 
Orange juice and grape fruit juice 
Tang, Kool-Aid, Hi-C, and other fruit drinks 
Other fruit juices such as apple, grape 
High f iber cereal such as bran, All-Bran, bran f lakes, oat bran 
Highly fortif ied cereals, such as Special K, Total 
Other dry cereals, e.g. Cornflakes, Rice Krispies, granola, etc. 
Chocolate milk, cocoa or ovaltine 
Pancakes, w affles, French toast 
Doughnuts, cookies, cakes, pastries, cinnamon rolls, danishes 
Pumpkin or sw eet potato pie 
Other non-fruit pies 
Chocolate candy 
Other candy 
Jellies, jam, honey syrup 
Ice cream 
Orange juice 
Other citrus juice such as grapefruit, tangerine, lemonade 
Other fruit juices including grape, cranberry, pineapple, etc. 
Any type of fruit pie, cobbler 
Caffeine-free soda (e.g. Pepsi-free, 7-up, Sprite, etc.) 
Sodas w ith caffeine (Coca Cola, Pepsi, Dr. Pepper, etc.) 
Other carbonated drinks including mineral w ater, fruit drinks, etc. 
Epidemiology and Incidence of BE 
Pancakes, w affles, French toast, Pop Tarts 
Breakfast bars, granola bars, pow er bars 
High-fiber cereals like All Bran, Raisin Bran, Fruit-n-Fiber 
Product 19, Just Right or Total cereal 
Any other cold cereal, like Corn Flakes, Cheerios, Special K 
Yogurt or frozen yogurt 
Doughnuts, Danish pastry 
Cake, sw eet rolls, coffee cake 
Cookies 
Ice cream, ice milk, ice cream, bars 
Pumpkin pie, sw eet potato pie 
Any other pie or cobbler 
Chocolate candy, candy bars 
Other candy, not chocolate, like hard candy, caramel, jelly beans 
Jelly, jam, or syrup 
Sugar on coffee, sugar on tea 
Regular soft drinks, or bottled drinks like Snapple (not diet drinks) 
Real 100% orange or grapefruit juice, including fresh, frozen, or bottled 
Other real fruit juices like apple juice, prune juice, lemonade 
Kool-Aid, Hi-C, or other drinks w ith added vitamin C 
Drinks w ith some juice in them, like Sunny Delight, Juice Squeeze 
Instant breakfast milkshakes, diet shakes, or liquid supplements  
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Table 2.6. Power calculations for risk of Barrett’s esophagus, esophageal and gastric cardia adenocarcinoma and survival among 
esophageal and gastric cardia adenocarcinoma cases. 
  
Barrett's Esophagus 
Development 
 
Risk of Esophageal and 
Gastric Cardia 
Adenocarcinoma 
 
Survival among Esophageal 
and Gastric Cardia 
Adenocarcinoma Cases 
Exposure 
Quantiles 
Dichoto
mous Tertile Quartile 
 
Dichoto
mous Tertile Quartile 
 
Dichoto
mous Tertile Quartile 
Minimum 
detectable 
odds/hazard 
Ratio 
           1.7 98% 91% 82% 
 
>99% >99% >99% 
 
>99% >99% >99% 
1.6 95% 84% 72% 
 
>99% >99% 99% 
 
>99% >99% >99% 
1.5 88% 72% 60%   99% 99% 96%   >99% >99% >99% 
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Table 2.7. Power calculations for interactions between added sugar and obesity or gastroesophageal reflux disease on risk of 
esophageal and gastric cardia adenocarcinomas. 
Prevalence of Exposure 
 
Theta1=2  Theta=3  Theta=0.5  Theta=0.3  
Obesity 
Added sugar 
intake  
OR (x, y)=6.4 OR (x, y)=9.6 OR (x, y)=1.6 OR (x, y)=0.96 
  
     
0.10 0.50 
 
91% >99% 85% >99% 
0.15 0.50 
 
95% >99% 93% >99% 
0.20 0.50 
 
98% >99% 97% >99% 
       
Gastroesophageal 
reflux disease 
Added sugar 
intake 
 
OR (x, y)=8.3 OR (x, y)=12.5 OR (x, y)=2.1 OR (x, y)=1.2 
       0.20 0.50 
 
98% >99% 98% >99% 
0.30 0.50 
 
98% >99% >99% >99% 
0.50 0.50   94% >99% >99% >99% 
1
Theta=OR (x, y)/ [OR (x)*OR (y)], w here OR (x)=the odds ratio for high relative to low  category of exposure to added sugar intake; OR (y)= 
the odds ratio for high (≥30) relative to low  BMI or for GERD positive relative to GERD negative; OR (x, y)=the hypothesized OR for persons 
w ith the high category of added sugar intake and BMI or GERD positive.  
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CHAPTER 3: DIETARY SUGAR/CARBOHYDRATE INTAKE AND BARRETT'S ESOPHAGUS 
- A POOLED ANALYSIS 
 
Introduction 
Incidence of esophageal adenocarcinoma (EA) has increased rapidly in many 
Westernized countries.1-3 However, EA prognosis remains poor, with a 5-year survival of less 
than 20%.4, 5 Barrett's esophagus (BE) is a key precursor lesion of EA.6 The increasing 
incidence and poor prognosis of EA points to the importance of identifying modifiable risk 
factors that act early during carcinogenesis. 
Known modifiable risk factors for BE are gastro-esophageal reflux disease (GERD), 
obesity, and cigarette smoking.7-9 However, GERD usually requires continued medical therapy 
to control, and many interventions, particularly weight loss, are difficult to achieve or maintain.10-
12 Therefore, additional modifiable risk factors need to be identified.  
Caloric sweetener intake has increased dramatically since 1960s,13 corresponding to the 
increase in BE/EA risk in the last four decades. However, few studies have examined the 
associations between sugar/carbohydrate and BE/EA.14-16 The link between sugar and cancer 
risk is biologically plausible. Long-term high intake of dietary sugar/carbohydrate may alter 
levels of insulin-like growth factor compounds, and subsequently promote carcinogenesis.17-19 
Specifically, insulin resistance may hamper the healing of esophageal mucosal injury and 
decrease cell apoptosis.20 Thus, exposure to sugar/carbohydrate intake may be associated with 
development of EA and its precursor BE.  
To comprehensively examine associations between multiple measures of 
sugar/carbohydrate intake and BE risk, we harmonized, pooled, and analyzed individual -level 
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participant data from two United States (US)-based case-control studies. If sugar/carbohydrate 
intake is found to be associated with BE risk, there is potential to reduce BE risk by providing 
clinical recommendations on limiting sugar/carbohydrate intake.  
 
Methods 
This study pooled data from two US community-based case-control studies of Barrett’s 
esophagus, including the western Washington-based Study of Reflux Disease21 and the 
Epidemiology and northern California-based Incidence of BE Study.8 The two parent studies, 
from the International Barrett’s and Esophageal Adenocarcinoma Consortium, were chosen due 
to their similarities in study design, study population, and data collection methodology (Table 
3.1). This study was approved by the institutional review boards of the participating institutions.  
Study Population. The Study of Reflux Disease was conducted in western Washington 
state.21 Eligible cases were between 20-80 years of age, without a previous BE diagnosis, and 
who underwent an upper endoscopy for GERD symptoms at one of four community 
gastroenterology clinics during 1997-2000. Cases were those with endoscopic findings of BE 
and specialized intestinal metaplasia on at least one of the four biopsy specimens taken within 
the tubular esophagus. Controls were residents of western Washington state identified using a 
random digit dialing technique during the same period that cases were diagnosed.   
The Epidemiology and Incidence of BE Study was conducted within the Kaiser 
Permanente Northern California (KPNC) population.8 Cases and controls were 18-79 year-old 
KPNC members who were continuously enrolled (in KPNC) for at least 2 years, and were able 
to understand spoken and written English. Cases comprised individuals diagnosed with incident 
BE (endoscopic findings and biopsies with intestinal metaplasia) during 2002-2005. BE cases 
were identified using the International Classification of Disease, Ninth Revision code 530.2 and 
confirmed by review of endoscopy and pathology records. Controls were randomly selected 
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from the eligible KPNC members without a prior diagnosis of BE at the time the cases were 
diagnosed. 
In total, the two studies provided 513 BE cases and 528 controls. We excluded 
individuals who did not complete a dietary intake assessment, or if their reported energy intake 
was beyond ±3 standard deviations from study-specific loge-transformed mean energy intake.
22 
After exclusions there remained 472 BE cases and 492 controls for this pooled study.  
Dietary Assessment. Both BE studies collected dietary information using a validated 
food frequency questionnaire (FFQ), either during a structured interview by trained 
interviewers23 or through a self-administered questionnaire.24 Participants were asked to report 
their dietary intake for the year before diagnosis (cases) or interview (controls).23, 24 The Study of 
Reflux Disease utilized the 131-item FFQ developed by Fred Hutchison Cancer Research 
Center23, and the Epidemiology and Incidence of BE Study utilized the 110-item FFQ (Block 
98).24 The two FFQs were similar in design and structure, including number of food items and 
frequency/portion size questions, which enhanced our ability to harmonize the diet data.  
Assessment of Sugar/Carbohydrate Intake. Twelve measures were used to assess 
sugar/carbohydrate intake, including: sugar components (free glucose, free fructose, sucrose); 
added sugar; total sugar; starch; total carbohydrate; glycemic index; glycemic load; servings of 
sweetened desserts/beverages (servings of sweetened desserts; servings of sweetened 
beverages, and servings of sweetened desserts/beverages). Added sugar was defined as 
sugars and syrups added to foods during food preparation or commercial food processing, 
including white sugar, brown sugar, powdered sugar, honey, pancake syrup, corn syrups, high 
fructose corn syrups, and molasses.25  
Primary data from the two study-specific FFQs were harmonized and linked with the 
University of Minnesota Nutrition Coordinating Center Food and Nutrient Database to estimate 
individual-level intake.25 For example, sucrose intake was calculated as follows.  
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                                  ( )           (    )                
Intake of sucrose per day was calculated by summing up the sucrose intake values across all 
line items in the FFQ.26 When a FFQ line item represented multiple foods, the nutrient contents 
of the line item were weighted according to the estimated relative national distribution of intake 
for each food.26  
FFQ items categorized as sweetened desserts/beverages were based on previous 
studies as listed in Table 3.6.27-29 Dietary glycemic index and glycemic load were developed to 
reflect the putative effect of diet on blood glucose.30, 31 For this pooled study, dietary glycemic 
index was calculated using the following formula.30-32  
∑(                        (     )                                                    )
                            (     )
 
Similarly, dietary glycemic load was calculated as follows.30-32  
∑(                        (     )                                                    )
   
 
 
Covariate Assessment. Covariate information for non-dietary factors was collected by 
each parent study during a structured in-person interview.8, 21 Responses were harmonized in 
preparation for pooled analyses, as previously described.9, 33, 34 Potential confounders were 
identified through the use of directed acyclic graphs (DAGs),35 and included age (continuous), 
sex (male/female), race (white/other), fruit/vegetable intake (≤study-specific median/>study-
specific median), body mass index (BMI, <25/≥25 kg/m2), frequency of GERD 
(≤weekly/>weekly), and total energy intake (kcal/day).  We adjusted for study (Study of Reflux 
Disease/Epidemiology and Incidence of BE) in all models. 
Statistical Analysis. Estimated intake of sugar/carbohydrate from each BE study was 
pooled based on study-specific quartiles, which were determined by the distributions of intake 
among the controls in each study (Table 3.7).36 The individual-level intake values were also 
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pooled based on using absolute cut-points, which were determined by the intake distributions 
among all controls from both studies.36 The results from both approaches were similar, and thus 
only the results based on the study-specific quartiles are shown.     
Logistic regression was used to calculate odds ratios (ORs) and 95% confidence 
intervals (CIs) for associations between sugar/carbohydrate intake (categorized in quartiles) and 
BE risk, with each intake measure modeled separately.35 Linear trends were tested by modeling 
the sugar/carbohydrate measures as continuous variables.  All final models included adjustment 
for age, sex, study indicator, and total energy intake.  Adjustment sets also included race, BMI, 
GERD frequency, and fruit/vegetable intake for select sugar/carbohydrate measures, if inclusion 
of the covariate changed the effect estimate on a loge scale by ≥10%.
35 Cigarette smoking was 
considered, but not identified as a confounder by DAG analysis; also, inclusion of this covariate 
did not change the effect estimates by ≥10%. We evaluated effect measure modification on a 
multiplicative scale by BMI at interview (<25/≥25 kg/m2), waist circumference at interview 
(≤101.6/>101.6 cm for male, ≤89.0/>89.0 cm for female), and frequency of GERD 
(≤weekly/>weekly) for any significant associations between sugar/carbohydrate (categorized at 
the median) and BE using the likelihood ratio test, by comparing models with and without 
interaction terms.35  
Multinomial logistic regression was used to calculate ORs and 95%CIs for  the 
associations between sugar/carbohydrate intake (categorized at the median) and BE by 
segment length (defined as short-segment BE (SSBE, <3 cm, n=248) and long-segment BE 
(LSBE, ≥3 cm, n=165)).35, 37 The Wald Test was used to formally evaluate differences by 
segment length (<3cm/≥3 cm).38 BE cases with unknown segment length (n=59) were not 
included in these models.  
We conducted sensitivity analyses by: (1) pooling study-specific ORs using a meta-
analytic approach9, 36 (fixed effect, Table 3.8); (2) excluding total energy intake (as it may be on 
the causal pathway) from the covariate sets; (3) using nutrient density energy adjustment 
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method; (4) utilizing wider exclusion criteria for plausible total energy intake values (lower/upper 
2.5%); (5) comparing effect estimates (ORs and CIs for carbohydrate intake-BE associations) 
derived using the intake values in the current study (estimated based on University of Minnesota 
nutrient database) versus the effect estimates derived using the previously calculated 
carbohydrate values by study-specific nutrient data processing center; and (6) categorizing the 
sugar/carbohydrate intake variables using cut-points other than the median, when examining 
effect measure modification. Our results were not substantially altered in any of the sensitivity 
analyses (data not shown for (2)-(6)). 
SAS version 9.3 (SAS Institute, Inc., Cary, NC) was used for all analyses except for 
meta-analysis, which was analyzed using Stata version 14.0 (StataCorp LP, College Station, 
TX). 
 
Results 
Distributions of demographic factors by study and case-control status are shown in 
Table 3.2. Participants in the Northern California-based Epidemiology and Incidence of BE 
study were more likely to be older, male, non-White, with LSBE and higher prevalence of proton 
pump inhibitors use, consume more servings of fruits/vegetables, and were less likely to report 
frequent GERD (>weekly), compared to participants in the western Washington-based Study of 
Reflux Disease.  
In both BE studies, the intake of sucrose, added sugar, and sweetened 
desserts/beverages, was higher in cases compared to controls (Table 3.3). In the Study of 
Reflux Disease, the intake of sucrose (g/day) was 36.07 and 33.51, the intake of added sugar 
(g/day) was 46.15 and 41.01, and the intake of sweetened desserts/beverages (servings/day) 
was 3.13 and 2.81, in cases and controls, respectively. In the Epidemiology and Incidence of BE 
study, the intake of sucrose (g/day) was 36.80 and 35.06, the intake of added sugar (g/day) was 
44.18 and 40.68, and the intake of sweetened desserts/beverages (servings/day) was 2.26 and 
 128 
 
2.10, in cases and controls, respectively.  
After adjustment, BE risk was increased 79% and 71%, respectively, among those in the 
highest vs. lowest quartiles of sucrose (ORQ4vs.Q1=1.79, 95%CI=1.07-3.02, Ptrend=0.004) and 
added sugar intake (ORQ4vs.Q1=1.71, 95%CI=1.05-2.80, Ptrend=0.15) (Table 3.4). Sweetened 
desserts/beverages were associated with 71% increase in BE risk (ORQ4v s.Q1=1.71, 
95%CI=1.07-2.73, Ptrend=0.04). The OR was also elevated for intake of sweetened beverages 
(ORQ4v s.Q1=1.47, 95%CI=0.95-2.26, Ptrend=0.29), although the 95%CI included the null. There 
were little or no associations between other measures of sugar/carbohydrate intake and BE risk. 
The association with sweetened desserts/beverages was elevated among those with lower 
waist circumference (OR=1.63, 95%CI=1.06-2.50), but not among those with higher waist 
circumference (OR=0.91, 95%CI=0.59-1.41, Pinteraction=0.05). Other statistically significant 
associations were not modified by BMI, waist circumference, or  GERD frequency (data not 
shown).  
As shown in Table 3.5, associations with most sugar/carbohydrate intake measures 
differed significantly by segment length.  Risk of SSBE was associated with increased intake of 
sucrose, total sugar, starch, total carbohydrate, glycemic load, sweetened desserts, or 
sweetened beverages. In contrast, the risk of LSBE was not associated with sugar/carbohydrate 
intake, except for glycemic load (OR≥median vs.<median=0.42, 95%CI=0.24-0.74). These findings did 
not vary by study site (data not shown).  
 
Discussion 
In this pooled US-based study, BE risk was increased by 71%-79% in association with 
added sugar, sucrose, and sweetened desserts/beverages for intake in the highest compared to 
the lowest quartile. Risk increased in a dose-dependent manner (Ptrend<0.05) for both sucrose 
and sweetened desserts/beverages. Waist circumference appeared to modify the sweetened 
desserts/beverages-BE association. Thus, altering diet to reduce intake of added sugar or 
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sweetened desserts/beverages (especially among those with lower waist circumference) may 
be a potential risk reduction strategy. 
Ours is the first study to investigate the role of added sugar, individual sugar 
components, and sweetened desserts/beverages in relation to BE risk. Our finding that added 
sugar was associated with increased risk of BE is consistent with a US-based cohort study that 
found that added sugar was associated with a 62% increase in EA risk.16 Thus, from the 
perspective of the cancer development continuum, added sugar may either play a role during 
the early (development of BE), or at both early and later (development of EA) stages of 
carcinogenesis.  
One previous BE study from Ireland considered several sugar/carbohydrate measures 
that were also examined in our study, including total sugar, starch, total carbohydrate, glycemic 
index, and glycemic load.14 However, none of these other measures were associated with BE in 
either the Irish study or in our pooled study. It is possible that it is easier for participants to recall 
intake of foods with added sugar, than foods with naturally occurring sugar, and that this 
improved measurement yields stronger observed associations for intake of added sugar and 
sweetened desserts/beverages. However, even though added sugar and naturally occurring 
sugar are chemically identical, their physiological effects may differ. Naturally occurring sugar is 
an integral part of a cellular structure of whole foods (e.g., fruit), and is usually accompanied 
with vitamins, minerals, and fiber, which may slow down the absorption of sugar and moderate 
its impact on blood glucose.39-41 Moreover, some of these substances can decrease 
inflammation or oxidative stress, and thus are potentially anti-carcinogenic.40, 42 In contrast, 
added sugar is usually present in processed foods that are low in micronutrients and fiber, more 
energy-dense, and are rapidly digestible. The quick absorption may lead to acute glucose 
fluctuations, which have been suggested to increase oxidative stress and subsequently to 
promote carcinogenesis.43, 44 Thus, our findings of a positive association between added sugar/ 
sweetened desserts/beverages and BE risk, but no association with the other 
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sugar/carbohydrate measures we considered, are biologically plausible.  
We found a positive association between sucrose and BE. Sucrose was not associated 
with esophageal cancer in a US cohort study.16 However, in that study, EA was not 
differentiated from esophageal squamous cell carcinoma. Because the epidemiology of these 
two tumor types differs substantially,1, 2 it is unclear whether sucrose may have been associated 
with EA in the US cohort study. Many fruits/vegetables contain sucrose, but mostly in small 
amounts.39 Sucrose is largely found in the form of table sugar that is added in preparation of 
baked goods, processed foods, and sweetened beverages.25 Given that naturally occurring 
sucrose only contributes a small proportion of total sucrose, and the source of natural sucrose 
(fruits/vegetables) is associated with BE risk reduction, it is likely that the association between 
sucrose and BE we observed was driven by added sucrose. Consequently, our results suggest 
that clinical recommendations could target limiting table sugar intake, by reducing the intake of 
foods and beverages that are high in table sugar.  
Multiple measures of sugar/carbohydrate intake were associated with SSBE, but were 
not associated (or in one instance, inversely associated), with LSBE. Given the small sample 
size for examining BE length despite our pooling efforts, our results regarding segment length 
may be spurious, and should be interpreted with caution. In addition, it remains unclear whether 
LSBE and SSBE have the same pathogenesis and natural history, or whether length of BE 
segment increases over time.45 Nonetheless, our findings suggest that it is possible that SSBE 
may be more susceptible to sugar/carbohydrate intake than LSBE. Further studies are needed 
to explore these associations. 
There are several limitations to our study. First, recall bias is possible due to the case-
control design. However, the general lack of awareness of the sugar/carbohydrate-BE risk 
association by participants at the time of data collection may reduce the possibility of recall bias. 
Second, there may be non-differential measurement error (introduced by utilization of FFQ) and 
non-differential misclassification error (introduced by data harmonization and pooling). Thus, to 
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reduce the impact from these potential non-differential errors, we appropriately pooled and 
compared intake data based on relative rankings of sugar/carbohydrate intake within each study, 
instead of the absolute values. Third, because information on diabetes mellitus was not 
collected as part of the two parent studies, we were not able to assess the influence of diabetes 
on the associations between sugar/carbohydrate intake and BE. However, obesity is a st rong 
risk factor for diabetes,46 yet, we found a stronger association between sweetened 
desserts/beverages and BE risk only among those with lower waist circumference but not 
among those with generalized obesity, suggesting that sweetened desserts/beverages intake, 
independent of obesity (or potentially diabetes), may be a risk factor for BE. Further wel l-
powered studies are needed to more formally evaluate the role of diabetes in the associations 
between sugar/carbohydrate and BE. 
There are several strengths to our study. This is the first US study to comprehensively 
examine associations between sugar/carbohydrate intake and BE. To better capture the 
complexity of sugar/carbohydrate intake, improve understanding of the underlying mechanisms, 
and provide support for specific evidence-based dietary recommendations, we examined 
multiple measures, among which added sugar, individual sugar components, and sweetened 
desserts/beverages, had not been examined in previous BE studies. Moreover, by pooling 
individual-level data from two existing studies, we increased our sample size, which yielded 
more precise estimates of association. Further, harmonization of the exposure variables and 
covariates, and standardization of the statistical models have minimized potential sources of 
heterogeneity between studies. Most importantly, food selection is a non-pharmaceutical and 
potentially sustainable method for disease prevention, and is of interest to patients. 47  
In summary, our pooled study examined multiple measures of sugar/carbohydrate intake 
in relation to the risk of developing BE, and we are the first to report that added sugar, sucrose, 
and sweetened desserts/beverages were associated with a 71%-79% increase in BE risk. Our 
results suggest that clinical recommendations to limit intake of foods and beverages that are 
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high in added sugar (especially table sugar) could potentially reduce the risk of developing BE, 
a precursor to the lethal tumor EA.  
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Table 3.1. Comparison between the two studies of Barrett’s esophagus. 
  Study of Reflux Disease Epidemiology and Incidence of BE 
Study design 
Community-based case-control 
study 
Community-based case-control study 
Time and 
location 
Western WA, 1997-2000 Northern CA, 2002-2005 
Sample size 193 BE cases, 211 controls 320 BE cases, 317 controls 
FFQ (# items) FHCRC (131) Block 98 (110) 
Frequency of 
consumption 
Never or less than once per 
month, 1 per month, 2-3 per 
month, 1 per week, 2 per week, 
3-4 per week, 5-6 per week, 1 per 
day 
Never or less than once per month, 1 
per month, 2-3 per month, 1 per week, 
2 per week, 3-4 per week, 5-6 per 
week, 1 per day 
Serving size Small, medium, large 1/4 cup, 1/2 cup, 1 cup, 2 cups 
FFQ: food frequency questionnaire 
FHCRC: Fred Hutchinson Cancer Research Center 
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Table 3.2. Demographic characteristics among 472 cases and 492 controls from two US case-
control studies of Barrett's esophagus. 
 
Study of Reflux Disease 
 
Epidemiology and 
Incidence of BE 
 
Controls Cases 
 
Controls Cases 
Characteristic N=191 N=176 
 
N=301 N=296 
Age, years, mean (SD) 53.37 (12.08) 54.75 (12.77) 
 
62.35 (10.26) 62.28 (10.71) 
Sex, n (%) 
        Male 119 (62.30) 105 (59.66) 
 
203 (67.44) 217 (73.31) 
   Female 72 (37.70) 71 (40.34) 
 
98 (32.56) 79 (26.69) 
Race, n (%) 
        White 175 (91.62) 157 (89.20) 
 
256 (85.05) 256 (86.49) 
   Other 16 (8.38) 19 (10.80) 
 
45 (14.95) 40 (13.51) 
BE segment length, n (%)     
   <3cm -- 139 (84.76)  -- 109 (43.78) 
   ≥3cm -- 25 (15.24)  -- 140 (56.22) 
Cigarette smoking, n (%) 
       Ever 92 (48.17) 114 (64.77) 
 
170 (56.48) 198 (67.12) 
   Never 99 (51.83) 62 (35.23) 
 
131 (43.52) 97 (32.88) 
Gastro-esophageal reflux disease, n (%)    
   Ever 126 (65.97) 160 (90.91)  138 (45.85) 250 (84.46) 
   Never 65 (34.03) 16 (9.09)  163 (54.15) 46 (15.54) 
GERD frequency, n (%) 
        ≤Weekly 144 (75.79) 47 (26.70) 
 
259 (86.05) 141 (47.64) 
    >Weekly 46 (24.21) 129 (73.30) 
 
42 (13.95) 155 (52.36) 
Proton pump inhibitors use, n (%)     
   Ever 12 (6.32) 79 (44.89)  41 (13.71) 201 (68.37) 
   Never 178 (93.68) 97 (55.11)  258 (86.29) 93 (31.63) 
Body mass index (kg/m2) 
       <25 62 (33.33) 35 (20.12) 
 
70 (23.25) 59 (19.93) 
   25-<30 76 (40.86) 73 (41.95)  111 (36.88) 121 (40.88) 
   ≥30 48 (25.81) 66 (37.93)  120 (39.87) 116 (39.19) 
Fruit/vegetable intake, 
servings/day1, median (SD)   
     
1.71 (1.49) 1.71 (1.43)  4.40 (2.92) 3.65 (2.54) 
1
Based on study-specif ic serving sizes and study-specif ic food frequency questionnaires. 
Missing values (N): GERD frequency (1), smoking (1), Proton Pump Inhibitors use (5), BMI (7), fruit/vegetable intake 
(32), BE segment length (59). 
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Table 3.3. Daily mean (SD) intake of sugar/carbohydrate among 472 cases and 492 controls in two US case-control studies of 
Barrett's esophagus. 
  Study of Reflux Disease   Epidemiology and Incidence of BE 
Measure 
Controls  
N=191 
Cases  
N=176 
 
Controls  
N=301 
Cases  
N=296 
Free glucose (g/day) 16.79 (13.42) 16.80 (11.57) 
 
23.93 (14.48) 22.49 (13.91) 
Sucrose (g/day) 33.51 (22.75) 36.07 (23.26) 
 
35.06 (19.38) 36.80 (21.77) 
Free fructose (g/day) 18.64 (17.16) 18.82 (14.69) 
 
26.84 (17.89) 24.68 (17.06) 
Total sugar (g/day) 86.30 (54.08) 91.14 (50.95) 
 
100.56 (50.03) 99.38 (49.90) 
Added sugar (g/day) 41.01 (42.96) 46.15 (36.00) 
 
40.68 (32.12) 44.18 (33.23) 
Starch (g/day) 75.84 (38.16) 74.97 (36.13) 
 
68.40 (37.53) 66.30 (38.22) 
Total carbohydrate (g/day) 196.95 (92.43) 200.92 (88.68) 
 
215.44 (93.77) 209.17 (95.55) 
Glycemic index 60.62 (4.43) 60.25 (4.68) 
 
60.96 (3.54) 60.62 (4.29) 
Glycemic load 109.23 (55.02) 111.34 (51.57) 
 
116.63 (52.79) 113.28 (53.06) 
All sweetened desserts/beverages1 
(servings/day) 
2.81 (2.26) 3.13 (2.18) 
 
2.10 (1.29) 2.26 (1.43) 
Sweetened desserts1 (servings/day) 1.58 (1.06) 1.76 (1.22) 
 
1.45 (1.08) 1.53 (1.21) 
Sweetened beverages1 (servings/day) 1.23 (1.84) 1.37 (1.57) 
 
0.64 (0.64) 0.73 (0.74) 
1
The differences in intakes of all sw eetened desserts/beverages, sw eetened desserts, and sw eetened beverages betw een the tw o s tudies may be attributed to the 
utilization of study-specif ic FFQs. Both the serving sizes and the number of FFQ line items that contained sw eetened desserts/beverages varied by study. There 
w ere 23 FFQ line items that contain sw eetened desserts/beverages (15 line items contain sw eetened desserts and 8 line items c ontain sw eetened beverages) in 
Study of Reflux Disease. There w ere 18 FFQ line items that contain sw eetened desserts/beverages (13 line items contain sw eetened desserts and 5 line items 
contain sw eetened beverages) in Epidemiology and Incidence of BE. 
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Table 3.4. Multivariable-adjusted ORs and 95%CIs for the associations between 
sugar/carbohydrate intake and risk of developing Barrett's esophagus among 472 cases and 
492 controls from two US case-control studies (pooled approach, based on study-specific 
quartiles). 
Measure Controls (N) Cases (N) OR (95%CI) Ptrend 
Free glucose (g/day)1 
    Q1 116 107 Ref. 
 Q2 120 134 1.44 (0.94-2.21) 
 Q3 123 115 1.26 (0.80-1.99) 
 Q4 122 94 1.29 (0.77-2.17) 0.85 
Sucrose (g/day)2 
    Q1 117 105 Ref. 
 Q2 120 108 1.07 (0.69-1.64) 
 Q3 117 97 1.17 (0.74-1.86) 
 Q4 122 138 1.79 (1.07-3.02) <0.01 
Free fructose (g/day)1 
   Q1 115 108 Ref. 
 Q2 123 131 1.35 (0.88-2.07) 
 Q3 121 113 1.28 (0.81-2.03) 
 Q4 122 98 1.26 (0.77-2.05) 0.66 
Total sugar (g/day)1 
    Q1 117 109 Ref. 
 Q2 120 116 1.15 (0.75-1.78) 
 Q3 122 103 1.09 (0.68-1.73) 
 Q4 122 122 1.54 (0.89-2.67) 0.15 
Added sugar (g/day)2 
    Q1 119 97 Ref. 
 Q2 118 100 1.12 (0.73-1.72) 
 Q3 120 112 1.14 (0.73-1.80) 
 Q4 119 139 1.71 (1.05-2.80) 0.15 
Starch (g/day)2 
    Q1 117 103 Ref. 
 Q2 118 109 1.00 (0.65-1.56) 
 Q3 121 133 1.36 (0.84-2.19) 
 Q4 120 103 1.00 (0.52-1.90) 0.74 
Total carbohydrate (g/day)1 
 Q1 117 109 Ref. 
 Q2 119 115 1.12 (0.72-1.75) 
 Q3 123 127 1.29 (0.78-2.16) 
 Q4 122 99 1.25 (0.61-2.54) 0.39 
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Glycemic index3 
 Q1 122 112 Ref. 
 Q2 122 109 0.83 (0.55-1.26) 
 Q3 119 113 0.93 (0.62-1.41) 
 Q4 118 116 0.93 (0.62-1.41) 0.39 
Glycemic load4 
 Q1 115 108 Ref. 
 Q2 119 124 1.18 (0.76-1.84) 
 Q3 123 109 1.12 (0.67-1.86) 
 Q4 119 107 1.39 (0.71-2.70) 0.35 
All sweetened desserts/beverages (servings/day)5 
 Q1 123 94 Ref. 
 Q2 123 124 1.33 (0.88-2.02) 
 Q3 122 116 1.27 (0.82-1.95) 
 Q4 123 138 1.71 (1.07-2.73) 0.04 
Sweetened desserts (servings/day)6 
 Q1 122 123 Ref. 
 Q2 122 81 0.63 (0.41-0.96) 
 Q3 121 126 1.12 (0.74-1.70) 
 Q4 121 140 1.26 (0.80-1.99) 0.10 
Sweetened beverages (servings/day)3 
 Q1 118 97 Ref. 
 Q2 121 108 1.11 (0.73-1.69) 
 Q3 120 107 1.29 (0.84-1.98) 
 Q4 122 138 1.47 (0.95-2.26) 0.29 
1
Adjusted for age, sex, study indicator, fruit/vegetable intake, GERD frequency, and total energy intake                                                                                                                                                            
2
Adjusted for age, sex, race, study indicator, BMI, fruit/vegetable intake, GERD frequency, and total energy intake                                                                                                                                                                                 
3
Adjusted for age, sex, race, study indicator, fruit/vegetable intake, GERD frequency, and total energy intake   
4
Adjusted for age, sex, study indicator, fruit/vegetable intake, GERD frequency, and total energy intake         
5
Adjusted for age, sex, study indicator, GERD frequency, and total energy intake  
6
Adjusted for age, sex, study indicator, BMI, GERD frequency, and total energy intake                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
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Table 3.5. Multivariable-adjusted ORs and 95%CIs for the associations between sugar/carbohydrate intake 
and risk of developing Barrett's esophagus by BE segment length among 413 cases and 492 controls from 
two US case-control studies (pooled approach, based on study-specific medians). 
   Short-segment BE(<3cm)   Long-segment BE (≥3cm) P-value* 
Measure 
Controls 
(N) 
Cases 
(N) 
OR (95%CI)   Cases 
(N) 
OR (95%CI)  
Free glucose (g/day)1 
      
 
<median 236 116 Ref. 
 
96 Ref.  
 ≥median 245 117 1.23 (0.83-1.83) 
 
65 0.74 (0.47-1.16) 0.04 
Sucrose (g/day)1 
      
 
<median 239 98 Ref. 
 
91 Ref.  
 ≥median 242 135 1.70 (1.12-2.58) 
 
70 0.82 (0.51-1.31) <0.01 
Free fructose (g/day)1 
      
 
<median 238 118 Ref. 
 
91 Ref.  
 ≥median 243 115 1.21 (0.82-1.79) 
 
70 0.92 (0.59-1.43) 0.27 
Total sugar (g/day)1 
      
 
<median 237 102 Ref. 
 
95 Ref.  
 ≥median 244 131 1.57 (1.03-2.39) 
 
66 0.72 (0.45-1.17) <0.01 
Added sugar (g/day)2 
      
 
<median 237 96 Ref. 
 
78 Ref.  
 ≥median 239 135 1.50 (0.99-2.26) 
 
83 0.95 (0.60-1.50) 0.07 
Starch (g/day)1 
      
 
<median 237 99 Ref. 
 
91 Ref.  
 ≥median 244 134 1.65 (1.05-2.58) 
 
70 0.76 (0.45-1.26) <0.01 
Total carbohydrate (g/day)1 
  
 
<median 236 102 Ref. 
 
96 Ref.  
 ≥median 245 131 1.72 (1.07-2.77) 
 
65 0.63 (0.37-1.10) <0.01 
Glycemic index3 
  
 
<median 244 108 Ref. 
 
86 Ref.  
 ≥median 232 123 1.06 (0.75-1.50) 
 
75 0.90 (0.60-1.33) 0.44 
Glycemic load1 
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<median 236 99 Ref. 
 
104 Ref.  
 ≥median 245 134 1.76 (1.10-2.82) 
 
57 0.42 (0.24-0.74) 0.01 
All sweetened desserts/beverages (servings/day)4 
   
 
<median 236 104 Ref. 
 
79 Ref.  
 ≥median 241 127 1.22 (0.84-1.75) 
 
82 1.04 (0.68-1.57) 0.51 
Sweetened desserts (servings/day)2 
  
 
 
 
<median 238 91 Ref. 
 
81 Ref.  
 ≥median 238 140 1.81 (1.20-2.71) 
 
80 1.08 (0.69-1.68) 0.04 
Sweetened beverages (servings/day)5 
  
 
 
 
<median 245 104 Ref. 
 
78 Ref.  
 ≥median 246 144 1.48 (1.05-2.11) 
 
87 1.27 (0.85-1.89) 0.47 
1
Adjusted for age, sex, study indicator, fruit/vegetable intake, GERD frequency, and total energy intake                                                                                                                                                                                 
2
Adjusted for age, sex, race, study indicator, BMI, fruit/vegetable intake, GERD frequency, and total energy intake                                                                                                                                                                                    
3
Adjusted for age, sex, study indicator, BMI, fruit/vegetable intake, GERD frequency, and total energy intake                                                                                                                                                                                 
4
Adjusted for age, sex, study indicator, BMI, fruit/vegetable intake, and total energy intake                                                                                                                                                                                  
5
Adjusted for age, sex, race, study indicator, fruit/vegetable intake, and total energy intake   
*P value for Wald test of equality of effect across the different outcome types 
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Table 3.6. Food frequency questionnaire items that were categorized as sweetened desserts/beverages in each of the two US case 
control studies of Barrett’s esophagus. 
Study of Reflux Disease (Western Washington State) 
Cold cereal 
Pancakes and waffles 
Nonfat yogurt (not frozen) 
All other yogurt (not frozen) 
Ice cream 
Pudding, custard, and flan 
Low-fat or non-fat frozen desserts 
Doughnuts, cakes, pastries, Pop-Tarts, pan dulce 
Cookies 
Pumpkin and sweet potato pie 
All other pies, fried pastries, pastelitos, and fruit empanadas                                                                                            
Chocolate candy and candy bars 
Hard candy, jam, jelly, honey, or syrup 
Sugar in coffee or tea and on cereal 
Regular Soft drinks (not diet) 
Orange juice and grape fruit juice 
Tang, Kool-Aid, Hi-C, and other fruit drinks 
Other fruit juices such as apple, grape 
 
 
Epidemiology and Incidence of BE (Northern California)  
Pancakes, waffles, French toast, Pop Tarts 
Breakfast bars, granola bars, power bars 
High-fiber cereals like All Bran, Raisin Bran, Fruit-n-Fiber 
Product 19, Just Right or Total cereal 
Any other cold cereal, like Corn Flakes, Cheerios, Special K 
Yogurt or frozen yogurt 
Doughnuts, Danish pastry 
Cake, sweet rolls, coffee cake 
Cookies 
Ice cream, ice milk, ice cream, bars 
Pumpkin pie, sweet potato pie 
Any other pie or cobbler 
Chocolate candy, candy bars 
Other candy, not chocolate, like hard candy, caramel, jelly beans 
Jelly, jam, or syrup 
Sugar on coffee, sugar on tea 
Regular soft drinks, or bottled drinks like Snapple (not diet drinks) 
Real 100% orange or grapefruit juice, including fresh, frozen,  
or bottled 
Other real fruit juices like apple juice, prune juice, lemonade 
Kool-Aid, Hi-C, or other drinks with added vitamin C 
Other fruit juices such as apple, grape 
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Table 3.7. Study-specific sugar/carbohydrate intake quartiles defined by the intake 
distribution of the controls from each of the two US case-control studies of Barrett’s 
esophagus. 
Measure 
Study of 
Reflux Disease 
Epidemiology and 
Incidence of BE 
Controls 
(N=492) 
Cases 
(N=472) 
Free glucose (g/day) 
    Q1 1.61-<9.45 2.93-<13.17 123 115 
Q2 9.45-<14.12 13.17-<20.89 123 135 
Q3 14.12-<19.93 20.89-<30.63 123 123 
Q4 ≥19.93 ≥30.63 123 99 
Sucrose (g/day) 
    Q1 2.26-<17.71 4.16-<22.14 123 111 
Q2 17.71-<30.30 22.14-<31.85 123 117 
Q3 30.30-<42.19 31.85-<44.17 123 100 
Q4 ≥42.19 ≥44.17 123 144 
Free fructose (g/day) 
    Q1 1.48-<9.69 1.92-<13.74 123 116 
Q2 9.69-<15.23 13.74-<22.50 123 134 
Q3 15.23-<22.04 22.50-<34.99 123 118 
Q4 ≥22.04 ≥34.99 123 104 
Total sugar (g/day) 
    Q1 10.85-<52.18 14.55-<65.72 123 115 
Q2 52.18-<79.96 65.72-<93.47 123 122 
Q3 79.96-<107.09 93.47-<123.44 123 105 
Q4 ≥107.09 ≥123.44 123 130 
Added sugar (g/day) 
    Q1 1.77-<19.08 1.77-<20.11 123 106 
Q2 19.08-<33.20 20.11-<32.15 123 101 
Q3 33.20-<50.32 32.15-<50.25 123 116 
Q4 ≥50.32 ≥50.25 123 149 
Starch (g/day) 
    Q1 4.48-<47.94 7.05-<41.29 123 113 
Q2 47.95-<69.39 41.29-<58.63 123 117 
Q3 69.39-<98.56 58.63-<86.34 123 136 
Q4 ≥98.56 ≥86.34 123 106 
Total carbohydrate (g/day) 
    Q1 35.56-<129.08 38.13-149.58 123 114 
Q2 129.09-<180.00 149.58-202.76 123 121 
Q3 180.00-<251.16 202.76-265.03 123 135 
Q4 ≥251.16 ≥265.03 123 102 
Glycemic index 
    Q1 22.27-<59.08 35.36-<58.77 123 122 
Q2 59.08-<61.01 58.77-<61.11 123 113 
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Q3 61.01-<63.10 61.11-<63.13 123 116 
Q4 ≥63.10 ≥63.13 123 121 
Glycemic load 
    Q1 16.69-<70.97 21.61-<78.20 123 117 
Q2 70.97-<97.77 78.20-<111.72 123 126 
Q3 97.77-<138.37 111.72-<142.48 123 119 
Q4 ≥138.37 ≥142.48 123 110 
All sweetened desserts/beverages (servings/day) 
  Q1 0-<1.29 0.06-<1.13 123 94 
Q2 1.29-<2.44 1.13-<1.88 123 124 
Q3 2.44-<3.75 1.88-<2.81 123 116 
Q4 ≥3.75 ≥2.81 123 138 
Sweetened desserts (servings/day) 
   Q1 0-<0.78 0-<0.68 123 124 
Q2 0.78-<1.36 0.68-<1.14 123 81 
Q3 1.36-<2.22 1.14-<1.98 123 127 
Q4 ≥2.22 ≥1.98 123 140 
Sweetened beverages (servings/day) 
   Q1 0-<0.20 0-<0.12 123 102 
Q2 0.20-<0.71 0.12-<0.52 123 109 
Q3 0.71-<1.47 0.52-<1.00 123 116 
Q4 ≥1.47 ≥1.00 123 145 
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Table 3.8. Multivariable-adjusted ORs and 95%CIs for the associations between 
sugar/carbohydrate intake and risk of developing Barrett's esophagus among 472 cases and 
492 controls from two US case-control studies (meta-analytic approach, fixed effect). 
Measure 
Controls 
(N) 
Cases 
(N) 
OR (95%CI) I2 (%) Pheterogeneity 
Free glucose (g/day)1 
    Q1 116 107 Ref. 
  Q2 120 134 1.43 (0.93-2.21) 0 0.68 
Q3 123 115 1.27 (0.80-2.02) 0 0.38 
Q4 122 94 1.28 (0.75-2.16) 0 0.32 
Ptrend 
  
0.78 0 0.79 
Sucrose (g/day)2   
   Q1 117 105 Ref. 
  Q2 120 108 1.07 (0.69-1.66) 4.4 0.31 
Q3 117 97 1.17 (0.73-1.86) 0 0.85 
Q4 122 138 1.78 (1.05-3.01)    0 0.997 
Ptrend 
  
0.08 51.1 0.15 
Free fructose (g/day)1 
    Q1 115 108 Ref. 
  Q2 123 131 1.36 (0.88-2.09) 0 0.70 
Q3 121 113 1.28 (0.81-2.05) 0 0.75 
Q4 122 98 1.23 (0.74-2.03) 43.4 0.18 
Ptrend 
  
0.63 0 0.66 
Total sugar (g/day)1  
   Q1 117 109 Ref. 
  Q2 120 116  1.17 (0.75-1.80) 28.1 0.24 
Q3 122 103 1.08 (0.67-1.73) 0 0.59 
Q4 122 122 1.57 (0.90-2.75) 0 0.76 
Ptrend 
  
0.24 0 0.83 
Added sugar (g/day)2 
    Q1 119 97 Ref. 
  Q2 118 100 1.11 (0.72-1.70) 0 0.78 
Q3 120 112 1.15 (0.73-1.82) 0 0.72 
Q4 119 139 1.69 (1.03-2.77)  0 0.81 
Ptrend 
  
0.22 0 0.46 
Starch (g/day)2   
   Q1 117 103 Ref. 
  Q2 118 109  0.99 (0.64-1.54) 0 0.43 
Q3 121 133 1.37 (0.84-2.21) 0 0.92 
Q4 120 103 0.98 (0.51-1.89) 0 0.69 
Ptrend 
  
0.76 0 0.81 
Total carbohydrate (g/day)1 
  Q1 117 109 Ref. 
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Q2 119 115 1.13 (0.72-1.78) 0 0.81 
Q3 123 127 1.31 (0.78-2.20) 0 0.61 
Q4 122 99 1.26 (0.61-2.61) 0 0.38 
Ptrend 
  
0.34 0 >0.99 
Glycemic index3 
  Q1 122 112 Ref. 
  Q2 122 109 0.83 (0.55-1.26) 0 0.36 
Q3 119 113 0.93 (0.61-1.40) 0 0.34 
Q4 118 116 0.93 (0.61-1.41) 0 0.72 
Ptrend 
  
0.36 0 0.82 
Glycemic load4 
  Q1 115 108 Ref. 
  Q2 119 124  1.18 (0.75-1.84) 0 0.89 
Q3 123 109 1.13 (0.67-1.89) 0 0.36 
Q4 119 107 1.36 (0.69-2.68) 26.8 0.24 
Ptrend      
All sweetened desserts/beverages (servings/day)5 
  Q1 123 94 Ref. 
  Q2 123 124 1.33 (0.88-2.01) 0 0.37 
Q3 122 116 1.25 (0.81-1.93) 0 0.79 
Q4 123 138 1.69 (1.06-2.72) 0 0.51 
Ptrend 
  
0.05 39.7 0.20 
Sweetened desserts (servings/day)6 
   Q1 122 123 Ref. 
  Q2 122 81  0.62 (0.40-0.95) 55.1 0.14 
Q3 121 126 1.11 (0.73-1.69) 38.3 0.20 
Q4 121 140 1.22 (0.77-1.93) 0 0.39 
Ptrend 
  
0.12 0 0.35 
Sweetened beverages (servings/day)3 
   Q1 118 97 Ref. 
  Q2 121 108 1.12 (0.73-1.72) 0.0 0.49 
Q3 120 107  1.30 (0.84-1.99) 0.0 0.45 
Q4 122 138  1.50 (0.97-2.30) 48.0 0.17 
Ptrend     0.29 0 0.41 
1
Adjusted for age, sex, study indicator, fruit/vegetable intake, GERD frequency, and total energy intake                                                                                                                                                            
2
Adjusted for age, sex, race, study indicator, BMI, fruit/vegetable intake, GERD frequency, and total energy intake                                                                                                                                                                                 
3
Adjusted for age, sex, race, study indicator, fruit/vegetable intake, GERD frequency, and total energy intake   
4
Adjusted for age, sex, study indicator, fruit/vegetable intake, GERD frequency, and total energy intake         
5
Adjusted for age, sex, study indicator, GERD frequency, and total energy intake  
6
Adjusted for age, sex, study indicator, BMI, GERD frequency, and total energy intake      
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CHAPTER 4: A POOLED ANALYSIS OF DIETARY SUGAR/CARBOHYDRATE INTAKE AND 
ESOPHAGEAL AND GASTRIC CARDIA ADENOCARCINOMA IN THE UNITED STATES (US)  
 
Introduction 
Incidence of esophageal adenocarcinoma (EA) and the adjacently located gastric cardia 
adenocarcinoma (GCA), have increased dramatically in westernized countries during the past 
four decades.1-9 The overall 5-year survival for these cancers remains low at <20%.10, 11 
Therefore, identification of safe and practical intervention strategies to reduce risk of developing 
or dying from these lethal cancers is a pressing clinical and public health need.  
In addition to gastro-esophageal reflux disease (GERD) and cigarette smoking, obesity 
is an established EA/GCA risk factor.12-14 As such, exploration of the role of glucose metabolism 
in the development of EA/GCA appears warranted.15-17 Long-term high sugar/carbohydrate 
intake may lead to chronic hyperinsulinemia, which may decrease esophageal cell apoptosis 
and prolong healing time after esophageal mucosal injury thereby promoting carcinogenesis. 17-20 
Intake of foods high in refined sugar leads to acute fluctuations in blood glucose, which may 
induce oxidative stress and modulate the carcinogenesis pathways.21-23 Whether sugar intake, 
which has also increased dramatically since 1960s,24 is associated with risk of developing EA 
has been investigated in several epidemiologic studies, with inconsistent results.16, 25, 26 Only 
one study has examined the role of sugar/carbohydrate intake in association with survival 
among individuals diagnosed with EA.27 
In this study, we harmonized and pooled individual-level data from two case-control 
studies conducted within the US, with cases followed for vital status, to investigate whether 
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sugar/carbohydrate intake is associated with the risk of developing EA/GCA or  mortality after 
diagnosis of EA/GCA. 
 
Methods 
This pooled analysis comprises two case-control studies of esophageal and gastric 
cancer: the US Multi-Center study and the Los Angeles (LA) Multi-Ethnic study, 28, 29 selected 
from the International Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON) 
because both are population-based with follow-up information on vital status and are similar in 
data collection methodology. The institutional review boards of all participating institutions 
approved this study.   
Study Population. The US Multi-Center study was conducted in Connecticut, New 
Jersey, and western Washington state.28 Eligible cases were 30-79 year-old English-speaking 
men and women diagnosed with first primary invasive cancer of the esophagus or stomach 
during 1993-1995. Cases were identified through population-based cancer registries using 
established rapid-reporting systems; a diagnosis of EA or GCA was confirmed through review of 
pathology materials. Controls were identified using random digit-dialing method for those aged 
30-64 years, and Health Care Financing Administration rosters for those aged 65-79 years. 
Controls were frequency matched to the expected case distribution by 5-year age group, sex, 
state of residence, and, in New Jersey, race. 
The LA Multi-Ethnic study was conducted in LA County, California.29 Cases were 30-74 
year-old men and women diagnosed with first primary cancer of esophagus or stomach during 
1992-1997. Cases were identified through the LA County cancer registry; EA or GCA diagnosis 
was confirmed by reviewing all available pathology reports. Controls were selected from a 
case’s neighborhood and individually matched by date of birth (±5 years), sex, and race. 
Respondents from the two studies included 513 EA cases, 538 GCA cases, and 2051 
controls. We excluded individuals with no information on dietary intake or those who reported 
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extreme total energy intake values (defined by beyond ±3 standard deviations from study-
specific loge-transformed mean total energy intake), yielding 500 EA cases, 529 GCA cases, 
and 2027 controls for this pooled analysis.30  
Dietary Assessment. In both studies, dietary information was collected using validated 
food frequency questionnaires (FFQs) during structured in-person interviews.31, 32 When 
subjects were unable to participate in the interview due to illness/death, interviews were 
administered to their closest next of kin, usually the spouse.31, 32 The US Multi-Center Study 
utilized a 104-item FFQ, a modification of the Fred Hutchinson Cancer Research Center 
instrument.33 Participants were asked to report their usual diet in the 3-5 years before diagnosis 
(cases) or interview (controls).31 The LA Multi-Ethnic Study utilized a 124-item FFQ developed 
at University of Hawaii.32 Cases were asked to report their diet in the year before the date of 
diagnosis, and controls were asked to report their diet during the same time period as their 
matched case.32 The two FFQs similarly assessed dietary intake (food items, frequency, and 
total number of food items) (Table 4.1), which enhanced our ability to harmonize and pool data. 
Sugar/Carbohydrate Intake Assessment. We estimated twelve intake measures 
including sugar components (free glucose, free fructose, sucrose); total sugar; added sugar; 
total carbohydrate; starch; glycemic index; glycemic load; servings of sweetened desserts, 
sweetened beverages, and sweetened desserts/beverages (Table 4.5). Added sugar was 
defined as sugars and syrups that were added to foods during food preparation/processing. 34 
For this pooled study, the study-specific FFQ information was linked with the University of 
Minnesota Nutrition Coordinating Center Food and Nutrient Database to determine 
sugar/carbohydrate intake.34 For example, daily starch intake from an FFQ line item was 
calculated as follows.35 
                                  ( )           (    )               
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Daily intake of starch was calculated by summing up starch intake across all FFQ line items. 
When FFQ line items represented >1 food item, the nutrient contents of the FFQ line item were 
weighted according to their weights estimated based on national consumption pattern. 35-37   
Dietary glycemic index and glycemic load were developed to estimate the effect of diet 
on blood glucose. For this study, the following formulas were used to calculate dietary glycemic 
index and dietary glycemic load,38-40 respectively. 
∑(                        ( )                            ( )                              )
                            ( )    
 
∑(                        ( )                           ( )                              )
   
 
Covariate Assessment. Information on non-dietary covariates was collected in-person 
by each study using interviewer-administered questionnaires.28, 29 Covariates were harmonized, 
as previously described.12-14  
Outcome Assessment. Vital status and date of death for EA/GCA cases were 
determined by linking participants with the National Death Index.41 An event was defined as 
death from any cause during follow-up. The maximum length of follow-up was 90 months in the 
US Multi-Center study and 129 months in the LA Multi-Ethnic study.  
Statistical Analysis. Estimated sugar/carbohydrate intake from each study was pooled 
based on study-specific quintiles (Q), based on the study-specific intake distributions among the 
controls (case-control analysis) or EA/GCA patients (survival analysis).30, 42  
We used multinomial logistic regression to calculate odds ratios (ORs) and 95% 
confidence intervals (CIs) for the association between sugar/carbohydrate intake and  EA/GCA 
incidence, with each of the intake measures and outcomes modeled separately. 43 We explored 
whether body mass index (BMI<25/≥25kg/m2 during adulthood44 or year before interview29), or 
frequency of GERD (<weekly/≥weekly) were effect measure modifiers of the associations 
between sugar/carbohydrate intake(comparing Q1-3 vs. Q4-5) and EA/GCA incidence. Effect 
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measure modification was assessed using the likelihood ratio test (multiplicative scale) and the 
interaction contrast ratio (ICR) and 95%CI (additive scale)45   
Cox proportional hazards regression was used to calculate hazard ratios (HRs) and 
95%CIs for the association between sugar/carbohydrate intake and EA/GCA survival, with each 
intake measure and outcome modeled separately.45 The proportional hazards assumption was 
evaluated using product terms with log-time and exposure, and product terms with log-time and 
each covariate. The assumption was not violated in any of the models.  
Potential confounders were first identified using directed acyclic graphs.46 After the initial 
adjustment set was identified, only those covariates that changed the effect estimate (on a log e 
scale) by ≥10% were included in final models.45 Case-control models included adjustment for 
age (continuous), sex (male/female), race (white/other), study indicator (US Multi -Center/LA 
Multi-Ethnic), cigarette smoking (ever/never), fruit/vegetable intake (servings, 
<median/≥median), GERD frequency (<weekly/≥weekly), and total energy intake (continuous 
kcal/day). Survival models included age, education (≤high school/some college or technical 
school/≥college graduate), study indicator, and total energy intake. BMI and education were not 
included in some of the models, because inclusion/removal of these covariates changed the 
effect estimate on a loge scale by <10%.
45 Linear trends were examined by modeling 
sugar/carbohydrate intake as continuous variables. 
Sensitivity analyses for both case-control and survival analyses were conducted as 
follows. First, we pooled study-specific effect estimates using a meta-analytic approach (fixed 
effect, Table 4.6). Second, we also examined pooled individual-level intake based on absolute 
cut-points derived from intake distributions among all controls (case-control analysis) or all 
EA/GCA patients (survival analysis).30, 42 Third, we utilized wider exclusion criteria for extreme 
total energy intake values (lower/upper 2.5%). Fourth, we excluded participants with proxy 
interviews. Fifth, we compared effect estimates derived using carbohydrate intake values 
estimated based on the University of Minnesota nutrient database with effect estimates derived 
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using carbohydrate intake values previously calculated by study-specific nutrient data 
processing centers. For the case-control analysis only, we additionally adjusted for potential 
confounding by physical activity and diabetes; explored diabetes as an effect measure modifier 
in the LA Multi-Ethnic study (since this information was not available from the other study); 
explored the effect of fructose from fruits/vegetables versus other fructose; used nutrient density 
energy adjustment method; and removed energy intake from the model.  
SAS (version 9.3; SAS Institute Inc., Cary, NC) and STATA software (version 14.0; 
StataCorp LP, College Station, TX) were used for the statistical analysis. 
 
Results 
As presented in Table 4.2, participants in the LA Multi-Ethnic study were more likely to 
be younger, non-White, obese (BMI>30), experience frequent GERD, consume more 
fruits/vegetables, and have higher total energy intake, compared to participants in the US Multi -
Center study (which was conducted in New Jersey, Connecticut, and western Washington state). 
As shown in Table 4.3, in both the US Multi-Center study and the LA Multi-Ethnic study, 
respectively, EA/GCA cases, compared to controls, had higher mean intake of sucrose (g/day: 
49.91/50.69 vs. 45.78; 47.16/41.99 vs. 41.42) and sweetened desserts/beverages (servings/day: 
4.33/4.42 vs. 3.94; 3.66/3.30 vs. 3.18).  
Multivariable-adjusted ORs for EA (comparing the highest to the lowest quintile) were 
increased by 51% to 58% in association with intake of sucrose (ORQ5vs.Q1=1.51, 95%CI=1.01-
2.27, Ptrend=0.19), sweetened desserts/beverages (ORQ5vs.Q1=1.55, 95%CI=1.06-2.27, 
Ptrend=0.28), and dietary glycemic index (ORQ5vs.Q1=1.58, 95%CI=1.13-2.21, Ptrend=0.32) (Table 
4.4). Fructose intake was inversely associated with risk of developing EA (ORQ5v s.Q1=0.60, 
95%CI=0.41-0.89, Ptrend=0.08), which remained when examining intake of natural fructose 
(ORQ5v s.Q1=0.52, 95% CI=0.34-0.82), but not for intake of other fructose (ORQ5vs.Q1=0.89, 95% 
CI=0.60-1.32). The 4th quintile of glucose intake was associated with 39% decrease in the OR 
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for EA (Ptrend=0.08). For carbohydrate intake, the individual ORs were close to null. However, 
there was a significant trend for these associations with EA and GCA (Ptrend ≤0.02), which 
appeared to be driven by very high intake of carbohydrate among some controls (data not 
shown). In sensitivity analyses, most findings were similar to those shown in Table 4.4., with 
several exceptions, including attenuation of positive sucrose-EA association, and more 
pronounced inverse association with carbohydrate intake (Table 4.7). In addition, after removing 
energy intake from the models, ORs were more pronounced for most measures (Table 4.8).  
BMI modified, on the multiplicative scale, associations between sucrose, sweetened 
desserts/beverages, or glycemic index and risk of developing EA. The OR for the sucrose-EA 
association was elevated among participants with BMI<25 (OR=1.79, 95%CI=1.26-2.56), but 
not among those with BMI≥25 (OR=1.05, 95%CI=0.76-1.44) (Pinteraction=0.02). Similarly, for the 
sweetened desserts/beverage-EA association, an elevated OR was found for BMI<25 (OR=1.45, 
95%CI=1.03-2.06), but not for BMI≥25 (OR=0.85, 95%CI=0.62-1.16) (Pinteraction=0.02). In 
contrast, the glycemic index-EA association was elevated for BMI≥25 (OR=1.38, 95%CI=1.03-
1.85), but not for BMI<25 (OR=0.88, 95%CI=0.62-1.24) (Pinteraction=0.05). On the additive scale, 
effect measure modification by BMI on the glycemic index-EA association was also evident 
(ICR=0.62, 95%CI=0.08-1.15). GERD modified, on the multiplicative scale, the sucrose-EA 
association: the OR was elevated for GERD<weekly (OR=1.58, 95%CI=1.16-2.14), but not for 
GERD≥weekly (OR=1.01, 95%CI=0.70-1.47) (Pinteraction=0.05). In the LA Multi-Ethnic study, there 
was no strong indication that diabetes was an effect measure modifier in any of the significant 
associations between sugar/carbohydrate and risk of developing EA (data not shown). 
Other sugar/carbohydrate measures were not associated with increased risk of 
developing GCA (Table 4.4), or mortality after EA/GCA (Table 4.9). 
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Discussion 
In this pooled study, the risk of developing EA was increased 51% to 58% in association 
with sucrose, sweetened desserts/beverages, and glycemic index; these associations were 
modified by BMI or frequency of GERD. Other sugar/carbohydrate measures were not 
associated with EA/GCA incidence nor mortality after EA/GCA. Our study suggests that 
reducing intake of sucrose and sweetened desserts/beverages (especially among those with 
BMI<25 or GERD<weekly), and dietary glycemic index (especially among those with BMI≥25), 
may be plausible EA risk reduction strategies.  
Ours is the first study to report that sweetened desserts/beverages are associated with 
increased risk of developing EA. Positive, but non-significant findings were reported by a small 
US case-control study of EA,47 based on assessment of only five dessert line items. In contrast, 
our larger pooled study included a more comprehensive dessert/beverage assessment based 
on 17-19 line items. Others,48-50 focused only on carbonated beverages, found no positive 
associations; however, our category of sweetened beverages enlarges the number of sugar-
containing food items considered. Compared to other sugar/carbohydrate measures, sweetened 
desserts/beverages are relatively easier for the general population to identify when 
implementing risk reduction strategies. Thus, our finding, if confirmed, has potential public 
health/clinical implications.  
Several studies have examined the association between glycemic index and risk of 
developing EA, but with inconsistent results.16, 25, 26 An Australian case-control study reported no 
association.16  In contrast, two studies - an Irish case-control study of EA25 and the prospective 
NIH-AARP study (combining EA and esophageal squamous cell carcinoma (ESCC)) 51 - 
reported significant 42% and 50% increases in the effect estimates, respectively. Results of the 
latter two investigations are consistent with our finding of a 58% increased OR for the glycemic 
index-EA association.  
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Sucrose intake was positively associated with EA incidence in our study, but the NIH-
AARP study reported no association.26 However, the NIH-AARP study did not distinguish the 
two types of esophageal cancer (EA/ESCC) that have different etiologies,52 and adjusted for 
different confounder sets than our study. However, the NIH-AARP study26  reported a positive 
association between added sugar and EA incidence, which contrasts with our finding of no 
association with added sugar. Sucrose exists naturally in fruits/vegetables, but is also commonly 
present as table sugar, which can be added by the consumer or in preparation of processed 
foods/beverages.53 Sucrose in fruits/vegetables co-exists with vitamins, protein, minerals, and 
fiber, which can preserve cell integrity and slow the rate of sucrose digestion. 53-55 In contrast, 
table sugar is present in foods/beverages that are low in fiber and micronutrients, and are 
rapidly digestible.53 The quick digestion of concentrated table sugar induces acute glucose 
fluctuations, which may increase oxidative stress and cancer risk.21-23 Therefore, it is possible 
that the positive sucrose-EA association we found was driven by table sugar intake.  
We are the first to report that free fructose was inversely associated with EA incidence, 
which in sensitivity analyses appeared to be driven by natural fructose.  Reasons for our 
findings are unclear. They could be spurious, given that in animal studies fructose has been 
shown to induce hyperinsulinemia by raising serum uric acid.56  In addition to the anti-
carcinogenic substances found in foods with natural fructose, another possible explanation for 
the inverse finding is the potential for under-reporting of fructose intake in EA patients. Although 
instructed otherwise, EA patients may have confused their current diet with their previous diet. 
As dysphagia is a common symptom of EA, patients may experience difficulty swallowing and 
therefore may reduce raw fruit intake.57 Further adequately-powered studies are needed to 
explore the appropriate window of exposure for fructose in association with EA incidence.  
In our study, glycemic index was associated with an increased risk of developing EA 
among participants with BMI≥25, but not among those with BMI<25. This finding suggests a 
synergistic effect of high glycemic index diet and obesity on carcinogenesis, possibly via insulin 
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resistance.20, 58 Similarly, in the stratified analysis, the positive glycemic index-esophageal 
cancer association reported in NIH-AARP study only remained in the high BMI group, and the 
positive association reported by the Irish study only remained in the BMI≥25 and high waist -to-
hip ratio group, although no significant interactions were found in either study.25, 51 We are first 
to report that both sucrose and sweetened desserts/beverages were associated with an 
elevated risk of developing EA among participants with BMI<25, but not among those with 
BMI≥25. There are two possible explanations: participants with BMI≥25 may be more likely to 
underreport their sweets intake due to social desirability; or obesity is such a strong, 
metabolically active risk factor for EA, that the metabolic impact of sucrose or sweetened 
desserts/beverages intake on carcinogenesis is therefore less evident among the obese. 
  There are several limitations to our study. First, recall bias is a possibility. Although the 
participants were instructed to report dietary intake during time periods before 
diagnosis/interview, it is possible that patients may have confused their previous diet with their 
current diet, as discussed above. Second, non-differential misclassification may be of concern, 
given dietary intake was collected using FFQs. Non-differential misclassification may have been 
introduced by data harmonization and pooling, given the discrepancies in data collection, 
variable definitions, and data management between the two studies. To mitigate this possibility, 
we appropriately pooled intake estimates based on relative rankings of intake in each study. 
Third, we were unable to fully assess the impact of diabetes, given that information on diabetes 
was available in one of the two pooled studies. But in sensitivity analysis within the LA Multi-
Ethnic study only, diabetes did not confound or modify the EA associations with sucrose, 
sweetened desserts/beverages, or glycemic index. Further adequately-powered studies are 
needed to explore the role of diabetes in these associations. 
There are also several strengths to our study. Ours is the first to comprehensively 
investigate the role of sugar/carbohydrate intake in relation to EA/GCA incidence and mortality 
after diagnosis of EA/GCA. Harmonizing and pooling of individual-level study data minimized 
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potential sources of heterogeneity between studies and improved study power. Consideration of 
multiple measures allowed us to more fully capture the complexity of sugar/carbohydrate intake. 
Finally, the population-based design enhances generalizability of our findings.  
In conclusion, we found increases in the risk of developing EA in association with three 
measures of sugar/carbohydrate intake assessed in our pooled study. Our results suggest that 
limiting intake of sucrose (especially table sugar), sweetened desserts/beverages, along with 
foods that contribute to a high dietary glycemic index, may be plausible risk reduction strategies 
for EA incidence. 
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Table 4.1. Comparison between the two studies of esophageal and gastric adenocarcinoma.  
  US Multi-Center study LA Multi-Ethnic study 
Study design Population-based case-control study Population-based case-control study 
Time and location CT, NJ,WA, 1993-1995 Los Angeles county, CA, 1992-1997 
Sample size 
282 EA cases, 256 GCA cases,                  
684 controls 
218 EA cases, 273 GCA cases,              
1343 controls 
FFQ (# items) Modified FHCRC (104) University of Hawaii (124) 
Frequency of consumption _  times per D W M Y _  times per D W M Y 
Serving size Assumed medium serving size 1/2 cup, 1 cup, 1 ½ cups  
FFQ: food frequency questionnaire; FHCRC: Fred Hutchinson Cancer Research Center 
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Table 4.2. Distribution of demographic and other relevant characteristics among 500 EA cases, 529 GCA cases, and 2027 
controls from two US case-control studies of esophageal and gastric cardia adenocarcinoma. 
 
US Multi-Center study 
 
LA Multi-Ethnic study 
 
Controls EA cases GCA cases 
 
Controls EA cases GCA cases 
Characteristic N=684 N=282 N=256 
 
N=1343 N=218 N=273 
Age, years, mean 
(SD) 62.74 (10.66) 64.34 (10.69) 63.14 (10.91) 
 
61.52 (11.25) 61.08 (9.47) 60.73 (10.19) 
Sex, n (%) 
          Male 548 (80.12) 235 (83.33) 218 (85.16) 
 
991 (73.79) 198 (90.83) 227 (83.15) 
   Female 136 (19.88) 47 (16.67) 38 (14.84) 
 
352 (26.21) 20 (9.17) 46 (16.85) 
Race, n (%) 
          White 615 (89.91) 268 (95.04) 243 (94.92) 
 
838 (62.40) 169 (77.52) 208 (76.19) 
   Other 69 (10.09) 14 (4.96) 13 (5.08) 
 
505 (37.60) 49 (22.48) 65 (23.81) 
Education, n (%) 
          ≤High school 302 (44.15) 152 (54.09) 138 (54.12) 
 
498 (37.08) 97 (44.50) 119 (43.59) 
   Some 
college/technical 172 (25.15) 75 (26.69) 59 (23.14) 
 
386 (28.74) 62 (28.44) 86 (31.50) 
   ≥College graduate 210 (30.70) 54 (19.22) 58 (22.75) 
 
459 (34.18) 59 (27.06) 68 (24.91) 
Cigarette smoking, n (%) 
         Ever 443 (64.74) 220 (79.71) 202 (82.11) 
 
806 (60.01) 170 (77.98) 195 (71.43) 
   Never 211 (32.26) 56 (20.29) 44 (17.89) 
 
537 (39.99) 48 (22.02) 78 (28.57) 
GERD, n (%)        
   Ever 356 (52.05) 183 (65.12) 110 (42.97)  890 (66.32) 176 (80.73) 185 (68.52) 
   Never 328 (47.95) 98 (34.88) 146 (57.03)  452 (33.68) 42 (19.27) 85 (31.48) 
GERD frequency, n (%) 
          <Weekly 553 (81.20) 157 (56.47) 192 (75.00) 
 
1068 (79.58) 101 (46.54) 166 (61.48) 
    ≥Weekly 128 (18.80) 121 (43.53) 64 (25.00) 
 
274 (20.42) 116 (53.46) 104 (38.52) 
BMI (kg/m2) 
          <25 379 (55.65) 118 (41.99) 113 (44.14)  652 (49.43) 78 (36.97) 111 (42.21) 
   25-<30 253 (37.15) 122 (43.42) 105 (41.02)  486 (36.85) 87 (41.23) 93 (35.36) 
   ≥30 49 (7.20) 41 (14.59) 38 (14.84)  181 (13.72) 46 (21.80) 59 (22.43) 
Diabetes, n (%)        
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   Yes -- -- --  113 (8.43) 32 (14.75) 25 (9.23) 
   No -- -- --  1227 (91.57) 185 (85.25) 246 (90.77) 
Total energy intake1, 
kcal/day, mean (SD) 
 
1838.13 
(663.60) 
2027.42 
(644.03) 
1999.68 
(711.85) 
 
2593.07 
(1224.59) 
2926.66   
(1343.77) 
2836.06 
(1467.32) 
Fruit/vegetable 
intake, 
servings/day1, 
median (SD)   2.00 (1.17) 1.71 (1.19) 1.86 (1.15) 
 
6.96 (5.32) 6.10 (4.21) 6.95 (4.48) 
1
Based on study-specif ic serving sizes and study-specif ic food frequency questionnaires.   
Missing values (N): education (2), GERD (5), GERD frequency (12), smoking (46), BMI (45), fruits and vegetables intake (28). 
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1
 Total sugar is defined as the sum of the individual monosaccharides (glucose, fructose and galactose) and disaccharides (sucrose, lactose and maltos e), 
including both added sugar and naturally occurring sugar. 
2
Added sugar is defined as sugars and syrups that w ere added to foods dur ing food preparation or processing, such as w hite sugar, pow dered sugar, brow n sugar, 
corn syrups, high fructose corn syrups, pancake syrup, honey, and molasses. 
3
The differences in intakes of all sw eetened desserts/beverages, sw eetened desserts, and sw eetened beverages betw een the tw o studies may be attributed to the 
utilization of study-specif ic FFQs. Both the serving sizes and the number of FFQ line items that contained sw eetened desserts/beverages varied by study. There 
w ere 17 FFQ line items that contain sw eetened desserts/beverages (12 line items contain sw eetened desserts and 5 line items contain sw eetened beverages) in 
US Multi-Center Study. There w ere 19 FFQ line items that contain sw eetened desserts/beverages (12 line items contain sw eetened desserts and 7 line items 
contain sw eetened beverages) in LA Multi-Ethnic Study. 
Table 4.3. Daily mean (standard deviation) intakes of sugar/carbohydrate among 500 EA cases, 529 GCA cases, and 2027 
controls in two US case-control studies of esophageal and gastric cardia adenocarcinoma. 
 
US Multi-Center Study 
 
LA Multi-Ethnic Study 
Measure 
Controls 
N=684 
EA cases 
N=282 
GCA cases 
N=256 
 
Controls 
N=1343 
EA cases   
N=218 
GCA cases 
N=273 
Free glucose (g/day) 20.97 (12.90) 20.24 (13.72) 21.96 (11.38) 
 
30.06 (19.67) 30.15 (18.72) 30.62 (17.89) 
Sucrose (g/day) 45.78 (27.83) 49.91 (27.50) 50.69 (28.64) 
 
41.42 (27.17) 47.16 (32.89) 41.99 (25.79) 
Free fructose (g/day) 22.56 (15.31) 21.50 (16.61) 23.18 (13.69) 
 
29.63 (19.49) 29.46 (19.28) 29.80 (18.61) 
Total sugar1 (g/day) 99.49 (48.02) 103.26 (50.85) 107.06 (46.06) 
 
120.62 (64.86) 129.32 (68.93) 123.04 (62.38) 
Added sugar2 
(g/day) 
48.83 (31.97) 54.78 (32.88) 55.27 (31.80) 
 
50.18 (34.86) 60.37 (46.82) 54.25 (35.83) 
Starch (g/day) 79.15 (29.24) 85.40 (30.15) 87.89 (32.29) 
 
126.25 (68.14) 130.27 (65.90) 128.31 (77.01) 
Total carbohydrate 
(g/day) 
220.34 
(78.67) 
232.54 (77.52) 241.48 (80.87) 
 
307.54 
(139.17) 
321.44 (144.92) 315.20 (152.56) 
% Carbohydrate 
calories  
47.11 (7.95) 44.41 (6.83) 45.41 (7.25)  48.58 (9.17) 44.69 (7.83) 45.81 (8.56) 
Glycemic index 61.03 (5.05) 60.60 (7.28) 60.92 (5.82) 
 
59.73 (4.88) 59.46 (5.06) 59.04 (5.57) 
Glycemic load 
123.06 
(45.79) 
129.65 (46.78) 134.71 (46.78) 
 
166.26 (77.04) 174.51 (81.75) 169.29 (85.70) 
All sweetened 
desserts/beverages3 
(servings/day) 
3.94 (2.74) 4.33 (2.70) 4.42 (2.75) 
 
3.18 (2.48) 3.66 (2.62) 3.30 (2.14) 
Sweetened 
desserts3 
(servings/day) 
1.95 (1.27) 2.12 (1.15) 2.25 (1.38) 
 
1.99 (1.88) 2.41 (1.92) 2.11 (1.68) 
Sweetened 
beverages3 
(servings/day) 
1.99 (2.37) 2.21 (2.20) 2.17 (2.25) 
 
1.19 (1.42) 1.26 (1.35) 1.19 (1.11) 
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Table 4.4. Multivariable-adjusted ORs and 95%CIs for the associations between 
sugar/carbohydrate intake and risk of developing esophageal and gastric cardia 
adenocarcinoma among 500 EA cases, 529 GCA cases, and 2027 controls from two US 
case-control studies (pooled approach, based on study-specific quintiles). 
  Esophageal 
Adenocarcinoma 
Gastric Cardia 
Adenocarcinoma 
 Measure 
Controls 
(N) 
Cases 
(N) 
OR (95%CI) Cases 
(N) 
OR (95%CI) 
Free glucose (g/day)1 
    Q1 385 104 Ref. 75 Ref. 
Q2 384 96 0.91 (0.65-1.27) 96 1.28 (0.90-1.80) 
Q3 396 96 0.88 (0.63-1.25) 104 1.36 (0.96-1.93) 
Q4 398 74 0.61 (0.42-0.89) 102 1.26 (0.88-1.82) 
Q5 393 103 0.74 (0.50-1.09) 122 1.43 (0.97-2.11) 
Ptrend 
  
0.08 
 
0.37 
Sucrose (g/day)1 
     Q1 391 69 Ref. 78 Ref. 
Q2 394 83 1.22 (0.85-1.77) 103 1.30 (0.93-1.82) 
Q3 393 90 1.16 (0.80-1.68) 99 1.15 (0.81-1.62) 
Q4 387 105 1.45 (1.00-2.12) 107 1.24 (0.87-1.76) 
Q5 391 126 1.51 (1.01-2.27) 112 1.10 (0.74-1.61) 
Ptrend 
  
0.19 
 
0.69 
Free fructose (g/day)1 
    Q1 382 110 Ref. 89 Ref. 
Q2 387 96 0.84 (0.60-1.17) 103 1.13 (0.81-1.56) 
Q3 398 91 0.74 (0.52-1.04) 88 0.90 (0.64-1.28) 
Q4 393 88 0.70 (0.49-1.01) 104 1.07 (0.75-1.52) 
Q5 396 88 0.60 (0.41-0.89) 115 1.07 (0.74-1.56) 
Ptrend 
  
0.08 
 
0.25 
Total sugar (g/day)1 
    Q1 385 82 Ref. 82 Ref. 
Q2 396 85 0.98 (0.69-1.40) 90 1.00 (0.72-1.42) 
Q3 393 103 1.13 (0.79-1.61) 107 1.16 (0.82-1.62) 
Q4 390 90 0.89 (0.61-1.30) 102 1.03 (0.72-1.48) 
Q5 392 113 0.98 (0.65-1.50) 118 1.05 (0.70-1.57) 
Ptrend 
  
0.79 
 
0.26 
Added sugar (g/day)1 
    Q1 385 70 Ref. 76 Ref. 
Q2 399 73 0.92 (0.63-1.35) 75 0.90 (0.63-1.29) 
Q3 392 96 1.08 (0.75-1.55) 106 1.18 (0.84-1.66) 
Q4 389 116 1.33 (0.92-1.92) 119 1.33 (0.94-1.87) 
Q5 391 118 1.06 (0.71-1.59) 123 1.14 (0.77-1.67) 
Ptrend 
  
0.14 
 
0.96 
Starch (g/day)1 
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Q1 389 70 Ref. 85 Ref. 
Q2 390 81 1.04 (0.72-1.51) 87 0.92 (0.65-1.29) 
Q3 390 109 1.33 (0.93-1.92) 117 1.17 (0.84-1.64) 
Q4 394 103 1.04 (0.71-1.54) 102 0.89 (0.62-1.28) 
Q5 393 110 1.03 (0.66-1.62) 108 0.84 (0.55-1.29) 
Ptrend 
  
0.34 
 
0.11 
Total carbohydrate (g/day)1 
Q1 386 79 Ref. 88 Ref. 
Q2 390 81 0.98 (0.68-1.41) 89 0.94 (0.67-1.32) 
Q3 393 88 0.91 (0.62-1.33) 83 0.79 (0.55-1.13) 
Q4 393 101 0.93 (0.62-1.39) 112 0.97 (0.67-1.41) 
Q5 394 124 0.93 (0.56-1.54) 127 0.94 (0.59-1.52) 
Ptrend 
  
0.02 
 
0.01 
Glycemic index2 
Q1 399 94 Ref. 106 Ref. 
Q2 397 95 1.29 (0.92-1.81) 86 0.98 (0.71-1.36) 
Q3 398 96 1.31 (0.93-1.84) 103 1.17 (0.85-1.61) 
Q4 395 85 1.09 (0.77-1.55) 114 1.28 (0.94-1.75) 
Q5 394 111 1.58 (1.13-2.21) 98 1.21 (0.88-1.67) 
Ptrend 
  
0.32 
 
0.69 
Glycemic load1 
Q1 387 86 Ref. 91 Ref. 
Q2 390 79 0.84 (0.59-1.21) 80 0.80 (0.57-1.13) 
Q3 395 87 0.85 (0.59-1.23) 90 0.85 (0.60-1.21) 
Q4 390 105 0.93 (0.63-1.36) 121 1.07 (0.75-1.54) 
Q5 394 116 0.81 (0.51-1.29) 117 0.86 (0.55-1.35) 
Ptrend 
  
0.32 
 
0.07 
All sweetened desserts/beverages (servings/day)1 
  
Q1 382 69 Ref. 75 Ref. 
Q2 392 79 1.09 (0.75-1.58) 90 1.13 (0.80-1.60) 
Q3 401 102 1.43 (0.99-2.05) 108 1.38 (0.98-1.93) 
Q4 391 87 1.02 (0.70-1.50) 105 1.16 (0.82-1.64) 
Q5 390 136 1.55 (1.06-2.27) 121 1.24 (0.86-1.79) 
Ptrend 
  
0.28 
 
0.88 
Sweetened desserts (servings/day)1 
   Q1 383 65 Ref. 74 Ref. 
Q2 392 72 1.01 (0.69-1.49) 96 1.20 (0.85-1.70) 
Q3 393 104 1.31 (0.91-1.89) 100 1.16 (0.82-1.63) 
Q4 399 103 1.28 (0.88-1.85) 112 1.26 (0.90-1.78) 
Q5 389 129 1.38 (0.94-2.03) 117 1.13 (0.78-1.62) 
Ptrend 
  
0.48 
 
0.92 
Sweetened beverages (servings/day)2 
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Q1 394 97 Ref. 86 Ref. 
Q2 398 88 0.97 (0.69-1.36) 100 1.18 (0.85-1.64) 
Q3 396 91 1.02 (0.73-1.43) 92 1.10 (0.79-1.54) 
Q4 400 83 0.84 (0.60-1.19) 116 1.31 (0.95-1.81) 
Q5 395 122 1.22 (0.87-1.70) 113 1.21 (0.86-1.69) 
Ptrend   0.60  0.93 
1
Adjusted for  age, sex, race, study indicator, BMI, fruits and vegetables intake, cigarette smoking, GERD 
frequency, and total energy intake                                                                                                                                                                           
2
Adjusted for  age, sex, race, study indicator, fruits and vegetables intake, cigarette smoking, GERD frequency, 
and total energy intake                                                                                                                                                     
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Table 4.5. Food frequency questionnaire items that were categorized as sweetened desserts/beverages in each of the two US case 
control studies of the esophageal and gastric cardia adenocarcinoma. 
US Multi-Center Study (CT, NJ, Western WA) LA Multi-Ethnic Study (Southern CA) 
Cereals, cold or cooked 
Pancakes or waffles 
Yogurt, all types, except frozen 
Ice cream or milkshakes 
Low-fat frozen desserts, 
including frozen yogurt, sherbet, or ice milk 
Pudding, custard, or flan 
Jello, any flavor 
Doughnuts, cakes, or pastries 
Cookies 
Pies 
Chocolate candy or candy bars 
Hard candy, jelly, jam, honey, or syrup 
Sugar in coffee or tea or on cereal 
Regular soft drinks or soda, not diet 
Orange juice, grapefruit juice or Vitamin C enriched fruit drinks 
Other fruit juices and fruit juice drinks 
Kool-Aid 
 
High fiber cereal such as bran, All-Bran, bran flakes, oat bran 
Highly fortified cereals, such as Special K, Total 
Other dry cereals, e.g. Cornflakes, Rice Krispies, granola, etc. 
Chocolate milk, cocoa or ovaltine 
Pancakes, waffles, French toast 
Doughnuts, cookies, cakes, pastries, cinnamon rolls, danishes 
Pumpkin or sweet potato pie 
Other non-fruit pies 
Chocolate candy 
Other candy 
Jellies, jam, honey syrup 
Ice cream 
Orange juice 
Other citrus juice such as grapefruit, tangerine, lemonade 
Other fruit juices including grape, cranberry, pineapple, etc. 
Any type of fruit pie, cobbler 
Caffeine-free soda (e.g. Pepsi-free, 7-up, Sprite, etc.) 
Sodas with caffeine (Coca Cola, Pepsi, Dr. Pepper, etc.) 
Other carbonated drinks including mineral water, fruit drinks, etc. 
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Table 4.6. Multivariable-adjusted ORs and 95%CIs for the associations between sugar/carbohydrate intake and risk of 
developing EA/GCA among 500 EA cases, 529 GCA cases, and 2027 controls from two US case-control studies (meta-analytic 
approach, fixed effect). 
  Esophageal Adenocarcinoma   Gastric Cardia Adenocarcinoma 
Measure 
Controls 
(N) 
Cases 
(N) 
OR (95%CI) I2 (%) 
Phetero-
geneity 
  
Cases 
(N) 
OR (95%CI) I2 (%) 
Phetero-
geneity 
Free glucose (g/day)1 
         Q1 385 104 Ref. 
   
75 Ref. 
  Q2 384 96 0.92 (0.65-1.30) 13.0 0.28 
 
96 1.23 (0.87-1.74) 0 0.71 
Q3 396 96  0.86 (0.61-1.24) 0 0.38 
 
104 1.29 (0.90-1.84) 0 0.64 
Q4 398 74  0.58 (0.39-0.86) 78.0 0.03 
 
102 1.15 (0.79-1.67) 0 0.96 
Q5 393 103  0.64 (0.42-0.97) 71.3 0.06  122 1.25 (1.04-1.50) 0 0.39 
Ptrend 
  
0.06 36.9 0.21 
  
0.42 0 0.82 
Sucrose (g/day)1 
          Q1 391 69 Ref. 
   
78 Ref. 
  Q2 394 83  1.26 (0.87-1.84) 50.9 0.15 
 
103 1.22 (0.87-1.72) 0 0.44 
Q3 393 90 1.14 (0.77-1.68) 34.7 0.22 
 
99 1.12 (0.79-1.59) 0 0.77 
Q4 387 105 1.48 (1.00-2.19) 0 0.78 
 
107 1.12 (0.78-1.60) 0 0.77 
Q5 391 126 1.51 (0.99-2.30) 0 0.54  112 0.97 (0.65-1.45) 0 0.54 
Ptrend 
  
0.26 62.9 0.10 
  
0.24 0 0.96 
Free fructose (g/day)1 
         Q1 382 110 Ref. 
   
89 Ref. 
  Q2 387 96 0.84 (0.60-1.18) 1.4 0.31 
 
103 1.08 (0.78-1.51) 0 0.47 
Q3 398 91 0.68 (0.47-0.97) 0 0.70 
 
88 0.86 (0.61-1.23) 0 0.99 
Q4 393 88 0.69 (0.47-1.01) 76.1 0.04 
 
104 0.98 (0.69-1.41)   0 0.61 
Q5 396 88 0.52 (0.34-0.78) 81.2 0.02  115 1.02 (0.70-1.49) 0 0.65 
Ptrend 
  
0.04 0 0.38 
  
0.26 0 0.79 
Total sugar (g/day)1 
         Q1 385 82 Ref. 
   
82 Ref. 
  Q2 396 85 0.97 (0.67-1.40) 0 0.41 
 
90 0.97 (0.68-1.37) 0 0.38 
Q3 393 103 1.08 (0.74-1.56) 0 0.40 
 
107 1.10 (0.78-1.56) 36.2 0.21 
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Q4 390 90 0.85 (0.57-1.26) 0 0.65 
 
102 0.92 (0.63-1.33) 25.0 0.25 
Q5 392 113 0.89 (0.57-1.40) 33.6 0.22  118 0.98 (0.82-1.18) 0 0.43 
Ptrend 
  
0.72 59.3 0.12 
  
0.25 0 0.73 
Added sugar (g/day)1 
         Q1 385 70 Ref. 
   
76 Ref. 
  Q2 399 73 0.90 (0.61-1.32) 0 0.50 
 
75 0.87 (0.60-1.25) 0 0.77 
Q3 392 96 1.08 (0.73-1.58) 84.7 0.01 
 
106 1.17 (0.83-1.65) 0 0.61 
Q4 389 116 1.26 (0.87-1.85) 0 0.32 
 
119 1.24 (0.87-1.77) 0 0.98 
Q5 391 118 0.98 (0.64-1.51) 0 0.37  123 1.03 (0.69-1.54) 0 0.50 
Ptrend 
  
0.27 0 0.62 
  
0.61 0 >0.99 
Starch (g/day)1 
          Q1 389 70 Ref. 
   
85 Ref. 
  Q2 390 81 1.01 (0.69-1.48) 0 0.64 
 
87 0.87 (0.62-1.24) 75.8 0.04 
Q3 390 109  1.26 (0.86-1.83) 0 0.81 
 
117 1.06 (0.75-1.50) 82.2 0.02 
Q4 394 103  0.94 (0.62-1.41) 0 0.91 
 
102 0.78 (0.54-1.14) 64.7 0.09 
Q5 393 110 0.87 (0.54-1.42) 0 0.95  108 0.68 (0.43-1.08) 83.2 0.02 
Ptrend 
  
0.32 0 0.82 
  
0.18 20.9 0.26 
Total carbohydrate (g/day)1 
  Q1 386 79 Ref. 
   
88 Ref. 
  Q2 390 81 0.93 (0.64-1.36) 0 0.38 
 
89 0.88 (0.62-1.24) 0 0.94 
Q3 393 88  0.81 (0.54-1.22) 0 0.76 
 
83 0.69 (0.48-1.01) 69.9 0.07 
Q4 393 101 0.77 (0.49-1.20) 0 0.79 
 
112 0.80 (0.54-1.19) 62.0 0.11 
Q5 394 124 0.68 (0.38-1.22) 0 0.71  127 0.68 (0.40-1.16) 60.2 0.11 
Ptrend 
  
0.01 56.8 0.13 
  
<0.01 0 0.22 
Glycemic index2 
  Q1 399 94 Ref. 
   
106 Ref. 
  Q2 397 95 1.23 (0.87-1.74) 0 0.89 
 
86 1.01 (0.73-1.41) 0 0.60 
Q3 398 96 1.26 (0.89-1.79) 0 0.86 
 
103 1.18 (0.85-1.62) 38.1 0.20 
Q4 395 85 1.09 (0.77-1.56) 5.1 0.31 
 
114 1.30 (0.94-1.79) 87.2 0.01 
Q5 394 111 1.57 (1.11-2.22) 0 0.72  98 1.27 (0.91-1.76) 0 0.37 
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Ptrend 
  
0.25 0 0.48 
  
0.61 38.4 0.20 
Glycemic load1 
  Q1 387 86 Ref. 
   
91 Ref. 
  Q2 390 79 0.82 (0.57-1.20) 0 0.35 
 
80 0.74 (0.52-1.05) 0 0.90 
Q3 395 87 0.81 (0.55-1.18) 0 0.69 
 
90 0.79 (0.55-1.13) 78.5 0.03 
Q4 390 105 0.83 (0.55-1.26) 0 0.86 
 
121 0.93 (0.64-1.36) 81.4 0.02 
Q5 394 116 0.69 (0.42-1.15) 0 0.35  117 0.72 (0.44-1.16) 61.6 0.11 
Ptrend 
  
0.22 0 0.37 
  
0.05 21.6 0.26 
All sweetened desserts/beverages (servings/day)1 
     
  Q1 382 69 Ref. 
   
75 Ref. 
  Q2 392 79 1.07 (0.73-1.57) 0 0.77 
 
90 1.08 (0.76-1.54) 0 0.69 
Q3 401 102 1.40 (0.97-2.03) 0 0.47 
 
108 1.36 (0.96-1.91) 0 0.51 
Q4 391 87 0.99 (0.66-1.47) 58.5 0.12 
 
105 1.08 (0.76-1.55) 0 0.33 
Q5 390 136 1.57 (1.05-2.33) 0 0.57  121 1.13 (0.77-1.66) 0 0.47 
Ptrend 
  
0.34 0 0.46 
  
0.66 0 0.49 
Sweetened desserts (servings/day)1 
      Q1 383 65 Ref. 
   
74 Ref. 
  Q2 392 72  0.97 (0.65-1.43) 0 0.92 
 
96 1.16 (0.82-1.64) 0 0.69 
Q3 393 104 1.25 (0.86-1.81) 0 0.90 
 
100 1.13 (0.80-1.60) 0 0.95 
Q4 399 103 1.19 (0.81-1.75) 18.9 0.27 
 
112 1.19 (0.84-1.68) 0 0.55 
Q5 389 129 1.33 (0.89-1.98) 41.7 0.19  117 1.01 (0.69-1.48) 0 0.85 
Ptrend 
  
0.51 41.8 0.19 
  
0.70 0 0.57 
Sweetened beverages (servings/day)2 
       Q1 394 97 Ref. 
   
86 Ref. 
  Q2 398 88 0.91 (0.64-1.29) 47.7 0.17 
 
100 1.13 (0.81-1.58) 25.7 0.25 
Q3 396 91  0.97 (0.68-1.37) 0 0.48 
 
92 1.06 (0.76-1.49) 36.0 0.21 
Q4 400 83 0.80 (0.56-1.15) 0 0.94 
 
116 1.26 (0.91-1.76) 10.7 0.29 
Q5 395 122 1.17 (0.82-1.66) 0 0.82  113 1.13 (0.80-1.60) 0 0.37 
Ptrend     0.67 0  0.89     0.67 0  0.78 
1
Adjusted for  age, sex, race, study indicator, BMI, fruits and vegetables intake, cigarette smoking, GERD frequency, and total energy intake                                                                                                                                                                           
2
Adjusted for  age, sex, race, study indicator, fruits and vegetables intake, cigarette smoking, GERD frequency, and total energy intake                                                                                                                                                     
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Table 4.7. Multivariable-adjusted ORs and 95%CIs for the associations between 
sugar/carbohydrate intake and risk of developing EA, derived from sensitivity analyses: (1) 
based on identical absolute intake cut-points; (2) after excluding proxy interviews; (3) using 
±2.5% as exclusion criteria); or (4) using nutrient density energy adjustment method.  
Measure Controls (N) Cases (N) OR1 (95%CI) 
(1) Pooling on identical absolute intake cut-points 
Sucrose (g/day) 
  Q1 390 71 Ref. 
Q2 396 78 1.04 (0.71-1.51) 
Q3 396 80 0.95 (0.65-1.39) 
Q4 383 113 1.39 (0.96-2.03) 
Q5 391 131 1.33 (0.89-1.99) 
Ptrend  
  
0.19 
(2) Excludes proxy interviews 
Sucrose (g/day) 
   Q1 391 54 Ref. 
Q2 394 58 1.07 (0.70-1.63) 
Q3 393 67 1.13 (0.75-1.72) 
Q4 387 73 1.28 (0.84-1.96) 
Q5 391 82 1.26 (0.79-1.99) 
Ptrend 
  
0.67 
(3) Increased exclusion criteria for total energy intake 
Sucrose (g/day) 
  Q1 377 77 Ref. 
Q2 378 72 0.92 (0.63-1.33) 
Q3 376 87 1.00 (0.69-1.45) 
Q4 371 101 1.21 (0.83-1.75) 
Q5 373 123 1.28 (0.85-1.91) 
Ptrend 
  
0.13 
(4) Nutrient density energy adjustment method   
Sucrose (g/day)    
Q1 395 106 Ref. 
Q2 393 96 1.01 (0.72-1.40) 
Q3 391 88 1.02 (0.73-1.43) 
Q4 393 86 1.00 (0.71-1.41) 
Q5 384 97 1.16 (0.83-1.62) 
Ptrend   0.33 
Total carbohydrate (g/day)    
Q1 389 143 Ref. 
Q2 393 123 0.99 (0.74-1.34) 
Q3 394 96 0.86 (0.63-1.19) 
Q4 394 70 0.65 (0.46-0.93) 
Q5 386 41 0.47 (0.31-0.71) 
Ptrend   <0.01 
1
Adjusted for  age, sex, race, study indicator, BMI, fruits and vegetables intake, cigarette smoking, GERD frequency, 
and total energy intake     
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Table 4.8. Multivariable-adjusted ORs and 95%CIs for the associations between 
sugar/carbohydrate intake and risk of developing EA/GCA among 500 EA cases, 529 GCA 
cases, and 2027 controls from two US case-control studies (pooled approach, based on 
study- specific quartiles, without adjusting for total energy intake). 
  EA GCA 
 Measure 
Controls 
(N) 
Cases 
(N) 
OR (95%CI) Cases 
(N) 
OR (95%CI) 
Free glucose (g/day)1 
    Q1: 0.12-<14.58 381 135 Ref. 99 Ref. 
Q2: 14.58-<19.96 384 93 0.98 (0.70-1.37) 89 1.33 (0.94-1.87) 
Q3: 19.96-<25.95 396 83 1.01 (0.72-1.41) 101 1.45 (1.03-2.04) 
Q4: 25.95-<36.21 394 83 0.74 (0.51-1.07) 113 1.39 (0.98-1.98) 
Q5: ≥36.21 401 79 1.03 (0.72-1.46) 97 1.69 (1.19-2.41) 
Ptrend 
  
0.95 
 
0.54 
Sucrose (g/day)1 
     Q1: 0.97-<21.62 390 71 Ref. 84 Ref. 
Q2: 21.62-<31.46 396 78 1.26 (0.87-1.82) 90 1.34 (0.96-1.87) 
Q3: 31.46-<42.33 396 80 1.24 (0.86-1.78) 96 1.24 (0.88-1.74) 
Q4: 42.33-<59.76 383 113 1.62 (1.13-2.32) 104 1.41 (1.01-1.98) 
Q5: ≥59.76 391 131 1.85 (1.30-2.63) 125 1.40 (1.00-1.96) 
Ptrend 
  
<0.01 
 
0.14 
Free fructose (g/day)1 
    Q1: 0.001-<14.25 381 126 Ref. 98 Ref. 
Q2: 14.25-<20.29 387 113 0.90 (0.65-1.25) 109 1.17 (0.84-1.62) 
Q3: 20.29-<26.00 392 71 0.83 (0.59-1.17) 86 0.97 (0.69-1.37) 
Q4: 26.00-<36.77  397 80 0.83 (0.58-1.19) 101 1.18 (0.84-1.67) 
Q5: ≥36.77 399 83 0.82 (0.57-1.17) 105 1.29 (0.91-1.82) 
Ptrend 
  
0.82 
 
0.87 
Total sugar (g/day)1 
    Q1: 2.40-<66.65 385 84 Ref. 78 Ref. 
Q2: 66.65-<89.47 392 104 1.03 (0.72-1.47) 102 1.05 (0.75-1.47) 
Q3: 89.47-<114.64 391 96 1.26 (0.89-1.78) 113 1.25 (0.90-1.75) 
Q4: 114.64-<150.37 390 86 1.09 (0.76-1.57) 102 1.19 (0.85-1.68) 
Q5: ≥150.37 398 103 1.41 (0.98-2.01) 104 1.36 (0.97-1.92) 
Ptrend 
  
0.03 
 
0.25 
Added sugar (g/day)1 
    Q1: 0.38-<23.52 386 68 Ref. 76 Ref. 
Q2: 23.52-<35.02 397 77 0.98 (0.67-1.42) 77 0.93 (0.65-1.33) 
Q3: 35.02-<48.57 393 92 1.18 (0.82-1.69) 102 1.25 (0.89-1.76) 
Q4: 48.57-<70.68 389 120 1.54 (1.08-2.19) 121 1.46 (1.05-2.04) 
Q5: ≥70.68 391 116 1.40 (0.99-2.00) 123 1.38 (0.99-1.93) 
Ptrend 
  
<0.01 
 
0.07 
Starch (g/day)1 
     Q1: 1.75-<63.69 383 87 Ref. 89 Ref. 
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Q2: 63.69-<85.40 385 106 1.12 (0.77-1.61) 123 0.98 (0.70-1.37) 
Q3: 85.40-<109.99 396 115 1.54 (1.08-2.19) 109 1.33 (0.97-1.84) 
Q4: 109.99-<145.37 393 84 1.31 (0.91-1.87) 96 1.09 (0.78-1.53) 
Q5: ≥145.37 399 81 1.54 (1.07-2.21) 82 1.23 (0.87-1.72) 
Ptrend 
  
0.03 
 
0.22 
Total carbohydrate (g/day)1 
Q1: 40.83-<178.96 380 88 Ref. 88 Ref. 
Q2: 178.96-<226.96 390 102 1.07 (0.75-1.53) 108 0.99 (0.71-1.39) 
Q3: 226.96-<279.63 393 105 1.08 (0.76-1.55) 99 0.89 (0.63-1.26) 
Q4: 279.63-<356.57 393 89 1.20 (0.84-1.72) 115 1.17 (0.84-1.63) 
Q5: ≥356.57 400 89 1.51 (1.06-2.16) 89 1.34 (0.96-1.89) 
Ptrend 
  
0.03 
 
0.14 
Glycemic index2 
Q1: 2.50-<57.40 401 85 Ref. 108 Ref. 
Q2: 57.40-<60.10 401 88 1.20 (0.86-1.68) 79 0.93 (0.67-1.28) 
Q3: 60.10-<61.82 398 82 1.20 (0.86-1.69) 85 1.10 (0.81-1.51) 
Q4: 61.82-<63.64 393 105 1.03 (0.73-1.45) 122 1.23 (0.90-1.67) 
Q5: ≥63.64 390 121 1.46 (1.05-2.04) 113 1.14 (0.83-1.58) 
Ptrend 
  
0.73 
 
0.89 
Glycemic load1 
Q1: 2.03-<96.51 382 95 Ref. 86 Ref. 
Q2: 96.51-<122.52 389 89 0.92 (0.64-1.31) 104 0.85 (0.61-1.20) 
Q3: 122.52-<153.57 394 113 1.00 (0.71-1.43) 107 0.95 (0.68-1.33) 
Q4: 153.57-<196.57 394 86 1.19 (0.84-1.69) 112 1.28 (0.93-1.77) 
Q5: ≥196.57 397 90 1.31 (0.92-1.86) 90 1.22 (0.87-1.71) 
Ptrend 
  
0.01 
 
0.15 
Sweetened desserts/beverages (servings/day)1 
  
Q1: 0-<1.57 385 61 Ref. 65 Ref. 
Q2: 1.57-<2.48 393 93 1.12 (0.77-1.63) 100 1.17 (0.82-1.65) 
Q3: 2.48-<3.43 397 83 1.50 (1.05-2.15) 100 1.44 (1.03-2.02) 
Q4: 3.43-<4.81 395 87 1.12 (0.78-1.63) 96 1.27 (0.90-1.78) 
Q5: ≥4.81 386 149 1.87 (1.32-2.64) 138 1.49 (1.07-2.08) 
Ptrend 
  
0.01  0.11 
Sweetened desserts (servings/day)1  
 Q1: 0-<0.75 387 64 Ref. 70 Ref. 
Q2: 0.75-<1.33 392 68 1.02 (0.70-1.50) 94 1.22 (0.86-1.72) 
Q3: 1.33-<1.98 389 105 1.37 (0.96-1.97) 99 1.21 (0.86-1.71) 
Q4: 1.98-<2.94 399 107 1.39 (0.97-2.00) 119 1.37 (0.98-1.92) 
Q5: ≥2.94 389 129 1.67 (1.17-2.38) 117 1.36 (0.97-1.90) 
Ptrend 
  
0.01 
 
0.15 
Sweetened beverages (servings/day)2 
  Q1: 0-<0.35 396 82 Ref. 75 Ref. 
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Q2: 0.35-<0.85 399 89 0.98 (0.70-1.37) 100 1.19 (0.86-1.65) 
Q3: 0.85-<1.27 399 83 1.04 (0.74-1.46) 100 1.11 (0.80-1.56) 
Q4: 1.27-<2.07 401 83 0.88 (0.63-1.25) 116 1.36 (0.98-1.87) 
Q5: ≥2.07 388 144 1.39 (1.00-1.92) 116 1.35 (0.97-1.88) 
Ptrend     0.14 
 
0.36 
1
Adjusted for  age, sex, race, study indicator, BMI, fruits and vegetables intake, cigarette smoking, GERD 
frequency, and total energy intake                                                                                                                                                                           
2
Adjusted for  age, sex, race, study indicator, fruits and vegetables intake, cigarette smoking, GERD frequency, 
and total energy intake                                                                                                                                                     
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Table 4.9. Multivariable-adjusted HRs and 95%CIs for the associations between 
sugar/carbohydrate intake and overall survival in esophageal and gastric cardia 
adenocarcinoma among 500 EA cases and 529 GCA cases from two US case-control studies 
(pooled approach, based on study-specific quintiles). 
 Esophageal Adenocarcinoma Gastric Cardia Adenocarcinoma 
Measure 
Deaths 
(N) 
EA 
Cases 
(N) 
HR (95%CI) Deaths 
(N) 
GCA 
Cases 
(N) 
HR (95%CI) 
Free glucose1 (g/day) 
     Q1 87 100 Ref. 86 104 Ref. 
Q2 89 100 0.96 (0.71-1.30) 95 106 1.05 (0.79-1.42) 
Q3 87 98 0.94 (0.70-1.28) 90 105 1.00 (0.74-1.36) 
Q4 86 98 1.00 (0.73-1.37) 89 106 0.82 (0.60-1.12) 
Q5 85 100 1.04 (0.74-1.46) 90 105 0.95 (0.69-1.31) 
Ptrend 
  
0.64 
  
0.86 
Sucrose1 (g/day) 
     Q1 86 99 Ref. 90 106 Ref. 
Q2 85 99 0.99 (0.73-1.34) 89 106 1.01 (0.75-1.35) 
Q3 85 99 1.02 (0.74-1.40) 92 104 1.06 (0.79-1.43) 
Q4 91 100 1.28 (0.93-1.76) 90 105 0.94 (0.68-1.29) 
Q5 87 99 1.21 (0.84-1.74) 89 105 0.87 (0.61-1.22) 
Ptrend 
  
0.39 
  
0.57 
Free fructose1 (g/day) 
     Q1 89 100 Ref. 87 106 Ref. 
Q2 86 100 0.86 (0.64-1.16) 96 105 1.24 (0.93-1.67) 
Q3 89 98 1.03 (0.76-1.39) 87 104 0.97 (0.72-1.31) 
Q4 85 99 0.92 (0.67-1.25) 90 106 0.90 (0.66-1.22) 
Q5 85 99 1.07 (0.76-1.49) 90 105 0.99 (0.72-1.35) 
Ptrend 
  
0.47 
  
0.79 
Total sugar2 (g/day)
     Q1 86 100 Ref. 89 106 Ref. 
Q2 90 99 1.29 (0.96-1.75) 86 105 0.92 (0.68-1.23) 
Q3 84 100 1.03 (0.75-1.41) 93 105 1.12 (0.83-1.50) 
Q4 89 99 1.22 (0.87-1.70) 99 106 1.12 (0.81-1.53) 
Q5 86 99 1.31 (0.90-1.91) 84 105 0.77 (0.54-1.09) 
Ptrend 
  
0.72 
  
0.77 
Added sugar1 (g/day) 
     Q1 90 100 Ref. 88 106 Ref. 
Q2 85 99 0.89 (0.66-1.20) 92 106 1.20 (0.89-1.62) 
Q3 82 99 0.79 (0.58-1.08) 87 103 1.00 (0.74-1.36) 
Q4 89 99 1.11 (0.82-1.52) 93 105 1.06 (0.78-1.45) 
Q5 88 99 1.09 (0.76-1.55) 90 106 0.94 (0.67-1.33) 
Ptrend 
  
0.67 
  
0.70 
Starch1 
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(g/day) 
Q1 91 100 Ref. 89 106 Ref. 
Q2 83 98 0.88 (0.65-1.18) 91 104 1.11 (0.83-1.50) 
Q3 87 100 0.99 (0.73-1.35) 88 105 0.96 (0.70-1.32) 
Q4 83 99 0.98 (0.70-1.37) 94 106 1.06 (0.77-1.47) 
Q5 90 99 1.33 (0.91-1.94) 88 105 0.99 (0.67-1.44) 
Ptrend 
  
0.18 
  
0.32 
Total carbohydrate1 (g/day) 
Q1 89 100 Ref. 89 107 Ref. 
Q2 82 98 0.86 (0.63-1.17) 91 106 1.03 (0.77-1.39) 
Q3 90 100 1.21 (0.87-1.68) 93 104 1.12 (0.82-1.52) 
Q4 90 99 1.14 (0.79-1.64) 91 105 0.90 (0.64-1.25) 
Q5 83 99 1.07 (0.68-1.71) 86 104 0.67 (0.43-1.04) 
Ptrend 
  
0.36 
  
0.82 
Glycemic index1 
Q1 88 100 Ref. 91 106 Ref. 
Q2 84 100 0.96 (0.71-1.31) 90 106 1.24 (0.92-1.67) 
Q3 90 98 1.16 (0.86-1.57) 90 104 1.18 (0.87-1.58) 
Q4 91 100 1.03 (0.76-1.39) 95 106 1.22 (0.91-1.63) 
Q5 81 98 0.97 (0.72-1.33) 84 104 1.01 (0.75-1.37) 
Ptrend 
  
0.87 
  
0.29 
Glycemic load1 
Q1 91 100 Ref. 89 106 Ref. 
Q2 78 98 0.77 (0.56-1.06) 88 106 0.90 (0.66-1.21) 
Q3 89 100 1.05 (0.77-1.44) 94 104 1.13 (0.83-1.53) 
Q4 90 99 1.12 (0.79-1.58) 93 104 0.94 (0.68-1.29) 
Q5 86 99 1.24 (0.82-1.87) 86 106 0.73 (0.49-1.08) 
Ptrend 
  
0.34 
  
0.93 
All sweetened desserts/beverages 1 (servings/day) 
   
Q1 86 98 Ref. 92 106 Ref. 
Q2 88 100 0.95 (0.70-1.28) 89 106 0.94 (0.70-1.27) 
Q3 84 100 0.89 (0.66-1.21) 85 103 0.86 (0.63-1.15) 
Q4 92 99 1.13 (0.83-1.53) 95 105 1.00 (0.74-1.35) 
Q5 84 99 1.02 (0.72-1.43) 89 106 0.80 (0.58-1.10) 
Ptrend 
  
0.54 
  
0.55 
Sweetened desserts1 (servings/day) 
   Q1 88 99 Ref. 92 106 Ref. 
Q2 83 100 0.91 (0.67-1.24) 90 106 1.01 (0.75-1.35) 
Q3 91 99 1.18 (0.87-1.59) 88 102 0.97 (0.72-1.30) 
Q4 83 98 0.95 (0.69-1.31) 89 106 0.92 (0.68-1.24) 
Q5 89 100 0.94 (0.68-1.30) 91 106 0.83 (0.60-1.14) 
Ptrend 
  
0.69 
  
0.26 
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Sweetened beverages1 (servings/day) 
   Q1 84 96 Ref. 86 105 Ref. 
Q2 90 99 1.12 (0.83-1.51) 98 107 1.14 (0.85-1.53) 
Q3 87 101 0.95 (0.70-1.29) 95 112 1.01 (0.75-1.35) 
Q4 86 100 1.01 (0.75-1.38) 81 97 0.86 (0.63-1.16) 
Q5 87 100 1.07 (0.79-1.47) 90 105 0.99 (0.73-1.35) 
Ptrend     0.60     0.84 
1
Adjusted for age, education, study indicator, and total energy intake 
2
Adjusted for age, study indicator, and total energy intake 
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CHAPTER 5: DISCUSSION 
 
Overview 
This dissertation examines the role of sugar/carbohydrate intake in relation to the 
Barrett’s esophagus (BE) - esophageal/gastric cardia adenocarcinoma (EA/GCA) continuum 
(normal tissueBarrett’s esophagusadenocarcinomadeath). Chapter 1 and Chapter 2 
describe the background and methods, Chapter 3 reports the findings on the association 
between intake of sugar/carbohydrate and risk of developing BE, and Chapter 4 reports the 
findings on the association between intake of sugar/carbohydrate and risk of developing or 
dying from EA/GCA.  In Chapter 5, I: summarize my dissertation findings, emphasizing 
commonalities across the BE-EA/GCA continuum and briefly compare my results to those from 
other studies; discuss the weaknesses and the strengths of my approach, which impact 
interpretation of my findings; and, finally, I propose possible future directions for addressing my 
study hypotheses.    
The overarching goal of this dissertation is to identify where along the cancer continuum 
sugar/carbohydrate intake may play a detrimental role and thereby potential risk reduction 
strategies could be implemented. The significance of this dissertation is that EA incidence is 
rapidly increasing, and the disease is highly fatal. Identification of potential risk reduction 
strategies could help to reduce the high clinical and public health burden associated with this 
disease. The innovation of this dissertation is that I considered twelve measures of 
sugar/carbohydrate intake in order to better capture the complexity inherent in the intake of 
these foods and the subsequent potential biologic response. Also, harmonizing and pooling data 
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from multiple high quality studies with similar methodological approaches increased study power 
providing more stable effect estimates and facilitated examination of high risk subgroups across 
the BE-EA/GCA continuum.  Finally, this is the first study to consider associations between 
sugar/carbohydrate intake and mortality after diagnosis with esophageal/gastric cardia 
adenocarcinoma.  
 
Summary of Results and Comparison with Previous Literature  
My dissertation findings across the BE-EA continuum are summarized in Figure 5.1.  
 
 
 
 
 
 
 
 
 
 
 
In my dissertation, sucrose was associated with 79% and 51% increase in risk of 
developing BE and EA, respectively, comparing the highest to the lowest intake quantile (Figure 
5.1). Similarly, intake of sweetened desserts/beverages was associated with both increased risk 
of developing BE (ORQ4 VS.Q1=1.71, 95%CI=1.07-2.73) and EA (ORQ5 VS.Q1 =1.55, 95%CI=1.06-
2.27). Sweetened beverages alone, may be associated with increased risk of developing BE 
(ORQ4 VS.Q1=1.47, 95%CI=0.95-2.26), although the 95%CI included the null. Added sugar was 
positively associated with risk of developing BE (ORQ4 VS.Q1=1.71, 95%CI=1.05-2.80), but not 
Sucrose*: 
OR
Q4 VS.Q1
=1.79 (1.07-3.02) 
Added sugar: 
OR
Q4 VS.Q1
=1.71 (1.05-2.80) 
Sweetened desserts/beverages*: 
OR
Q4 VS.Q1
=1.71 (1.07-2.73) 
Sweetened beverages: 
OR
Q4 VS.Q1
=1.47 (0.95-2.26) 
Death 
Normal 
tissue 
Esophageal and 
Gastric Cardia 
Adenocarcinoma 
Barrett’s 
Esophagus 
EA: 
Sucrose:  
OR
Q5 VS.Q1
 =1.51 (1.01-2.27) 
Glycemic index: 
OR
Q5 VS.Q1
 =1.58 (1.13-2.21) 
Sweetened desserts/beverages: 
OR
Q5 VS.Q1
 =1.55 (1.06-2.27) 
Fructose: 
OR
Q5 VS.Q1
 = 0.60 (0.41-0.89) 
GCA: No associations 
No associations 
* Ptrend <0.05 
Figure 5.1. Summary results for sugar/carbohydrate intake and Barrett’s-esophageal/gastric 
cardia adenocarcinoma continuum. 
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with EA. In contrast, glycemic index was associated with 58% increase in risk of developing EA, 
but not with BE. Fructose appeared to be inversely associated with risk of developing EA. Other 
sugar/carbohydrate intake measures were not associated with risk of developing BE or EA. 
Neither risk of developing GCA nor mortality after EA/GCA was associated with intake of 
sugar/carbohydrate. Not illustrated in Figure 5.1 are my findings regarding effect measure 
modification. I observed that waist circumference appeared to modify the association between 
sweetened desserts/beverages and BE, body mass index (BMI) modified all of the above 
positive associations with EA, and gastro-esophageal reflux disease (GERD) modified the 
sucrose-EA incidence association. My results suggest that reducing intake of sucrose 
(especially among those with BMI<25 or with GERD<weekly) and sweetened 
desserts/beverages (especially among those with lower waist circumference or BMI<25) may be 
plausible BE/EA risk reduction strategies. Reducing added sugar intake and dietary glycemic 
index (especially among those with BMI≥25), respectively, may be plausible risk reduction 
strategies for BE and EA. 
An Irish case-control study previously examined associations between 
sugar/carbohydrate intake and risk of developing BE and EA, using only some of the intake 
measures considered in my dissertation.1 The Irish investigators found glycemic index was 
positively associated with EA incidence (but not with BE incidence), which is consistent with my 
findings. An Australian case-control study also examined associations between a limited 
number of measures of sugar/carbohydrate intake and risk of developing EA, but found no 
associations.2 Neither of the two studies examined individual sugar components (e.g. sucrose), 
sweetened desserts/beverages, or differentiated added sugar from naturally occurring sugar. A 
summary of findings from previous studies can be found in Figure 1.3. 
 
 186 
 
Limitations 
There are several limitations to this dissertation and therefore the results need to be 
interpreted with caution. First, there might be recall bias due to the case-control design. For 
example, in the pooled analysis of EA/GCA studies, the participants were instructed to report 
their dietary intake during the time period before diagnosis (cases) or interview (controls). 
However, patients may alter their diet due to EA/GCA-related symptoms such as dysphasia (i.e. 
avoid eating raw fruits that are difficult to swallow and may stick in throat), and therefore they 
may confuse their previous diet with their current diet and tend to report their current dietary 
intake.3  
Further, there are potential non-differential misclassification errors, given that food 
frequency questionnaires (FFQs) were used to collect dietary intake data. Dietary assessment 
may be limited by the food items covered by the FFQ, and the participants (regardless of their 
case/control status) may not be able to accurately recall their average intake.4 However, each of 
the study-specific FFQs included more than 100 FFQ line items, with most line items 
representing more than one food item, and therefore the FFQs have a wide coverage of food 
items. In addition, in this pooled analysis, effect estimates were calculated based on the relative 
ranking of dietary intake rather than absolute intake, and therefore the effect estimates were 
less likely to be affected by the limitations of FFQ. 
There is also potential non-differential misclassification introduced by the data 
harmonization and pooling process, due to the minor discrepancies in data collection, data 
management, and variable definitions among the parent studies. However, the above two 
sources of misclassification would most likely result in attenuation of the effect estimates. 5  
Another limitation is that the nutrient database utilized in this dissertation was released in 
2014, whereas the parent studies were conducted over a couple of decades ago. There fore, 
there may be changes in sugar/carbohydrate contents in certain food items. However, because 
the nutrient intakes were harmonized based on a unified nutrient database and intake was 
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pooled and compared based on relative rankings rather than absolute values, it is unlikely the 
effect estimates were substantially altered. The sensitivity analysis of using original calculated 
carbohydrate values by study-specific nutrient data processing center had shown similar results 
as my main findings, which further confirmed the robustness of my results. 
Multiple comparisons might be of concern given that the associations between 12 
measures of exposure and three outcomes were examined. However, adjusting for multiple 
comparisons may undeservedly reduce statistical power.6 In this dissertation, the significant 
results were consistent across the cancer development continuum (sucrose and sweetened 
desserts/beverages), across the parent studies (sucrose, sweetened desserts/beverages, 
added sugar, and glycemic index), or were consistent with previous published results (glycemic 
index). Therefore, it is unlikely that the significant results were purely due to chance. 
Because EA and GCA are lethal cancers with poor prognoses, proxy interviews were 
administered to the closest next of kin (usually the spouse) when participants were unable to be 
interviewed due to illness/death.7, 8 Therefore, there might be potential misclassification due to 
proxy interviews. However, a sensitivity analysis was conducted by excluding participants with 
proxy interviews, and the results were not substantially altered except for attenuation of the 
sucrose-EA incidence association. 
In addition, the information on diabetes was available in only one parent study, and 
therefore the impact of diabetes cannot be fully assessed. A sensitivity analysis was conducted 
within the Los Angeles Multi-Ethnic study by additionally adjusting for or stratifying by diabetes. 
Diabetes did not appear to confound or modify the signif icant associations between 
sugar/carbohydrate intake and risk of developing EA. Further well-powered studies are needed 
to more formally evaluate the role of diabetes in the associations between sugar/carbohydrate 
intake and incidence of BE and EA/GCA. 
Finally, although this pooled study has a larger sample size to examine the associations 
with BE and EA/GCA, the sample size was still limited when examining the associations by BE 
 188 
 
segment length. Further well-powered studies are needed to confirm the relevant findings in this 
dissertation. 
 
Strengths 
There are several strengths to this study. This is the first United States (US) study to 
comprehensively examine the role of sugar/carbohydrate intake in associations with BE-
EA/GCA cancer development continuum (normal tissueBEadenocarcinomadeath). To 
better capture the complexity of sugar/carbohydrate intake and provide support for clinical 
dietary recommendations/public health risk reduction strategies, twelve measures of the 
exposure were examined. Previous studies used inadequate measurement of the 
sugar/carbohydrate intake, and usually focused on EA incidence as outcome.1, 2, 9-11 As a result, 
the associations with BE incidence, GCA incidence, and EA/GCA survival were rarely studied in 
previous studies. Examination of the entire cancer continuum allows identification of key 
windows along the cancer development continuum that potential risk reduction strategies could 
be implemented. Food selection, as a non-pharmaceutical and potentially sustainable method 
for disease prevention, affects almost everyone in their daily life, and is of interest to patients.12 
If findings from this dissertation are confirmed, there could be potential to reduce the disease 
burden from these lethal cancers by helping individuals limit sugar/carbohydrate intake.  
 Further, the study-specific FFQs used to collect dietary intake data are valid and reliable, 
and include 17-23 line items that contain sweetened desserts or beverages, which allows for 
better assessment of sugar/carbohydrate intake (e.g. added sugar, sweets) than previous 
studies. The two FFQs from BE parent studies and the two FFQs from the EA/GCA studies 
share a lot of similarities, which enhanced my ability to harmonize dietary intake data. The 
estimates of sugar/carbohydrate intake were calculated by linking with the most recent 
University of Minnesota nutrient database, which contains more food items compared to other 
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databases, includes minimal missing nutrient values, and provides values of all nutrients of 
interest in this dissertation.13 
In addition, by pooling two similarly-conducted BE studies and two similar-designed 
EA/GCA studies, the sample size of my dissertation was enlarged, which enabled more precise 
estimates. With a larger sample size than relevant studies published previously, this is the first 
study to report that BMI modifies the sucrose-EA incidence, glycemic index-EA incidence, and 
sweetened desserts/beverages-EA incidence associations, and the first to report that waist 
circumference modifies the sweetened desserts/beverages-BE incidence association. Also, my 
dissertation is the first study to report GERD as an effect measure modifier of the sucrose-EA 
incidence association. 
In this dissertation, individual-level participant data, rather than published effect 
estimates, were pooled, which allowed for standardization of the statistical models and 
harmonization of the exposure variables and covariates, and therefore the heterogeneity 
between the studies were minimized.  For example, there was a difference in sweetened 
desserts/beverages intake by study, which may be partly attributed to the differences in the 
study-specific serving sizes and the number of FFQ line items that contained sweets, and partly 
explained by the true differences in sweets intake. This study is also more time-/cost-efficient by 
pooling existing studies. 
Multiple sensitivity analyses were conducted to examine the robustness of my results. 
For example, I primarily pooled sugar/carbohydrate intake on study-specific quantiles, although I 
also considered pooling on absolute cut-points.14, 15 Additionally,  study-specific ORs were 
pooled using a meta-analytic approach, wider exclusion criteria for plausible total energy intake 
values (lower/upper 2.5%) were utilized, and effect estimates derived using the intake values in 
the current study were compared with the effect estimates derived using the previously 
calculated intake values by study-specific nutrient data processing center. The results were not 
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substantially altered in most of the sensitivity analyses, which support the robustness of my 
findings. 
Finally, this dissertation benefits from the four well-conducted parent studies. The parent 
studies were either population-based or community-based case-control studies, with incident BE 
or EA/GCA cases identified through population-based cancer registries or clinical settings with 
wide coverage, which allows for stronger inferences regarding BE or EA/GCA incidence. 5, 8, 16-18 
Vital status of EA/GCA patients were determined by linking with national death index (NDI), 
which is a standard, high-sensitivity resource for assessing mortality in the US19 In addition, this 
pooled study has a wide coverage of US population, which greatly enhances generalizability of 
my findings. 
 
Public Health/Clinical Implications 
The rapid increase in incidence and the sustained poor prognoses of EA/GCA 
underscore the importance of identifying risk reduction strategies for BE and EA.  If findings 
from this dissertation are confirmed, there could be potential to reduce the risk of developing BE 
or EA by helping individuals limit intake of sweetened desserts/beverages, or reduce the table 
sugar contents in commercial and homemade desserts/beverages.      
 
Future Directions 
To confirm whether select measures of sugar/carbohydrate intake are associated with 
BE-EA/GCA continuum outcomes along specific windows of exposure, future studies should 
consider improvements in the following areas: study design; exposure assessment; windows of 
exposure; sample size; and examination of potential high-risk subgroups (BE segment length, 
fat/fat patterning, history of diabetes, and frequency of GERD). These issues are discussed in 
more detail below. 
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Study Design. The case-control study design usually examines one disease outcome. 
Although multiple disease outcomes were examined in this dissertation by pooling four case -
control studies, I was not able to examine how sugar/carbohydrate intake impacts the 
progression from BE to EA/GCA in this study within the same study subjects. Therefore, to 
identify the key windows of susceptibility along the entire cancer development continuum, a 
prospective cohort study that follows participants who are free of BE/EA/GCA at baseline for BE 
outcomes, EA/GCA outcomes, and mortality after a diagnosis of EA/GCA, would be a better 
study design. 
Exposure Assessment Method. Future studies should consider a comprehensive 
battery of measures to capture the complexity of sugar/carbohydrate intake, as was done in this 
dissertation. This approach is dependent upon the quality of the methods used to assess dietary 
intake in an epidemiologic study.  
Potential measurement of sugar/carbohydrate intake in an epidemiologic study includes 
utilizing a FFQ, 24-hour recalls, or biomarkers, but each of these assessment methods has its 
strengths and limitations. A FFQ captures usual intake, whereas 24-hour recall and biomarker 
assessment reflect short-term intake, and therefore are subject to day-to-day variations in 
dietary intake.4 24-hour recalls may provide more accuracy in dietary intake reporting, but may 
not reflect dietary patterns that vary by season, or even by the day of the week;4 although this 
drawback can be overcome by the administration of repeated 24-hour recalls throughout the 
year. Biomarkers could provide an objective measure of dietary intake, however, biomarkers for 
sugar intake are still understudied.20 Because the development of cancer is more likely to be 
associated with long-term (rather than short-term) exposure to sugar/carbohydrate intake, a 
FFQ which reflects usual dietary intake may be the better exposure assessment method, 
particularly if repeated 24-hour recalls over an extended period of time (for example over 
multiple years) are not feasible. 
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Windows of Exposure. To more accurately capture dietary intake, and identify the 
windows of exposure that impacts carcinogenesis along the BE-EA/GCA continuum, future 
studies should assess dietary sugar/carbohydrate intake with repeated 24-hour recalls or FFQs 
to capture the dietary intake at different time periods. To be specific, participants should be 
asked to self-report their dietary intake using a validated FFQ at baseline and every 5 years 
thereafter (or, if feasible, collect 24 hours recalls up to six times per year every year on a 
quintennial basis). In addition, future studies should incorporate additiona l questions inquiring 
diet change in the FFQs to help BE or EA/GCA patients disentangle their previous vs. current 
diet.  
Sample Size. Despite of the rapid increase, the incidence of BE and EA/GCA remains 
relatively low in the general population.21, 22 Given the long induction period of cancer outcomes, 
the ideal cohort study would by necessity last more than a decade, and therefore there might be 
a large number of participants who are lost to follow-up. Thus, the rarity of these cancer 
outcomes, the lost to follow-up, and the need to examine effect measure modification, would 
require an extraordinarily large sample size to guarantee sufficient statistical power. 
High-Risk Subgroup: Segment Length of Barrett’s Esophagus. In this dissertation, 
the sample size to examine the sugar/carbohydrate intake and BE incidence by segment length 
– a possible measure of disease severity -- was restricted, and therefore the results need to be 
interpreted with caution. Future well-powered studies with BE segment length information 
collected are needed to confirm my findings. 
High-Risk Subgroup: Fat/Fat Patterning. Obesity, and perhaps abdominal obesity, is 
consistently associated with BE and EA/GCA, and one potential mechanism is via insulin 
resistance pathway.23 Long-term high sugar/carbohydrate intake may also increase the risk of 
developing BE/EA/GCA by promoting insulin resistance.24-26 Therefore, it is plausible that 
obesity and/or abdominal obesity confound, mediate, or modify the sugar/carbohydrate-cancer 
association. Common measures for obesity and abdominal obesity include BMI and waist 
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circumference, respectively. Both measures have been found to be associated with EA/GCA 
incidence, with waist circumference more consistently associated with risk of developing BE. 27, 
28 However, in this dissertation, data on waist circumference were collected in the BE parent 
studies, but not in the EA/GCA parent studies. I am the first to report effect measure 
modification by BMI, and perhaps waist circumference, in some of the sugar/carbohydrate -
cancer associations; further studies are needed to confirm my findings. Therefore, future well-
powered cohort studies should collect data on BMI and waist circumference (preferably 
adulthood BMI and waist circumference prior to symptomatic disease onset), and formally 
evaluate their role in the associations between sugar/carbohydrate and outcomes in the BE-
adenocarcinoma continuum. 
High-Risk Subgroup: Diabetes Mellitus. One potential underlying biological 
mechanism is that sugar/carbohydrate intake may promote carcinogenesis though the insulin 
resistance pathway. Therefore, it is of interest to know the role of diabetes (which is strongly 
associated with insulin resistance), in the sugar/carbohydrate-cancer association.29 In this 
dissertation, data on diabetes was only collected in one parent study, and therefore I was not 
able to fully evaluate its role in the associations between sugar/carbohydrate in take and 
Barrett’s esophagus-adenocarcinoma continuum. Future cohort studies with diabetes data 
collected are needed to evaluate the role of diabetes, whether as a mediator, confounder, or an 
effect measure modifier.  
High-Risk Subgroup: Frequency of GERD. This dissertation is the first to report that 
frequency of GERD (<weekly/≥weekly) modified the association between sucrose intake and 
risk of developing EA, and a higher risk was found among those with less frequent GERD 
(<weekly).  As discussed in Chapter 1, GERD symptomology (frequency, intensity and duration) 
– both current and historical – is difficult to assess in an epidemiologic study, due to cultural and 
individual variations in the experience of GERD symptoms.30-33 Future studies, with improved 
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GERD measures, are needed to confirm our findings, and to explore the role of GERD as an 
effect measure modifier. 
In summary, given the large sample size needed and the long induction period of BE 
and EA/GCA, the ideal cohort study design is likely to be very costly and inefficient. Although 
the study design used in this dissertation was less than ideal, it was much more practical and 
time-/cost-efficient when compared to the ideal study approach proposed above. 
 
Conclusions  
This dissertation is the first to examine whether multiple measures of sugar/carbohydrate 
intake are associated with multiple outcomes in the BE-EA/GCA continuum in the US. I 
conducted a pooled analysis drawing upon the resources of four case-control studies (of which 
two included a follow-up component to assess mortality after EA/GCA) that were conducted 
using similar methodologies, which facilitated harmonization of the study responses. I 
considered a comprehensive number of exposure measures to better capture the intake of 
these complex foods. I found that dietary intake of sucrose and sweetened desserts/beverages 
was positively associated with both BE and EA incidence. Added sugar intake and the glycemic 
index were associated with increased incidence of BE and EA, respectively. If these findings are 
confirmed by future studies, limiting intake of sweetened desserts/beverages may be a potential 
risk reduction strategy for BE and EA incidence. 
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APPENDIX: ADDITIONAL TABLES  
Table A.1. Multivariable-adjusted ORs and 95%CIs for the associations between sugar/carbohydrate intake and risk of developing 
Barrett's esophagus, stratified by BMI, among 472 cases and 492 controls from two US case-control studies. 
 
  
BMI (kg/m2) Measure Controls 
(N) 
Cases 
(N) 
Multiplicative scale   Additive scale 
 
Stratified ORs        
(95%CIs) 
Pinteracti
on 
 Single referent 
ORs (95%CIs) 
Interaction 
contrast ratio        
(95%CI) 
 
Sucrose 
    
   
<25    <median 61 39 1.00 
 
 1.00  
 
   ≥median 70 50 1.55 (0.81-2.95) 
 
 1.55 (0.81-2.95)  
≥25    <median 176 174 1.00 
 
 1.37 (0.81-2.30)  
 
   ≥median 169 185 1.27 (0.86-1.88) 0.58  1.74 (0.99-3.05) -0.18 (-1.16, 0.80) 
 Added sugar 
   
   
<25    <median 68 32 1.00 
 
 1.00  
    ≥median 63 57 1.97 (1.03-3.78) 
 
 1.97 (1.03-3.78)  
≥25    <median 169 165 1.00 
 
 1.68 (0.99-2.86)  
    ≥median 176 194 1.12 (0.77-1.64) 0.12 
 1.89 (1.07-3.33) -0.76 (-2.06, 0.54) 
 
Sweetened desserts/beverages 
  
   
<25    <median 62 38 1.00 
 
 1.00  
 
   ≥median 70 56 1.48 (0.80-2.73) 
 
 1.48 (0.80-2.73)  
≥25    <median 181 178 1.00 
 
 1.40 (0.84-2.33)  
 
   ≥median 173 198 1.18 (0.83-1.70) 0.52  1.66 (0.97-2.82) -0.22 (-1.17, 0.72) 
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Table A.2. Multivariable-adjusted ORs and 95%CIs for the associations between sugar/carbohydrate intake and risk of developing 
Barrett's esophagus, stratified by waist circumference categories, among 472 cases and 492 controls from two US case -control 
studies. 
 
  
Waist 
circumferenc
e1 
Measure Controls 
(N) 
Cases 
(N) 
Multiplicative scale   Additive scale 
 
Stratified ORs        
(95%CIs) 
Pinteracti
on 
 Single referent 
ORs (95%CIs) 
Interaction 
contrast ratio        
(95%CI) 
 
Sucrose 
    
   
   <median    <median 120 91 1.00 
 
 1.00  
 
   ≥median 137 125 1.39 (0.88-2.19) 
 
 1.39 (0.88-2.19)  
   ≥median    <median 118 121 1.00 
 
 1.09 (0.71-1.66)  
 
   ≥median 103 109 1.21 (0.76-1.92) 0.64  1.31 (0.81-2.14) -0.16 (-0.89, 0.57) 
 Added sugar 
   
   
   <median    <median 124 87 1.00 
 
 1.00  
    ≥median 133 129 1.41 (0.90-2.22) 
 
 1.41 (0.90-2.22)  
   ≥median    <median 114 109 1.00 
 
 1.15 (0.75-1.77)  
 
   ≥median 107 121 1.09 (0.70-1.72) 0.39  1.26 (0.78-2.02) -0.30 (-1.06, 0.45) 
 
Sweetened desserts/beverages 
  
   
   <median    <median 125 88 1.00 
 
 1.00  
 
   ≥median 136 138 1.63 (1.06-2.50) 
 
 1.63 (1.06-2.50)  
   ≥median    <median 119 127 1.00 
 
 1.43 (0.94-2.17)  
 
   ≥median 108 115 0.91 (0.59-1.41) 0.05  1.31 (0.83-2.06) -0.75 (-1.64, 0.14) 
1
Sex-specif ic w aist circumference category 
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Table A.3. Multivariable-adjusted ORs and 95%CIs for the associations between sugar/carbohydrate intake and risk of developing 
Barrett's esophagus, stratified by GERD frequency, among 472 cases and 492 controls from two US case-control studies.   
 
 
 
 
 
 
GERD 
frequency 
Measure Controls 
(N) 
Cases 
(N) 
Multiplicative scale   Additive scale 
 
Stratified ORs        
(95%CIs) 
Pinteracti
on 
 Single referent 
ORs (95%CIs) 
Interaction 
contrast ratio        
(95%CI) 
 
Sucrose 
    
   
≤Weekly    <median 195 81 1.00 
 
 1.00  
 
   ≥median 198 99 1.40 (0.93-2.10) 
 
 1.40 (0.93-2.10)  
>Weekly    <median 42 132 1.00 
 
 8.71 (5.56-13.65)  
 
   ≥median 41 136 1.22 (0.71-2.08) 0.66  10.59 (6.41-17.49) 1.48 (-3.75, 6.71) 
 Added sugar 
   
   
≤Weekly    <median 198 82 1.00 
 
 1.00  
    ≥median 195 98 1.31 (0.88-1.96) 
 
 1.31 (0.88-1.96)  
>Weekly    <median 39 115 1.00 
 
 8.35 (5.25-13.29)  
 
   ≥median 44 153 1.20 (0.71-2.05) 0.79  10.05 (6.26-16.13) 1.39 (-3.48, 6.26)  
 
Sweetened desserts/beverages 
 
   
≤Weekly    <median 203 87 1.00 
 
 1.00  
 
   ≥median 200 101 1.24 (0.85-1.81) 
 
 1.24 (0.85-1.81)  
>Weekly    <median 43 131 1.00 
 
 8.11 (5.23-12.58)  
 
   ≥median 45 153 1.17 (0.71-1.94) 0.84  9.50 (6.02-14.99) 1.14 (-3.31, 5.60) 
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Table A.4. Multivariable-adjusted ORs and 95%CIs for the associations between 
sugar/carbohydrate intake and risk of developing BE among 472 cases and 492 controls from two 
US case-control studies (pooled approach, based on identical absolute intake cut-points). 
Measure Controls (N) Cases (N) OR (95%CI) 
Free glucose (g/day)1 
   Q1: 1.61-<11.53 115 113 Ref. 
Q2: 11.53-<17.88 121 107 0.82 (0.53-1.26) 
Q3: 17.88-<26.28 122 121 1.23 (0.78-1.93) 
Q4: ≥26.28 123 109 1.08 (0.64-1.81) 
Ptrend 
  
0.85 
Sucrose (g/day)2 
   Q1: 2.26-<20.24 117 98 Ref. 
Q2: 20.24-<31.69 119 120 1.26 (0.82-1.94) 
Q3: 31.69-<43.81 118 93 1.21 (0.76-1.94) 
Q4: ≥43.81 122 137 1.90 (1.12-3.21) 
Ptrend 
  
<0.01 
Free fructose (g/day)1 
   Q1: 1.48-<11.19 115 98 Ref. 
Q2: 11.19-<18.90 121 126 1.26 (0.82-1.94) 
Q3: 18.90-<29.73 122 130 1.55 (0.99-2.45) 
Q4: ≥29.73 123 96 1.14 (0.69-1.90) 
Ptrend 
  
0.66 
Total sugar (g/day)1 
   Q1: 10.85-<58.54 115 101 Ref. 
Q2: 58.54-<86.74 122 114 1.29 (0.83-2.00) 
Q3: 86.74-<118.73 122 117 1.37 (0.86-2.20) 
Q4: ≥118.73 122 118 1.69 (0.96-2.97) 
Ptrend 
  
0.15 
Added sugar (g/day)2 
   Q1: 1.77-<19.97 119 97 Ref. 
Q2: 19.97-<32.55 118 100 1.06 (0.69-1.63) 
Q3: 32.55-<50.28 120 112 1.16 (0.74-1.83) 
Q4: ≥50.28 119 139 1.70 (1.04-2.78) 
Ptrend 
  
0.15 
Starch (g/day)2 
   Q1: 4.48-<43.22 117 103 Ref. 
Q2: 43.22-<61.84 118 109 0.84 (0.54-1.30) 
Q3: 61.84-<91.87 121 133 1.28 (0.80-2.07) 
Q4: ≥91.87 120 103 0.98 (0.51-1.90) 
Ptrend 
  
0.74 
Total carbohydrate (g/day)1 
Q1: 35.56-<142.13 116 107 Ref. 
Q2: 142.13-<196.04 120 121 1.13 (0.72-1.75) 
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Q3: 196.04-<260.82 123 122 1.17 (0.70-1.94) 
Q4: ≥260.82 122 100 1.26 (0.62-2.54) 
Ptrend 
  
0.39 
Glycemic index3 
Q1: 22.27-<58.93 122 110 Ref. 
Q2: 58.93-<61.10 122 114 0.92 (0.61-1.39) 
Q3: 61.10-<63.12 119 110 0.95 (0.63-1.44) 
Q4: ≥63.12 118 116 0.97 (0.64-1.47) 
Ptrend 
  
0.39 
Glycemic load4 
Q1: 16.69-<75.64 115 107 Ref. 
Q2: 75.64-<106.06 119 121 1.13 (0.73-1.76) 
Q3: 106.06-<141.08 123 115 1.17 (0.71-1.94) 
Q4: ≥141.08 119 105 1.34 (0.69-2.61) 
Ptrend 
  
0.35 
Sweetened desserts/beverages (servings/day)5 
 
Q1: 0-<1.20 123 98 Ref. 
Q2: 1.20-<2.00 123 112 1.12 (0.74-1.70) 
Q3: 2.00-<3.10 122 124 1.27 (0.83-1.95) 
Q4: ≥3.10 123 138 1.65 (1.03-2.64) 
Ptrend 
  
0.04 
Sweetened desserts (servings/day)6 
 Q1: 0-<0.72 121 124 Ref. 
Q2: 0.72-<1.22 123 85 0.65 (0.43-0.99) 
Q3: 1.22-<2.08 121 124 1.07 (0.71-1.63) 
Q4: ≥2.08 121 137 1.14 (0.73-1.79) 
Ptrend 
  
0.10 
Sweetened beverages (servings/day)3 
 Q1: 0-<0.15 118 98 Ref. 
Q2: 0.15-<0.53 120 112 1.21 (0.79-1.84) 
Q3: 0.53-<1.11 123 117 1.24 (0.81-1.89) 
Q4: >1.11 120 123 1.46 (0.94-2.28) 
Ptrend     0.29 
1
Adjusted for age, sex, study indicator, fruit/vegetable intake, GERD frequency, and total energy intake                                                                                                                                                            
2
Adjusted for age, sex, race, study indicator, BMI, fruit/vegetable intake, GERD frequency, and total energy intake                                                                                                                                                                                 
3
Adjusted for age, sex, race, study indicator, fruit/vegetable intake, GERD frequency, and total energy intake   
4
Adjusted for age, sex, study indicator, fruit/vegetable intake, GERD frequency, and total energy intake         
5
Adjusted for age, sex, study indicator, GERD frequency, and total energy intake  
6
Adjusted for age, sex, study indicator, BMI, GERD frequency, and total energy intake                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
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Table A.5. Multivariable-adjusted ORs and 95%CIs for the associations between 
sugar/carbohydrate intake and risk of developing BE among 448 cases and 472 controls from 
two US case-control studies (using lower and upper 2.5% as exclusion criteria). 
Measure Controls (N) Cases (N) OR (95%CI) 
Free glucose (g/day)1 
   Q1 
  
Ref. 
Q2 111 107 1.36 (0.87-2.11) 
Q3 115 122 1.24 (0.78-1.97) 
Q4 118 111 1.26 (0.75-2.10) 
Ptrend 118 87 0.47 
Sucrose (g/day)2 
   Q1 112 96 Ref. 
Q2 115 107 1.12 (0.72-1.74) 
Q3 112 92 1.21 (0.75-1.96) 
Q4 118 130 2.01 (1.18-3.43) 
Ptrend   <0.01 
Free fructose (g/day)1    
Q1 110 100 Ref. 
Q2 119 127 1.43 (0.92-2.22) 
Q3 116 105 1.35 (0.85-2.16) 
Q4 117 95 1.39 (0.84-2.29) 
Ptrend   0.59 
Total sugar (g/day)1    
Q1 112 101 Ref. 
Q2 116 114 1.23 (0.79-1.92) 
Q3 116 100 1.21 (0.74-1.96) 
Q4 118 112 1.60 (0.91-2.81) 
Ptrend   0.02 
Added sugar (g/day)2    
Q1 114 92 Ref. 
Q2 113 95 1.11 (0.71-1.72) 
Q3 115 107 1.17 (0.73-1.86) 
Q4 115 131 1.75 (1.06-2.90) 
Ptrend   0.01 
Starch (g/day)2    
Q1 112 99 Ref. 
Q2 113 103 0.96 (0.61-1.51) 
Q3 116 129 1.40 (0.84-2.31) 
Q4 116 94 1.06 (0.53-2.10) 
Ptrend   0.62 
Total carbohydrate (g/day)1 
Q1 112 102 Ref. 
Q2 115 112 1.28 (0.80-2.04) 
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Q3 117 123 1.56 (0.89-2.74) 
Q4 118 90 1.66 (0.75-3.65) 
Ptrend   0.09 
Glycemic index3 
Q1 116 105 Ref. 
Q2 118 105 0.85 (0.56-1.30) 
Q3 115 101 0.88 (0.58-1.34) 
Q4 113 116 0.93 (0.61-1.43) 
Ptrend 
  
0.39 
Glycemic load4 
Q1 110 103 Ref. 
Q2 115 119 1.18 (0.74-1.87) 
Q3 117 106 1.19 (0.69-2.05) 
Q4 115 97 1.50 (0.73-3.08) 
Ptrend 
  
0.07 
Sweetened desserts/beverages (servings/day)5 
 
Q1 117 90 Ref. 
Q2 118 120 1.33 (0.87-2.03) 
Q3 118 103 1.18 (0.75-1.84) 
Q4 118 135 1.79 (1.11-2.88) 
Ptrend 
  
<0.01 
Sweetened desserts (servings/day)6 
 Q1 116 116 Ref. 
Q2 118 80 0.63 (0.41-0.98) 
Q3 116 118 1.12 (0.73-1.72) 
Q4 116 132 1.31 (0.83-2.08) 
Ptrend 
  
0.12 
Sweetened beverages (servings/day)3 
 Q1 114 89 Ref. 
Q2 118 104 1.12 (0.72-1.72) 
Q3 115 104 1.40 (0.90-2.18) 
Q4 115 130 1.60 (1.03-2.50) 
Ptrend     0.02 
1
Adjusted for age, sex, study indicator, fruit/vegetable intake, GERD frequency, and total energy intake                                                                                                                                                            
2
Adjusted for age, sex, race, study indicator, BMI, fruit/vegetable intake, GERD frequency, and total energy intake                                                                                                                                                                                 
3
Adjusted for age, sex, race, study indicator, fruit/vegetable intake, GERD frequency, and total energy intake   
4
Adjusted for age, sex, study indicator, fruit/vegetable intake, GERD frequency, and total energy intake         
5
Adjusted for age, sex, study indicator, GERD frequency, and total energy intake  
6
Adjusted for age, sex, study indicator, BMI, GERD frequency, and total energy intake                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
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Table A.6. Multivariable-adjusted ORs and 95%CIs for the associations between 
sugar/carbohydrate intake and risk of developing Barrett's esophagus among 472 cases and 
492 controls from two US case-control studies (pooled approach, based on study-specific 
quartiles, without adjusting for total energy intake). 
Measure Controls (N) Cases (N) OR (95%CI) Ptrend 
Free glucose (g/day)1 
    Q1 116 107 Ref. 
 Q2 120 134 1.42 (0.94-2.15) 
 Q3 123 115 1.24 (0.80-1.91) 
 Q4 122 94 1.26 (0.79-1.99) 0.95 
Sucrose (g/day)2 
    Q1 117 105 Ref. 
 Q2 120 108 1.02 (0.67-1.56) 
 Q3 117 97 1.07 (0.69-1.65) 
 Q4 122 138 1.50 (0.99-2.29) 0.02 
Free fructose (g/day)1 
    Q1 115 108 Ref. 
 Q2 123 131 1.34 (0.88-2.04) 
 Q3 121 113 1.27 (0.82-1.97) 
 Q4 122 98 1.24 (0.78-1.95) 0.76 
Total sugar (g/day)1 
    Q1 117 109 Ref. 
 Q2 120 116 1.11 (0.73-1.68) 
 Q3 122 103 1.01 (0.66-1.55) 
 Q4 122 122 1.35 (0.88-2.08) 0.24 
Added sugar (g/day)2 
    Q1 119 97 Ref. 
 Q2 118 100 1.09 (0.71-1.67) 
 Q3 120 112 1.07 (0.70-1.64) 
 Q4 119 139 1.53 (1.01-2.33) 0.16 
Starch (g/day)2 
    Q1 117 103 Ref. 
 Q2 118 109 1.01 (0.66-1.55) 
 Q3 121 133 1.39 (0.91-2.12) 
 Q4 120 103 1.05 (0.67-1.65) 0.89 
Total carbohydrate (g/day)1 
 Q1 117 109 Ref. 
 Q2 119 115 1.09 (0.72-1.66) 
 Q3 123 127 1.23 (0.81-1.88) 
 Q4 122 99 1.13 (0.72-1.79) 0.57 
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Glycemic index3 
 Q1 122 112 Ref. 
 Q2 122 109 0.83 (0.55-1.26) 
 Q3 119 113 0.93 (0.62-1.41) 
 Q4 118 116 0.93 (0.62-1.41) 0.38 
Glycemic load4 
 Q1 115 108 Ref. 
 Q2 119 124 1.15 (0.76-1.75) 
 Q3 123 109 1.07 (0.69-1.64) 
 Q4 119 107 1.26 (0.80-1.99) 0.41 
Sweetened desserts/beverages (servings/day)5 
 
 Q1 123 94 Ref. 
 Q2 123 124 1.28 (0.85-1.93) 
 Q3 122 116 1.17 (0.77-1.77) 
 Q4 123 138 1.45 (0.96-2.18) 0.13 
Sweetened desserts (servings/day)6 
 Q1 122 123 Ref. 
 Q2 122 81 0.61 (0.40-0.93) 
 Q3 121 126 1.04 (0.70-1.55) 
 Q4 121 140 1.10 (0.74-1.63) 0.22 
Sweetened beverages (servings/day)3 
 Q1 118 97 Ref. 
 Q2 121 108 1.10 (0.72-1.69) 
 Q3 120 107 1.28 (0.84-1.97) 
 Q4 122 138 1.45 (0.95-2.20) 0.29 
1
Adjusted for age, sex, study indicator, fruit/vegetable intake, GERD frequency, and total energy intake                                                                                                                                                            
2
Adjusted for age, sex, race, study indicator, BMI, fruit/vegetable intake, GERD frequency, and total energy intake                                                                                                                                                                                 
3
Adjusted for age, sex, race, study indicator, fruit/vegetable intake, GERD frequency, and total energy intake   
4
Adjusted for age, sex, study indicator, fruit/vegetable intake, GERD frequency, and total energy intake         
5
Adjusted for age, sex, study indicator, GERD frequency, and total energy intake  
6
Adjusted for age, sex, study indicator, BMI, GERD frequency, and total energy intake                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
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Table A.7. Multivariable-adjusted ORs and 95%CIs for the associations between 
sugar/carbohydrate intake and risk of developing Barrett's esophagus among 472 cases and 
492 controls from two US case-control studies (nutrient density energy adjustment method).  
Measure Controls (N) Cases (N) OR (95%CI) Ptrend 
Free glucose (g/day)1 
    Q1 118 117 Ref. 
 Q2 118 130 1.27 (0.85-1.91) 
 Q3 123 102 0.97 (0.63-1.49) 
 Q4 122 101 1.07 (0.69-1.65) 0.98 
Sucrose (g/day)2 
    Q1 117 92 Ref. 
 Q2 119 108 1.10 (0.71-1.69) 
 Q3 121 103 1.07 (0.70-1.65) 
 Q4 119 145 1.84 (1.21-2.79) <0.01 
Free fructose (g/day)1 
   Q1 118 120 Ref. 
 Q2 118 121 1.11 (0.74-1.66) 
 Q3 123 117 1.12 (0.73-1.70) 
 Q4 122 92 0.90 (0.58-1.40) 0.85 
Total sugar (g/day)1 
    Q1 119 102 Ref. 
 Q2 120 116 1.34 (0.89-2.04) 
 Q3 121 110 1.18 (0.78-1.80) 
 Q4 121 122 1.39 (0.91-2.12) 0.12 
Added sugar (g/day)2 
    Q1 119 94 Ref. 
 Q2 120 85 0.89 (0.57-1.37) 
 Q3 119 104 1.15 (0.75-1.76) 
 Q4 118 165 1.67 (1.11-2.51) 0.05 
Starch (g/day)2 
    Q1 121 120 Ref. 
 Q2 118 100 0.88 (0.58-1.33) 
 Q3 118 118 0.98 (0.65-1.47) 
 Q4 119 110 0.95 (0.63-1.43) 0.55 
Total carbohydrate (g/day)1 
 Q1 118 105 Ref. 
 Q2 121 134 1.33 (0.89-1.99) 
 Q3 119 105 1.00 (0.65-1.53) 
 Q4 123 106 1.22 (0.79-1.87) 0.43 
1
Adjusted for age, sex, study indicator, fruit/vegetable intake, GERD frequency, and total energy intake                                                                                                                                                            
2
Adjusted for age, sex, race, study indicator, BMI, fruit/vegetable intake, GERD frequency, and total energy intake                                                                                                                                                                                 
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Table A.8. Multivariable-adjusted ORs and 95%CIs for the associations between 
carbohydrate intake and risk of developing BE among 472 cases and 492 controls from two 
US case-control studies (originally calculated carbohydrate values vs. new carbohydrate 
values). 
Measure 
Controls (N) Cases 
(N) 
OR1 (95%CI) 
Old total carbohydrate values (g/day) 
Q1 117 105 Ref. 
Q2 119 110 1.01 (0.65-1.58) 
Q3 123 128 1.27 (0.77-2.07) 
Q4 122 107 1.26 (0.65-2.45) 
Ptrend 
  
0.32 
    New total carbohydrate values (g/day) 
Q1 117 109 Ref. 
Q2 119 115 1.12 (0.72-1.75) 
Q3 123 127 1.29 (0.78-2.16) 
Q4 122 99 1.25 (0.61-2.54) 
Ptrend     0.39 
1
Adjusted for age, sex, study indicator, fruit/vegetable intake, GERD frequency, and total energy intake                                                                                                                                                         
  
 
2
0
9 
Table A.9. Multivariable-adjusted ORs and 95%CIs for the associations between sweetened desserts/beverages intake and risk of 
developing Barrett's esophagus, stratified by waist circumference categories, among 472 cases and 492 controls from two US ca se-
control studies (using extreme quartiles for sweetened desserts/beverages measure). 
 
 
 
 
 
 
 
 
 
  
Waist 
circumference1 
Sweetened 
desserts 
/beverages 
Controls 
(N) 
Cases 
(N) 
Multiplicative scale   Additive scale 
 
Stratified ORs        
(95%CIs) 
Pinteract
ion 
 Single referent 
ORs (95%CIs) 
Interaction 
contrast ratio        
(95%CI) 
   
   
  <median Q1 61 35 1.00 
 
 1.00  
 
Q4 73 76 2.07 (1.08-3.96)  2.07 (1.08-3.96)  
  ≥median Q1 62 58 1.00 
 
 1.54 (0.84-2.84)  
 
Q4 49 61 1.28 (0.65-2.52) 0.25  1.98 (0.96-4.08) -0.63 (-2.11, 0.85) 
1
Sex-specif ic w aist circumference category 
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Table A.10. Study-specific sugar/carbohydrate intake quintiles defined by the intake distribution of the controls from each of the two 
US case-control studies of EA/GCA (quintiles for case-control analysis). 
Measure 
US Multi-Center 
Study 
LA Multi-Ethnic 
Study 
EA cases 
(N=500) 
GCA cases 
(N=529) 
Controls 
(N=2027) 
Free glucose (g/day) 
     Q1 0.12-<13.29 1.21-<16.11 118 83 406 
Q2 13.29-<16.11 16.11-<22.64 98 100 405 
Q3 16.11-<20.69 22.64-<29.12 99 111 405 
Q4 20.69-<26.29 29.12-<39.83 79 106 406 
Q5 ≥26.29 ≥39.83 106 129 405 
Sucrose (g/day) 
     Q1 2.26-<23.90 0.97-<20.09 75 82 405 
Q2 26.90-<34.45 20.09-<30.23 88 107 406 
Q3 34.45-<45.71 30.23-<40.90 95 104 405 
Q4 45.71-<64.25 40.90-<58.08 110 115 406 
Q5 ≥64.25 ≥58.08 132 121 405 
Free fructose (g/day) 
     Q1 0.00-<12.18 0.61-<15.91 123 98 405 
Q2 12.18-<16.88 15.91-<22.24 98 108 406 
Q3 16.88-<22.03 22.24-<28.37 95 94 405 
Q4 22.03-29.58 28.37-<40.19 93 107 405 
Q5 ≥29.58 ≥40.19 91 122 406 
Total sugar (g/day) 
     Q1 2.40-<61.31 3.75-<69.99 89 88 405 
Q2 61.31-<79.47 69.99-<95.79 92 93 406 
Q3 79.47-<121.58 95.79-<122.55 108 116 405 
Q4 102.75-130.24 122.55-<160.64 94 106 406 
Q5 ≥130.24 ≥160.64 117 126 405 
Added sugar (g/day) 
     Q1 1.10-<23.84 0.38-<23.28 75 81 405 
Q2 23.84-<34.59 23.28-<35.26 80 78 406 
  
 
2
1
1 
Q3 34.59-<49.50 35.26-<47.94 101 112 405 
Q4 49.50-<69.27 47.94-71.86 120 125 406 
Q5 ≥69.27 ≥71.86 124 133 405 
Starch (g/day) 
     Q1 1.75-<54.43 3.73-<72.92 77 89 405 
Q2 54.43-<69.03 72.92-<99.91 87 90 406 
Q3 69.03-<83.73 99.91-<126.58 113 122 405 
Q4 83.73-101.44 ≥126.58 104 109 406 
Q5 ≥101.44  119 119 405 
Total carbohydrate (g/day) 
    Q1 54.70-<155.09 40.83-<195.80 85 95 405 
Q2 155.09-<190.36 195.80-<254.03 90 90 406 
Q3 190.36-<228.77 254.03-<311.53 92 89 406 
Q4 228.77-277.00 311.53-399.25 102 117 405 
Q5 ≥277.00 ≥399.25 131 138 405 
Glycemic index 
     Q1 2.50-<59.00 19.93-<56.83 96 110 405 
Q2 59.00-<61.38 56.83-<59.53 99 89 405 
Q3 61.38-<62.84 59.53-<61.28 98 108 406 
Q4 62.84-64.28 61.28-<63.09 87 117 406 
Q5 ≥64.28 ≥63.09 120 105 405 
Glycemic load 
     Q1 2.03-<86.29 7.21-<105.08 93 96 405 
Q2 86.29-<104.58 105.08-<136.65 85 85 406 
Q3 104.58-<127.22 136.65-<167.90 92 95 405 
Q4 127.22-157.79 ≥167.90-<216.01 107 125 405 
Q5 ≥157.79 ≥216.01 123 128 406 
Sweetened desserts/beverages (servings/day) 
    Q1 0-<1.98 0-<1.39 77 80 405 
Q2 1.98-<2.92 1.39-<2.21 84 93 407 
Q3 2.92-<3.90 2.21-<3.17 107 114 405 
  
 
2
1
2 
 
  
Q4 3.90-5.41 3.17-<4.51 88 112 406 
Q5 ≥5.41 ≥4.51 144 130 404 
Sweetened desserts (servings/day) 
    Q1 0-<0.88 0-<0.66 74 80 404 
Q2 0.88-<1.46 0.66-<1.25 76 99 406 
Q3 1.46-<2.04 1.25-<1.95 108 105 406 
Q4 2.04-2.94 1.95-<2.94 108 119 406 
Q5 ≥2.94 ≥2.94 134 126 405 
Sweetened beverages (servings/day) 
    Q1 0-<0.57 0-<0.31 101 91 404 
Q2 0.57-<1.04 0.31-<0.66 92 101 407 
Q3 1.04-<1.71 0.66-<1.12 93 96 405 
Q4 1.71-3.00 1.12-<1.75 87 121 407 
Q5 ≥3.00 ≥1.75 127 120 404 
  
 
2
1
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Table A.11. Study-specific sugar/carbohydrate intake quintiles defined by the intake distribution of the EA/GCA from each of 
the two US case-control studies of EA/GCA (quintiles for survival analysis). 
 EA cases  GCA cases 
Measure 
US Multi-Center 
Study 
LA Multi-Ethnic 
Study  N 
 US Multi-Center 
Study 
LA Multi-Ethnic 
Study N 
Free glucose (g/day) 
   
   
 Q1 0.12-<10.73 4.16-<16.17 100  3.76-<12.99 1.38-<17.68  105 
Q2 10.73-<14.89 16.17-<22.36 100  12.99-<17.81 17.68-<23.31 106 
Q3 14.89-<19.08 22.36-<29.13 100  17.81-<22.09 23.31-<30.48 106 
Q4 19.08-<26.34 29.13-<41.49 100  22.09-<29.24 30.48-<41.23 106 
Q5 ≥26.34 ≥41.49 100  ≥29.24 ≥41.23 106 
Sucrose (g/day) 
   
   
 Q1 2.26-<28.10 3.30-<20.91 100  6.00-<26.23 4.32-<21.46 106 
Q2 28.10-<40.19 20.91-<31.30 100  26.23-<40.15 21.46-<30.53 106 
Q3 40.19-<50.26 31.30-<46.40 100  40.15-<52.51 30.53-<40.81 106 
Q4 50.26-<68.86 46.40-<71.99 100  52.51-<71.99 40.81-<57.98 105 
Q5 ≥68.86 ≥71.99 100  ≥71.99 ≥57.98 106 
Free fructose (g/day) 
   
   
 Q1 0-<10.50 3.63-<15.47 100  2.75-<12.64 0.61-<16.28 106 
Q2 10.50-<15.04 15.47-<21.60 100  12.64-<17.17 16.28-<22.68 106 
Q3 15.04-<19.80 21.60-<28.66 100  17.17-<23.18 22.68-<29.34 105 
Q4 19.80-<28.31 28.66-<40.29 100  23.18-<32.21 29.34-<41.62 106 
Q5 ≥28.31 ≥40.29 100  ≥32.21 ≥41.62 106 
Total sugar (g/day) 
   
   
 Q1 2.40-<65.89 27.85-<73.44 100  17.97-<71.05 25.82-<76.02 106 
Q2 65.89-<84.05 73.44-<96.99 100  71.05-<90.28 76.02-<97.02 105 
Q3 84.05-<103.11 96.99-<129.87 100  90.28-<113.58 97.02-<122.55 106 
Q4 103.11-<134.78 129.87-<170.80 100  113.58-<141.66 122.55-<165.79 106 
Q5 ≥134.78 ≥170.80 100  ≥141.66 ≥165.79 106 
Added sugar (g/day) 
   
   
 Q1 1.10-29.48 4.03-<25.37 100  7.93-<28.09 4.39-<27.05 106 
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Q2 29.48-<42.51 25.37-<37.99 100  28.09-<43.04 27.05-<39.28 106 
Q3 42.51-<53.65 -37.99<58.49 100  43.04-<58.94 39.28-<54.43 105 
Q4 53.65-<74.67 58.49-<86.37 100  58.94-<79.80 54.43-<75.22 106 
Q5 ≥74.67 ≥86.37 100  ≥79.80 ≥75.22 106 
Starch (g/day) 
   
   
 Q1 1.75-<60.20 21.15-<78.85 100  21.13-<63.21 20.63-<70.09 106 
Q2 60.20-<77.44 78.85-<103.50 100  63.21-<78.17 70.09-<100.55 105 
Q3 77.44-<89.63 103.50-<130.02 100  78.17-<90.57 100.55-<125.01 106 
Q4 89.63-<107.37 130.02-<172.82 100  90.57-<108.77 125.01-<163.29 106 
Q5 ≥107.37 ≥172.82 100  ≥108.77 ≥163.29 106 
Total carbohydrate 
(g/day) 
   
   
 Q1 71.30-<164.25 84.31-<201.49 100  77.47-<175.11 94.82-<197.24 107 
Q2 164.25-<204.85 201.49-<259.63 100  175.11-<216.62 197.24-<253.10 107 
Q3 204.85-<244.70 259.63-<331.54 100  216.62-<255.35 253.10-<325.11 105 
Q4 244.70-<298.57 331.54-<420.39 100  255.35-<302.61 325.11-<415.59 106 
Q5 ≥298.57 ≥420.39 100  ≥302.61 ≥415.59 104 
Glycemic index 
   
   
 Q1 2.50-<59.15 32.52-<57.53 100  35.01-<59.57 29.77-<55.63 106 
Q2 59.15-<61.68 57.53-<59.54 100  59.57-<62.03 55.63-<59.19 106 
Q3 61.68-<63.10 59.54-<60.97 100  62.03-<63.21 59.19-<60.95 106 
Q4 63.10-<64.69 60.97-<63.15 100  63.21-<64.33 60.95-<62.89 106 
Q5 ≥64.69 ≥63.15 100  ≥64.33 ≥62.89 105 
Glycemic load 
   
   
 Q1 2.03-<89.59 45.36-<106.54 -<  38.87-<96.86 41.53-<101.35 106 
Q2 89.59-<112.37 106.54-<137.77 100  96.86-<119.66 101.35-<131.53 106 
Q3 112.37-<134.67 137.77-<176.03 100  119.66-<143.09 131.53-<172.41 105 
Q4 134.67-<166.29 176.03-<228.82 100  143.09-<173.37 172.41-<222.97 106 
Q5 ≥166.29 ≥228.82 100  ≥173.37 ≥222.97 106 
Sweetened desserts/beverages (servings/day) 
 
   
 Q1 0-<2.29 0.03-<1.62 100  0.08-<2.30 0-<1.72 106 
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Q2 2.29-<3.35 1.62-<2.36 100  2.30-<3.46 1.72-<2.45 106 
Q3 3.35-<4.41 2.36-<3.45 100  33.46-<4.51 2.45-<3.17 105 
Q4 4.41-<6.11 3.45-<5.57 100  4.51-<5.93 3.17-<4.69 106 
Q5 ≥6.11 ≥5.57 100  ≥5.93 ≥4.69 106 
Sweetened desserts (servings/day) 
  
   
 Q1 0-<1.11 0.01-<0.80 100  0.06-<1.08 0-<0.82 106 
Q2 1.11-<1.73 0.80-<1.53 100  1.08-<1.72 0.82-<1.38 106 
Q3 1.73-<2.34 1.53-<2.28 100  1.72-<2.34 1.38-<2.06 105 
Q4 2.34-<3.12 2.28-<4.04 99  2.34-<3.28 2.06-<3.16 106 
Q5 ≥3.12 ≥4.04 101  ≥3.28 ≥3.16 106 
Sweetened beverages (servings/day) 
  
   
 Q1 0-<0.57 0-<0.33 97  0-<0.63 0-<0.39 105 
Q2 0.57-<1.14 0.33-<0.64 100  0.63-<1.13 0.39-<0.73 107 
Q3 1.14-<2.14 0.64-<1.09 102  1.13-<2.00 0.73-<1.21 112 
Q4 2.14-<3.46 1.09-<1.96 100  2.00-<3.16 1.21-<1.79 99 
Q5 ≥3.46 ≥1.96 101  ≥3.16 ≥1.79 106 
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Table A.12. Multivariable-adjusted ORs and 95%CIs for the associations between sugar/carbohydrate intake and risk of 
developing EA, stratified by BMI, among 500 EA cases, 529 GCA cases, and 2027 controls from two US case-control studies. 
BMI 
(kg/m2) 
Measure Controls(N) 
  
Cases (N) 
  
Multiplicative scale   Additive scale 
    
Stratified ORs        
(95%CIs) 
Pinteraction  Single referent 
ORs (95%CIs) 
Interaction 
contrast ratio        
(95%CI) 
                   Sucrose        
<25    Q1-Q3 636 88 1.00 
  
1.00 
 
 
   Q4-Q5 367 100 1.79 (1.26-2.56) 
  
1.79 (1.26-2.56)  
≥25    Q1-Q3 542 154 1.00 
  
2.00 (1.48-2.72)  
     Q4-Q5 411 131 1.05 (0.76-1.44) 0.02   2.10 (1.48-2.98) -0.70 (-1.54, 0.14) 
   Sweetened desserts/beverages      
<25    Q1-Q3 613 86 1.00   1.00  
    Q4-Q5 390 102 1.45 (1.03-2.06)   1.45 (1.03-2.06)  
≥25    Q1-Q3 562 164 1.00   1.99 (1.47-2.70)  
    Q4-Q5 391 121 0.85 (0.62-1.16) 0.02  1.69 (1.19-2.41) -0.75 (-1.51, 0.01) 
                   Glycemic index      
<25    Q1-Q3 582 118 1.00   1.00  
    Q4-Q5 421 70 0.88 (0.62-1.24)   0.88 (0.62-1.24)  
≥25    Q1-Q3 597 161 1.00   1.29 (0.97-1.72)  
    Q4-Q5 356 124 1.38 (1.03-1.85) 0.05  1.79 (1.31-2.44) 0.62 (0.08, 1.15) 
    Free fructose        
<25    Q1-Q3 629 125 1.00   1.00  
    Q4-Q5 374 63 0.81 (0.56-1.17)   0.81 (0.56-1.17)  
≥25    Q1-Q3 538 172 1.00   1.60 (1.21-2.11)  
    Q4-Q5 415 113 0.75 (0.54-1.04) 0.74  1.20 (0.85-1.68) -0.21 (-0.74, 0.32) 
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Table A.13. Multivariable-adjusted ORs and 95%CIs for the associations between sugar/carbohydrate intake and risk of 
developing EA, stratified by GERD frequency, among 500 EA cases and 2027 controls from two US case-control studies. 
GERD Measure Cases 
(N) 
Controls 
(N) 
Multiplicative scale   Additive scale 
        
Stratified ORs        
(95%CIs) 
Pinteraction  Single referent 
ORs (95%CIs) 
Additive ICR        
(95%CI) 
 
Sucrose 
  
     <Weekly    Q1-Q3 120 962 1.00 
  
1.00 
 
 
   Q4-Q5 125 602 1.58 (1.16-2.14) 
  
1.58 (1.16-2.14) 
 ≥Weekly    Q1-Q3 122 216 1.00 
  
4.47 (3.28-6.08) 
 
 
   Q4-Q5 106 176 1.01 (0.70-1.47) 0.05 
 
4.51 (3.18-6.40) -0.53 (-2.20, 1.14) 
 
Glycemic index  
     <Weekly    Q1-Q3 155 949 1.00 
  
1.00 
 
 
   Q4-Q5 94 638 1.01 (0.76-1.35) 
  
1.01 (0.76-1.35) 
 ≥Weekly    Q1-Q3 130 245 1.00 
  
3.35 (2.52-4.46) 
 
 
   Q4-Q5 102 151 1.32 (0.93-1.88) 0.24   4.44 (3.22-6.13)  1.08 (-0.21, 2.36) 
 
Sweetened desserts/beverages 
     <Weekly    Q1-Q3 128 955 1.00 
  
1.00 
 
 
   Q4-Q5 117 609 1.21 (0.90-1.64)   1.21 (0.90-1.64) 
 ≥Weekly    Q1-Q3 122 220 1.00 
  
4.19 (3.08-5.69)  
     Q4-Q5 106 172 0.89 (0.62-1.28) 0.18   3.72 (2.65-5.22) -0.68 (-2.15, 0.79) 
 Free fructose       
<Weekly    Q1-Q3 159 951 1.00   1.00  
    Q4-Q5 86 613 0.81 (0.59-1.12)   0.81 (0.59-1.12)  
≥Weekly    Q1-Q3 138 216 1.00   3.85 (2.89-5.14)  
     Q4-Q5 90 176 0.72 (0.49-1.05) 0.59  2.77 (1.96-3.91) -0.90 (-2.14, 0.35) 
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Table A.14. Multivariable-adjusted HRs and 95%CIs for the associations between sugar/carbohydrate intake and overall survival 
in EA/GCA among 500 EA cases and 529 GCA cases from two US case-control studies (meta-analytic approach, fixed effect). 
 Esophageal Adenocarcinoma   Gastric Cardia Adenocarcinoma 
 Measure 
Deat
hs 
(N) 
Total 
EA 
Cases 
(N) 
HR1 (95%CI) I2 
(%) 
Phetero
geneity 
 Death
s (N) 
Total 
GCA 
Cases 
(N) 
HR1 (95%CI) I2 (%) Pheterogen
eity 
Free glucose (g/day)1  
          Q1 87 100 Ref. 
   
86 104 Ref. 
  Q2 89 100 0.95 (0.70-1.29) 0 0.68 
 
95 106 1.07 (0.79-1.43) 0 0.38 
Q3 87 98 0.89 (0.65-1.22)  70.1 0.07 
 
90 105 1.04 (0.77-1.41) 0 0.63 
Q4 86 98 0.96 (0.70-1.33) 0 0.42 
 
89 106 0.86 (0.62-1.18) 11.4 0.29 
Q5 85 100 0.95 (0.81-1.11)    90 105 0.99 (0.72-1.37) 0 0.59 
Ptrend 
  
0.49 0 0.89 
   
0.93 0 0.46 
Sucrose (g/day)1  
          Q1 86 99 Ref. 
   
90 106 Ref. 
  Q2 85 99 0.96 (0.70-1.30) 6.0 0.30 
 
89 106 1.02 (0.76-1.38) 30.5 0.23 
Q3 85 99 1.01 (0.73-1.40) 0 0.56 
 
92 104 1.15 (0.84-1.56) 0 0.62 
Q4 91 100 1.25 (0.91-1.73) 0 0.57 
 
90 105 1.04 (0.75-1.45)   0 0.82 
Q5 87 99 1.15 (0.79-1.69) 0 0.59  89 105 0.97 (0.68-1.39) 67.3 0.08 
Ptrend 
  
0.48 0 0.81 
   
>0.99 0 0.67 
Free fructose (g/day)1  
          Q1 89 100 Ref. 
   
87 106 Ref. 
  Q2 86 100 0.85 (0.63-1.15) 0 0.75 
 
96 105 1.26 (0.94-1.69) 0 0.95 
Q3 89 98 0.97 (0.72-1.32) 0 0.83 
 
87 104 1.01 (0.74-1.37) 0 0.53 
Q4 85 99 0.87 (0.63-1.20) 18.9 0.27 
 
90 106 0.93 (0.68-1.28)  0 0.34 
Q5 85 99 1.03 (0.73-1.45) 0 0.76  90 105 1.03 (0.75-1.41) 0 0.96 
Ptrend 
  
0.40 0 0.87 
   
0.98 0 0.48 
Total sugar (g/day)2  
         Q1 86 100 Ref. 
   
89 106 Ref. 
  Q2 90 99 1.30 (0.96-1.75) 0 0.58 
 
86 105 0.95 (0.70-1.28) 77.4 0.04 
Q3 84 100 1.08 (0.79-1.49) 67.2 0.08 
 
93 105  1.17 (0.87-1.59) 0 0.78 
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Q4 89 99 1.26 (0.89-1.78) 0 0.57 
 
99 106 1.20 (0.87-1.66) 0 0.83 
Q5 86 99 1.35 (0.91-2.00) 0 0.49  84 105 0.81 (0.57-1.16) 0 0.47 
Ptrend 
  
0.36 0 0.36 
   
0.75 0 0.71 
Added sugar (g/day)1  
          Q1 90 100 Ref. 
   
88 106 Ref. 
  Q2 85 99 0.90 (0.67-1.23)   0 0.67 
 
92 106 1.26 (0.94-1.70)  0 0.61 
Q3 82 99  0.79 (0.58-1.09) 0 0.95 
 
87 103 1.09(0.79-1.49)  53.9 0.14 
Q4 89 99  1.12 (0.81-1.54)   0 0.45 
 
93 105 1.17 (0.85-1.62) 0 0.76 
Q5 88 99 1.09 (0.75-1.59) 0 0.55  90 106 1.04 (0.73-1.49) 0 0.53 
Ptrend 
  
0.89 0 0.54 
   
>0.99 0 >0.99 
Starch (g/day)1  
         Q1 91 100 Ref. 
   
89 106 Ref. 
  Q2 83 98  0.87 (0.64-1.19) 85.0 0.01 
 
91 104 1.21 (0.89-1.65) 0 0.41 
Q3 87 100 0.96 (0.70-1.31) 75.9 0.04 
 
88 105 1.03 (0.74-1.41) 72.5 0.06 
Q4 83 99 1.02 (0.72-1.44) 84.0 0.01 
 
94 106 1.15 (0.81-1.62) 80.8 0.02 
Q5 90 99 1.26 (0.85-1.88) 71.6 0.06  88 105 1.08 (0.72-1.62) 85.1 0.01 
Ptrend 
  
0.20 21.3 0.26 
   
0.70 86.1 0.01 
Total carbohydrate (g/day)1  
  Q1 89 100 Ref. 
   
89 107 Ref. 
  Q2 82 98  0.86 (0.63-1.18) 0 0.89 
 
91 106  1.11 (0.82-1.50)    0 0.85 
Q3 90 100 1.23 (0.87-1.75) 0 0.45 
 
93 104 1.25 (0.90-1.74)    63.7 0.10 
Q4 90 99 1.17 (0.77-1.77) 0 0.58 
 
91 105 1.02 (0.71-1.46)    0 0.91 
Q5 83 99 1.20 (0.69-2.08) 31.7 0.23  86 104 0.80 (0.49-1.29) 0 0.69 
Ptrend 
  
0.51 0 0.38 
   
>0.99 0 >0.99 
Glycemic index1 
  Q1 91 100 Ref. 
   
89 106 Ref. 
  Q2 78 98 0.94 (0.69-1.28) 74.2 0.05 
 
88 106 1.23 (0.91-1.66) 29.0 0.24 
Q3 89 100 1.16 (0.86-1.57) 0 0.40 
 
94 104 1.15 (0.85-1.55)  30.2 0.23 
Q4 90 99 0.99 (0.73-1.35) 20.1 0.26 
 
93 104 1.24 (0.92-1.66) 0 0.46 
Q5 86 99 0.94 (0.69-1.28) 37.5 0.21  86 106 0.99 (0.73-1.34) 0 0.47 
Ptrend 
  
0.68 6.3 0.30 
   
0.54 50.1 0.16 
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Glycemic load1 
  Q1 91 100 Ref. 
   
89 106 Ref. 
  Q2 78 98  0.77 (0.56-1.06) 0 0.63 
 
88 106 0.95 (0.70-1.29)  48.9 0.16 
Q3 89 100 1.10 (0.79-1.52) 78.3 0.03 
 
94 104 1.24 (0.90-1.70)  48.8 0.16 
Q4 90 99 1.11 (0.76-1.60) 0 0.42 
 
93 104 1.03 (0.74-1.43) 45.3 0.18 
Q5 86 99 1.30 (0.82-2.05) 69.6 0.07  86 106 0.81 (0.53-1.22) 41.2 0.19 
Ptrend 
  
0.45 27.6 0.24 
   
0.86 0 0.49 
Sweetened desserts/beverages (servings/day)1  
      
  Q1 86 98 Ref. 
   
92 106 Ref. 
  Q2 88 100  0.95 (0.70-1.29) 0 0.42 
 
89 106 0.98 (0.73-1.32) 0 0.80 
Q3 84 100 0.88 (0.65-1.21) 0 0.36 
 
85 103 0.91 (0.67-1.24)   0 0.56 
Q4 92 99 1.10 (0.81-1.50) 0 0.97 
 
95 105  1.12 (0.82-1.54)  17.5 0.27 
Q5 84 99 0.97 (0.68-1.39) 0 0.91  89 106 0.89 (0.64-1.23) 3.1 0.31 
Ptrend 
  
0.58 0 0.97 
   
0.41 0 0.88 
Sweetened desserts (servings/day)1 
       Q1 88 99 Ref. 
   
92 106 Ref. 
  Q2 83 100  0.92 (0.67-1.25) 41.7 0.19 
 
90 106 1.02 (0.76-1.37)  44.2 0.18 
Q3 91 99 1.21 (0.89-1.64) 0 0.94 
 
88 102 1.01 (0.75-1.35) 50.6 0.16 
Q4 83 98 0.95 (0.69-1.32) 27.2 0.24 
 
89 106 0.96 (0.71-1.29)  0 0.79 
Q5 89 100 0.94 (0.67-1.33) 0 0.71  91 106 0.89 (0.64-1.24) 0 0.59 
Ptrend 
  
0.75 0 0.95 
   
0.52 20.9 0.26 
Sweetened beverages (servings/day)1 
       Q1 84 96 Ref. 
   
86 105 Ref. 
  Q2 90 99 1.11 (0.82-1.50) 0 0.99 
 
98 107 1.16 (0.86-1.55) 13.3 0.28 
Q3 87 101  0.92 (0.68-1.26) 0 0.88 
 
95 112 1.05 (0.78-1.41) 66.7 0.08 
Q4 86 100 0.97 (0.71-1.32) 0 0.35 
 
81 97  0.93 (0.68-1.28) 42.1 0.19 
Q5 87 100 1.03 (0.75-1.42) 0 0.59  90 105 1.02 (0.75-1.39) 23.1 0.25 
Ptrend     0.60 0 0.97       0.44  0 0.44  
1
Adjusted for age, education, study indicator, and total energy intake 
2
Adjusted for age, study indicator, and total energy intake 
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Table A.15. Multivariable-adjusted ORs and 95%CIs for the associations between 
sugar/carbohydrate intake and risk of developing EA/GCA among 500 EA cases, 529 GCA 
cases, and 2027 controls from two US case-control studies (pooled approach, based on 
identical absolute intake cut-points). 
  EA GCA 
 Measure 
Controls 
(N) 
Cases 
(N) 
OR (95%CI) Cases 
(N) 
OR (95%CI) 
Free glucose (g/day)1 
    Q1: 0.12-<14.58 381 135 Ref. 99 Ref. 
Q2: 14.58-<19.96 384 93 0.74 (0.54-1.03) 89 0.97 (0.70-1.35) 
Q3: 19.96-<25.95 396 83 0.63 (0.45-0.89) 101 1.06 (0.76-1.48) 
Q4: 25.95-<36.21 394 83 0.67 (0.47-0.96) 113 1.27 (0.90-1.79) 
Q5: ≥36.21 401 79 0.61 (0.40-0.93) 97 1.07 (0.72-1.59) 
Ptrend 
  
0.08 
 
0.37 
Sucrose (g/day)1 
     Q1: 0.97-<21.62 390 71 Ref. 84 Ref. 
Q2: 21.62-<31.46 396 78 1.04 (0.71-1.51) 90 0.96 (0.69-1.35) 
Q3: 31.46-<42.33 396 80 0.95 (0.65-1.39) 96 0.98 (0.70-1.39) 
Q4: 42.33-<59.76 383 113 1.39 (0.96-2.03) 104 1.06 (0.75-1.51) 
Q5: ≥59.76 391 131 1.33 (0.89-1.99) 125 1.06 (0.72-1.55) 
Ptrend 
  
0.19 
 
0.69 
Free fructose (g/day)1 
    Q1: 0.001-<14.25 381 126 Ref. 98 Ref. 
Q2: 14.25-<20.29 387 113 1.01 (0.73-1.38) 109 1.20 (0.87-1.65) 
Q3: 20.29-<26.00 392 71 0.61 (0.43-0.88) 86 0.93 (0.66-1.31) 
Q4: 26.00-<36.77  397 80 0.68 (0.47-0.98) 101 1.09 (0.77-1.55) 
Q5: ≥36.77 399 83 0.67 (0.45-1.01) 105 1.11 (0.76-1.63) 
Ptrend 
  
0.08 
 
0.25 
Total sugar (g/day)1 
    Q1: 2.40-<66.65 385 84 Ref. 78 Ref. 
Q2: 66.65-<89.47 392 104 1.24 (0.88-1.74) 102 1.24 (0.89-1.74) 
Q3: 89.47-<114.64 391 96 1.07 (0.75-1.54) 113 1.35 (0.96-1.89) 
Q4: 114.64-<150.37 390 86 0.93 (0.63-1.37) 102 1.16 (0.81-1.68) 
Q5: ≥150.37 398 103 1.11 (0.72-1.72) 104 1.10 (0.72-1.68) 
Ptrend 
  
0.79 
 
0.26 
Added sugar (g/day)1 
    Q1: 0.38-<23.52 386 68 Ref. 76 Ref. 
Q2: 23.52-<35.02 397 77 0.97 (0.67-1.42) 77 0.90 (0.63-1.29) 
Q3: 35.02-<48.57 393 92 1.06 (0.73-1.54) 102 1.13 (0.80-1.60) 
Q4: 48.57-<70.68 389 120 1.37 (0.95-1.98) 121 1.32 (0.93-1.86) 
Q5: ≥70.68 391 116 1.09 (0.72-1.64) 123 1.15 (0.78-1.69) 
Ptrend 
  
0.14 
 
0.96 
Starch (g/day)1 
     Q1: 1.75-<63.69 383 87 Ref. 89 Ref. 
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Q2: 63.69-<85.40 385 106 1.16 (0.82-1.63) 123 1.28 (0.93-1.76) 
Q3: 85.40-<109.99 396 115 1.15 (0.81-1.64) 109 1.03 (0.74-1.45) 
Q4: 109.99-<145.37 393 84 1.04 (0.70-1.55) 96 0.97 (0.67-1.41) 
Q5: ≥145.37 399 81 1.10 (0.66-1.84) 82 0.73 (0.45-1.19) 
Ptrend 
  
0.34 
 
0.11 
Total carbohydrate (g/day)1 
Q1: 40.83-<178.96 380 88 Ref. 88 Ref. 
Q2: 178.96-<226.96 390 102 1.13 (0.80-1.59) 108 1.14 (0.82-1.59) 
Q3: 226.96-<279.63 393 105 1.09 (0.75-1.57) 99 0.98 (0.69-1.40) 
Q4: 279.63-<356.57 393 89 0.91 (0.60-1.38) 115 1.05 (0.71-1.54) 
Q5: ≥356.57 400 89 0.91 (0.51-1.61) 89 0.68 (0.39-1.18) 
Ptrend 
  
0.02 
 
0.01 
Glycemic index2 
Q1: 2.50-<57.40 401 85 Ref. 108 Ref. 
Q2: 57.40-<60.10 401 88 1.37 (0.96-1.94) 79 0.87 (0.63-1.22) 
Q3: 60.10-<61.82 398 82 1.16 (0.81-1.65) 85 0.91 (0.66-1.27) 
Q4: 61.82-<63.64 393 105 1.42 (1.01-2.01) 122 1.28 (0.94-1.74) 
Q5: ≥63.64 390 121 1.53 (1.09-2.16) 113 1.21 (0.88-1.66) 
Ptrend 
  
0.32 
 
0.69 
Glycemic load1 
Q1: 2.03-<96.51 382 95 Ref. 86 Ref. 
Q2: 96.51-<122.52 389 89 0.91 (0.64-1.28) 104 1.15 (0.83-1.60) 
Q3: 122.52-<153.57 394 113 1.02 (0.72-1.45) 107 1.10 (0.78-1.55) 
Q4: 153.57-<196.57 394 86 0.85 (0.57-1.26) 112 1.13 (0.78-1.64) 
Q5: ≥196.57 397 90 0.86 (0.52-1.44) 90 0.81 (0.49-1.33) 
Ptrend 
  
0.32 
 
0.07 
Sweetened desserts/beverages (servings/day)1 
  
Q1: 0-<1.57 385 61 Ref. 65 Ref. 
Q2: 1.57-<2.48 393 93 1.32 (0.91-1.91) 100 1.34 (0.94-1.91) 
Q3: 2.48-<3.43 397 83 1.17 (0.79-1.72) 100 1.33 (0.93-1.90) 
Q4: 3.43-<4.81 395 87 0.95 (0.64-1.40) 96 1.08 (0.75-1.55) 
Q5: ≥4.81 386 149 1.58 (1.07-2.33) 138 1.47 (1.01-2.14) 
Ptrend 
  
0.28  0.88 
Sweetened desserts (servings/day)1  
 Q1: 0-<0.75 387 64 Ref. 70 Ref. 
Q2: 0.75-<1.33 392 68 0.85 (0.58-1.26) 94 1.14 (0.81-1.62) 
Q3: 1.33-<1.98 389 105 1.21 (0.84-1.75) 99 1.14 (0.80-1.61) 
Q4: 1.98-<2.94 399 107 1.17 (0.81-1.70) 119 1.30 (0.92-1.84) 
Q5: ≥2.94 389 129 1.27 (0.86-1.87) 117 1.12 (0.78-1.63) 
Ptrend 
  
0.48 
 
0.92 
Sweetened beverages (servings/day)2 
  Q1: 0-<0.35 396 82 Ref. 75 Ref. 
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Q2: 0.35-<0.85 399 89 1.30 (0.91-1.84) 100 1.47 (1.05-2.07) 
Q3: 0.85-<1.27 399 83 0.97 (0.68-1.38) 100 1.23 (0.87-1.73) 
Q4: 1.27-<2.07 401 83 0.96 (0.67-1.37) 116 1.43 (1.03-2.00) 
Q5: ≥2.07 388 144 1.36 (0.97-1.93) 116 1.23 (0.87-1.74) 
Ptrend     0.60 
 
0.93 
1
Adjusted for  age, sex, race, study indicator, BMI, fruits and vegetables intake, cigarette smoking, GERD 
frequency, and total energy intake                                                                                                                                                                           
2
Adjusted for  age, sex, race, study indicator, fruits and vegetables intake, cigarette smoking, GERD frequency, 
and total energy intake                                                                                                                                                     
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Table A.16. Multivariable-adjusted HRs and 95%CIs for the associations between 
sugar/carbohydrate intake and overall survival in esophageal and gastric cardia 
adenocarcinoma among 500 EA cases and 529 GCA cases from two US case-control studies 
(pooled approach, based on identical absolute intake cut-points). 
 Esophageal Adenocarcinoma Gastric Cardia Adenocarcinoma 
 Measure 
Deaths 
(N) 
Total 
EA 
Cases 
(N) 
HR1 (95%CI) 
Deaths 
(N) 
Total 
GCA 
Cases 
(N) 
HR1 (95%CI) 
Free glucose (g/day)1  
     Q1 90 100 Ref. 90 105 Ref. 
Q2 84 99 0.93 (0.68-1.25) 90 105 0.95 (0.70-1.27) 
Q3  89 100 1.04 (0.77-1.41) 87 106 0.79 (0.58-1.07) 
Q4  85 98 0.99 (0.72-1.36) 92 106 0.95 (0.70-1.29) 
Q5 86 99 0.79 (0.74-1.49) 91 104 0.85 (0.61-1.19) 
Ptrend   0.64 
  
0.86 
Sucrose (g/day)1  
     Q1 85 99 Ref. 87 106 Ref. 
Q2 88 99 1.05 (0.77-1.43) 91 105 1.15 (0.86-1.55) 
Q3  84 99 0.93 (0.67-1.29) 92 106 1.13 (0.83-1.54) 
Q4  90 100 1.33 (0.95-1.84) 93 104 1.18 (0.85-1.63) 
Q5 87 99 1.17 (0.81-1.69) 87 105 0.94 (0.66-1.35) 
Ptrend 
  
0.39 
  
0.57 
Free fructose (g/day)1  
     Q1 92 100 Ref. 91 106 Ref. 
Q2 84 100 0.82 (0.61-1.11) 90 104 0.97 (0.72-1.31) 
Q3  88 99 0.96 (0.71-1.30) 91 107 0.85 (0.63-1.14) 
Q4  85 98 0.85 (0.62-1.16)  87 105 0.77 (0.57-1.05) 
Q5 85 99 0.95 (0.67-1.34) 91 104 0.85 (0.61-1.18) 
Ptrend 
  
0.47 
  
0.79 
Total sugar (g/day)2  
     Q1 85 100 Ref. 88 106 Ref. 
Q2 92 99 1.25 (0.92-1.69) 89 106 1.05 (0.78-1.41) 
Q3  82 100 1.05 (0.76-1.43) 93 105 1.13 (0.84-1.53) 
Q4  90 99 1.28 (0.92-1.78) 95 106 1.10 (0.80-1.51) 
Q5 86 99 1.22 (0.83-1.79) 86 104 0.81 (0.56-1.15) 
Ptrend 
  
0.70 
  
0.80 
Added sugar (g/day)1  
     Q1 90 100 Ref. 88 106 Ref. 
Q2 84 98 0.91 (0.68-1.23) 91 105 1.17 (0.87-1.57) 
Q3  84 100 0.81 (0.59-1.13) 90 105 1.06 (0.78-1.43) 
Q4  88 99 1.08 (0.79-1.47) 92 105 1.04 (0.76-1.42) 
Q5 88 99 1.06 (0.74-1.51) 89 105 0.92 (0.65-1.29) 
Ptrend 
  
0.67 
  
0.70 
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Starch (g/day)1  
 
     Q1 92 100 Ref. 87 106 Ref. 
Q2 81 99 0.70 (0.51-0.94) 97 106 1.43 (1.06-1.92) 
Q3  83 99 0.83 (0.61-1.13) 84 103 1.05 (0.74-1.44) 
Q4  90 100 1.09 (0.79-1.50) 92 105 1.14 (0.82-1.58) 
Q5 88 98 1.20 (0.81-1.78) 90 106 0.99 (0.66-1.47) 
Ptrend 
  
0.18 
  
0.32 
Total carbohydrate (g/day)1  
Q1 88 99 Ref. 86 105 Ref. 
Q2 82 99 0.89 (0.66-1.21) 94 107 1.17 (0.87-1.58) 
Q3  88 100 1.08 (0.78-1.49) 92 104 1.19 (0.87-1.62) 
Q4  90 99 1.18 (0.83-1.68) 90 105 0.86 (0.61-1.20) 
Q5 86 99 1.16 (0.73-1.85) 88 105 0.76 (0.49-1.20) 
Ptrend 
  
0.36 
  
0.82 
Glycemic index1 
Q1 87 100 Ref. 91 105 Ref. 
Q2 88 99 1.02 (0.76-1.39) 90 104 1.28 (0.95-1.72) 
Q3  88 99 1.12 (0.82-1.51) 96 107 1.23 (0.92-1.64) 
Q4  89 99 1.00 (0.74-1.36) 86 105 1.00 (0.74-1.36) 
Q5 82 99 0.95 (0.70-1.31) 87 105 1.05 (0.78-1.42) 
Ptrend 
  
0.87 
  
0.29 
Glycemic load1 
Q1 91 100 Ref. 89 106 Ref. 
Q2 82 98 0.84 (0.62-1.14) 91 106 1.00 (0.75-1.35) 
Q3  82 100 0.77 (0.56-1.07) 92 103 1.14 (0.84-1.56) 
Q4  95 100 1.31 (0.94-1.82) 87 106 0.82 (0.59-1.12) 
Q5 84 98 0.94 (0.61-1.45) 91 105 0.86 (0.57-1.29) 
Ptrend 
  
0.34 
  
0.93 
Sweetened desserts/beverages (servings/day)1 
   
Q1 86 99 Ref. 91 105 Ref. 
Q2 88 99 1.09 (0.81-1.47) 89 106 0.88 (0.66-1.18) 
Q3  86 100 1.00 (0.73-1.37) 89 106 0.86 (0.63-1.16) 
Q4  88 98 1.08 (0.79-1.49) 94 104 0.99 (0.72-1.36) 
Q5 86 100 1.13 (0.80-1.60) 87 105 0.78 (0.56-1.09) 
Ptrend 
  
0.67 
  
0.50 
Sweetened desserts (servings/day)1 
   Q1 89 99 Ref. 91 107 Ref. 
Q2 83 100 0.82 (0.61-1.11) 90 104 1.06 (0.79-1.42) 
Q3  90 99 1.15 (0.85-1.55) 89 104 0.94 (0.70-1.27) 
Q4  85 99 0.88 (0.64-1.21) 89 105 0.98 (0.73-1.33) 
Q5 87 99 0.92 (0.66-1.28) 91 106 0.85 (0.62-1.17) 
Ptrend 
  
0.90 
  
0.77 
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Sweetened beverages (servings/day)1 
   Q1 90 102 Ref. 85 105 Ref. 
Q2 76 85 0.89 (0.66-1.21) 87 96 1.23 (0.91-1.67) 
Q3  96 110 0.96 (0.72-1.29) 106 121 1.06 (0.79-1.41) 
Q4  87 99 1.06 (0.79-1.43) 84 99 1.06 (0.78-1.43) 
Q5 85 100 0.98 (0.71-1.34) 88 105 0.99 (0.72-1.36) 
Ptrend     0.51     0.40 
1
Adjusted for age, education, study indicator, and total energy intake 
2
Adjusted for age, study indicator, and total energy intake 
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Table A.17. Multivariable-adjusted ORs and 95%CIs for the associations between 
sugar/carbohydrate intake and risk of developing esophageal and gastric cardia 
adenocarcinoma among 500 EA cases, 529 GCA cases, and 2027 controls from two US 
case-control studies (nutrient density energy adjustment method). 
  Esophageal 
Adenocarcinoma 
Gastric Cardia 
Adenocarcinoma 
 Measure 
Controls 
(N) 
Cases 
(N) 
OR (95%CI) Cases 
(N) 
OR (95%CI) 
Free glucose (g/day)1 
    Q1 389 144 Ref. 120 Ref. 
Q2 390 109 0.92 (0.68-1.26) 109 1.04 (0.76-1.41) 
Q3 391 96 0.85 (0.61-1.17) 86 0.87 (0.63-1.21) 
Q4 390 66 0.67 (0.47-0.95) 87 0.97 (0.69-1.35) 
Q5 396 58 0.59 (0.40-0.85) 97 1.09 (0.78-1.52) 
Ptrend 
  
0.01 
 
0.89 
Sucrose (g/day)1 
     Q1 395 106 Ref. 112 Ref. 
Q2 393 96 1.01 (0.72-1.40) 97 0.94 (0.68-1.28) 
Q3 391 88 1.02 (0.73-1.43) 108 1.13 (0.83-1.53) 
Q4 393 86 1.00 (0.71-1.41) 99 1.05 (0.76-1.44) 
Q5 384 97 1.16 (0.83-1.62) 83 0.91 (0.66-1.27) 
Ptrend 
  
0.33 
 
0.74 
Free fructose (g/day)1 
    Q1 387 141 Ref. 128 Ref. 
Q2 395 113 0.92 (0.68-1.25) 108 0.92 (0.68-1.25) 
Q3 389 96 0.92 (0.67-1.28) 90 0.86 (0.62-1.19) 
Q4 393 68 0.66 (0.46-0.94) 78 0.77 (0.55-1.08) 
Q5 392 55 0.55 (0.38-0.81) 95 0.96 (0.69-1.35) 
Ptrend 
  
0.01 
 
0.55 
Total sugar (g/day)1 
    Q1 395 124 Ref. 116 Ref. 
Q2 389 102 0.94 (0.69-1.30) 111 1.06 (0.78-1.44) 
Q3 391 101 0.99 (0.72-1.36) 99 0.98 (0.71-1.34) 
Q4 392 76 0.82 (0.58-1.16) 87 0.94 (0.68-1.31) 
Q5 389 70 0.81 (0.57-1.16) 86 0.98 (0.70-1.37) 
Ptrend 
  
0.21 
 
0.51 
Added sugar (g/day)1 
    Q1 392 86 Ref. 102 Ref. 
Q2 390 110 1.34 (0.96-1.88) 90 0.92 (0.67-1.28) 
Q3 391 78 0.90 (0.63-1.29) 100 1.00 (0.72-1.37) 
Q4 397 90 1.00 (0.71-1.41) 93 0.87 (0.63-1.20) 
Q5 386 109 1.28 (0.91-1.79) 114 1.16 (0.85-1.58) 
Ptrend 
  
0.30 
 
0.56 
Starch (g/day)1 
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Q1 391 116 Ref. 133 Ref. 
Q2 392 102 0.98 (0.71-1.35) 116 0.95 (0.71-1.27) 
Q3 391 107 1.11 (0.80-1.52) 94 0.80 (0.59-1.09) 
Q4 396 91 1.00 (0.72-1.40) 93 0.85 (0.62-1.16) 
Q5 386 57 0.71 (0.49-1.05) 63 0.67 (0.47-0.96) 
Ptrend 
  
0.19 
 
0.03 
Total carbohydrate (g/day)1 
Q1 389 143 Ref. 151 Ref. 
Q2 393 123 0.99 (0.74-1.34) 105 0.77 (0.58-1.04) 
Q3 394 96 0.86 (0.63-1.19) 90 0.71 (0.52-0.97) 
Q4 394 70 0.65 (0.46-0.93) 91 0.77 (0.56-1.05) 
Q5 386 41 0.47 (0.31-0.71) 62 0.61 (0.43-0.88) 
Ptrend 
  
<0.01 
 
0.01 
1
Adjusted for  age, sex, race, study indicator, BMI, fruits and vegetables intake, cigarette smoking, GERD 
frequency, and total energy intake                                                                                                                                                                            
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Table A.18. Multivariable-adjusted ORs and 95%CIs for the associations between 
sugar/carbohydrate intake and risk of developing EA/GCA among 348 EA cases, 379 GCA 
cases, and 2027 controls from two US case-control studies (after excluding cases with proxy 
interviews). 
  Esophageal 
Adenocarcinoma 
Gastric Cardia 
Adenocarcinoma 
 Measure 
Control
s (N) 
Cases 
(N) OR (95%CI) Cases (N) OR (95%CI) 
Free glucose (g/day)1 
    Q1 385 74 Ref. 54 Ref. 
Q2 384 70 0.95 (0.65-1.39) 68 1.27 (0.86-1.89) 
Q3 396 70 0.91 (0.61-1.35) 78 1.42 (0.96-2.11) 
Q4 398 50 0.60 (0.38-0.93) 75 1.31 (0.87-2.00) 
Q5 393 70 0.72 (0.46-1.13) 89 1.48 (0.96-2.30) 
Ptrend 
  
0.07 
 
0.43 
Sucrose (g/day)1 
     Q1 391 54 Ref. 57 Ref. 
Q2 394 58 1.07 (0.70-1.63) 76 1.31 (0.90-1.92) 
Q3 393 67 1.13 (0.75-1.72) 68 1.11 (0.74-1.65) 
Q4 387 73 1.28 (0.84-1.96) 78 1.27 (0.85-1.90) 
Q5 391 82 1.26 (0.79-1.99) 85 1.20 (0.78-1.86) 
Ptrend 
  
0.67 
 
0.88 
Free fructose (g/day)1 
   Q1 382 77 Ref. 65 Ref. 
Q2 387 74 0.93 (0.64-1.35) 75 1.13 (0.78-1.65) 
Q3 398 60 0.69 (0.46-1.03) 62 0.87 (0.58-1.29) 
Q4 393 67 0.79 (0.52-1.19) 79 1.13 (0.76-1.68) 
Q5 396 56 0.55 (0.35-0.86) 83 1.07 (0.70-1.62) 
Ptrend 
  
0.07 
 
0.37 
Total sugar (g/day)1 
    Q1 385 62 Ref. 60 Ref. 
Q2 396 60 0.89 (0.60-1.34) 65 0.98 (0.67-1.45) 
Q3 393 76 1.09 (0.73-1.62) 76 1.13 (0.76-1.66) 
Q4 390 65 0.84 (0.54-1.30) 74 1.05 (0.69-1.58) 
Q5 392 71 1.12 (0.71-1.77) 89 0.84 (0.54-1.30) 
Ptrend 
  
0.27 
 
0.36 
Added sugar (g/day)1 
    Q1 385 52 Ref. 57 Ref. 
Q2 399 52 0.91 (0.59-1.41) 51 0.84 (0.55-1.27) 
Q3 392 70 1.11 (0.73-1.68) 76 1.17 (0.80-1.73) 
Q4 389 81 1.30 (0.85-1.97) 88 1.35 (0.92-2.00) 
Q5 391 79 1.00 (0.63-1.59) 92 1.22 (0.79-1.88) 
Ptrend 
  
0.61 
 
0.54 
Starch (g/day)1 
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Q1 389 54 Ref. 59 Ref. 
Q2 390 58 0.98 (0.64-1.49) 67 1.04 (0.71-1.54) 
Q3 390 80 1.29 (0.85-1.95) 90 1.34 (0.92-1.97) 
Q4 394 72 0.95 (0.61-1.48) 71 0.92 (0.61-1.40) 
Q5 393 70 0.85 (0.51-1.44) 77 0.91 (0.56-1.49) 
Ptrend 
  
0.06 
 
0.03 
Total carbohydrate (g/day)1 
Q1 386 63 Ref. 59 Ref. 
Q2 390 54 0.80 (0.53-1.22) 72 1.16 (0.79-1.71) 
Q3 393 63 0.78 (0.51-1.20) 54 0.80 (0.52-1.22) 
Q4 393 76 0.85 (0.54-1.33) 85 1.18 (0.77-1.82) 
Q5 394 78 0.65 (0.36-1.15) 94 1.17 (0.68-2.02) 
Ptrend 
  
<0.01 
 
0.01 
Glycemic index2 
Q1 399 70 Ref. 82 Ref. 
Q2 397 72 1.33 (0.91-1.95) 62 0.92 (0.63-1.33) 
Q3 398 59 1.08 (0.72-1.60) 72 1.05 (0.73-1.51) 
Q4 395 60 1.03 (0.70-1.54) 82 1.20 (0.85-1.70) 
Q5 394 78 1.49 (1.02-2.17) 69 1.11 (0.77-1.60) 
Ptrend 
  
0.61 
 
0.98 
Glycemic load1 
Q1 387 65 Ref. 65 Ref. 
Q2 390 57 0.78 (0.51-1.17) 59 0.83 (0.56-1.24) 
Q3 395 61 0.78 (0.51-1.18) 62 0.84 (0.82-1.70) 
Q4 390 79 0.90 (0.58-1.38) 93 1.21 (0.81-1.82) 
Q5 394 72 0.61 (0.36-1.05) 85 0.95 (0.57-1.58) 
Ptrend 
  
0.04 
 
0.09 
Sweetened desserts/beverages (servings/day)1 
  
Q1 382 51 Ref. 54 Ref. 
Q2 392 60 1.14 (0.75-1.74) 65 1.17 (0.78-1.74) 
Q3 401 72 1.41 (0.93-2.13) 77 1.41 (0.95-2.08) 
Q4 391 60 1.00 (0.65-1.54) 72 1.15 (0.77-1.72) 
Q5 390 91 1.47 (0.95-2.28) 96 1.47 (0.97-2.23) 
Ptrend 
  
0.66 
 
0.38 
Sweetened desserts (servings/day)1 
 Q1 383 50 Ref. 53 Ref. 
Q2 392 55 0.99 (0.65-1.53) 67 1.17 (0.78-1.74) 
Q3 393 67 1.12 (0.74-1.70) 78 1.28 (0.87-1.89) 
Q4 399 71 1.20 (0.79-1.83) 73 1.19 (0.80-1.77) 
Q5 389 91 1.35 (0.87-2.08) 93 1.32 (0.87-1.99) 
Ptrend 
  
0.51 
 
0.61 
Sweetened beverages (servings/day)2 
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Q1 394 70 Ref. 61 Ref. 
Q2 398 60 0.89 (0.60-1.31) 70 1.16 (0.80-1.70) 
Q3 396 67 1.06 (0.72-1.55) 68 1.16 (0.79-1.70) 
Q4 400 58 0.83 (0.56-1.24) 84 1.36 (0.94-1.97) 
Q5 395 84 1.17 (0.80-1.73) 84 1.30 (0.88-1.90) 
Ptrend     0.80   0.59 
1
Adjusted for  age, sex, race, study indicator, BMI, fruits and vegetables intake, cigarette smoking, GERD 
frequency, and total energy intake                                                                                                                                                                           
2
Adjusted for  age, sex, race, study indicator, fruits and vegetables intake, cigarette smoking, GERD frequency, 
and total energy intake                                                                                                                                                     
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Table A.19. Multivariable-adjusted ORs and 95%CIs for the associations between 
sugar/carbohydrate intake and risk of developing EA/GCA among 485 EA cases, 503 GCA 
cases, and 1939 controls from two US case-control studies (using lower and upper 2.5% as 
exclusion criteria). 
  Esophageal 
Adenocarcinoma 
Gastric Cardia 
Adenocarcinoma 
 Measure 
Controls 
(N) 
Cases 
(N) 
OR (95%CI) Cases 
(N) 
OR (95%CI) 
Free glucose (g/day)1 
    Q1 372 106 Ref. 81 Ref. 
Q2 368 94 0.86 (0.62-1.21) 95 1.22 (0.86-1.71) 
Q3 378 91 0.80 (0.56-1.13) 94 1.20 (0.85-1.70) 
Q4 381 72 0.56 (0.38-0.82) 97 1.20 (0.83-1.74) 
Q5 376 97 0.68 (0.46-1.00) 108 1.35 (0.92-1.98) 
Ptrend 
  
0.13 
 
0.41 
Sucrose (g/day)1 
     Q1 377 77 Ref. 86 Ref. 
Q2 378 72 0.92 (0.63-1.33) 94 1.08 (0.77-1.51) 
Q3 376 87 1.00 (0.69-1.45) 92 1.04 (0.74-1.47) 
Q4 371 101 1.21 (0.83-1.75) 96 1.11 (0.78-1.59) 
Q5 373 123 1.28 (0.85-1.91) 107 1.16 (0.78-1.71) 
Ptrend   0.13 
 
0.94 
Free fructose (g/day)1 
    Q1 370 110 Ref. 98 Ref. 
Q2 371 90 0.78 (0.56-1.10) 93 0.95 (0.69-1.33) 
Q3 381 91 0.74 (0.53-1.06) 83 0.82 (0.58-1.16) 
Q4 374 83 0.67 (0.46-0.97) 92 0.94 (0.66-1.35) 
Q5 379 86 0.61 (0.41-0.90) 109 1.06 (0.73-1.53) 
Ptrend 
  
0.12 
 
0.30 
Total sugar (g/day)1 
    Q1 373 79 Ref. 85 Ref. 
Q2 378 88 1.06 (0.74-1.52) 88 1.00 (0.71-1.41) 
Q3 377 97 1.10 (0.77-1.59) 102 1.16 (0.82-1.64) 
Q4 372 79 0.81 (0.54-1.21) 92 1.03 (0.71-1.49) 
Q5 375 117 1.05 (0.68-1.61) 108 1.15 (0.76-1.75) 
Ptrend 
  
0.93 
 
0.40 
Added sugar (g/day)1 
    Q1 345 63 Ref. 74 Ref. 
Q2 389 76 0.93 (0.64-1.37) 74 0.94 (0.65-1.34) 
Q3 392 92 1.05 (0.72-1.52) 99 1.17 (0.83-1.65) 
Q4 384 118 1.27 (0.88-1.85) 116 1.37 (0.96-1.94) 
Q5 365 111 1.04 (0.69-1.57) 112 1.32 (0.89-1.95) 
Ptrend 
  
0.09 
 
0.58 
Starch (g/day)1 
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Q1 337 82 Ref. 86 Ref. 
Q2 383 106 1.03 (0.71-1.50) 122 0.86 (0.61-1.21) 
Q3 392 114 1.26 (0.87-1.83) 107 1.10 (0.78-1.55) 
Q4 386 80 0.90 (0.60-1.35) 92 0.87 (0.60-1.27) 
Q5 377 78 1.00 (0.63-1.58) 68 0.85 (0.55-1.32) 
Ptrend 
  
0.47 
 
0.07 
Total carbohydrate (g/day)1 
Q1 374 84 Ref. 96 Ref. 
Q2 373 76 0.82 (0.56-1.19) 79 0.83 (0.58-1.17) 
Q3 376 82 0.71 (0.48-1.05) 82 0.82 (0.57-1.19) 
Q4 375 101 0.76 (0.50-1.90) 102 1.00 (0.66-1.50) 
Q5 377 117 0.65 (0.38-1.11) 116 1.13 (0.67-1.90) 
Ptrend 
  
0.04 
 
0.01 
Glycemic index2 
Q1 382 89 Ref. 99 Ref. 
Q2 380 88 1.24 (0.88-1.76) 80 0.94 (0.67-1.31) 
Q3 379 97 1.38 (0.98-1.95) 98 1.15 (0.83-1.59) 
Q4 380 84 1.12 (0.79-1.59) 111 1.29 (0.94-1.77) 
Q5 377 109 1.58 (1.12-2.22) 94 1.16 (0.84-1.61) 
Ptrend 
  
0.26 
 
0.70 
Glycemic load1 
Q1 376 87 Ref. 96 Ref. 
Q2 372 77 0.83 (0.58-1.20) 76 0.80 (0.56-1.13) 
Q3 378 81 0.77 (0.53-1.13) 84 0.85 (0.60-1.22) 
Q4 372 103 0.84 (0.57-1.26) 115 1.15 (0.79-1.68) 
Q5 377 112 0.71 (0.44-1.15) 104 0.99 (0.62-1.59) 
Ptrend   0.48 
 
0.07 
Sweetened desserts/beverages (servings/day)1 
  
Q1 369 69 Ref. 78 Ref. 
Q2 375 79 1.18 (0.81-1.71) 87 1.12 (0.80-1.59) 
Q3 383 96 1.40 (0.97-2.02) 101 1.33 (0.95-1.87) 
Q4 374 83 1.00 (0.68-1.47) 95 1.12 (0.79-1.60) 
Q5 374 133 1.56 (1.07-2.29) 114 1.35 (0.93-1.95) 
Ptrend 
  
0.24 
 
0.81 
Sweetened desserts (servings/day)1 
  Q1 370 67 Ref. 76 Ref. 
Q2 377 71 0.94 (0.64-1.38) 92 1.12 (0.79-1.58) 
Q3 375 96 1.20 (0.83-1.73) 94 1.12 (0.79-1.58) 
Q4 379 98 1.18 (0.82-1.72) 100 1.19 (0.84-1.68) 
Q5 374 128 1.32 (0.90-1.94) 113 1.23 (0.85-1.77) 
Ptrend 
  
0.50 
 
0.81 
Sweetened beverages (servings/day)2 
  
 234 
 
Q1 382 94 Ref. 86 Ref. 
Q2 378 83 0.94 (0.66-1.33) 98 1.18 (0.85-1.64) 
Q3 373 91 1.06 (0.75-1.50) 86 1.07 (0.76-1.50) 
Q4 390 81 0.84 (0.59-1.19) 111 1.28 (0.92-1.77) 
Q5 375 118 1.22 (0.87-1.72) 101 1.19 (0.84-1.67) 
Ptrend     0.51   0.91 
1
Adjusted for  age, sex, race, study indicator, BMI, fruits and vegetables intake, cigarette smoking, GERD 
frequency, and total energy intake                                                                                                                                                                           
2
Adjusted for  age, sex, race, study indicator, fruits and vegetables intake, cigarette smoking, GERD frequency, 
and total energy intake                                                                                                                                                     
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Table A.20. Multivariable-adjusted ORs and 95%CIs for the associations between carbohydrate 
intake and risk of developing EA/GCA among 500 EA cases, 529 GCA cases, and 2027 
controls from two US case-control studies (originally calculated carbohydrate values vs. new 
carbohydrate values). 
  Esophageal 
Adenocarcinoma 
Gastric Cardia Adenocarcinoma 
Measure 
Controls 
(N) 
Cases 
(N) 
OR1 (95%CI) Cases 
(N) 
OR1 (95%CI) 
Old total carbohydrate values (g/day) 
Q1 385 96 Ref. 101 Ref. 
Q2 395 86 0.86 (0.61-1.22) 100 0.92 (0.66-1.27) 
Q3 389 95 0.86 (0.60-1.24) 96 0.84 (0.59-1.20) 
Q4 390 102 0.81 (0.55-1.21) 102 0.83 (0.57-1.21) 
Q5 397 94 0.60 (0.36-1.02) 100 0.67 (0.41-1.11) 
Ptrend 
  
0.01 
 
0.01 
New total carbohydrate values (g/day) 
  Q1 386 79 Ref. 88 Ref. 
Q2 390 81 0.98 (0.68-1.41) 89 0.94 (0.67-1.32) 
Q3 393 88 0.91 (0.62-1.33) 83 0.79 (0.55-1.13) 
Q4 393 101 0.93 (0.62-1.39) 112 0.97 (0.67-1.41) 
Q5 394 124 0.93 (0.56-1.54) 127 0.94 (0.59-1.52) 
Ptrend 
  
0.02 
 
0.01 
1
Adjusted for  age, sex, race, study indicator, BMI, fruits and vegetables intake, cigarette smoking, GERD 
frequency, and total energy intake                                                                                                                                                                            
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Table A.21. Multivariable-adjusted ORs and 95%CIs for the associations between sugar/carbohydrate intake and risk of 
developing EA, stratified by BMI, among 500 EA cases, 529 GCA cases, and 2027 controls from two US case-control studies 
(using medians as cut-points for sugar/carbohydrate measures). 
BMI 
(kg/m2) 
Measure Controls(N) 
  
Cases (N) 
  
Multiplicative scale   Additive scale 
    
Stratified ORs        
(95%CIs) 
Pinteraction  Single referent 
ORs (95%CIs) 
Interaction 
contrast ratio        
(95%CI) 
                   Sucrose        
<25 <median 523 73 1.00 
  
1.00 
 
 
≥median 480 115 1.48 (1.04-2.11) 1.48 (1.04-2.11)  
≥25 <median 460 124 1.00 
 
 1.90 (1.36-2.65)  
  ≥median 493 161 1.04 (0.76-1.43) 0.13  1.98 (1.39-2.82) -0.40 (-1.14, 0.35) 
   Sweetened desserts/beverages      
<25 <median 501 71 1.00   1.00  
 ≥median 502 117 1.29 (0.91-1.84)   1.29 (0.91-1.84)  
≥25 <median 473 133 1.00   1.92 (1.38-2.69)  
 ≥median 480 152 0.88 (0.65-1.19) 0.09  1.69 (1.19-2.40) -0.53 (-1.24, 0.19) 
                   Glycemic index      
<25 <median 472 99 1.00   1.00  
 ≥median 531 89 0.88 (0.63-1.22)   0.88 (0.63-1.22)  
≥25 <median 512 139 1.00   1.28 (0.94-1.74)  
 ≥median 441 146 1.30 (0.98-1.74) 0.08  1.66 (1.22-2.27) 0.51 (0.02, 1.00) 
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Table A.22. Multivariable-adjusted ORs and 95%CIs for the associations between sugar/carbohydrate intake and risk of 
developing EA, stratified by BMI, among 500 EA cases, 529 GCA cases, and 2027 controls from two US case-control studies 
(using extreme quintiles for sugar/carbohydrate measures). 
BMI 
(kg/m2) 
Measure Controls(N) 
  
Cases (N) 
  
Multiplicative scale   Additive scale 
    
Stratified ORs        
(95%CIs) 
Pintera
ction 
 Single referent 
ORs (95%CIs) 
Interaction 
contrast ratio        
(95%CI) 
                   Sucrose        
<25    Q1 212 23 1.00 
  
1.00 
 
 
   Q5 181 48 2.31 (1.23-4.32) 2.31 (1.23-4.32)  
≥25    Q1 179 46 1.00 
  
2.51 (1.42-4.43)  
     Q5 210 78 1.60 (0.93-2.77) 0.32   4.02 (2.13-7.58) 0.20 (-1.61, 2.02) 
   Sweetened desserts/beverages      
<25    Q1 188 23 1.00   1.00  
    Q5 203 55 1.96 (1.08-3.56)   1.96 (1.08-3.56)  
≥25    Q1 194 46 1.00   2.11 (1.19-3.75)  
    Q5 187 81 1.73 (1.04-2.87) 0.72  3.65 (1.98-6.72) 0.57 (-0.96, 2.10) 
                   Glycemic index      
<25    Q1 179 41 1.00   1.00  
    Q5 219 40 1.07 (0.64-1.79)   1.07 (0.64-1.79)  
≥25    Q1 216 52 1.00   1.05 (0.64-1.71)  
    Q5 167 69 2.22 (1.39-3.55) 0.04  2.32 (1.42-3.81) 1.21 (0.30, 2.12) 
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Table A.23. Multivariable-adjusted ORs and 95%CIs for the associations between sugar/carbohydrate intake and risk of 
developing EA, stratified by GERD frequency, among 500 EA cases and 2027 controls from two US case-control studies 
(using extreme quintiles or medians for sucrose intake). 
GERD Sucrose Controls 
(N) 
Cases (N) Multiplicative scale   Additive scale 
        
Stratified ORs        
(95%CIs) 
Pintera
ction 
 Single referent 
ORs (95%CIs) 
Additive ICR        
(95%CI) 
 
Sucrose 
  
     <Weekly <median 806 107 1.00 
  
1.00 
 
 
≥median 758 138 1.28 (0.94-1.73) 
  
1.28 (0.94-1.73) 
 ≥Weekly <median 177 90 1.00 
  
3.88 (2.75-5.46) 
 
 
≥median 215 138 1.12 (0.77-1.63) 0.58 4.35 (3.12-6.06) 0.19 (-1.33, 1.72) 
 
Sucrose 
 
     <Weekly Q1 318 38 1.00 
  
1.00 
 
 
Q5 293 62 1.91 (1.11-3.26) 
  
1.91 (1.11-3.26) 
≥Weekly Q1 73 31 1.00 
  
3.45 (1.96-6.08)  
 
Q5 98 64 1.80 (0.95-3.41) 0.88   6.22 (3.55-10.90) 1.86 (-1.12, 4.83) 
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Table A.24. Multivariable-adjusted ORs and 95%CIs for the associations between sugar/carbohydrate intake and risk of 
developing EA/GCA among 218 EA cases, 273 GCA cases, and 1343 controls from the LA Multi-Ethnic study (results 
additionally adjusted for diabetes). 
  Esophageal Adenocarcinoma Gastric Cardia Adenocarcinoma 
 Measure 
Controls 
(N)  
Cases 
(N) 
OR (95%CI) OR (95%CI)3 Cases 
(N) 
OR (95%CI) OR (95%CI)3 
Free glucose (g/day)1 
     Q1 259 40 Ref. Ref. 41 Ref. Ref. 
Q2 259 43 1.09 (0.67-1.80) 1.11 (0.67-1.82) 50 1.16 (0.73-1.84) 1.16 (0.73-1.85) 
Q3 266 41 1.03 (0.61-1.72) 1.03 (0.61-1.72) 55 1.20 (0.75-1.92) 1.20 (0.75-1.92) 
Q4 266 37 0.89 (0.51-1.57) 0.91 (0.52-1.59) 57 1.19 (0.72-1.95) 1.19 (0.72-1.96) 
Q5 264 48 1.10 (0.59-2.04) 1.11 (0.59-2.06) 56 1.08 (0.62-1.91) 1.09 (0.62-1.92) 
Ptrend 
  
0.56 0.55 
 
0.35 0.36 
Sucrose (g/day)1 
      Q1 261 34 Ref. Ref. 42 Ref. Ref. 
Q2 265 47 1.44 (0.87-2.39) 1.46 (0.88-2.41) 62 1.38 (0.88-2.14) 1.37 (0.88-2.14) 
Q3 262 29 0.79 (0.45-1.39) 0.81 (0.46-1.43) 53 1.07 (0.67-1.70) 1.07 (0.67-1.70) 
Q4 262 39 1.26 (0.73-2.19) 1.27 (0.73-2.21) 52 1.08 (0.66-1.74) 1.08 (0.67-1.75) 
Q5 264 60 1.61 (0.90-2.88) 1.66 (0.93-2.97) 50 0.83 (0.48-1.44) 0.84 (0.48-1.45) 
Ptrend 
  
0.05 0.04 
 
0.19 0.20 
Free fructose (g/day)1 
     Q1 259 43 Ref. Ref. 48 Ref. Ref. 
Q2 258 42 1.01 (0.62-1.65) 1.01 (0.62-1.65) 50 0.99 (0.63-1.55) 0.99 (0.63-1.56) 
Q3 265 34 0.77 (0.46-1.31) 0.75 (0.44-1.27) 49 0.87 (0.55-1.39) 0.87 (0.55-1.39) 
Q4 267 46 1.03 (0.60-1.75) 1.02 (0.60-1.74) 55 0.92 (0.57-1.50) 0.92 (0.57-1.50) 
Q5 265 44 0.97 (0.53-1.76) 0.96 (0.53-1.76) 57 0.93 (0.54-1.58) 0.93 (0.54-1.59) 
Ptrend 
  
0.52 0.48 
 
0.24 0.24 
Total sugar (g/day)1 
      Q1 259 37 Ref. Ref. 46 Ref. Ref. 
Q2 265 43 1.10 (0.67-1.82) 1.11 (0.67-1.83) 57 1.08 (0.69-1.68) 1.08 (0.69-1.68) 
Q3 262 35 0.91 (0.54-1.56) 0.90 (0.53-1.54) 51 0.91 (0.58-1.45) 0.91 (0.58-1.45) 
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Q4 264 40 0.95 (0.54-1.66) 0.97 (0.56-1.70) 49 0.77 (0.47-1.27) 0.77 (0.47-1.27) 
Q5 264 54 1.28 (0.68-2.39) 1.28 (0.69-2.40) 56 0.77 (0.43-1.36) 0.77 (0.44-1.37) 
Ptrend   0.42 0.40  0.15 0.15 
Added sugar (g/day)1 
     Q1 257 38 Ref. Ref. 41 Ref. Ref. 
Q2 267 36 0.82 (0.49-1.37) 0.82 (0.49-1.39) 42 0.88 (0.55-1.42) 0.88 (0.55-1.42) 
Q3 262 28 0.59 (0.34-1.02) 0.58 (0.33-1.01) 54 1.09 (0.68-1.72) 1.08 (0.68-1.72) 
Q4 265 50 1.07 (0.64-1.78) 1.09 (0.66-1.82) 64 1.23 (0.77-1.95) 1.23 (0.77-1.96) 
Q5 263 57 0.84 (0.48-1.49) 0.86 (0.48-1.51) 58 0.87 (0.51-1.49) 0.88 (0.51-1.49) 
Ptrend 
  
0.16 0.16 
 
0.55 0.56 
Starch (g/day)1 
      Q1 261 34 Ref. Ref. 58 Ref. Ref. 
Q2 265 39 0.98 (0.58-1.67) 1.01 (0.60-1.71) 45 0.63 (0.41-0.99) 0.64 (0.41-0.99) 
Q3 264 50 1.25 (0.75-2.10) 1.25 (0.75-2.10) 57 0.75 (0.48-1.16) 0.75 (0.48-1.16) 
Q4 262 41 0.86 (0.48-1.51) 0.85 (0.48-1.51) 53 0.59 (0.36-0.95) 0.58 (0.36-0.94) 
Q5 262 45 0.79 (0.40-1.60) 0.78 (0.39-1.57) 46 0.39 (0.21-0.72) 0.39 (0.21-0.72) 
Ptrend 
  
0.18 0.19 
 
0.03 0.03 
Total carbohydrate (g/day)1 
 Q1 258 38 Ref. Ref. 52 Ref. Ref. 
Q2 266 41 0.99 (0.59-1.65) 0.98 (0.59-1.64) 56 0.90 (0.58-1.40) 0.90 (0.58-1.39) 
Q3 264 38 0.80 (0.46-1.38) 0.79 (0.46-1.38) 38 0.52 (0.32-0.86) 0.52 (0.32-0.86) 
Q4 265 42 0.72 (0.40-1.32) 0.72 (0.40-1.32) 58 0.63 (0.38-1.06) 0.63 (0.38-1.06) 
Q5 261 50 0.76 (0.34-1.68) 0.76 (0.34-1.70) 55 0.47 (0.23-0.96) 0.47 (0.23-0.97) 
Ptrend 
  
0.16 0.17 
 
<0.01 <0.01 
Glycemic index2 
 Q1 267 41 Ref. Ref. 64 Ref. Ref. 
Q2 266 45 1.33 (0.82-2.15) 1.32 (0.81-2.14) 51 0.90 (0.59-1.37) 0.90 (0.59-1.37) 
Q3 268 44 1.35 (0.83-2.19) 1.34 (0.82-2.17) 55 0.96 (0.63-1.45) 0.96 (0.63-1.45) 
Q4 268 42 1.29 (0.79-2.11) 1.29 (0.79-2.11) 46 0.83 (0.54-1.27) 0.83 (0.54-1.27) 
Q5 269 44 1.65 (1.01-2.71) 1.66 (1.01-2.73) 51 1.08 (0.70-1.65) 1.08 (0.70-1.66) 
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Ptrend 
  
0.27 0.27 
 
0.52 0.52 
Glycemic load1 
 Q1 259 40 Ref. Ref. 56 Ref. Ref. 
Q2 265 41 0.90 (0.54-1.50) 0.92 (0.55-1.53) 52 0.76 (0.49-1.17) 0.75 (0.49-1.17) 
Q3 265 38 0.85 (0.50-1.45) 0.85 (0.50-1.44) 41 0.56 (0.35-0.91) 0.57 (0.35-0.91) 
Q4 263 38 0.77 (0.43-1.36) 0.77 (0.43-1.36) 56 0.66 (0.40-1.08) 0.66 (0.40-1.08) 
Q5 262 52 0.89 (0.43-1.81) 0.91 (0.44-1.86) 54 0.49 (0.26-0.95) 0.50 (0.26-0.96) 
Ptrend 
  
0.68 0.72 
 
0.01 0.01 
Sweetened desserts/beverages (servings/day)1 
   Q1 256 31 Ref. Ref. 39 Ref. Ref. 
Q2 261 37 1.01 (0.59-1.73) 1.03 (0.60-1.76) 53 1.15 (0.73-1.83) 1.16 (0.73-1.83) 
Q3 267 48 1.50 (0.90-2.51) 1.53 (0.92-2.56) 63 1.42 (0.91-2.22) 1.42 (0.91-2.23) 
Q4 268 26 0.68 (0.38-1.22) 0.70 (0.39-1.27) 49 0.92 (0.57-1.49) 0.93 (0.58-1.51) 
Q5 262 67 1.76 (1.01-3.05) 1.85 (1.06-3.22) 55 0.95 (0.57-1.59) 0.96 (0.57-1.61) 
Ptrend 
  
0.20 0.16 
 
0.31 0.33 
Sweetened desserts (servings/day)1 
    Q1 256 29 Ref. Ref. 39 Ref. Ref. 
Q2 264 33 0.95 (0.55-1.66) 0.95 (0.55-1.66) 56 1.25 (0.79-1.98) 1.25 (0.79-1.97) 
Q3 262 46 1.25 (0.74-2.12) 1.27 (0.75-2.16) 53 1.11 (0.70-1.77) 1.11 (0.70-1.77) 
Q4 267 33 0.92 (0.53-1.61) 0.95 (0.54-1.66) 52 1.06 (0.67-1.70) 1.07 (0.67-1.71) 
Q5 265 68 1.61 (0.95-2.75) 1.68 (0.98-2.88) 59 1.02 (0.62-1.66) 1.02 (0.63-1.67) 
Ptrend 
  
0.22 0.17 
 
0.38 0.40 
Sweetened beverages (servings/day)2 
    Q1 265 41 Ref. Ref. 40 Ref. Ref. 
Q2 269 49 1.14 (0.71-1.83) 1.12 (0.70-1.80) 55 1.32 (0.84-2.07) 1.32 (0.84-2.07) 
Q3 268 40 1.06 (0.65-1.74) 1.06 (0.65-1.74) 51 1.28 (0.81-2.03) 1.28 (0.81-2.03) 
Q4 265 33 0.82 (0.48-1.38) 0.81 (0.48-1.37) 62 1.47 (0.93-2.31) 1.47 (0.93-2.31) 
Q5 271 53 1.22 (0.74-2.02) 1.21 (0.73-2.01) 59 1.31 (0.81-2.11) 1.31 (0.81-2.11) 
Ptrend     0.64 0.65   0.65 0.66 
1
Adjusted for  age, sex, race, study indicator, BMI, fruits and vegetables intake, cigarette smoking, GERD frequency, and total energy intake                                                                                                                                                                                                     
2
Adjusted for  age, sex, race, study indicator, fruits and vegetables intake, cigarette smoking, GERD frequency, and total energy intake  
3
Additionally adjusted for diabetes                                                                                                                                                    
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Table A.25. Multivariable-adjusted ORs and 95%CIs for the associations between sugar/carbohydrate intake and risk of 
developing EA/GCA among 282 EA cases, 256 GCA cases, and 684 controls from the US Multi-Center study (results 
additionally adjusted for income category). 
  Esophageal Adenocarcinoma Gastric Cardia Adenocarcinoma 
 Measure 
Controls 
(N)  
Cases 
(N) 
OR (95%CI) OR3 (95%CI) Cases 
(N) 
OR (95%CI) OR3 (95%CI) 
Free glucose (g/day)1 
      Q1 126 64 Ref. Ref. 34 Ref. Ref. 
Q2 124 52 0.77 (0.48-1.23) 0.78 (0.49-1.26) 45 1.31 (0.78-2.21) 1.34 (0.79-2.26) 
Q3 128 55 0.71 (0.43-1.15) 0.72 (0.44-1.17) 49 1.38 (0.81-2.34) 1.41 (0.83-2.40) 
Q4 132 37 0.39 (0.23-0.67) 0.40 (0.23-0.68) 45 1.10 (0.63-1.92) 1.13 (0.65-1.98) 
Q5 129 55 0.50 (0.29-0.85) 0.50 (0.30-0.85) 65 1.52 (0.88-2.64) 1.53 (0.89-2.66) 
Ptrend 
  
0.04 0.04 
 
0.61 0.57 
Sucrose (g/day)1 
      Q1 130 35 Ref. Ref. 36 Ref. Ref. 
Q2 128 35 0.91 (0.52-1.58) 0.92 (0.53-1.60) 40 1.04 (0.61-1.76) 1.05 (0.62-1.78) 
Q3 130 61 1.45 (0.86-2.45) 1.47 (0.87-2.48) 46 1.14 (0.68-1.94) 1.16 (0.68-1.97) 
Q4 124 66 1.50 (0.88-2.58) 1.50 (0.88-2.58) 55 1.21 (0.71-2.07) 1.21 (0.71-2.07) 
Q5 127 66 1.30 (0.72-2.36) 1.29 (0.71-2.34) 61 1.09 (0.61-1.97) 1.08 (0.60-1.95) 
Ptrend 
  
0.75 0.74 
 
0.66 0.66 
Free fructose (g/day)1 
      Q1 123 67 Ref. Ref. 41 Ref. Ref. 
Q2 128 53 0.73 (0.46-1.17) 0.75 (0.47-1.20) 52 1.22 (0.75-1.99) 1.25 (0.77-2.05) 
Q3 131 57 0.65 (0.40-1.05) 0.66 (0.41-1.06) 39 0.84 (0.49-1.43) 0.85 (0.50-1.44) 
Q4 126 42 0.47 (0.28-0.80) 0.48 (0.28-0.82) 49 1.07 (0.63-1.82) 1.09 (0.64-1.86) 
Q5 131 44 0.39 (0.23-0.66) 0.39 (0.23-0.66) 57 1.05 (0.62-1.78) 1.05 (0.62-1.78) 
Ptrend 
  
0.05 0.05 
 
0.50 0.45 
Total sugar (g/day)1 
     Q1 126 45 Ref. Ref. 36 Ref. Ref. 
Q2 131 41 0.81 (0.48-1.35) 0.81 (0.48-1.36) 32 0.79 (0.46-1.37) 0.79 (0.46-1.38) 
Q3 129 68 1.25 (0.76-2.06) 1.25 (0.76-2.07) 56 1.37 (0.81-2.30) 1.37 (0.82-2.31) 
Q4 126 50 0.74 (0.42-1.29) 0.75 (0.43-1.30) 53 1.14 (0.65-1.99) 1.15 (0.66-2.01) 
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Q5 127 59 0.69 (0.37-1.27) 0.68 (0.37-1.25) 61 1.08 (0.58-2.00) 1.06 (0.57-1.96) 
Ptrend 
  
0.15 0.14 
 
0.43 0.42 
Added sugar (g/day)1 
      Q1 128 32 Ref. Ref. 35 Ref. Ref. 
Q2 131 37 0.98 (0.56-1.72) 0.99 (0.57-1.73) 32 0.82 (0.47-1.43) 0.82 (0.47-1.44) 
Q3 129 67 1.65 (0.97-2.79) 1.64 (0.97-2.79) 52 1.25 (0.74-2.12) 1.25 (0.74-2.11) 
Q4 123 66 1.47 (0.84-2.55) 1.46 (0.84-2.53) 55 1.22 (0.71-2.11) 1.21 (0.70-2.09) 
Q5 128 51 1.13 (0.61-2.10) 1.12 (0.60-2.08) 64 1.16 (0.64-2.12) 1.14 (0.63-2.08) 
Ptrend 
  
0.96 >0.99 
 
0.84 0.79 
Starch (g/day)1 
      Q1 128 36 Ref. Ref. 27 Ref. Ref. 
Q2 125 41 0.98 (0.57-1.68) 0.97 (0.56-1.67) 41 1.34 (0.76-2.36) 1.34 (0.76-2.36) 
Q3 126 59 1.23 (0.72-2.10) 1.22 (0.72-2.09) 60 1.81 (1.04-3.16) 1.79 (1.03-3.12) 
Q4 130 62 0.97 (0.55-1.72) 0.97 (0.55-1.72) 49 1.14 (0.62-2.09) 1.14 (0.62-2.08) 
Q5 130 65 0.90 (0.47-1.75) 0.89 (0.46-1.72) 61 1.26 (0.64-2.51) 1.24 (0.62-2.47) 
Ptrend 
  
0.95 0.92 
 
0.55 0.59 
Total carbohydrate (g/day)1 
 Q1 128 41 Ref. Ref. 35 Ref. Ref. 
Q2 124 39 0.81 (0.47-1.40) 0.81 (0.47-1.39) 33 0.83 (0.47-1.47) 0.83 (0.47-1.45) 
Q3 129 50 0.82 (0.46-1.45) 0.82 (0.46-1.44) 45 0.96 (0.54-1.71) 0.95 (0.53-1.70) 
Q4 126 59 0.83 (0.44-1.55) 0.83 (0.44-1.54) 54 1.12 (0.60-2.11) 1.11 (0.59-2.09) 
Q5 132 74 0.66 (0.30-1.49) 0.65 (0.29-1.46) 71 0.98 (0.44-2.20) 0.95 (0.42-2.14) 
Ptrend 
  
0.35 0.32 
 
0.01 0.01 
Glycemic index2 
 Q1 131 53 Ref. Ref. 42 Ref. Ref. 
Q2 129 50 1.23 (0.75-2.02) 1.24 (0.76-2.04) 34 1.12 (0.65-1.91) 1.13 (0.67-1.94) 
Q3 130 51 1.21 (0.74-1.96) 1.23 (0.75-2.01) 47 1.56 (0.94-2.60) 1.58 (0.95-2.63) 
Q4 127 43 0.98 (0.59-1.62) 0.98 (0.59-1.61) 68 2.15 (1.33-3.47) 2.14 (1.32-3.45) 
Q5 125 67 1.52 (0.95-2.44) 1.51 (0.94-2.41) 47 1.49 (0.90-2.47) 1.47 (0.89-2.44) 
Ptrend 
  
0.63 0.62 
 
0.17 0.17 
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Glycemic load1 
 Q1 128 46 Ref. Ref. 34 Ref. Ref. 
Q2 125 37 0.69 (0.41-1.17) 0.69 (0.40-1.17) 28 0.75 (0.42-1.33) 0.74 (0.42-1.33) 
Q3 130 49 0.75 (0.44-1.28) 0.75 (0.44-1.27) 49 1.18 (0.68-2.04) 1.17 (0.67-2.02) 
Q4 125 67 0.87 (0.49-1.52) 0.80 (0.44-1.47) 65 1.51 (0.85-2.71) 1.50 (0.84-2.69) 
Q5 131 64 0.55 (0.28-1.09) 0.54 (0.27-1.07) 62 1.01 (0.50-2.05) 0.99 (0.49-2.01) 
Ptrend 
  
0.13 0.12 
 
0.83 0.79 
Sweetened desserts/beverages (servings/day)1 
   
 Q1 126 38 Ref. Ref. 36 Ref. Ref. 
Q2 129 42 1.09 (0.64-1.86) 1.12 (0.65-1.90) 37 1.03 (0.60-1.77) 1.06 (0.62-1.81) 
Q3 134 53 1.21 (0.72-2.04) 1.23 (0.73-2.07) 44 1.16 (0.68-1.97) 1.18 (0.69-2.00) 
Q4 122 61 1.26 (0.74-2.14) 1.27 (0.75-2.16) 56 1.33 (0.78-2.25) 1.34 (0.79-2.28) 
Q5 128 69 1.28 (0.73-2.22) 1.26 (0.73-2.20) 65 1.32 (0.76-2.31) 1.30 (0.75-2.28) 
Ptrend 
  
0.95 0.98 
 
0.84 0.88 
Sweetened desserts (servings/day)1 
    Q1 127 36 Ref. Ref. 35 Ref. Ref. 
Q2 127 39 1.01 (0.59-1.73) 1.03 (0.60-1.76) 40 1.06 (0.63-1.81) 1.08 (0.64-1.84) 
Q3 130 57 1.24 (0.74-2.08) 1.26 (0.75-2.12) 47 1.11 (0.66-1.88) 1.13 (0.67-1.91) 
Q4 131 70 1.45 (0.86-2.46) 1.47 (0.87-2.49) 59 1.33 (0.78-2.25) 1.35 (0.79-2.28) 
Q5 124 61 0.94 (0.53-1.69) 0.96 (0.54-1.73) 57 0.97 (0.54-1.74) 1.00 (0.55-1.79) 
Ptrend 
 
 0.31 0.31 
 
0.66 0.66 
Sweetened beverages (servings/day)2 
    Q1 128 56 Ref. Ref. 46 Ref. Ref. 
Q2 127 39 0.73 (0.45-1.21) 0.74 (0.45-1.22) 44 0.92 (0.56-1.50) 0.94 (0.57-1.53) 
Q3 128 50 0.90 (0.56-1.45) 0.91 (0.56-1.46) 41 0.83 (0.51-1.38) 0.85 (0.51-1.40) 
Q4 135 50 0.80 (0.50-1.30) 0.81 (0.50-1.30) 54 1.05 (0.65-1.70) 1.06 (0.66-1.71) 
Q5 124 69 1.12 (0.70-1.80) 1.11 (0.69-1.78) 53 0.93 (0.57-1.53) 0.92 (0.56-1.51) 
Ptrend     0.78 0.82   0.79 0.74 
1
Adjusted for  age, sex, race, study indicator, BMI, fruits and vegetables intake, cigarette smoking, GERD frequency, and total energy intake                                                                                                                                                                           
2
Adjusted for  age, sex, race, study indicator, fruits and vegetables intake, cigarette smoking, GERD frequency, and total energy intake 
3
Additionally adjusted for income                                                                                                                                                     
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Table A.26. Multivariable-adjusted ORs and 95%CIs for the associations between sugar/carbohydrate intake and risk of 
developing EA/GCA among 218 EA cases, 273 GCA cases, and 1343 controls from the LA Multi-Ethnic study (results 
additionally adjusted for physical activity). 
  Esophageal Adenocarcinoma Gastric Cardia Adenocarcinoma 
Measure 
Controls 
(N)  
Cases 
(N) 
OR (95%CI) OR (95%CI)3 Cases 
(N) 
OR (95%CI) OR (95%CI)3 
Free glucose (g/day)1 
      Q1 259 40 Ref. Ref. 41 Ref. Ref. 
Q2 259 44 1.11 (0.68-1.83) 1.11 (0.68-1.83) 50 1.14 (0.72-1.82) 1.14 (0.72-1.82) 
Q3 268 41 1.03 (0.61-1.71) 1.03 (0.61-1.72) 55 1.17 (0.73-1.88) 1.17 (0.73-1.87) 
Q4 266 37 0.91 (0.52-1.58) 0.91 (0.52-1.58) 56 1.14 (0.69-1.89) 1.15 (0.70-1.90) 
Q5 264 48 1.11 (0.60-2.07) 1.11 (0.60-2.07) 57 1.08 (0.61-1.90) 1.08 (0.61-1.89) 
Ptrend 
  
0.58 0.57 
 
0.33 0.34 
Sucrose (g/day)1 
      Q1 261 34 Ref. Ref. 42 Ref. Ref. 
Q2 265 48 1.47 (0.89-2.42) 1.46 (0.89-2.42) 63 1.38 (0.89-2.14) 1.38 (0.89-2.15) 
Q3 263 29 0.79 (0.45-1.39) 0.79 (0.45-1.40) 53 1.05 (0.66-1.67) 1.05 (0.66-1.67) 
Q4 263 39 1.27 (0.73-2.19) 1.27 (0.73-2.21) 51 1.03 (0.64-1.68) 1.02 (0.63-1.66) 
Q5 264 60 1.64 (0.92-2.94) 1.66 (0.93-2.96) 50 0.82 (0.47-1.42) 0.81 (0.47-1.40) 
Ptrend 
  
0.05 0.05 
 
0.19 0.17 
Free fructose (g/day)1 
      Q1 259 43 Ref. Ref. 48 Ref. Ref. 
Q2 258 43 1.02 (0.63-1.67) 1.02 (0.62-1.66) 50 0.98 (0.62-1.53) 0.98 (0.63-1.54) 
Q3 267 34 0.77 (0.45-1.30) 0.77 (0.46-1.31) 49 0.85 (0.53-1.36) 0.84 (0.53-1.35) 
Q4 267 46 1.04 (0.61-1.77) 1.03 (0.61-1.76) 54 0.88 (0.54-1.44) 0.89 (0.55-1.46) 
Q5 265 44 0.98 (0.54-1.79) 0.98 (0.54-1.78) 58 0.92 (0.54-1.56) 0.91 (0.53-1.56) 
Ptrend 
  
0.54 0.53 
 
0.22 0.22 
Total sugar (g/day)1 
      Q1 259 37 Ref. Ref. 46 Ref. Ref. 
Q2 264 44 1.13 (0.68-1.86) 1.13 (0.69-1.87) 58 1.09 (0.70-1.69) 1.07 (0.69-1.67) 
Q3 264 35 0.91 (0.53-1.55) 0.91 (0.53-1.55) 50 0.87 (0.55-1.39) 0.88 (0.55-1.39) 
Q4 264 40 0.96 (0.55-1.67) 0.96 (0.55-1.68) 48 0.74 (0.45-1.22) 0.74 (0.45-1.21) 
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Q5 265 54 1.28 (0.69-2.40) 1.28 (0.69-2.40) 57 0.76 (0.43-1.35) 0.76 (0.43-1.34) 
Ptrend 
  
0.43 0.44 
 
0.14 0.14 
Added sugar (g/day)1 
      Q1 257 38 Ref. Ref. 41 Ref. Ref. 
Q2 268 36 0.81 (0.48-1.37) 0.82 (0.49-1.38) 43 0.89 (0.55-1.43) 0.88 (0.55-1.42) 
Q3 262 29 0.60 (0.35-1.05) 0.60 (0.35-1.05) 54 1.07 (0.68-1.70) 1.06 (0.67-1.69) 
Q4 266 50 1.07 (0.65-1.78) 1.08 (0.65-1.80) 64 1.20 (0.76-1.91) 1.18 (0.74-1.87) 
Q5 263 57 0.86 (0.48-1.51) 0.86 (0.49-1.53) 57 0.84 (0.49-1.44) 0.83 (0.48-1.41) 
Ptrend 
  
0.16 0.14 
 
0.55 0.49 
Starch (g/day)1 
       Q1 261 34 Ref. Ref. 58 Ref. Ref. 
Q2 264 40 1.01 (0.60-1.70) 1.01 (0.60-1.69) 46 0.65 (0.42-1.00) 0.65 (0.42-1.01) 
Q3 264 50 1.25 (0.75-2.10) 1.25 (0.75-2.10) 56 0.73 (0.47-1.13) 0.73 (0.47-1.13) 
Q4 264 41 0.85 (0.48-1.51) 0.85 (0.48-1.50) 53 0.57 (0.36-0.93) 0.57 (0.35-0.93) 
Q5 263 45 0.80 (0.40-1.61) 0.80 (0.40-1.60) 46 0.38 (0.20-0.71) 0.38 (0.20-0.71) 
Ptrend 
  
0.18 0.17 
 
0.02 0.03 
Total carbohydrate (g/day)1 
 Q1 258 38 Ref. Ref. 53 Ref. Ref. 
Q2 265 42 1.01 (0.61-1.68) 1.01 (0.61-1.68) 56 0.87 (0.57-1.35) 0.87 (0.57-1.35) 
Q3 264 38 0.80 (0.46-1.38) 0.80 (0.46-1.39) 37 0.48 (0.29-0.80) 0.48 (0.29-0.80) 
Q4 267 42 0.72 (0.39-1.31) 0.72 (0.39-1.31) 58 0.59 (0.35-0.99) 0.59 (0.35-0.98) 
Q5 262 50 0.76 (0.34-1.69) 0.76 (0.34-1.69) 55 0.43 (0.21-0.88) 0.43 (0.21-0.88) 
Ptrend 
  
0.16 0.15 
 
<0.01 <0.01 
Glycemic index2 
 Q1 267 41 Ref. Ref. 64 Ref. Ref. 
Q2 266 45 1.31 (0.81-2.12) 1.31 (0.81-2.13) 51 0.91 (0.60-1.38) 0.91 (0.60-1.38) 
Q3 268 44 1.38 (0.85-2.24) 1.38 (0.85-2.24) 55 0.98 (0.65-1.48) 0.98 (0.65-1.48) 
Q4 268 42 1.30 (0.79-2.12) 1.29 (0.79-2.11) 46 0.83 (0.54-1.27) 0.83 (0.54-1.28) 
Q5 269 44 1.62 (0.99-2.66) 1.62 (0.99-2.66) 51 1.04 (0.68-1.60) 1.04 (0.68-1.61) 
Ptrend   0.29 0.29  0.44 0.48 
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Glycemic load1 
 Q1 259 40 Ref. Ref. 57 Ref. Ref. 
Q2 264 42 0.92 (0.56-1.53) 0.92 (0.56-1.53) 52 0.73 (0.47-1.13) 0.73 (0.47-1.14) 
Q3 265 38 0.85 (0.50-1.45) 0.85 (0.50-1.44) 40 0.53 (0.33-0.86) 0.53 (0.33-0.86) 
Q4 265 38 0.76 (0.43-1.36) 0.76 (0.43-1.36) 56 0.62 (0.38-1.02) 0.63 (0.38-1.02) 
Q5 263 52 0.89 (0.43-1.83) 0.89 (0.43-1.83) 54 0.46 (0.24-0.89) 0.50 (0.24-0.89) 
Ptrend 
  
0.69 0.68 
 
0.01 0.08 
Sweetened desserts/beverages (servings/day)1 
   
 Q1 256 31 Ref. Ref. 39 Ref. Ref. 
Q2 263 37 1.01 (0.59-1.72) 1.01 (0.59-1.72) 52 1.12 (0.71-1.78) 1.11 (0.70-1.77) 
Q3 266 49 1.53 (0.92-2.56) 1.53 (0.92-2.55) 64 1.44 (0.92-2.26) 1.45 (0.93-2.27) 
Q4 269 26 0.68 (0.38-1.22) 0.68 (0.38-1.22) 48 0.90 (0.56-1.45) 0.90 (0.56-1.46) 
Q5 262 67 1.78 (1.03-3.09) 1.78 (1.03-3.09) 56 0.97 (0.58-1.62) 0.97 (0.58-1.62) 
Ptrend 
  
0.19 0.19 
 
0.35 0.35 
Sweetened desserts (servings/day)1 
     Q1 256 29 Ref. Ref. 38 Ref. Ref. 
Q2 265 33 0.94 (0.54-1.63) 0.95 (0.55-1.66) 56 1.29 (0.82-2.05) 1.25 (0.79-1.97) 
Q3 263 47 1.25 (0.74-2.12) 1.27 (0.75-2.16) 53 1.14 (0.71-1.81) 1.11 (0.70-1.77) 
Q4 267 33 0.91 (0.52-1.60) 0.95 (0.54-1.66) 53 1.12 (0.70-1.79) 1.07 (0.67-1.71) 
Q5 265 68 1.62 (0.95-2.76) 1.68 (0.98-2.88) 59 1.04 (0.64-1.71) 1.02 (0.63-1.67) 
Ptrend 
  
0.20 0.17 
 
0.44 0.40 
Sweetened beverages (servings/day)2 
    Q1 266 41 Ref. Ref. 40 Ref. Ref. 
Q2 271 48 1.12 (0.69-1.80) 1.12 (0.69-1.81) 55 1.31 (0.84-2.06) 1.30 (0.83-2.04) 
Q3 267 41 1.10 (0.67-1.80) 1.10 (0.67-1.80) 51 1.29 (0.81-2.04) 1.29 (0.82-2.04) 
Q4 265 33 0.83 (0.49-1.40) 0.83 (0.49-1.40) 62 1.47 (0.94-2.31) 1.48 (0.94-2.34) 
Q5 271 53 1.26 (0.76-2.09) 1.26 (0.76-2.09) 59 1.30 (0.81-2.10) 1.30 (0.81-2.09) 
Ptrend     0.57 0.57   0.64 0.65 
1
Adjusted for  age, sex, race, study indicator, BMI, fruits and vegetables intake, cigarette smoking, GERD frequency, and total energy intake                                                                                                                                                                           
2
Adjusted for  age, sex, race, study indicator, fruits and vegetables intake, cigarette smoking, GERD frequency, and total energy intake   
3
Additionally adjusted for physical activity   
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Table A.27. Multivariable-adjusted ORs and 95%CIs for the associations between sugar/carbohydrate intake and risk of 
developing EA, stratified by diabetes, among 218 EA cases, 273 GCA cases, and 1343 controls from the LA Multi-Ethnic study. 
Diabetes Measure Cases 
(N) 
Controls 
(N) 
Multiplicative scale   Additive scale 
        
Stratified ORs        
(95%CIs) 
Pinteraction  Single referent 
ORs (95%CIs) 
Additive ICR        
(95%CI) 
 
Sucrose 
  
     No    Q1-Q3 96 715 1.00 
  
1.00 
 
 
   Q4-Q5 82 486 1.30 (0.88-1.93)   1.30 (0.88-1.93) 
 Yes    Q1-Q3 14 73 1.00 
  
1.50 (0.78-2.89) 
 
 
   Q4-Q5 17 40 1.66 (0.67-4.11) 0.62  2.48 (1.22-5.07) 0.68 (-1.20, 2.56) 
 
Glycemic index  
     No    Q1-Q3 112 729 1.00 
  
1.00 
 
 
   Q4-Q5 72 496 1.20 (0.85-1.69)   1.20 (0.85-1.69) 
 Yes    Q1-Q3 18 72 1.00 
  
1.49 (0.81-2.73) 
 
 
   Q4-Q5 14 41 1.62 (0.67-3.92) 0.53  2.41 (1.18-4.91) 0.72 (-1.15, 2.59) 
 
Sweetened desserts/beverages 
     No    Q1-Q3 99 705 1.00 
  
1.00 
 
 
   Q4-Q5 79 496 0.91 (0.62-1.32)   0.91 (0.62-1.32) 
 Yes    Q1-Q3 17 79 1.00 
  
1.45 (0.79-2.67)  
     Q4-Q5 14 34 1.29 (0.51-3.27) 0.48  1.86 (0.86, 4.05) 0.51 (-1.09, 2.11) 
 Free fructose        
No    Q1-Q3 104 714 1.00   1.00  
    Q4-Q5 74 487 1.04 (0.70-1.55)   1.04 (0.70-1.55)  
Yes    Q1-Q3 15 68 1.00   1.40 (0.74-2.66)  
     Q4-Q5 16 45 1.55 (0.63-3.82) 0.41  2.17 (1.06-4.44) 0.73 (-0.94, 2.40) 
 
 
